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Abstract 
 
Introduction: In England the 5-year survival for colorectal cancer (CRC) is 50%, significantly lower 
than in other countries of comparable wealth, largely due to patients presenting late with the disease. 
Late presentation is strongly correlated with emergency presentation to hospital.  
The NHS Bowel Cancer Screening Programme (BCSP) has been the most significant nationwide 
intervention attempting to improve CRC outcomes. This programme began in 2006 and was active 
throughout the country by 2010. Screening programmes are notoriously difficult to evaluate and so far 
there is limited robust evidence of its effectiveness.  
Administrative data from hospitals can be used to study diseases, including cancers. Through careful 
interrogation of the data, it may be possible to identify factors associated with improved CRC outcomes, 
including the impact of introducing the BCSP.  
 
Aims: To develop a new methodology for identifying a national cohort of incident CRC cases, by 
applying clinical knowledge to the analysis of administrative data for English hospitals (Hospital Episode 
Statistics, HES).  
To use this new methodology to identify which admission signifies a patient’s first presentation to 
hospital care with CRC and identify which patients present as an emergency (Chapter 2).  
To establish whether emergency presentation is a valid outcome measure for patients with CRC 
(Chapter 3). 
To test whether the benefits of launching a BCSP extend beyond the minority of individuals targeted by 
the screening program, specifically, if there are early, indirect benefits for the population as a whole 
resulting from enhanced awareness regarding CRC (Chapter 4).   
To ensure that the findings in Chapter 4 are robust and not accounted for by confounding (Chapter 5).  
To determine whether the algorithm that dictates which Faecal Occult Blood test (gFOBt) results are 
referred for colonoscopy can be improved, to more effectively use the limited colonoscopy resources 
(Chapter 6). 
 
Design and method: All hospital admissions relating to incident cases of CRC in England from 2006-
2008 were extracted from HES data to form my main cohort. Traditionally HES-based studies mark a 
patient’s presentation from the first admission containing a coding of CRC (CRC1). In my thesis, all 
codes indicative of CRC presentation to secondary care were identified and any admission occurring 
prior to CRC1, flagged as the presenting admission, and termed “first relevant admission” (REL1). The 
primary outcome measure was emergency presentation with CRC, while secondary outcomes were 
major surgical resection and mortality at one-year (Chapter 2).  Data was analysed to assess the factors 
associated with, and outcomes related to, an emergency presentation (Chapter 3).   
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I then matched each patient to the date when their local Primary Care Trust (PCT) began referring to 
the BCSP to ascertain which patients were living in an area with an active BCSP at the time of their 
presentation (“exposed” group) and the length of exposure. To exclude confounding based on overall 
healthcare quality in an area, outcomes for a distinct cancer (Oesophageal and Gastric (OG)) presenting 
during the same period, were compared, based on their screening exposure (Chapter 4).   
To further exclude confounding, the effect of living in an area with active screening, yet restricted to 
those PCTs that began screening during the same time period (the middle year) was analysed (Chapter 
5). The Bowel Cancer Screening System database was studied to identify individuals with two 
consecutive episodes of screening between April 2009 and March 2011. Each test kit was coded 
depending on the specific FOBt result for each round. The overall percentage of positive results was 
termed the Spot Positivity percentage (SP%). The results at Episode 1 were analysed for individuals 
with cancer diagnosed at Episode 2. This could identify a combination of FOBt results that would 
benefit from earlier colonoscopy (Chapter 6).	 
 
Results: Chapter 2 identifies 32,299 incident cases of CRC. Older patients and females were more 
likely to be diagnosed with proximal cancer and deprived patients had lower rates of surgical resection 
and survival. The overall rates of patient characteristics were similar to matched populations that used a 
different methodology. However the emergency presentation rate was higher in my cohort (36.1% vs. 
32.0%, p<0.001) and the surgical resection and one-year survival rates were lower.  Lower 
gastrointestinal endoscopy is the gold standard when establishing the CRC diagnosis. My new 
methodological approach of REL1, rather than the CRC1, increased the proportion of patients identified 
with an endoscopy at presentation (52.5% vs. 36.8%, p<0.001) suggesting a more accurate start of a 
patient’s journey was identified.  
Chapter 3 shows that patients presenting as an emergency were significantly less likely to have surgical 
resection, (35.4% vs. 59.1%, p<0.001). Furthermore, the Odds Ratio for mortality at one year 
following emergency presentation was 4.11 (p<0.001). This was the single strongest predictor of 
adverse outcomes. Within the first 30 days of presentation, the mortality rate was almost four times 
higher in emergency patients (6.5% vs.1.7%, P<0.001). 
In Chapter 4 patients “exposed” to local screening had significantly lower crude emergency 
presentation rates than the “non-exposed” group (34.9% [2,492/7,142] vs. 37.0% [7,599/20,520], 
p=0.002). Using exposure as a continuous variable, there was a 2% reduction in emergency 
presentations for every month “exposed” to local screening (OR =0.98 [CI: 0.97-0.99], p<0.001). By 
studying the non-screening age population, indirect effect of screening could be tested. Those with 
greater than 6 months screening exposure had an Odds Ratio (OR) of 0.85 (CI: 0.77-0.94, p<0.001) 
for emergency presentation compared to those non-exposed. 
 6	
During the same period, 9,319 patients presented with OG cancer. These patients showed no significant 
difference in emergency presentation rates between patients “non-exposed” (28.0%), and those 
“exposed” for less than six months (29.7%) or longer (28.0%).  
Chapter 5 analyses 48 PCTs that began screening in the middle year and demonstrated the same 
association with screening exposure as chapter 4. There were more daycase colonoscopies in the six 
months after screening was introduced (30,347 vs. 31,805). The 4.8% increase in activity, implies 
either extra capacity and/or extra referrals followed the introduction of screening. Analysis of PCTs 
that began screening in the first 6 months of the year, showed that prolonged exposure to screening (6-
12 months) was associated with a significantly lower emergency presentation rate (34.1 vs. 38.9%, 
p<0.001). 
Chapter 6 examines the data of 284,261 subjects that completed gFOBTs, of which 3,891 (1.4%) had 
a colonoscopy at Episode 2. As the SP% increased from 11 to 100%, so the CRC detection rate 
increased from 4 to 25%. At the lower SP%s, from 11% to 25%, the CRC risk was relatively static at 
4%. Above an SP% of 25%, every 10-percentage points increase in the SP%, was associated with an 
increase in cancer detection of 2.5%. 
 
Conclusion 
Clinical knowledge may be applied to routine administrative data (HES) to more accurately identify 
incident cases of CRC. Using this clinical knowledge creates a better understanding than the traditional 
methods of when the presenting admission occurred. In particular, patients often present before CRC is 
recorded in the administrative data, evidenced by the higher rate of endoscopy coded at presentation, 
using the new methodology. Chapter 2 also demonstrated that more patients than previously thought 
had presented as an emergency.  
There is strong evidence to suggest emergency presentation is a valid independent outcomes measure; 
one strongly associated with reduced access to surgical resection and an increased one-year mortality. 
Specifically, it is associated with an excess of early deaths after presentation, suggesting an association 
with the late presentation of cancer. 
Areas with active screening were significantly associated with a reduced risk of emergency presentation. 
This reduction extended outside the screening age group, implying an indirect benefit to the population. 
The reduction became apparent within 6-12 months of the start-up of screening. Longer exposure was 
incrementally associated with improved CRC outcomes. The outcomes for OG cancer were unaffected 
by screening exposure, implying the effect was not due to broader differences between local services. 
There was no obvious confounding factor to the findings in chapter 4 and increasing colonoscopy activity 
in the immediate six months after screening began, was likely to relate to increased CRC awareness.  
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The BCSP data demonstrated a strong correlation between SP% and cancer detection. Some subjects 
with an SP% of 11% proceed to colonoscopy, whereas others with an SP% of 22% do not. This suggests 
that the programme could be adjusted to increase the detection of CRCs without substantially increasing 
the colonoscopy workload. 
 
Overall conclusion 
My thesis describes how routine administrative data, augmented with clinical knowledge may be used to 
study CRC. Specifically, it describes how the introduction of the BCSP was associated with an early and 
population-wide reduction in the risk of emergency presentation. This demonstration of indirect 
benefits for symptomatic cases of CRC is likely to reflect enhanced public and/or professional awareness 
of CRC, leading to more timely clinical presentation and investigation in the symptomatic population.  
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Definitions and Abbreviations 
 
CRC1 
The patient’s first (earliest) hospital admission when a diagnostic code for 
CRC was recorded. 
REL1 
The patient’s first (earliest) ‘relevant’ admission. This corresponds to the 
first admission with a diagnostic or procedural code consistent with a 
clinical presentation of CRC and occurring within six months of the first 
admission containing a cancer code (CRC1). 
Index admission 
The admission corresponding to the first clinical presentation with CRC. 
This is either REL1 (where a clinically relevant admission occurred before 
the first coding of cancer) or CRC1 (if no such earlier admission was 
recorded). 
Primary diagnosis 
(DIAG01) 
The position one (or first) diagnostic code. 
DIAG02-DIAG14  
 
Position of the secondary diagnosis codes or associated co-morbidity in HES   
 
Primary procedure 
(OPERTN01) 
The position one (or first) procedure code. 
OPERTN02-
OPERTN14  
 
Position of the secondary procedure code in HES  
 
FCE Episode of care or Finished Consultant Episode.  
HESID The identifier that is unique to each patient and their HES record.  
ICD International Statistical Classification of Diseases.  
OPCS Office of Population, Censuses and Surveys Classification of Interventions  
IMD score 
Index of Multiple Deprivation score. A score of deprivation, that ranks 
small geographical areas according to their relative deprivation. 
PbR Payment by Results. A national tariff of fixed prices for hospital procedures  
FOBt Faecal Occult Blood test 
Patient delay The time between noticing a symptom and consulting a GP. 
Primary care delay The time between a patient’s first GP consultation and referral. 
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Secondary care delay The time between referral and cancer diagnosis. 
Short stay emergency 
admissions 
Patients whose initial emergency admission length of stay was <1 day. 
NBOCAP National Bowel Cancer Audit 
ONS Office of National statistics  
PCT Primary Care Trust.  
SHA Strategic Health Authorities 
LSUD 
Local Start Up Date (LSUD) of screening. The date in which a patient’s 
PCT began referring to the BCSP. 
OG cancer Oesophageal and Gastric cancer  
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Chapter 1 - Introduction and general overview 
1.1. Introduction 
Colorectal cancer (CRC) is the second most common cause of cancer in the United Kingdom, 
accounting for 33,000 new cases and 16,000 deaths every year(1,2). Incidence increases with age(2) and 
the lifetime risk is 6.1% for men and 5.0% for women(3). If CRC is diagnosed at an early stage then the 
five year survival rate is over 90%, compared with less than 10% if it has spread(4,5). Furthermore, the 
disease is entirely preventable if the precursor adenomatous polyps are removed. Reducing the 
morbidity and mortality associated with the condition is a major health priority for the nation(6).  
Knowledge about the genetics and pathophysiology of CRC has improved over the last few decades, as 
have diagnostic tests and treatments(7). Despite this, many patients continue to present with advanced 
disease. In such cases not only is survival drastically reduced, but these patients require significantly 
greater amounts of treatment and incur much greater costs to manage the condition(8). For these 
reasons patients with early cancer or those at risk of cancer must be identified rapidly and managed 
expectantly. This will require improvements at all levels of healthcare: from the patients and family 
recognising and acting on symptoms; to primary and secondary care referring and managing patients 
quickly. To do this there must be greater emphasis on educating the general public about the symptoms 
of CRC. There need to be rapid referral pathways from primary to secondary care. There must be 
adequate endoscopy services to offer rapid and accurate examination of the colorectum. Once 
diagnosed, patients need to be assessed by cancer networks teams and have surgery and/or 
chemotherapy and radiotherapy offered promptly. Finally, at a national level there should be a 
programme for quality improvement initiatives to identify variability in practice and implement 
strategies to eliminate bad variation.  
Currently the UK has worse outcomes for CRC than countries of comparable wealth(9). The main 
reason for this is not the standard of treatment provided once diagnosed, but the late presentation of 
patients. Therefore any serious attempt to improve the quality of CRC care in the UK needs to address 
this problem. An example of a national intervention to reduce late presentation and improve outcomes 
was the introduction of the two week wait (2WW) rule; which aims to reduce delays in the diagnosis of 
symptomatic patients by speeding the referral from primary to secondary care. However no evidence 
has yet shown that interventions to reduce these delays improve outcomes(10). The second major 
national intervention was the NHS Bowel Cancer Screening Programme (BCSP), which sought to 
identify cancer in asymptomatic patients. Diagnosing these asymptomatic patients is likely to be 
beneficial, with studies showing that patients enrolling in a screening programme, had a 25% reduction 
in their CRC mortality(11). However there was no reduction in overall mortality and this group of 
asymptomatic patients only represent 3% of all CRC patients. Hence any intervention looking to see a 
larger change in outcomes would also need to focus on the 97% of cases still presenting to the 
symptomatic service. 
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My central thesis was that the major intervention of the BCSP was not with the 3% of asymptomatic 
cancers diagnosed but with the 97% of symptomatic patients. I propose that the mechanism of action 
was through an indirect effect on these patients by increasing awareness of CRC among patients and 
health professionals. I hope to describe the impact of its introduction, to identify which patient groups, 
if any, improve most and identify the mechanisms by which these improvements occur. I also want to 
study whether within the BCSP itself, the algorithms for referral to colonoscopy can be adjusted to 
maximise the programmes efficiency in terms of CRC diagnosis. 
The most common routinely collected healthcare data are the Hospital Episode Statistics (HES). This 
provides the primary dataset I have used in chapters 2-5 investigating variation in national CRC care. In 
chapter 6 I have used separate data from the Bowel Cancer Screening System database. 
This chapter reviews the pathology, epidemiology, clinical presentation, diagnosis, staging and 
treatment of CRC. It then describes how patients with CRC are managed within the NHS in England 
and why, compared to other countries of comparable wealth, prognosis is worse. I then describe some 
of the strategies attempted so far to improve the situation, with particular focus on the NHS BCSP. 
Finally, this chapter explores using routinely collected NHS data to describe CRC care pathways, 
identify important outcomes measures and interrogate why variations in outcomes exist.  
Reasons why some patients have poor outcomes is vital. Some reasons may be based on individual 
characteristics, such as a patient’s age or level of deprivation. Others factors could relate to the local 
healthcare system managing the patient, examples of variation include; the local referral practices for 
patients with gastrointestinal symptoms and the quality of the treating hospital. Outcomes may also be 
affected by national interventions, such as the BCSP. Ultimately understanding these factors will allow 
recommendations to be made to the way CRC healthcare is delivered. This will in turn lead to a 
reduction in unwanted variation and poor outcomes.  
Overview of the colorectum  
1.1.1. Anatomy of the colon and rectum 
The large intestine (colon) is approximately 6 cm wide and 1.5 m long, beginning at the ileocaecal valve 
(ICV) in the right iliac fossa and finishing at the junction with the anal canal. The large intestine is 
comprised of the caecum, ascending colon, transverse colon, descending colon, sigmoid colon and 
rectum.  
The ICV is typically on the last fold before the caecum is reached and traditionally termed a 
physiological, but not anatomical, sphincter. However, recent cadaveric studies have shown local 
thickening at the ileal papilla base, indicative of an intrinsic anatomical sphincter(12). Approximately 2 
L of fluid (chyme) enter the large bowel discontinuously every day and the ICV has a crucial role in 
reducing the flow of colonic contents back into the small bowel. When the terminal ileum distends the 
ICV will relax from a resting tone of 20 mmHg and allow contents to enter the large bowel. The ICV is 
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also opened by the gastro-ileal reflex, which causes relaxation after meals when gut motility and gastrin 
levels are high and closure when colonic distension occurs. This allows time for the colon to achieve its 
absorptive functions and also prevents colonic bacteria entering the normally aseptic small bowel. At the 
ICV the cellular architecture switches from villous mucosa to colonic columnar. 
The pouch-like caecum, transverse colon and sigmoid are all intraperitoneal structures and attached to a 
mesentery, which makes them mobile. By contrast the ascending colon, descending colon and rectum 
are retroperitoneal and more fixed. The distal 12 cm of the rectum lies below the peritoneal reflection. 
The anal canal is 2.5-4 cm long running from the ano-rectal junction to the anus and is not part of the 
colorectum. The anus consists of an internal and external sphincter. The colonic inner circular muscle 
thickens to form the internal anal sphincter, under involuntary control, and is held in continuous 
contraction. The external anal sphincter is formed of striated muscle and is under voluntary control. 
1.1.2. Histology 
The innermost layer of the colorectum is the mucosa. It is lined with simple columnar epithelium and 
appears smooth as there are no villi present. Instead, the mucosa is shaped into many straight tubular 
glands (crypts of Lieberkuhn), Figure 1.1. Throughout the mucosa there are abundant absorptive 
enterocytes that actively transport sodium (and with it water) and goblet cells that secrete mucus. The 
epithelium of the crypts also contains stem cells, which replace the epithelium every few days, along 
with enteric endocrine cells.  
The lamina propria separates the crypts and contains loose connective tissue, along with numerous 
lymphoid cells. The muscularis mucosa lies deep to the bottom of the crypts and is composed of a thin 
layer of circular and longitudinal muscle. The submucosa is a relatively unspecialised thin layer of 
connective tissue.  
Between the muscularis mucosa and submucosa are numerous organized lymphoid nodules, Peyer's 
patches. These are found throughout the colon and have a role in immune surveillance of the intestinal 
lumen and in facilitating the generation of the immune response against pathogenic microorganisms. 
Beneath the submucosa lies the important muscularis propria. This is composed of an inner circular and 
outer longitudinal muscle layer, with the Auerbach plexus (a part of the enteric nervous system, 
providing motor innervation to both layers) scattered between. The longitudinal layer lies just beneath 
the serosa, but doesn’t cover the entire bowel wall; instead it runs as three bands (teniae coli). Between 
the teniae coli bands, the wall bulges out to produce the three haustral folds. The three muscle bands 
converge at the appendix and at the rectosigmoid junction, where they merge to form a singular 
longitudinal muscle layer. When the teniae coli contract lengthwise, then the colon folds in on itself to 
produce the distinctive semilunar folds. Finally, the outer layer of the colorectum is the serosa, which is 
attached to mesentery. 
Arterial supply of the colon is from branches of the superior and inferior mesenteric arteries. The 
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superior mesenteric artery supplies the colon up to the splenic flexure, from where the inferior 
mesenteric artery takes over. Venous drainage mirrors the arterial supply, with the superior mesenteric 
vein joining the splenic vein to form the portal vein. The inferior mesenteric vein also joins the splenic 
vein.  
Lymphatic drainage of the colorectum follows the vascular supply. The colon and proximal two-thirds 
of the rectum drain via the paraaortic lymph nodes. The distal third of the rectum and anus has 
lymphatic drainage to the paraaortic nodes as well as the inguinal and internal iliac lymph nodes. Small 
lymph nodes run alongside the mesenteric vessels, with larger groups present at the root of the superior 
and inferior mesenteric arteries. Lymph fluid then passes to the cisterna chyli, which ultimately leads to 
the thoracic duct.  
 
Figure 1.1 The anatomy and histology of the colorectum. Adapted from: Medical Physiology, Second 
Edition, Boron Walter F. and Boulpaepemile L. 2009, Figure 41-3, page 885. 
1.1.3. Physiology 
The primary role of the colon is to process the undigested chyme into more solid and bulky faeces 
before it enters the rectum ready for infrequent excretion. This is achieved by absorbing most of the 
water across the mucosa. Following the active absorption of sodium by enterocytes, water follows by 
obligatory osmosis, while potassium is secreted into the lumen. This predominantly occurs in the 
ascending and transverse colon. At the same time, viscous mucus is secreted to help the passage of stool. 
Meanwhile the descending colon, sigmoid and rectum are predominately used for storage. 
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Transit within the large bowel is relatively slow, taking several days instead of the several hours taken in 
the small bowel. Movement within the colon is achieved through three mechanisms; segmentation, 
peristalsis and mass movement. Segmentation traps colonic contents between contracted haustra and 
churns the contents to facilitate sodium and water absorption. Peristalsis causes waves of slow and 
regular contractions, transporting stool to the descending colon for storage. Mass movement occurs in 
the descending colon and sigmoid, where strong peristaltic waves force a large mass of stool into the 
rectum. These contractions occur several times a day, normally after meals. Distention of the rectum 
activates defecation via the defecation reflex, which causes the simultaneous contraction of the sigmoid 
and rectum and relaxation of the anal sphincters. In adults the defecation reflex can be inhibited 
voluntarily.  
Colonic motility and the defecation reflex are controlled by the myenteric (Auerbach) plexus, which is 
part of the enteric nervous system, and extrinsic parasympathetic innervation. The upper large intestine 
is controlled by the vagus nerve and lower colon, rectum and anus by sacral nerves. Segmentation and 
peristalsis are predominantly controlled by the myenteric plexus (but also affected by parasympathetic 
drive), while mass movements, although initiated by the myenteric plexus, receive input from the 
central and parasympathetic nervous systems to regulate rate and intensity.  
1.1.4. Gut flora 
Gut flora are the microorganisms (microbiota) that live in the intestinal tract. There are an estimated 10 
trillion organisms in the large bowel, 10 times the number of human cells(13,14). Within the large 
bowel most of the flora is bacterial, with up to 1,000 different species present and bacteria and their 
products accounting for 60% of the dry weight of faeces. It is clear that flora is not merely commensal 
but actively involved in a diverse range of processes including: adapting the immune system and 
excluding pathogenic bacteria; creating vitamins and hormones and fermenting energy substrates. 
Furthermore, the intestinal microbiota is intrinsically linked with overall health and the in particular 
with the risk of developing CRC(15). There is still much to learn about the host microbiota interaction, 
including how CRC risk can potentially be modified by alterations in dietary components and eating 
behaviors(16).  
1.2. Colorectal cancer 
Colorectal cancer refers to a cancer originating in the large intestine, including the colon and rectum, 
but excluding those derived from the anus. Cancers of the colon and rectum are considered a single 
disease, with the rectum defined as the 15 cm closest to the anal margin. Importantly CRCs do not 
include adenomas, where the basement membrane and muscularis mucosae are intact. However, most 
cancers develop at the mucosa from adenomas, through the acquisition of genetic changes. Beneath the 
mucosa lie the submucosa, muscularis propria and the serosa. The submucosa contains blood and 
lymphatic vessels and so once breached by a cancer can lead to distant spread.  
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1.2.1. Pathological sub-types of colorectal cancer 
Table 1.1 shows the classification of CRCs as proposed by the World Health Organization(17). 
Approximately 95% of CRCs are adenocarcinomas deriving from the glandular epithelium. The 
majority of adenocarcinomas are mucinous (meaning the cells secrete mucus and are surrounded by a 
pool of mucus), while a small proportion (2%) are Signet-Ring adenocarcinomas, where the mucus is 
trapped within the cells. Other histological types account for an estimated 2% to 5% of CRCs and are 
shown in Table 1.2 (18). The prognostic impact of the histological subtype is not fully understood, but is 
not considered a major factor. Instead the tumour grade has greater prognostic implications. In the case 
of adenocarcinomas this is based on the proportion of the tumour that is gland forming. The higher the 
percentage of gland formation, the more differentiated the tumour and better the prognosis, even when 
adjusted for stage(19). 
 
Table 1.1. The WHO classification of CRCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adenocarcinoma 
Medullary carcinoma 
Mucinous (colloid) adenocarcinoma (>50% mucinous) 
Signet-ring cell carcinoma (>50% signet-ring cells) 
Squamous cell (epidermoid) carcinoma 
Adenosquamous carcinoma 
Small-cell (oat cell) carcinoma 
Undifferentiated carcinoma 
Other (e.g., papillary carcinoma) 
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Table 1.2 A full description of colorectal tumour types. 
1.2.1.1. Sporadic and hereditary cancer 
CRC is a multifactorial disease, but causality can broadly be categorised as either sporadic or inherited. 
Sporadic cancers are the commonest type and occur when there is no family history of the disease. 
These cancers develop from the accumulation of mutations over a lifetime(20). By contrast, inherited 
cancer accounts for approximately 5%-10% of cases, and is caused by inherited high penetrance 
mutations and usually presents at an earlier age.  
The commonest type of hereditary cancer is the autosomal dominant Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC), which accounts for 2-5% of CRC cases, and can be divided into Lynch 
syndrome I (familial colon cancer) and Lynch syndrome II (HNPCC associated with cancers in other 
gastrointestinal sites and gynaecological cancers). In HNPCC, mutations are found in the mismatch 
repair genes, hMLH1 and hMSH2, which leads to microsatellite instability(21). The lifetime risk of 
colon cancer in HNPCC is 80%, with a mean age of 44 at diagnosis and two-thirds of cancers are found 
Epithelial tumours; 
Adenoma 
Tubular 
Villous 
Tubulovillous 
Serrated 
Intraepithelial neoplasia (dysplasia) associated with chronic inflammatory diseases 
   Low-grade glandular intraepithelial neoplasia 
   High-grade glandular intraepithelial neoplasia 
Carcinoma 
Adenocarcinoma 
Mucinous adenocarcinoma 
   Signet-ring cell carcinoma 
   Small cell carcinoma 
   Adenosquamous carcinoma 
   Medullary carcinoma 
   Undifferentiated carcinoma 
Carcinoid (well-differentiated neuroendocrine neoplasm) 
   Enterochromaffin (EC)-cell, serotonin-producing neoplasm. 
L-cell, glucagon-like peptide and pancreatic polypeptide/peptide YY (PYY)-
producing tumour 
   Others 
Non-epithelial tumours; 
  Lipoma 
  Leiomyoma 
Gastrointestinal stromal tumor 
Leiomyosarcoma 
Angiosarcoma 
Kaposi sarcoma 
Melanoma 
Others 
Malignant lymphomas; 
Marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type 
Mantle cell lymphoma 
Diffuse large B-cell lymphoma 
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in the proximal colon.  
The second commonest hereditary form is Familial Adenomatous Polyposis Coli (FAP), an autosomal 
dominant syndrome, responsible for 1% of CRC cases. This leads to mutations in the tumour suppressor 
gene Adenomatous Polyposis Coli (APC). In FAP, hundreds of adenomatous polyps develop from 
puberty onwards, which inevitably develop into CRC. Variants of FAP include Turcot and Gardner 
syndromes. Other rare autosomal dominant disorders causing CRC include; Juvenile Polyposis 
syndrome, Cowden syndrome, MUTYH-associated Polyposis (MYH) and Peutz-Jeghers syndrome. In 
addition to these distinct syndromes, independent familial cancer predispositions also exist. 
1.2.1.2. Polyp–carcinoma sequence 
The pathogenesis of adenocarcinoma was described by Fearon and Vogelstein in 1990(22). It describes 
carcinogenesis as a multistep process from adenomatous polyp to carcinoma, which is characterised by 
DNA instability. Mutations in the APC gene (as seen in FAP) are also found in the majority of sporadic 
cancers and cause the activation of oncogenes including c-myc and cyclin D1, which leads to the 
development of the malignant phenotype(23). Further mutations include, abnormal DNA methylation, 
which either activates other oncogenes or disrupts tumor suppressor genes. This accumulation of 
mutations can eventually lead to malignant transformation.  
Polyps initially form as simple aggregations of epithelial cells caused by the proliferation of crypt cells 
that then fail to differentiate and trigger the changes described above. Over time these adenomas grow 
and develop increasing dysplasia with the composition changing from tubular to villous components. 
Malignant transformation occurs when local invasion develops. However the majority of polyps do not 
develop into carcinomas and not all adenocarcinomas develop via this sequence. Recently, alternate 
pathways have been described, including the sessile serrated adenoma (SSA) pathway(20). SSAs are 
similar in morphology to hyperplastic polyps, which are serrated but non-dysplastic and mostly 
innocuous. However SSAs do have malignant potential via mutations in the BRAF and KRAS oncogenes 
and may account for up to 20% of sporadic CRCs(24,25). These cancers are predominantly right-sided 
colon lesions and predominantly affect middle-aged women(26). 
1.2.2. Epidemiology of colorectal cancer 
1.2.2.1. Incidence and prevalence 
In 2008, the Office of National Statistics (ONS) found the annual incidence of CRC was 33,604 in 
England and 40,695 in the whole of the UK (2). In the UK, 13% of all new cancers are colorectal, 
making it the third most common cancer after breast (n=49,961) and lung cancer (n=42,026), Figure 
1.2. Among male patients, prostate cancer is the most common, while there are roughly equal numbers 
of lung cancer cases and CRC. In females, breast is by far the most common cancer with similar 
numbers of lung and CRC cases. ONS data shows there has been a 3% increase in CRC between 1999-
 34	
2001 and 2008-2010, Figure 1.3. In 2006, there were an estimated 143,500 prevalent cases in the 
UK(27). 
 
 
Figure 1.2 The 20 most commonly diagnosed cancers in the United Kingdom in 2010 (excluding non-
melanoma skin cancer)(28). 
 
 
Figure 1.3 CRC incidence rates have marginally increased in United Kingdom since the mid-1990s(28). 
 
1.2.2.2. Age 
CRC risk increases markedly with age and 84% of cases occur in patents aged 60 years and over(2). 
Incidence begins to rise noticeably over 50 years of age and peaks in patients over 80 years, Figure 1.4. 
There is a higher incidence in male patients at all ages but this is widest between 65-74 years and 
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thereafter the gap falls modestly. At younger ages, there are more male than female patients, but over 
80 years this reverses in accordance with higher overall survival rates among females. 
 
Figure 1.4 The average number of new CRC cases per year and age-specific incidence rates per 100,000 
population in the UK in 2007 (for colorectal and anal cancer). Chart taken directly from Cancer 
Research UK (28).  
1.2.2.3. Gender 
Gender influences on cancer risk, with a higher incidence in men (69 per 100,000 cases a year) 
compared to women (46 per 100,00 cases a year) (29). In England from 1999-2006 there were 186,977 
CRCs diagnosed. Of these, 102,772 (55.0%) were male patients and 84,205 (45.0%) females(30).  
1.2.2.4. Site 
There are two common sets of terminology used to describe cancer site distribution. The first uses a 
proximal (up to and including the splenic flexure) and distal division. The second splits the large bowel 
into three sites; colonic, rectosigmoid and rectal. In the UK around 60% of CRCs are distal (and 40% 
proximal), while using the alternative division of sites finds that 64.4% are colonic, 7.4% are at the 
rectosigmoid and 28.2% are rectal(2).  
There are marked gender differences in the site distribution of CRC, with more rectal cancers seen in 
male patients and more proximal colon cancers seen among females(31). Among females, 42% of all 
CRCs are proximal, compared to only 31% in males(32). The reason for this difference is unknown but 
may be due to different levels of exposure to risk factors and their response to them. This difference has 
a major impact on the diagnostic strategies used and the effectiveness of screening programmes, across 
the UK. 
It has been suggested that, over the last few decades, there has been a shift towards more proximal 
cancers (33). However recently it has been demonstrated that this is not a true shift but rather a 
reflection of effective prevention of distal cancers through screening and an increasing aged population, 
where proximal cancer is more common(34).  
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1.2.2.5. Deprivation  
There is a paucity of readily comparable date to study the impact of deprivation on CRC rates. The 
latest available ONS data for England covers the period 2000-2004 and reports no statistically significant 
differences in rates dependent on deprivation. However, one study found men in the most deprived 
areas had a 11% higher age-stratified risk of CRC compared to the least deprived areas (35). Another 
study from England during a similar time period (1996-2004), found no clear relationship between the 
frequency of CRCs and deprivation levels, even when separately analysing for site and gender(30). 
1.2.2.6. Co-morbidity 
Apart from the disease-specific risk described above, co-morbidities do not appear to affect the 
incidence of CRC(36). Co-morbidity does, however, have a significant impact on survival and this is 
discussed below.  
1.2.2.7. Ethnicity  
There are difficulties in identifying ethnic minorities correctly in the UK cancer databases which makes 
it hard to accurately identify rates and outcomes (37). The main ethnic minorities in the UK are 
catergorised as African, Caribbean or South East Asian. Earlier studies have shown CRC incidence and 
survival to be lower in ethnic minority groups. However, some evidence suggests that incidence is 
increasing in these groups towards that of the Caucasian population. This maybe a consequence of 
adopting a more western lifestyle(38,39).  
1.2.3. Risk factors for colorectal cancer 
A risk factor is defined as ‘an aspect of personal behaviour or lifestyle, an environmental exposure, or an 
inborn or inherited characteristic which on the basis of epidemiological evidence is known to be 
associated with health-related condition(s) considered important to prevent.’(40).  
1.2.3.1. Genetic factors 
In addition to the hereditary cancers syndromes described above, certain ethnic groups have a greater 
risk of CRC. In particular, Ashkenazi Jews have a much greater lifetime risk of between 9-15%(41). 
1.2.3.2. Environmental factors 
Acquired environmental factors are very important and modulate the risk of the genetic mutations, 
which can ultimately lead to cancer. There are large variations in age standardised incidence rates across 
the world, with a 15-fold difference seen between the highest and lowest risk populations(42). Risk is 
highest in developed countries, especially in the USA and Europe, although incidence rates seem to have 
stabilised. Incidence rates are now increasing in the developing world, driven by the adoption of 
western lifestyles(43). Specific risk factors include; reduced physical activity(44), a diet low in fibre, 
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fruit and vegetables and high in red meat(45), and specific risk factors such as alcohol consumption and 
cigarette smoking (46). 
 
1.2.3.3. Other disease risk factors 
1.2.3.3.1. Inflammatory Bowel Disease (IBD) 
IBD predisposes patients to CRC, although the risk is difficult to quantify. IBD comprises of Ulcerative 
Colitis (UC), Crohn’s disease and Indeterminate Colitis. Early studies into UC overestimated the risk, 
by including patients with predominately severe disease, while later studies may have underestimated 
the risk by including patients with proctitis or following colectomy. Overall 2% of CRC cases have IBD 
and the cancer risk begins to increase 8 years after diagnosis. After 10 years of UC, the risk is 2%, at 20 
years 8% and after 30 years the risk is 18%(47). The crude annual incidence rates is between 0.06%-
0.16% and the relative risk is 1-2.75 that of the general population. Recently the cancer risk in UC 
patients has actually been falling, due to 5-aminosalicylic acid (5-ASA) maintenance therapy and possibly 
endoscopic surveillance(48).  
Patients with longstanding Crohn's colitis as opposed to those with small bowel involvement only, are 
thought to have a similar cancer risk as UC patients(49). CRC in IBD follows a sequence from no 
dysplasia, through to indefinite dysplasia, low-grade and high-grade dysplasia and finally carcinoma. This 
is driven by inflammation, with the risk of CRC directly linked to the severity of inflammation(50). 
1.2.3.3.2. Previous adenomatous polyp 
Most adenocarcinomas are derived from adenomatous polyps, which become more common with 
advancing age(51). Between the ages of 50-54 years, an average risk individual has an 11% risk of having 
an adenoma. This increases to 33-50% in individuals aged 65-75 years(52,53). Despite this the majority 
of polyps do not result in cancer. The risk of progression to cancer depends on the number of adenomas 
found, the size and histological components. The strongest predictor of adenoma recurrence (and 
subsequent cancer) is the number of adenomas detected at the index colonoscopy. When three or more 
adenomas are detected, the risk of recurrent adenomas at three-year follow-up is 6%, compared to only 
3% in patients with one or two(54). Size is also relevant and patients with a polyp over 1 cm have a 
significantly higher chance of recurrent adenoma at three-year follow-up(55). Finally adenomas with 
tubulovillous or villous features or high-grade dysplasia are associated with the development of further 
advanced adenomas during follow-up(56,57).   
It has been clearly demonstrated that removing polyps reduces the risk of CRC (58,59). A study 
following 1,418 patients for a mean of 5.9 years following polypectomy for one or more adenomas, 
found the CRC incidence was 76%-90% lower than expected. However despite polypectomy these 
patients are at a greater risk of both adenoma recurrence and CRC than the general population and may 
need ongoing colonoscopy surveillance.  
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1.2.3.3.3. Previous CRC 
Patients diagnosed with CRC are at increased risk of having another lesion at the time of diagnosis 
(synchronous lesions) and subsequently (metachronous lesions). Synchronous carcinomas are defined as 
two or more lesions, detected either before surgery, intra-operatively, or within 6 months following 
surgery. By definition, these lesions should be separated by 4 cm of normal bowel and not represent 
submucosal spread or a satellite lesion. Metachronous lesions are diagnosed 6 months after the primary 
lesion, and away from the site of the original lesion, thus not representing recurrence of the primary 
lesion(60).  
Synchronous carcinomas are detected in 2% of cases, which supports the practice of perioperative 
colonoscopy assessment(61). The cumulative risk of metachronous carcinomas was 2% among 5-year 
survivors and 7% among 20-year survivors and therefore justifies the long-term follow-up of CRC 
patients(62). 
1.2.3.3.4. Other diseases and operations  
Patients with diabetes and acromegaly are at increased risk of CRC(63,64), as are those who have 
received an organ transplant (65,66).  
1.2.4. Clinical presentation of colorectal cancer  
The majority of CRC patients are diagnosed electively after presenting with symptoms to their primary 
care doctor. The commonest presentations are rectal bleeding, a change in bowel habit or symptoms of 
anaemia(6). These patients are then referred on to secondary hospital care for investigations. A second 
group will present as an emergency directly to secondary care. This is commonly because of significant 
constitutional symptoms, a large rectal bleed or with symptoms related to bowel obstruction or 
perforation, Table 1.3. Internationally, rates of emergency presentation range from 3-34%(67-71). The 
UK has a high rate at around 30%(69,72). The reasons for this are explored later in the chapter and 
forms the basis of my thesis. 
A small group of patients will be diagnosed during a surveillance programme for conditions such as IBD 
or following a history of colorectal neoplasia. Some cancers may be identified during bowel cancer 
screening programmes. In the UK, currently 3% of patients are diagnosed through the NHS-
implemented national Bowel Cancer Screening Programme (BCSP)(73), Figure 1.5. A similar 
proportion of patients are diagnosed through national screening programmes in countries with 
comparable health systems(74).  
1.2.4.1. Signs and symptoms   
Patients commonly present with rectal bleeding, a change in bowel habit, anaemia or constitutional 
symptoms depending on the cancer site and whether metastases are present, Table 1.3. Distal cancers 
more commonly present with overt rectal bleeding and symptoms caused by luminal obstruction. 
Symptoms of proximal cancer are often absent or vague until the cancer is advanced and the diagnosis is 
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often made following the identification of anaemia. As CRC is common and curable if detected early, 
any patient especially over 40 years of age should be thoroughly investigated if their symptoms suggest 
CRC. See Table 1.4 for a full description of which patients should be urgently referred according to UK 
guidelines.  
Rectal bleeding is an important symptom, but is also non-specific. Most patients with new onset rectal 
bleeding will initially attend primary care (75). The overall risk of CRC in isolated rectal bleeding is 
between 1.0% and 2.4% (76,77). Patients over 40 years with new or persistent rectal bleeding should 
be investigated. The positive predictive value of rectal bleeding representing CRC is less than 1 in 1000 
in the community setting, 1 in 50 in primary care and 1 in 3 in patients referred to secondary care (78). 
This shows how patients themselves and then general practitioners act as gatekeepers to secondary care. 
In patients with rectal bleeding, the presence or absence of other symptoms will alter the probability of 
a cancer diagnosis, but no additional factor will shift the probability in such a way to refute the need to 
investigate further(79). 
Bleeding from proximal cancers is less likely to be noticed by the patient, as degradation of the blood 
and mixing in the stool often makes this unnoticeable (occult). Instead proximal cancers more 
commonly present with symptoms caused by the ensuing anaemia or following blood tests(80). The 
positive predictive value of anaemia is between 2.3% and 7.4%(81,82). Anaemia tends to be more 
insidious as a presenting symptom, compared with rectal bleeding, and is associated with a lower overall 
survival(83). Other symptoms such as weight loss, abdominal pain, diarrhoea and constipation all have a 
lower predictive value, however the presence of multiple symptoms is associated with an increased 
probability of CRC and therefore should be investigated(82).  
Luminal obstruction from cancer encroachment leads to symptoms such as a change in bowel habit 
(predominantly constipation, although partial obstruction can cause diarrhoea), abdominal pain, 
distention and nausea and vomiting. It is more common in the distal colon, which is narrower and at this 
point the stool is harder due to water reabsorption in the proximal bowel. Once cancers become 
advanced, more generalised cachexia symptoms such as anorexia, weight loss and weakness become 
apparent.  
Apart from anaemia, the signs that should alert the clinician to CRC include an abdominal or rectal mass 
and their presence increases the probability of a diagnosis of CRC. Specifically, one study found over a 
third of patients with CRC had a palpable mass on rectal examination(84).  
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Table 1.3 Common presenting features of CRC 
Abdominal pain, including symptoms of bowel obstruction  
Change in bowel habit  
Rectal bleeding or melaena stool  
Abdominal mass  
Iron deficiency anaemia 
 
1.2.4.2. Referral pathways to diagnosis  
As illustrated above there are four pathways to diagnosis; a) an elective admission following a primary 
care referral, b) an emergency hospital presentation, c) bowel cancer screening and d) routine 
endoscopic surveillance, Figure 1.5. Currently in the UK, most patients present electively through 
primary care or as an emergency directly to secondary care. Only a minority of cancer diagnoses are 
made by the BCSP or through surveillance programmes. 
Figure 1.5 shows how each of the referral pathways can be affected by delays differently. This time 
period is comprised of a combination of patient delay, primary care delay and secondary care delay. The 
patient delay occurs from time taken to decide to access primary care once symptoms appear, the 
primary care delay is the time a general practitioner takes to arrange referral and secondary care delay is 
made up of the time waiting for outpatient appointments and appropriate diagnostic investigations. 
Beyond the time to make the diagnosis, patients will face further delays while preoperative staging 
investigations are performed and then treatment (usually surgical) is arranged. 
The NHS BCSP selects patients with a greater risk of malignancy, because of the age cut-off used 
(currently screening 60-74 years). This programme relies on the sensitivity of the Faecal Occult Blood 
test (FOBt) to decide which patients are offered a colonoscopy, the gold standard test for diagnosing 
CRC. Patient uptake rates, and to a lesser extent colonoscopy quality, also affect the effectiveness of the 
BCSP. The effectiveness of endoscopic surveillance is based on identifying high risk patients in the first 
place. This includes patients with a family history or previous CRC or IBD. Surveillance also relies on 
patient motivation, accurate colonoscopy and ensuring the correct follow-up is carried out.  
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Figure 1.5 The four possible diagnostic routes for any patient with CRC. The total delay for each of the 
four routes may include; patient, primary care or secondary care (system) delay. 
 
Between 5% and 20% of CRC patients present asymptomatically as a result of surveillance or screening 
(85-87). Screened patients are diagnosed with an earlier stage of cancer and as the volume of screening 
increases within a country, the rate of emergency presentation appears to fall(88). This will be discussed 
in more detail in chapter 4 (11,88). However, within the UK the majority of patients still present with 
symptoms to their GP or as an emergency directly to hospital. Earlier diagnosis of patients would likely 
reduce the number of emergency presentations and improve outcomes by diagnosing earlier stage 
disease and avoiding the high morbidity and mortality associated with subsequent emergency 
operations(85).  
As longer delays are associated with worse outcomes, resources could be used to target the causes of 
delays and reduce detrimental outcomes caused by cancers presenting at a late stage. To this end the 
‘National Awareness and Early Diagnosis Initiative’ (NAEDI) was created in the UK. The aim of which 
was to support activities which lead to the earlier diagnosis of cancer and so improve cancer survival 
rates. The NAEDI used routinely collected data to interrogate the pathways leading to the diagnosis, and 
linked relative survival at 12 months, for CRC in England between 2006 and 2008. The study found 
26% of CRC patients presented as an emergency, 67% through an elective route (including 2% as 
screen detected) and 7% were unknown. There was dramatically lower survival following diagnosis 
through the emergency route, with 12-month survival in only 50% of patients identified through the 
emergency route compared with 80-84% for elective routes and 98% in the screen detected group. 
Emergency routes were commoner with increasing age, accounting for 45% of diagnoses in the over 85 
years age group. Deprivation was also associated with emergency diagnoses, accounting for 32% of the 
most deprived quintile of patients compared to 22% of the least deprived. Of note, in 2006 there were 
0% screen detected cancers, increasing to 5% by 2008, due to the BCSP roll out. In total there were 
2,086 screen detected cancers over the 2-year period. This demonstrates the need to understand the 
causes of emergency presentation and poses the question that I address in my thesis and discuss in depth 
in chapter 4(89).  
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1.2.4.2.1. Elective presentation (primary care referral) 
Primary care has an important role in identifying patients who may have CRC and ensuring they are 
promptly referred for necessary investigations.  
The majority of patients with abdominal symptoms present to primary care(82). The difficulty for 
general practitioners is identifying those which warrant referral to exclude CRC from all the patients 
presenting with abdominal symptoms(90,91). This is set in the context of each general practitioner 
seeing only around one new CRC case a year(92). Guidelines have been developed to help identify 
which patients to refer; these are based on a mixture of evidence and expert agreement. They have an 
important goal in trying to reduce delays to diagnosis, which is associated with late presentation and 
poorer outcomes. Equally guidelines allow patients without cancer to avoid unnecessary investigations, 
which itself will help to control waiting times(93). Table 1.4 lists the clinical scenarios which should 
necessitate 2-week referral for suspected cancer. These patients are seen in secondary care by a CRC 
specialist within 2 weeks of presenting to their general practitioner. 
Guidelines are useful provided they reduce primary care delay, but not at the expense of secondary care 
delay. However a substantial minority of patients with CRC fall outside the guidelines for referral. This 
makes the case for general practitioners to use their clinical judgment and refer any other patients they 
consider may have cancer(94).  
 
Table 1.4 Referral Guidelines for Suspected Cancer. Department of Health(90). 
Refer urgently patients: 
• aged 40 years and older, reporting rectal bleeding with a change of bowel habit towards 
looser stools and/or increased stool frequency persisting 6 weeks or more 
• aged 60 years and older, with rectal bleeding persisting for 6 weeks or more without a change 
in bowel habit and without anal symptoms 
• aged 60 years and older, with a change in bowel habit to looser stools and/or more frequent 
stools persisting for 6 weeks or more without rectal bleeding 
• of any age with a right lower abdominal mass consistent with involvement of the large bowel 
• of any age with a palpable rectal mass (intraluminal and not pelvic; a pelvic mass outside the 
bowel would warrant an urgent referral to a urologist or gynaecologist) 
• who are men of any age with unexplained iron deficiency anaemia and a haemoglobin of 11 
g/100 ml or below 
• who are non-menstruating women with unexplained iron deficiency anaemia and a 
haemoglobin of 10 g/100 ml or below 
 
 
1.2.4.2.2.  Emergency presentation  
An emergency presentation occurs when the initial secondary care episode leading to the diagnosis of 
CRC was an emergency admission. An emergency admission is one made at short notice at the request 
of accident and emergency services, general practitioners, bed bureau, or consultant outpatient clinics. 
Patients presenting as an emergency with CRC are more often; older, female, from lower 
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socioeconomic groups and have more advanced disease(11,95-98). Emergency presentations are less 
likely to have surgical resection with curative intent. Surgical intervention following emergency 
presentation is associated with high morbidity (45–50%) and mortality (15–45%)(73,99). Many such 
patients had actually had symptoms for some weeks, and often months, before the presentation. Later in 
the thesis, I will explore the consequences of emergency presentation and strategies to avoid late 
presentation. 
1.2.5. Diagnosis of colorectal cancer 
To confidently confirm or refute the suspicion of CRC an investigation must adequately examine the 
entire colon and rectum. The options include colonoscopy, sigmoidoscopy, colon capsule, barium 
enema and Computerized Tomography Colonography (CTC), all of which require some form of bowel 
cleansing (preparation). All procedures have potential complications and miss rates and multiple 
procedures may be necessary. The ideal diagnostic strategy is not yet known. However the initial 
diagnosis is made, a full examination of the large bowel involving colonoscopy or CTC should always 
take place prior to surgery to identify the 5% of cases that have a synchronous lesion(61). 
1.2.5.1. Colonoscopy 
Colonoscopy has a high sensitivity and specificity and is the established gold standard investigation(100). 
It allows visualization of the whole of the large bowel, with the ability to biopsy any suspicious lesions 
and remove any adenomas by polypectomy. Furthermore it doesn’t expose the patient to any ionizing 
radiation. However some patients have co-morbidities that prevent colonoscopy from being performed 
or result in an inadequate examination, where the operator fails to reach the caecum. In the UK pre-
2005, inadequate examination was a common outcome with at least 23% of procedures being 
incomplete. Following a quality improvement programme this has improved recently, with caecal 
intubation rates of 96% recorded nationally in 2013(101,102). Failed examinations may occur due to: 
poor operator skill; patient’s intolerance of the procedure; inadequate bowel preparation or an 
obstruction to complete colonoscopy (such as a diverticular stricture). In such cases alternative 
investigations are required. Complications of colonoscopy include bleeding, perforation, readmission to 
hospital and, very rarely death(103,104).  
1.2.5.2. Barium enema 
Double contrast barium enema (DCBE) has long been used to diagnose CRC and, although safer than 
other examinations, it is less sensitive than both colonoscopy and CTC and should not be used 
routinely(100).  
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1.2.5.3. CT colonography (CTC) 
CTC is a relatively recent innovation and uses 2-D and 3-D image reconstruction techniques to view the 
abdomen and pelvis in cross-section. It requires laxative preparation and air or carbon dioxide 
insufflation.  
The sensitivity of CTC was thought to lie between that of DCBE and colonoscopy but this was based on 
the surrogate finding of polyps, as the prevalence of invasive cancer in individual trials was low(105). A 
recent meta-analysis has, however, shown equivalence between CTC and colonoscopy for the detection 
of invasive cancer, with overall sensitivity of 96.1% vs. 94.7%(106). A recent, pragmatic multi-centre 
randomised trial (the SIGGAR trial) compared the two techniques, and found similar sensitivities for the 
two tests. However patients initially referred for CTC required more additional investigations(107). 
Finally, CTC offers additional benefits over colonoscopy in being able to image structures outside the 
bowel lumen(108). CTC should be used when colonoscopy is unsuccessful or inappropriate. In frail and 
elderly patients that require colonic investigation but cannot tolerate full bowel preparation then 
minimal preparation CT colonography is an acceptable alternative(109).  
1.2.5.4. Sigmoidoscopy 
When sigmoidoscopy is used on its own, a negative test can effectively eliminate distal but not proximal 
cancer(110). Traditionally sigmoidoscopy has been used in combination with barium enema (which can 
image proximal CRC), however this approach is still less sensitive than colonoscopy. Compared to 
colonoscopy more cancers are missed overall(111,112). 
1.2.5.5. Colon capsule 
Specifically designed capsule endoscopy is a new and less invasive way of examining the large bowel. 
Currently there is not enough evidence to support its general use in diagnosing colon cancer(113). 
However in the future it may provide an accurate assessment of the large bowel and cancer risk, but 
without the ability to biopsy any suspicious lesions. 
1.2.5.6. Other tests 
Carcinoembryonic antigen (CEA) is a tumour marker that has no role in diagnosing CRC, but can be 
used in the follow-up of patients after surgery. If the CEA falls immediately after surgery, then 
monitoring levels can identify patients with early recurrence, which may be treatable. Recent advances 
in molecular technology have identified many putative biomarkers relevant to the diagnosis of CRC. 
Currently, most are in the discovery phase and few have undergone clinical evaluation. Therefore at 
present biomarkers are not part of the diagnostic algorithm(114).  
1.2.6. Colorectal cancer staging 
Tumour staging is the most important prognostic predictor of clinical outcome for patients with 
colorectal carcinoma. This requires the assessment of local spread and detection of the presence or 
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absence of distant metastases. The original staging system was developed by Cuthbert Duke in 
1932(115), Table 1.5. A cancer limited to the submucosa is defined as a Dukes A stage and by definition 
has no lymph node or distant metastases and has excellent prognosis. Further progression into and 
through the muscular layers is defined as Dukes B, while Dukes C defines cancer that has spread to 
regional lymph nodes with a corresponding worse prognosis. Despite being revised over the years, this 
classification’s prognostic accuracy suffers from not assessing the extent of lymph node involvement or 
tumor grade. The Tumour, Nodes and Metastases (TNM) classification was introduced to address these 
weaknesses and provide greater accuracy and standardisation. The TNM staging can be used to estimate 
prognosis, Table 1.6. The T-stage describes the depth of tumour infiltration into the bowel wall, the N-
stage the extent of regional lymph nodes involvement and the M-stage the presence of distant metastases 
or residual tumour following treatment. In Table 1.7, a comparison is made between the two staging 
systems as well as showing the relative percentage of cases in each stage and their 5-year relative 
survival. 
 
Table 1.5 Description of the Dukes stage classification(116). 
Dukes Stage Description of CRC spread 
Stage A: Limited to mucosa 
Stage B1:  Extending into muscularis propria but not penetrating through it; nodes not involved 
Stage B2:  Penetrating through muscularis propria; nodes not involved 
Stage C1:  Extending into muscularis propria but not penetrating through it. Nodes involved 
Stage C2:  Penetrating through muscularis propria. Nodes involved 
Stage D:  Distant metastatic spread 
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Table 1.6 TNM classification (version 5, 1997) with sub-classifications. 
TNM Stage Extension to 
Tis N0 M0 0 Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 N0 M0 I Submucosa 
T2 N0 M0 I Muscularis propria 
T3 N0 M0 IIA Subserosa/perirectal tissue 
 Sub-staging  
           T3a <1 mm 
           T3b 1–5 mm 
           T3c 5–15 mm 
           T3d 15+ mm 
T4 N0 M0 IIB Perforation into visceral peritoneum (b) or invasion to other 
organs (a) 
T1–2 N1 M0 IIIA 1–3 regional nodes involved 
T3–4 N1 M0 IIIB 1–3 regional nodes involved 
T1–4 N2 M0 IIIC ≥4 regional nodes involved 
T1–4 N2 M1 IV Distant metastases 
 
Table 1.7 A comparison of the Dukes and TNM staging classifications, showing the proportion of cases 
with each stage disease and their 5-year survival. The table is UK data from the ONS between 1996 and 
2006(2) 
Dukes stage TNM stage % of cases* 5-year relative survival (%) 
A T1N0M0 or T2N0M0 13.2 93 
B T3N0M0 or T4N0M0 36.9 77 
C Any T, N1M0 or any T, N2 
M0  
35.9 48 
D Any T, any N, M1 14.0 7 
*excluding patients with an unknown stage  
1.2.6.1. Colonic cancer  
Staging is less important in colonic cancer compared to rectal cancer, as surgery is not usually stage 
dependent. Most patients will undergo the same operation whether for curative or palliative intent. The 
single most sensitive test for local spread or distant metastases is contrast-enhanced Computerized 
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Tomography (CT) of the chest, abdomen and pelvis. CT assesses for synchronous lesions, contiguous 
organ involvement and metastases. The ability of CT to identify locally stage disease was addressed in a 
recent meta-analysis, which showed a T staging sensitivity of 77%, N staging sensitivity of 76% and M 
staging sensitivity of 85%(117). CT is particularly good for identifying invasion beyond the muscularis 
propria (stage T3+), with a sensitivity of 86%(118). If the CT demonstrates an indeterminate lesion in 
the liver, then an MRI is more sensitive than contrast-enhanced US to further characterise the lesion. 
This is especially important if a metastectomy (removing the metastasis) is being considered(119).  
1.2.6.2. Rectal cancer  
Rectal cancer staging is more complex due to the high recurrence risk. The risk of disabling local pelvic 
recurrence needs to be assessed preoperatively. CT can help stage distal disease, while MRI is superior 
for staging the tumour (T), nodes (N) and circumferential resection margin (CRM). Endoscopic 
ultrasound is also used selectively to assess early stage tumours (T1-T2) and can be used to compliment 
MRI in establishing the tumour depth(120). 
The risk of local recurrence is dependent on the CRM, which can be predicted by careful staging before 
surgery. Staging is used to select patients for neoadjuvant chemotherapy and radiotherapy(121). When 
total mesorectal excision surgery is performed, the mesorectal fascia forms the plane of dissection and 
any tumour within 1mm of the potential circumferential resection margin makes local recurrence and 
poor survival more likely. Positron emission tomography-computed tomography (PET/CT) is based on 
identifying abnormal metabolic activity in the body. It has not yet established a role in diagnosing or 
staging CRC, but may occasionally be used to investigate recurrence, especially before 
metastectomy(122).  
1.2.7. Treatment options for colorectal cancer 
There are a number of different ways to describe CRC treatments, based on:  
-The aim of treatment: either to remove the cancer entirely (curative intent) or to palliate a 
patient to maximise the length and quality of a patient’s life. At the beginning of treatment it is 
often unclear which pathway the patient will follow.  
-The timing of treatment: either planned (elective) or required urgently due to pressing clinical 
need (emergency). Treatment performed as an emergency is usually associated with higher 
mortality and morbidity rates(72).  
-Treatment modalities: including surgery, the commonest and most effective therapy by far, 
endoscopic resection, chemotherapy and radiotherapy. Surgery can be a resection with 
anastomosis, involve a defunctioning stoma either as a fully open procedure or laparoscopically 
assisted. Early stage CRC can occasionally be successfully treated by endoscopic resection and 
with obstructing cancers palliated with a self-expanding metal stent (SEMS). For patients with 
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advanced cancer, chemotherapy and/or radiotherapy are also frequently used(6). 
1.2.7.1. Surgical resection 
The primary treatment modality for CRC is surgical resection. The aim is to resect the tumour with a 
wide local excision, including the removal of associated regional lymphatics and lymph nodes, while 
avoiding the creation of a stoma.  
Local recurrence usually occurs following a full thickness radial extension of the tumour. This means 
recurrence is more often seen in the peritoneum, omentum and surrounding organs, such as ovaries, 
bladder or spleen. For this reason, the surgeon will usually attempt en bloc resection, including the 
removal of all or part of any involved structures. On the other hand, proximal or distal mucosal spread 
is less common and recurrence at the site of anastomosis is rare.  
Surgery alone is used for Dukes A and B cancer. Once a tumour has spread to the lymph nodes (Dukes 
C), then chemotherapy is required to optimise outcomes. Adjuvant chemotherapy usually means 6 
months of treatment, using 5-fluorouracil (5-FU) and leucovorin following surgery. Patients with 
metastatic disease commonly receive palliative chemotherapy including 5-fluorouracil, leucovorin and 
ironotecan(123). 
Most surgery is performed via an exploratory laparotomy, although laparoscopic surgery is becoming 
more common. A meta-analysis of 33 randomised clinical trials showed there was no significant 
differences in survival, recurrence or complications between open and laparoscopic surgery(124). 
Guidance is available from the National Institute for Health and Care Excellence (NICE) and advice 
depends on the lesion’s suitability for resection, patient preference and the surgeons experience of each 
procedure(125). 
1.2.7.1.1. Colonic surgery 
Radical resection of a colonic tumour includes complete mesocolic excision with flush ligation of the 
colonic vessels; it is associated with reduced local recurrence and improved survival, especially in stage 
III cancers(126,127). 
 
The main types of surgical operation for colonic cancer are: 
  -Right hemicolectomy: for caecal and right colonic cancers. 
  -Extended right hemicolectomy: for cancers in the proximal or middle transverse colon. 
  -Transverse colectomy: for certain cancers in the transverse colon. 
  -Left hemicolectomy: for cancers at the splenic flexure and left colon. 
  -Sigmoid colectomy: for sigmoid cancers. 
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-Total abdominal colectomy with ileorectal anastomosis: for hereditary nonpolyposis colon 
cancer (HNPCC), attenuated familial adenomatous polyposis (FAP), metachronous cancers in 
separate colon segments, or acute malignant colon obstruction (sometimes). 
-Panprotcocolectomy: for FAP and UC with high grade dysplasia or carcinoma, Figure 1.6. 
 
 
Figure 1.6 A schematic representation of the major types of colonic resections. 
 
1.2.7.1.2. Rectal surgery 
The primary goal of rectal surgery is to entirely remove the cancer, as local recurrence is associated with 
a poor survival and quality of life. Secondary goals include restoration of bowel function with acceptable 
anal continence and the preservation of genitourinary functions. For cancers in the middle and lower 
thirds of the rectum, the surgical technique of total mesorectal excision (TME) reduces the risk of local 
recurrence and improves survival(128). This is because a clear circumferential resection margin is more 
reliably achieved. Efforts should be made to preserve the autonomic nerves in the pelvis to minimise 
bladder and sexual dysfunction, but not at the expense of tumour clearance. Cancers in the upper third 
of the rectum do not need total excision of the mesorectum, providing careful resection is 
performed(129).  
The main types of surgical operations for rectal cancer are: 
-Lower Anterior Resection (LAR); cancers of the proximal two thirds of the rectum, leaving 
the rectal sphincter intact. 
-Abdominoperineal Excision of the Rectum (APER); cancers of the distal third of the rectum. 
This involves the removal of the rectum, anus and part of the sigmoid colon, through incisions 
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in the abdomen and perineum. The end of the remaining sigmoid colon is brought out as a 
permanent stoma. 
The LAR operation is more successful than APER in preventing local recurrence due to the higher rate 
of clear circumferential resection margin achieved. Some low rectal tumours still require an APER or if 
an anterior resection is used, then a defunctioning stoma should be considered to reduce the risk of an 
anastomotic leak(130,131). 
1.2.7.1.3. Other procedures 
Metastatic CRC may still benefit from surgery to improve symptoms and overall quality of life. Options 
include a palliative resection and anastomosis or a simpler defunctioning ileostomy or colostomy. An 
alternative to surgery is to insert a Self Expanding Metal Stent (SEMS) which can be used to reestablish 
luminal patency and continence(132). There is also some evidence that carefully selected patients with 
isolated metastatic disease may benefit from hepatic and pulmonary resections(133).  
1.2.7.1.4. Surgical complications 
Complications can be divided into intraoperative and postoperative complications. Intraoperative 
complications include bleeding and bowel, ureteral and bladder injuries. The main postoperative 
complications include wound infection, anastomotic leakage, prolonged ileus and bleeding. Patients may 
also suffer from infective complications at other sites (e.g. pneumonia), decompensation of 
cardiovascular disease (e.g. heart failure) or thrombotic complications (e.g. deep vein thrombosis or 
pulmonary embolus)(134). 
1.2.7.2. Chemotherapy and radiotherapy 
Chemotherapy usually kills fast growing cells within the body, targeting malignant cells but also normal 
tissues such as skin, gut and bone marrow leading to the commonest side effects. Chemotherapy in CRC 
can be used as mono-therapy or in combination and delivered either orally or intravenously. 
Radiotherapy uses ionizing radiation to destroy malignant tissue and may act synergistically when 
combined with chemotherapy. 
Colonic cancer is predominately treated with chemotherapy. Rectal cancer is treated with a 
combination of chemotherapy and radiotherapy. However the treatment decision is complex, needing a 
Multi-Disciplinary team (MDT) to discuss the balance between the benefits of treatment and the 
likelihood and severity of side effects. The use of preoperative magnetic resonance imaging (MRI) 
staging to risk-stratify patients helps the assessment process. When there is mesorectal fascia 
involvement the combined use of chemotherapy and radiotherapy can usefully downstage tumours.  
Below is a simplified stratification of the use of chemotherapy dependent on the stage of CRC; 
-Stage I: chemotherapy in not required. 
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-Stage II: this covers T2-T4 tumours with no nodal or metastatic disease. Adjuvant 
chemotherapy may be worthwhile in patients with greater tumour burden (e.g. T4), that are 
otherwise free from co-morbidities which would make them less tolerant of chemotherapy and 
its attendant side effects(135).  
-Stage III: all patients should be considered for adjuvant chemotherapy as survival is 
improved(136). 
-Stage IV: when metastases are confined to the liver, long-term survival is possible if resection 
is undertaken along with perioperative chemotherapy. Average 5-year survival after resection is 
40%(123). In patients with metastatic disease not restricted to the liver or where liver 
resection is not appropriate, then the standard of care is systemic chemotherapy which 
significantly improves survival(137). 5-FU with the addition of either leucovorin or oxaliplatin 
and possibly irinotecan plus bevacizumab is the current standard of therapy in patients with a 
good performance status(138).  
1.2.7.3. Palliative treatment 
Patients with advanced disease will frequently experience multiple symptoms. These commonly include 
pain, fatigue and emotional distress, with the number and severity of symptoms increasing as the cancer 
advances. Treatments include analgesics, anti-emetics and anti-secretory drugs as well as nasogastric 
suction and parenteral nutrition in patients with obstruction. There is also a need to provide 
psychological and social support to patients and their families, with evidence suggesting palliative care 
services improve quality of life(139). 
1.2.8. Prognosis in the UK and other counties with comparable health systems  
Survival is the primary outcome measure for how a healthcare system manages its patients with cancer. 
Survival is strongly linked to the stage of disease at diagnosis and treatment thereafter(27). In the UK, 
the current 5-year relative survival rate for CRC is 51%. In patients with Dukes A cancer, survival is 
93%, compared to 7% with Dukes D. At present only 13% of patients in the UK are diagnosed with 
Dukes A and any intervention that could increase this proportion should greatly reduce preventable 
deaths and improve national cancer outcomes(140).  
Currently survival rates vary considerably across Europe, including between the UK’s 5-year survival 
rate and the European average of 57%. Countries of comparable wealth such as Germany (62.2%), 
Austria (61.2%) and France (59.7%) all have markedly better survival that the UK (51%). It is 
estimated that if the UK could match the best results in Europe, then around 1,700 deaths per year 
would be avoided(7).  
The first comparative data studies on cancer survival in countries with similar health systems and wealth 
began in the mid-1990s. The relative survival for CRC was approximately 10% lower in the UK at both 
1 and 5 years(141). These results were used to create the political imperative to develop the NHS 
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Cancer Plan for England (2000) that focused on improving cancer services and in particular raising the 
5-year survival to the levels of the best-performing countries in Europe by 2010. The plan emphasized 
the need to act quickly when symptoms and signs of potential cancer were identified and to improve 
screening and treatment options. 
Over the next seven years until 2007 relative survival increased in the UK, especially after the full 
implementation of the plan in 2006-2007(142). Despite this, because improvements in other countries 
kept pace, the survival gap between UK and other countries remained at 10% by 2007, Figure 1.7(27). 
The finding that the survival difference is the same at 1 and 5 years is important, as it shows most of the 
difference arises soon after diagnosis.  
In the UK patients on average present later, with later stage disease, than in Europe. The reasons for this 
may include: failure to diagnose cancer before symptoms occur (due to inadequate screening and 
surveillance programmes); lower public awareness of cancer symptoms and diagnostic delay. All of 
these potential weaknesses will be explored later in this thesis. Poorer survival may also be caused by 
differences in overall health variables between countries including obesity and physical activity rates, 
population co-morbidity, deprivation and suboptimal treatments(143). 
 
 
Figure 1.7 Age-standardised relative survival for CRC in countries with similar health systems and 
wealth, to the UK(27). 
 
1.2.9. Reasons for poorer survival in the UK; late diagnosis 
Poor CRC survival in a population is caused by late diagnosis and inferior treatment. Identifying which 
factor is more significant may be determined by assessing if survival improves more in; 
a) the total series of cases (due to earlier diagnosis)  
b) stage specific analyses (due to better treatments)  
Interestingly, survival between the UK and the best performing countries are comparable once stage had 
been accounted for. This suggests that the main reason for the low survival in the UK is late diagnosis 
and not inferior treatment(143).  
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In the remainder of this chapter, I will outline evidence to support this late diagnosis theory. I will then 
show how UK outcomes (including earlier presentation) have improved over time, but not narrowed 
the survival gap with other countries. Lastly, I will discuss how variation in outcomes within the UK 
itself, may explain some of the challenges with the national results. 
Deaths within one-year of a diagnosis are usually from patients with late stage disease. Thus relative 
survival rates at one-year is a useful indicator of the proportion of early and late cancer diagnoses. 
Compared to other countries, many more UK deaths occur in the early post diagnosis period(9). In fact 
almost all the excess mortality in the UK is accounted for by early (one-year) mortality. In colon cancer, 
the majority of the UK excess mortality (the difference between UK and European mortality) occurs in 
the first 3 months after diagnosis(140). Emergency presentation, which is associated with a high early 
death rate and low rates of elective surgery, is also more common in the UK (7). 
In England access to better treatments and earlier diagnoses have improved over time. Between 1971 
and 1975 the one-year survival rate was 39% for men and 40% for women. This has risen to 73% for 
men and 72% for women between 2005 and 2009. This implies that along with improvements in 
surgery and chemotherapy, there has also been a reduction in the rate of late presenting cancers(2,144).  
Variations in practice are present at all levels within the NHS; between different GP practices, primary 
care trusts, hospitals and region of the country. This has been shown in every annual Care Quality 
Commission (CQC) report so far and in the NHS Atlas of Variation in Healthcare(145,146). These 
differences affect many aspects of healthcare provision from referral rates from primary care through to 
the type and volume of surgery in a given area(147,148). This is illustrated most dramatically in 
variations in survival across the UK, with areas of the north-east of England and east London having 5-
year survival of less than 25%(2). These variations hold even when adjusting for other risk factors such 
as deprivation(149). Another marker of quality is the permanent stoma rate for rectal cancer. The 
national average was at least 34%, but there was a wide variation between cancer networks ranging 
from 3% to 51%(150). These findings imply there is variation in the provision and quality of services 
across the country. Other known confounding factors affecting survival include age, gender, co-
morbidity, deprivation, cancer site and mode of presentation (Emergency or Elective) and are discussed 
elsewhere in the thesis in more detail in sections 2.5.3 and 3.5.6.  
Late presentation and variation in healthcare delivery across England appear to explain some of the 
poorer outcomes compared to other countries. In the next two sections, I will list some of the reasons 
for late presentation and then explore strategies that may reduce delays in presentation. 
1.2.10. The causes of late presentation in the UK 
Late presentation leads to increased emergency presentations, higher costs and poorer survival. The 
reasons for late presentation are complex and multifactorial with limited data currently available.   
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Many studies have looked at whether patient or doctor delay causes late presentation. To date no clear 
conclusion has emerged(151,152). Certain factors are however associated with patient delay, and these 
include; a failure to recognise the seriousness of symptoms(153), denial about the potential cause of the 
symptoms(154), a lack of knowledge about CRC itself or how screening can benefit patients(155,156) 
and those patients who self-medicated their symptoms(153). Finally, patients who recognised symptoms 
but did not deem them important were also more likely to delay their presentation to primary 
care(157). Studies have identified several reasons why primary care doctors delay the referral of a 
patient with underlying CRC; the most obvious reason being attributing the symptoms to benign 
conditions, i.e. misdiagnosis of the cancer(158,159). Linked to this is a failure of the practitioner to 
carry out a full examination of the patient(160). One study found that many patients subsequently 
diagnosed with CRC believed that their GP had delayed their referral by acting as an over-influential 
gatekeeper(161). Reassurance from falsely negative investigations was also a factor linked to delayed 
referral and this is especially important for patients with suboptimal investigations, such as barium 
enema and flexible sigmoidoscopies(162). 
Some authors believe reduced awareness of CRC symptoms in the UK population affects 
outcomes(163). Others believe that reducing the time delay between the onset of symptoms and the 
beginning treatment improves survival(164). However studies so far have failed to show any association 
between the overall duration of symptoms and the stage of the tumour or outcomes(165-167).  
In an era of robust referral guidelines for GPs and rapid access to secondary care clinics, there is 
evolving evidence that patients with delays between referral and diagnosis may paradoxically have a 
trend toward less aggressive tumours and better subsequent long-term survival. The use of these same 
guidelines and rapid access clinics appear to have only a minimal effect on aggressive cancers (168). The 
reason for this paradox is likely to be in the biological nature of different CRCs. Aggressive tumours 
with poor outcomes will present quickly, while slow growing tumours may be diagnosed after a longer 
duration of symptoms and still have better outcomes(85). This suggests cancers do not move to more 
advanced stage (TNM or Dukes) during the symptomatic phase. This makes sense when we recall that 
the adenoma to cancer development may take from 5-15 years and the symptomatic phase is typically 
very late in the natural history, presenting in the last few months(169). Thus the assumption that the 
symptomatic phase of cancer is sufficiently long that earlier referral (e.g. through rapid access clinics) 
leads to mortality improvements may be implausible(170).  
At present there are no studies to show that reducing symptom delay actually improves outcomes; 
possibly due to the fact that the symptomatic phase is late in the disease process or because the studies 
were too small to show a difference. This suggests that further speeding up referral from primary care 
and/or access to secondary care is unlikely to lead to significant improvement in outcome. Instead 
delays appear to be due patients not seeking healthcare early in the course of their symptoms, GPs not 
referring these early vague symptoms and healthcare professionals not identifying enough high risk 
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patients either through screening programmes or enrolling at risk patient such as those with a family 
history into surveillance programmes.  
It may be that in order to reduce late presentations a dual approach is required. Firstly, to diagnose 
more patients before symptoms occur and secondly to ensure patients present as soon as symptoms to 
appear. This idea is explored in more detail in the thesis justification section below. In the next section 
1.2.11, I discuss some of the strategies for improving survival. 
1.2.11. Strategies to improve CRC survival in England 
Few CRC patients are currently diagnosed asymptomatically and in the majority that present with 
symptoms, the CRC is often advanced (89). Earlier in this chapter, in sections 1.2.2 and 1.2.3, I 
presented some of the known associations between patient characteristics and survival. Many of these 
factors cannot be changed and so to see improvements in outcomes then modifiable factors need to be 
identified and targeted for interventions. These include improving the health-seeking behaviour of 
patients with symptoms, the speed of referral of suitable patients from GPs, the uptake of the BCSP and 
the diagnostic and treatment capabilities in secondary care(6). 
Currently too many UK patients are diagnosed late(89). Delay can be reduced by: improving awareness 
of symptoms and reducing barriers to accessing services; encouraging GPs to refer patients for 
diagnostic tests when they have symptoms possibly linked to CRC (sometimes called opportunistic 
screening); increasing diagnostic availability (most importantly access to colonoscopy) and involving 
appropriate patients in national screening and surveillance programmes. 
Finally, BCSP and other surveillance programmes have a role in identifying patients with pre-
symptomatic cancer and maximising population participation is very important in optimising 
outcomes(171). Identifying the impact of the BCSP on CRC and emergency presentations is important 
and in chapter 4, I will present the first national data looking at this.  
1.2.11.1. UK government initiatives; NHS Cancer Plan for England (2000) 
The NHS Cancer plan for England (2000) set out ways to reduce death rates and improve the prospects 
of survival based on improving prevention, promoting early detection, effective screening practice and 
guaranteeing high quality treatment and care throughout the country. It was particularly committed to 
addressing health inequalities by reducing waiting times and the establishing national standards for 
cancer services. There is evidence showing the plan has been at least partially successful, especially after 
the full role out in 2006, when one-year survival began to improve(27).  
1.2.11.2. Public awareness    
The goal of improving public awareness is two-fold; firstly to encourage individuals to visit their doctor 
if they have symptoms potentially attributable to CRC and secondly to take part in regular screening. 
These two positive public health messages may be linked. Currently, there is low awareness of the signs 
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and symptoms of CRC in the public and also widely held negative beliefs about cancer(172). These 
beliefs discourage early presentation and uptake of screening. If there are perceived or real barriers to 
accessing primary care then delayed presentations occur and patients are more often left to access 
healthcare as an emergency admission straight to secondary care.  
To improve the situation various forms of awareness campaigns have been studied. These range from 
simple leaflet distribution in GP surgeries and community centres, to postal campaigns right through to 
mass media including newspaper articles, billboard and television adverts. Any campaign needs to be 
aware of barriers to reaching certain populations, including those lacking English language skills or with 
literacy problems. Most studies to date have been small with minimal follow-up time and it is difficult to 
draw any firm conclusions. For example, one study from the UK found that after volunteers took the 
message about cancer awareness to pubs and community halls and the proportion of new cancer cases 
diagnosed through the urgent 2-week referral route increased significantly (from 43% to 51%). 
However there was no significant decrease in the stage of cancer at diagnosis(173). This is the pattern 
for many of the awareness campaigns to date; they seem able to demonstrate an increase in surrogate 
markers such as patient symptom awareness or 2-week referral rate, without conclusively showing an 
improvement in outcomes such as survival. The ‘UK bowel awareness campaign’ aimed to increase 
public awareness of CRC and prompt symptomatic individuals to seek medical attention. Two pilot sites 
in the South West and Yorkshire studied results after a seven-week campaign in 2011. The campaign 
message was:  
“If you have (1) A persistent change in normal bowel habit, such as going to the toilet more often and diarrhoea, 
especially if you are also bleeding from your back passage, or (2) Bleeding from the back passage without any reason, 
particularly over the age of 55, then it’s important to go and see your GP. The sooner you see your doctor to have it 
checked, the better.”  
The medium included regional TV, print media (regional/local press etc.), and inserts into regional 
editions of national press, online, regional/local radio, and shopping centres campaign. The results 
failed to demonstrate either an increase in CRC diagnoses, nor earlier stage or improved survival, 
despite a significant rise by 55–60% of 2-week referral(174). The only randomised controlled trial 
(RCT) on improving awareness comes from The Netherlands and involved distributing an information 
leaflet. The study reported an increase in patient knowledge and a change in their intentions but no 
survival advantage(175). 
1.2.11.3. Introduction of the 2-week referrals route 
In another attempt to tackle late diagnosis, NICE published a report entitled ‘Improving Outcomes in 
Colorectal Cancer’ in 2004. Its aim was to improve all aspects of CRC care from disease prevention to 
referral to secondary care management(6). Its recommendations included standardising referral 
guidelines, with the aim of increasing appropriate referral rates, and reducing waiting times for 
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diagnostic tests.  
One of the report’s suggestions was to introduce the “2-week referral” route, designed to reduce delays 
between presentation, diagnosis and treatment. The idea being that these fast-tracked patients would be 
been seen within 2 weeks of presentation by a secondary care specialist. If there was underlying CRC 
then the outcomes would be improved by earlier diagnosis and treatment and adverse outcomes such as 
emergency hospital admission avoided, Figure 1.8. However 2-week referrals still only diagnose 25-50% 
of CRCs and can lead to an increase in routine appointments(176,177). It has also been estimated that 
30% of CRC cases don’t meet current 2-week referral guidelines(177). This report coincided with an 
effort to increase national endoscopy capacity, to prevent increasing waiting times for endoscopy. This is 
particularly important given that a study from 2000 found over one-third of patients waited over three 
months from seeing their GPs with symptoms to their first hospital appointment(178). There is 
particular concern for delays in patients presenting to GPs with only anaemia, which can result in 
substantial delays(179). Overall the report recommended reducing the threshold to investigate patients 
with potential CRC. To accomplish this, GPs were encouraged to take up any opportunity for 
opportunistic screening and reduce any delay in the referral of patients to appropriate tests.  
 
 
Figure 1.8 This flowchart shows the route and potential delays for patients presenting with CRC.  
 
 58	
1.2.11.4. Referral rate and colonoscopy volume 
Most patients are diagnosed electively after presenting to their GP with symptoms of concern. Those 
patients with symptoms caused by partial intestinal obstruction or significant bleeding would 
immediately warrant referral for colonoscopy. However in other cases where the patient is minimally 
symptomatic, then they might only be referred for colonoscopy if their GP was a “colonoscopy 
enthusiast”. It might be argued that these GPs are taking part in informal optimistic screening. In a 
Canadian study, GPs with the highest discrepancy colonoscopy referral rate (referring patients beyond 
the strict interpretation of guidelines) had the lowest CRC incidence and mortality. Outcomes in the 
study improved incrementally from the lowest to highest referrers(180). 
In conclusion, while it seems credible that poor outcomes are linked to late diagnosis, it is less obvious 
what is behind the delay. In particular, whether the delay is a function of patient delay once symptoms 
are apparent or a delay in either primary or secondary care. This is because studies to date have not 
accounted for the impact of cancer aggressiveness on both the speed of presentation and survival. 
Secondly there is a lack of long term data on awareness campaigns aimed at improving patient 
presentation and GP attitudes towards optimistic referral. Further work is required into understanding 
how more pre-symptomatic and early symptomatic cancer patients can be referred for diagnostic tests at 
a cost that is sustainable by the NHS, Figure 1.9. I will explain in my justification for the thesis, section 
1.5, how my work attempts to address this knowledge gap.  
 
 
Figure 1.9 A model describing the reasons patients with CRC present late to hospital; including the 
hypothesised role of screening uptake. 
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1.3. NHS Bowel Cancer Screening Programme 
Despite the interventions described above, the continuing poorer prognosis for UK patients, makes the 
case for further large scale efforts to improve CRC survival. Since 2006, the biggest single intervention 
has been the introduction of the NHS national Bowel Cancer Screening Programme (BCSP). The 
evidence supporting its introduction comes from screening programmes in other countries and RCTs 
that have shown CRC related mortality can reduce by 25% after introducing a national programme(11). 
Four randomised controlled trials, involving 327,043 participants, have shown guaiac-based faecal 
occult blood test (gFOBt) screening results in a Relative Risk Reduction (RRR) in CRC related 
mortality of between 11% and 33%(11,96,98,181). A meta-analysis of the same trials showed FOB 
testing of asymptomatic individuals reduces deaths from CRC by 16% [odds ratio (OR) 0.84; 
confidence interval (CI) 0.78–0.89](182). 
The principle of bowel cancer screening is to detect cancer at a pre-symptomatic stage, leading to earlier 
diagnosis and thereby improving clinical outcome(183,184). Screening also enables the detection and 
excision of adenomas, thereby reducing CRC risk. Following a review of all screening options, the 
National Health Service (NHS) adopted a gFOBt screening programme.  
The NHS Bowel Cancer Screening Programme (BCSP) in England began offering biennial gFOBt 
screening to men and women aged 60–69 years (approximately 10% of the population) in July 2006. An 
invitation to participate in the BCSP requires an individual to be in the defined age range and be 
registered with a GP. Individuals are called throughout the two-year period, with the next round 
invitation going out two years after the previous round is closed. The phased roll-out achieved national 
coverage in January 2010 and from 2008 the screening age range was extended to 74 years. An early 
analysis of the first 2.1 million subjects invited to screening showed uptake was 55-60%. Of all subjects 
tested, 2% were gFOBt positive and 8% of these were found to have cancer(185). From its inception to 
December 2013, the BCSP had diagnosed 17,893 cancers (personal communication from National 
Office), with a higher proportion of Dukes’ A cancers compared with non-screened patients (35% vs. 
13%)(73,185). Currently around 3% of patients with CRC are diagnosed through the NHS BCSP(73) 
and a similar figure is seen in countries with similar health systems(74,143).  
The BCSP uses the gFOBt (hema-screen; Immunostics, New Jersey, USA), which is designed to identify 
subjects at a higher risk of colonic neoplasia by detecting intraluminal bleeding from vascularised CRCs 
and adenomas. The amount of bleeding is related to the size, stage and site of the neoplasia(186). 
Subjects perform the test at home by placing two faecal samples from three separate stools onto each 
one of six windows in turn. The gFOBt test relies on the pseudoperoxidase activity of haem (from 
haemoglobin). Each window is impregnated with guaiac and the presence of the haem component of 
haemoglobin in blood present in faeces releases oxygen from hydrogen peroxide and converts colourless 
guaiac to a blue colour in the screening laboratory(187).  
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The BCSP in England is co-ordinated by five regional Hubs; screening kits are returned to one of the 
five accredited Hub laboratories where stool samples in all six windows are analysed by a manual 
qualitative process. A kit is reported as ‘normal’ if none of the six windows (spots) is positive. A kit 
with five or six positive spots is deemed ‘abnormal’ and further investigation, usually colonoscopy, is 
recommended. A kit with between one and four positive spots is deemed ‘unclear’ and a second kit is 
sent out to the subject. If the second kit result is normal, a third kit is sent out. If either the second or 
third kits contain one or more positive spots then the outcome is described as ‘weak positive’ and 
colonoscopy is recommended. Following an unclear result in kit one, if both kits are normal then 
patients are returned to the screening programme for repeat testing in two years’ time.  
Subjects with abnormal and weak positive test results are referred for colonoscopy. If this is normal the 
subject is returned to the screening programme for a repeat gFOBt in two years’ time. Subjects 
diagnosed with CRC are referred to their local CRC multidisciplinary team (MDT). If polyps or 
adenomas are found then surveillance follows the British Society of Gastroenterology (BSG) 
guidelines(188). In chapter 6, I will explore the performance of the programmes algorithm for 
determining whether a given result should lead to colonoscopy. The aim is to identify if more cancers 
and adenomas can be diagnosed without substantially increasing the cost of the programme. To date no 
other work has analysed the BCSP algorithm in this way. 
Broadly speaking, there are two distinct ways a screening programme can improve outcomes. Firstly, 
the direct effect of diagnosing pre-symptomatic CRCs in patients undergoing screening. This has been 
the focus of almost all the research in this area. Such patients will have their cancer diagnosed earlier 
(and possibly at a lower stage) than had they waited until symptoms developed. These patients will have 
also avoided many of the potential delays in the current pathways. The second potential impact has been 
much less studied and involves the issue of raising public awareness of CRC. This impact relates to how 
the introduction of the programme affects the population as a whole. Introducing a screening 
programme has given a clear message to the population that the healthcare system is determined to 
identify and treat CRC quickly, as a priority. This itself gives the message to the public of the need to be 
aware of CRC symptoms and act quickly if they occur. This may lead to a change in population attitudes 
regarding CRC. A population “exposed” to a screening programme may believe more strongly in the 
“treatability” of CRC. This would reduce nihilistic attitudes and encourage patients to report symptoms. 
It is important to realize the two effects affect different populations differently. Patients in the screening 
age group can benefit from both direct and indirect effects while those outside the screening age group 
can only benefit from the indirect effect. Further work is required to address causality and eliminate 
confounding variables. This is explained further in my justification section below and in chapter 4. 
Screening can diagnose patients pre-symptomatically and may encourage other symptomatic patients to 
present sooner. Both of these effects could reduce delay and also potentially reduce the variation in 
outcomes throughout the country. However, the effectiveness of a programme is reliant on the uptake 
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rate(189). Uptake of screening is known to be worse in areas with high deprivation, which already have 
worse CRC outcomes (164). A consequence of which, more deprived patients will still present as an 
emergency to hospital, Figure 1.9.  
 
1.4. Determining variation in practice of CRC care 
Clinicians and healthcare providers rely on accurate information to provide safe and effective care to 
their patients. Information is used to determine which services need to be commissioned and then to 
measure the service performance and identify how improvements can be made. This is done by 
comparing quality indicators, such as length of stay and overall survival. It can also highlight trends in 
healthcare to enable changes to be implemented. For example, if there was increasing incidence of a 
certain condition then increased resources can be allocated. To allow fair comparison between different 
providers, confounding variables such as age and co-morbidity need to be adjusted for. Being scrupulous 
with data quality and making the necessary adjustment means the information supplied to be trusted by 
those using it. 
My thesis studies how methodological changes based on clinically derived algorithms can be applied to 
routinely collected hospital data. This allows more accurate identification of patients with CRC, as well 
as a better understanding of their clinical pathway including whether they first presented to hospital care 
as an emergency. Once a cohort of patients has been accurately identified in this way, then the impact of 
changes in practice, in this case the introduction of the BCSP, can be studied. This can allow the 
judgments to be made on the impact and relative worth of the programme across the entire country. 
This requires accurate data and any missing or inaccurate data could introduce bias and invalidate my 
conclusions. The most useful data for this type of research is routinely-collected prospective data, found 
in the HES database. HES allows me to determine if there is differing practice and outcomes for CRC 
across the country.  
I identified an important quality indicator in CRC to be emergency admissions. In section 1.4.1, I 
explore the rationale for choosing this indicator and describe some other possible data sources, along 
with HES and why this was chosen for the basis of my thesis. 
1.4.1. Candidate Quality Indicators; emergency admission at presentation 
Quantifying the real-world benefits is a challenging for all cancer screening programmes. Survival 
benefit takes many years to realise (190,191) and a range of other healthcare advances may occur over 
this period to confound the interpretation of national trends in cancer incidence or survival. In the case 
of CRC screening, a recent meta-analysis of trial data estimated that it took 10.3 years before one death 
from CRC was prevented for 1,000 patients screened(191). Therefore I needed to identify a reliable 
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quality indicator that acts as a surrogate for survival and is measured routinely and prospectively in HES 
data.  
In general, healthcare quality can be measured by comparing the performance of an individual or a 
group of individuals with an ideal or benchmark(192). Quality of care can also be defined as ‘the degree to 
which health services for individuals and populations increase the likelihood of desired health outcomes and are 
consistent with current professional knowledge.’(193). This defines quality as a multidimensional concept, 
which is best described by the use of quality indicators and expressed as standards. Most quality 
indicators tend to be negative, such as; death, disease, disability, discomfort, and dissatisfaction and can 
be generic and relevant to all diseases, or disease-specific measures(194). Once quality indicators are 
established, then the performance of a given organisation or patient identifier (e.g. ethnicity) can be 
measured and compared to the standard and to other organisations or patient groups. These finding can 
then be used to identify variation and set priorities to inform a quality improvement programme. 
Results can also support providers’ decision around commissioning and for accountability and 
accreditation purposes.   
It is clearly important to understand the reasons for persistent unwarranted variations in outcomes, as it 
allows resources to be focused on the areas of greatest need. Despite this, the eradication of all variation 
is not what health services should aim to achieve. This is because “If all variation were bad, solutions 
would be easy. The difficulty is in reducing the bad variation, which reflect limits of professional 
knowledge or failures in its application while preserving the good variation that makes care patient 
centred.”(195). The task is to know what drives bad variation, and to do this we need to be able to 
identify candidate quality indicators. 
Once a variation in practice (such as 5-year survival) has been identified between two or more groups of 
patients, the next question is: how to improve the outcome for the disadvantaged group. For this, the 
different steps associated with a poor outcome need to be established and robust markers associated with 
these steps identified(196). As an example, if outcomes were worse for a particular group, say those 
with greater deprivation, can quality indicators be identified that are associated with a specified aspect of 
care more likely to be present in deprived population groups. It is established that screening can 
improve outcomes by preventing delayed presentation through the diagnosis of asymptomatic 
patients(11). Therefore it makes sense to look at screening uptake as a potential quality indicator related 
to late presentation and worse outcomes. If it can be shown that there are lower screening rates in 
deprived patients then one method for improving overall outcomes in deprived patients might be to 
improve screening uptake(171). 
In addition to survival rates, other quality indicators have recently been shown to be important. These 
include measures to evaluate the quality of care at a given population level. Assessing care quality is 
increasingly important as it allows care providers, purchasers (e.g. Clinical Commissioning Groups 
(CCGs)) and patients to choose services based on optimal clinical practice, especially in the current 
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climate of increasing demand and constrained resources(197). One problem is that most of the 
established quality indicators discuss management of treatments following the diagnosis.  
The major problem in the UK is not the treatment provided, but late presentation. Therefore the 
candidate quality indicators of particular interest in my thesis relate to the pre-hospital and pre-
diagnostic time period, as this is where most improvement can occur. Emergency presentation is 
another quality indicator as it is associated with reduced five-year survival compared with elective 
presentation and is an indicator of the quality of pre-diagnostic care(198). The UK has a high emergency 
presentation rate at around 30%, compared with international rates (3-30%)(67-71,184). Other 
indicators looking at delayed diagnosis include early mortality and the proportion of patients not 
amenable to surgical resection. 
Therefore my main candidate quality indicator to identify the impact of the screening programme is 
emergency admission at presentation. This is because it is strongly associated with poor outcomes, 
marks pre-diagnosis care pathways and the rate is high in the UK.  
1.4.2. Sources of NHS data 
There are many different sources of information in the NHS that can be used to study CRC care. 
Broadly speaking, these can be divided into routinely collected national data and locally collected data.  
National data tends to use standardised collection procedures and principally collects data on patient 
activity, examples include: 
-Hospital Episode Statistics (HES) 
-Bowel Cancer Screening System (BCSS) database 
-National Audits such as the NBOCAP (National Bowel Cancer Audit) 
-NHS Performance Statistics 
-Office of National Statistics (ONS) 
-Hospital activity records 
-Primary care records 
-Prescribing records  
-Insurance claims 
-Emergency service records  
With the exception of the BCSS and NBOCAP audit, the databases described above are used for 
measuring overall healthcare activity and are not specific to CRC. The original purpose of these 
databases was to allocate resources to meet healthcare demands. However relatively recently, 
researchers have found they can be used to perform observational studies of health care practice(199).  
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The advantages of using these national, routinely-collected datasets are the prospective nature of the 
collection (reducing bias), the large size and high case ascertainment rate. Additionally, the data are 
relatively inexpensive to acquire and the extraction and analysis process is relatively straightforward. 
These features can be particularly useful when trying to externally validate other studies, especially 
those published by tertiary units where results may not be directly comparable to the “real world” 
situation. Such unbiased datasets can also be used to assess the performance of individual clinicians, 
units, hospitals, specific areas and the whole country(200). 
There are also potential weaknesses with using routinely-collected, national data including issues of data 
quality, a lack of flexibility (the results may not be relevant to the proposed study) and difficultly 
manipulating such large databases.  
There were alternatives to using HES data to describe national standards of clinical care, the most 
commonly used example was clinical registries, which were purpose built for the disease of interest. 
These were commonly used in the fields of cancer and surgery and exist for CRC in the form of the 
National Bowel Cancer Audit Programme (NBOCAP). In contrast to HES, clinical registries can contain 
more detailed clinical information for individuals; this can help predict risk factors for adverse outcomes 
and performance variability more accurately(201). However the quality of the data collected in clinical 
registries can be variable. The major problem is incomplete data capture as clinical registries are usually 
run voluntarily and rely on motivated clinicians to add data. This may skew submissions towards more 
complex cases and lead to the omission of routine cases and those with adverse outcomes. Clinical 
registries are also costly to maintain and often lack the infrastructure to reach their full potential(202).  
In the case of the national CRC audit, the NBOCAP is rich in clinical detail but suffers from a limited 
case ascertainment rate of 69% and only a 50% rate of data completeness. This compromises its use in 
analysing national interventions(150). The NBOCAP is very useful in identifying variations in quality, 
for example it has shown a variation in surgical practice across different areas of the country, with 
abdomino-perineal resection rates varying from 20% to 40%. These types of results are useful in 
suggesting variations in outcomes across the UK. The problem arises when analysing causation, trying to 
unpick causes related to care quality, rather than epidemiological and socio-economic factors. It is only 
by applying further advanced analytical techniques (as performed later in this thesis) that validated 
clinically useful measures of care can be presented to help front-line teams improve their service. 
Recent studies comparing the accuracy of routinely collected data (including HES) with clinical 
registries confirmed a close correlation between the two. In 2001, Campbell et al, found the accuracy of 
HES with registry data was 84% for diagnostic codes and 97% for procedure codes(203). A more recent 
study also reported a good association between the two forms of data capture, with an 80% accuracy for 
diagnoses and 84% for procedures(204). The same study also found that accuracy had increased since 
the introduction in 2002 of ‘Payment by Results’. Reasons for the discrepancy that still exists between 
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routine and registry data include the use of different definitions for diagnoses, procedures and even 
mortality(205).  
Locally collected data are more variable in the quality of information recorded and mainly involve audit 
and registries. Examples of local data sources include: endoscopy reporting systems; local use of 
Hospital Patient Administration Systems (PAS); electronic and manual clinical records, MDT datasets 
and clinical notes-based audits. These can be useful in helping with quality improvement programmes in 
the area conducted but their wider use is limited. Given the aims of my thesis, the reasons above 
demonstrate why the HES dataset was most appropriate. 
1.4.3. Hospital Episode Statistics (HES) Data 
HES is a national data warehouse containing the information coded routinely at discharge for all 
inpatient care episodes occurring in NHS hospitals. This includes elective day case procedures, elective 
admissions and unplanned (emergency) admissions (15,16). The original purpose of HES was to 
describe activity in the service and help with the allocation of resources. Over time, the range of uses of 
the data has widened. 
HES was introduced in 1987 as a method of collecting detailed information for every in-patient and day 
case hospital episode delivered by NHS hospitals including personal, administrative and clinical 
information, with more than 15 million records collected annually. It is the most comprehensive and 
inclusive of all NHS datasets and was established in response to the Körner Report, which found that 
“inaccuracy, a lack of timeliness and certain inherent defects” were leading to poor quality routine 
hospital statistics(206). HES also records episodes in the private sector commissioned by the NHS.   
1.4.3.1. The structure of the HES database 
Each hospital episode of care under a single consultant generates a single HES record. Most patients only 
have a single episode during an admission (or spell) in hospital, but some will have multiple episodes. 
While the intention of the data is for administrative purposes, important information on a patient’s 
diagnosis, any procedures occurring and outcome is also recorded. The process begins when a patient is 
first admitted to hospital. At this point their relevant administrative and demographic details are entered 
into the hospital’s patient administration system (PAS). Once discharged, the patient’s clinical notes go 
to the hospitals coding department where staff extract relevant clinical information, assign appropriate 
codes and enter them onto a database. The data are extracted directly from clinical information held 
within patients’ records, in the same way as many local audits and studies. Patients’ hospital notes 
(written by the patient’s medical team), discharge summaries and letters are scrutinised for information 
regarding diagnosis and procedures. This process is performed by clinical coders and not clinicians. They 
study the clinical data to translate the medical terms into an alphanumeric code using the International 
Statistical Classification of Diseases and Related Health Problems (ICD-10) for diagnoses, and the Office 
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of Population, Censuses and Surveys Classification of Interventions and Procedures (OPCS-4) for 
procedures performed.  
HES is held nationally and data are regularly submitted by local hospitals from their own information 
systems throughout the year. Selected extracts from PAS are sent from all hospitals to the HES dataset 
via the Secondary Uses Service (SUS). Once collected centrally, the data are further processed and 
cleansed to remove inaccurate or nonsensical data and then archived for subsequent use. HES is thus a 
repository for England’s hospital level activity based on episodes of inpatient and day case care, Figure 
1.10. HES data are based on the financial year, running from 1st April to 31st March. 
HES only codes inpatient episodes including day case episodes such as most endoscopy procedures. Any 
visits to the outpatient department, including radiology, are not captured. The Health and Social Care 
Information Centre (HSCIC) does hold a separate ‘outpatient’ dataset, but this outpatient dataset 
doesn’t contain diagnostic or procedure information, and is not currently linked to HES.  
 
Figure 1.10 The steps taken in the collection and storage of HES data.  
 
The basic unit of the HES dataset is the Finished Consultant Episode (FCE), covering the continuous 
period of time during which a patient was under the care of one consultant. As a patient may be 
transferred to the care of other consultants during the same admission (spell), there could be two or 
more episode records for a single admission. Episodes of care are linked into admissions and those 
ending in transfer to another hospital will be linked together to avoid multiple counting, Figure 1.11. 
Each episode contains up to 50 pieces of data. The dataset includes a unique patient identifier (HESID), 
age, gender, ethnicity, admission time and method (elective or emergency), geographical data for the 
Hospital)Episode)
Sta.s.cs)(HES))
Clinical)Coding)
(ICD710,)OPCS74))
Pa.ent)Notes) Administra.ve)Detail)
Hospital)PAS)
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area where the patient lives and the treating hospital. Clinical data includes the primary diagnosis (the 
main reason for admission) and up to thirteen secondary diagnosis fields. In addition there are up to 
twelve procedural fields and the length of stay and method of discharge are also recorded. Finally, the 
discharge date and any in-patient deaths are recorded. 
 
 
Patient A has three episodes of care (each under a different consultant team) and therefore three 
separate HES records during a single admission.
 
Patient B has a single episode of care (a single HES record) during the single admission. 
Figure 1.11 Illustration of how HES records the number of episodes of care (Finished Consultant 
Episodes) rather than the number of admissions. Each admission may comprise of one or more episodes. 
 
1.4.3.2. A demonstration of the HES record  
Table 1.8 shows the partial HES record for a single patient’s pathway of care relating to CRC. Some of 
the 50 fields in each line of data are not shown due to size constraints but four care episodes covering 
three admissions to hospital are all shown split across two tables. The tables record the unique hospital 
identifier (HESID) for the patient (ending as….037F), as well as the beginning (EPISTART) and end 
(EPIEND) date of each episode. The patient’s age (ENDAGE) and sex (SEX) is also recorded. In Table 
1.8, the same patient’s episodes are shown and describe the different specialties caring for the patient 
(MAINSPEF). For the 1st, 3rd and 4th episode the code 100 denotes the patient was under the care of a 
general surgical team. The different types of admission method (ADMIMETH) are recorded, where for 
example a code 11 denotes an elective admission from a waiting list. The primary diagnostic (DIAG01) 
and procedural (OPERTN1) codes are recorded (the additional 13 possible diagnostic codes and 11 
procedures codes have been removed from this table for simplicity). Finally, there is record of the 
patient’s inpatient death date (DEATHDATE). 
Additional data columns and flags for events can be customised for the specific audit or research project. 
I have added the first episode CRC was mentioned (1stCRC) and when the date was also shown 
(FIRSTCRCDATE). The column OPERTN1 describes the first procedure that occurred in the episode. 
Episode 1 e.g     
A patient presents with acute 
bowel obstruction under 
surgical on call team  
Episode 2 e.g 
Patient referred a colorecatal 
team for the operation 
Episode 3 e.g  
Patient referred to a 
gereatrics team for rehab 
prior to discharge 
Episode 1 e.g admitted to a general medical team with symptomatic anaemia, then discharged post transfusion for 
outpatient investigations   
 68	
In this case, H244 is a code for the endoscopic insertion of expanding metal stent into lower bowel. 
Therefore the example shown in Table 1.8 describes a patient whose first episode was on the 
02.05.2007 aged 67 years. The patient subsequently had a diagnosis of CRC and metal stent inserted 
during an episode from the 04-08.06.2007. Unfortunately a more prolonged episode from 20.10.2007-
02.11.2007 ended in the patient’s death.  
 
Table 1.8 The HES database is configured so each line of data records a single hospital episode of care. 
Records for one patient’s four episodes of care are displayed (not all data is shown). 
HESID EPISTART EPIEND 
ENDAG
E SEX PROCODE 
RELAVENT 
PRODODE 
…..037F 02.05.2007 02.05.2007 67 1 RW6 1 
…..037F 04.06.2007 08.06.2007 67 1 RW6 1 
…..037F 19.10.2007 19.10.2007 67 1 RW6 1 
…..037F 20.10.2007 02.11.2007 67 1 RW6 1 
 
MAINS
PEF 
ADMI
METH 
FIRSTCRC  1st CRC 
DATE 
DEATHDA
TE 
DIAG
O1 
OPERT
N1 
OPDATE
1 
100 11       K529 
  
301 11 1 
08.06.200
7   C189 H244 
08.06.200
7 
100 22       C19X -   
100 28     2.11.2007 C19X H152 
24.10.200
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1.4.3.3. Potential uses of the HES record 
Given the size, detail and accuracy of the data, HES has been used extensively as a research tool to 
define variations in population heath and health delivery across geographic and economic areas. HES can 
be used to investigate potential causality factors and healthcare trends over time(207). This makes 
analysis of HES useful for detecting variations in the national provision of CRC care. It also allows 
reliable markers predictive for this variability to be developed. Finally, it allows the impact of healthcare 
change (such as the beginning of national screening) to be studied.  
1.4.3.4. Quality of HES data and limitations 
HES data presents several challenges, including concerns about coding accuracy, coding depth (for 
example cancer stage is not recorded) and the occasional use of symptom rather than diagnostic codes. 
Put simply the quality of data reflects the quality of the clinical records and the ability of the coders to 
interrogate the records. Some of the individual limitations of HES, including identifying the date of 
diagnosis and accuracy of coding are covered in more detail in chapter 2, where there is also a 
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comparison with other potential data sources. HES contains no information on outpatient (clinic) 
attendances and doesn’t include a complete capture of some treatments such as chemotherapy and 
radiotherapy. Finally HES does not contain all useful outcome data, in particular outpatient deaths and 
quality of life measures (Patient Reported Outcome Measures [PROMs]). However on balance, HES is 
the single best national database the UK has to offer. Therefore, to determine the impact in England on 
CRC emergency presentation rates following the introduction of BCSP, it seems appropriate to use HES 
as the primary data source. 
1.5. Justification for the thesis; the direct and indirect effect of introducing 
the BCSP 
Currently the national impact that the introduction of the BCSP has had on CRC care is unknown. 
Outcomes for CRC in England are worse than other countries and this is largely because patients 
present later and with more advanced disease. Other national screening programmes have successfully 
identified a small proportion of patients with pre-symptomatic cancer, so it is important to determine if 
the BCSP has had this effect, since its roll out in 2006.  
Two studies have looked at the impact of bowel cancer screening on overall emergency admissions for 
CRC. The Nottingham screening study was a randomized controlled trial, comparing 75,253 patients in 
the screened group (60% response rate) and 74,998 well-matched, unscreened controls (age range; 45 
and 74 years). The emergency presentation rate was 23.9% in the screened group, compared to 27.9% 
in the control group, but the difference was not statistically significant (possibly due to lack of study 
power)(88). An uncontrolled, observational study from Coventry and North Warwickshire, looked at 
patients aged 50 to 69 years, as part of a screening programme pilot. The authors reported that 29.4% 
of CRC patients presented as an emergency in the year before the pilot (1999) but that the local rate had 
fallen to just 15.8% by 2004. Surprisingly, the proportion of Dukes stage cancers was unchanged over 
the study period and the annual number of cases did not rise as might be expected if extra screen-
detected cases were contributing to the reported totals(208) Expert commentators questioned whether 
screening itself, or other changes in local or national CRC care over the 5 year period was responsible 
for the time-trends reported(209). Similar uncontrolled local data for sigmoidoscopy-based colon 
cancer screening has shown a trend for reduced emergency admissions(210).  
However these studies were local, occurring during the screening trials prior to the national 
programme, with relatively short follow-up. One study failed to show any significant effect and the 
other was criticized for failing to properly account for confounding variables. Therefore, no study has 
attempted to understand the nationwide effect of the BCSP. 
In my thesis, I begin by reporting the development and validation of methods to analyse HES data to 
identify a national incident cohort of patients with CRC and then describe their characteristics and a 
methodology to flag key milestones in the patient journey (Chapter 2). I focus particularly on creating a 
candidate metric of CRC care, namely emergency admission during the diagnostic pathway.  Data are 
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presented to describe the development of a novel, clinically generated algorithm for categorizing all 
relevant emergency admissions within the coded hospital episodes.  Subsequent work establishes the 
associations between the candidate indicator, patient characteristics and other outcomes (Chapter 3), 
thereby establishing this specific metric as a surrogate outcome measure for use in comparing services or 
the impact of interventions. I then deploy this metric as a primary outcome measure in a retrospective, 
observational study focused on the roll-out of the BCSP across England (Chapter 4). Specifically, I focus 
on the idea that the launch of the program may have early, population wide and indirect benefits.  To 
support this hypothesis, I examine whether living in an area with a recently activated BCSP is associated 
with a reduced risk of emergency admission for the population as a whole, and particularly for those of 
non-screening age.  In order to account for various sources of confounding, I use comparable data for 
oesophagogastric cancer to illustrate that any associations are specific to CRC, rather than reflecting 
more general features of local services.  I next sought to exclude any further confounding factors for the 
findings in chapter 4 (Chapter 5). Finally, independently from the rest of the thesis, I showed how the 
BCSP database could itself be analysed. By interrogating the programme, I was able to suggest ways in 
which the algorithms for referring FOBt results for colonoscopy might be altered in a way to improve 
the efficiency of CRC diagnosis (Chapter 6). 
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Chapter 2 - Validation of data extraction from the Hospital 
Episode Statistics (HES) database for a one-year cohort of 
incident cases of Colorectal Cancer in England 
 
 
2.1. Introduction  
The HES database is a record of all inpatient hospital activity, including patients seen as a day case and 
those admitted to a hospital bed. The database covers all NHS hospitals in England and describes the 
diagnoses and procedures relevant to each episode. HES has been used to study a variety of conditions in 
an attempt to understand temporal trends of disease incidence, survival, care pathways and results of 
treatments and other interventions. It has also been used to study the reason for variation in outcomes 
between healthcare providers(205,211,212). 
2.1.1. Hospital Episode Statistics (HES)  
The use of routine administrative NHS datasets, such as the HES database, has become increasingly 
common in the literature. My challenge was to work with data not primarily designed for research in 
such a way that the results and conclusions were accurate and clinically meaningful.  
As reviewed in chapter 1, HES data presents several challenges including concerns about coding 
accuracy, coding depth and the use of non-specific symptom codes rather than diagnostic terms. 
Furthermore, HES contains no information on outpatient (clinic) attendances and does not include 
complete capture of some treatments such as chemotherapy and radiotherapy. Finally, HES does not 
record any quality of life indices. In addition, two particular concerns with the HES data are addressed 
here in chapter 2, the methods development chapter. These were a) the lack of a date of diagnosis and b) 
the accuracy and timing of diagnostic and procedural codes; these two concerns are connected. The lack 
of recording of a specific date of diagnosis within the routine dataset represents a key obstacle for using 
HES data to study cancer care. This is because the first time a cancer code appears, may be late in the 
care pathway and after the clinical diagnosis has been made. Instead at the time of first clinical 
presentation of the cancer, non-specific diagnostic codes may be recorded. Therefore, to get to the stage 
of using HES to study national CRC care, considerable manipulation of the raw data was required. In 
fact, developing novel analytical and linkage methods to overcome or compensate for these issues was a 
key aim of the thesis. 
 
2.1.1.1. Date of diagnosis 
Although HES data contains a number of fields for the recording of diagnostic codes, the actual date of 
diagnosis is not recorded in the dataset. This presents significant challenges: 
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Firstly, this creates uncertainty as to when a patient’s inpatient journey began. This has implications for 
understanding how a patient initially presents (electively or as an emergency) and for calculating the 
timing of important procedures and overall survival time. All studies using routinely recorded data 
struggle to find the date when patient’s symptoms first presented. One study based on comparing 
hospital records with structured interviews found that hospital records tend to underestimate symptom 
duration by around 2 months(213). Importantly, patients admitted as an emergency with CRC were less 
likely to be coded with a cancer diagnosis on their first admission than those presenting electively(214). 
This may erroneously lead to a patient’s pathway beginning at a subsequent elective admission (where 
the cancer code appears for the first time) and not the presenting emergency admission. Without 
adjustment, for when these patients actually first presented then these pathways may record an incorrect 
start date and presentation type, and thus provide unreliable data.  
Secondly, the lack of a date of diagnosis presents difficulties in distinguishing new (incident) cases from 
patients with a previously established diagnosis. 
2.1.1.2. Coding of diagnoses and procedures 
Coding is the process in which written information in patients’ clinical notes is transferred into coded 
data and recorded into the hospitals information systems. Skilled clinical coders perform the task after 
the patient has been discharged from hospital. Their primary role is to enable hospitals to be reimbursed 
for their activity through the ‘Payments by Results’ (PbR) system. Clinical coders convert diagnostic 
terms recorded in medical notes into International Classification of Diseases (ICD-10) codes and 
procedures performed into Office of Population Censuses and Surveys Classification of Surgical 
Operations and Procedures (OPCS-4.5) codes.  
The quality of the source documentation, as well as the skill of the coders, therefore determines the 
accuracy of patients’ records. There are well documented concerns regarding coding accuracy, 
especially incomplete or inaccurate information that lacks sufficient depth to be clinically useful 
(205,215,216). Most clinical coders are well trained and accurate in converting clinical terms into 
codes, however they have difficulties identifying the correct information from unstructured clinical 
notes. This has led to a number of interventions over recent years to improve the recording of medical 
records and define certain standards(204).  
There are other elements to the recording of HES data that need to be acknowledged. 
Coding in HES can be vague and lack clinical detail. For example the use of an ‘unknown colon cancer 
site’ code instead of a site specific code, such as sigmoid cancer. While it is generally recognised that 
primary diagnostic codes (diagnostic position 1) are accurately recorded (with a 96% agreement with 
matched clinical registries), the accuracy of secondary codes is more disputed(204).  
Secondly, procedural codes can be underreported, especially when undertaken as a day case(204). This 
has improved recently, especially following the introduction of PbR. It used to be the case that some 
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hospitals recorded ‘day cases’ as outpatient attendances without procedure details (rather than recording 
them as day cases in HES). This was potentially important in my study cohort, as procedural codes for 
investigations such as a colonoscopy often identify the beginning of a patient’s pathway. 
To comply with PbR rules, coding needs to be completed quickly after a patient’s discharge from 
hospital. Patients are often discharged with a probable but not confirmed diagnosis, so in these cases, a 
cancer code cannot be used. This might occur if a day case colonoscopy identifies a mass with the 
appearance of cancer but where histological confirmation was still pending.  
Between hospital trusts there are different policies and practices for the depth of diagnostic codes 
recorded. This can create the apparent appearance of higher or lower levels of co-morbidities between 
trusts and can affect the case-mix adjustments used to compare trust’s quality of care. This problem has 
been described as the ‘constant risk fallacy’(207). In practice, it means that highly coding practices 
generate the appearance of a population with a higher burden of co-morbidity. It is a common problem 
in all observational studies(217). There is also the theoretical possibility that some units might 
deliberately use inaccurate codes to maximise reimbursement. Despite this, organisational inaccuracies 
occur randomly across specific patient characteristics (such as gender) and so should not affect any 
conclusion based on the HES data nationally. 
Overall, the evidence suggests that HES data accurately records the diagnoses and procedures in over 
90% of cases(203). Therefore it is useful to study factors associated with disease outcomes nationally, 
using metrics derived from the available administrative and clinical content of the dataset (e.g. process 
measures such as emergency hospital presentation). There is the potential for inaccuracy when using 
HES, but this is addressed by applying the robust methodological approach described in sections 2.5.1-
2.5.5. In addition HES can be useful to analyse individual hospital units, although any conclusions must 
be supported by an alternate source of data that is not influenced by individual coding practices. In the 
remainder of this chapter, I describe the steps taken to establish my cohort of CRC patients, after briefly 
setting out some of the main facts regarding CRC in England. 
2.1.2. Established associations in Colorectal Cancer (CRC) 
CRC is slowly and steadily becoming more common in England, with incidence increasing from 
45/100,000 in 1975 to 58/100,000 in 2007(2). This is in part due to an aging population, as 84% of 
cases occur in patients over 60 years of age, Figure 2.1.  
The association between CRC and individual patient characteristics, such as age, gender, co-morbidity, 
deprivation and cancer site have been well described and reviewed in chapter 1. To briefly review, there 
is a disparity in incidence between the genders, with males more likely to have CRC at all ages(218). 
The presence of co-morbidity in general is not consistently associated with susceptibility to CRC(219), 
although certain co-morbidities, such as Primary Sclerosing Cholangitis and Inflammatory Bowel 
Disease, are associated with an increased susceptibility to CRC(50,220). Furthermore, the risk of CRC 
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in patients with Ulcerative Colitis increases with the severity and duration of the colitis(47). While the 
association between deprivation and CRC is not clearly understood, incidence does not appear to be 
affected(30).  
 
Figure 2.1 Chart taken directly from Cancer Research UK, showing the number of new cases (of 
colorectal and anal cancer) in different age groups and age-specific incidence rates per 100,000 
population in the UK in 2007.  
2.1.2.1. Associations between patient characteristics and outcomes 
The stage of the CRC at diagnosis has a significant impact on patient outcome(5). In addition, older 
patients have worse outcomes and are less likely to be referred for major surgery. This may be related to 
delayed presentation, as a greater proportion of older patients have non-specific symptoms(221). Older 
patients are also more likely to have colonic cancer, which tends to present later. Other reasons for 
worse outcomes include the increased likelihood of co-morbidities and general frailty in older 
patients(222,223). By contrast younger patients tend to present earlier, due the presence of more 
specific symptoms such as rectal bleeding, and consequently achieve better outcomes(223). 
Female patients have poorer outcomes; this is thought to be related to delays in seeking assistance from 
healthcare providers (224).  
The impact of co-morbidity on the outcome of CRC is debated in the literature. Some studies have 
found that co-morbidity is associated with earlier stage diagnosis and better outcomes. This may be due 
to patients having more contact with their healthcare providers (related to their co-morbidity) allowing 
earlier identification of the cancer (225,226). Alternatively, the ‘competing demands model’ states that 
co-morbidities may distract healthcare providers attention away from early symptoms of CRC, leading 
to delayed diagnosis and worse outcomes (222,227). A meta-analysis found that co-morbidity in general 
does not directly affect the stage of diagnosis or outcomes(219). However, after excluding co-
morbidities in general, there are some specific conditions such as diabetes, and dementia that affect CRC 
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outcomes. Diabetes, especially when poorly controlled, is associated with CRC developing at a younger 
age and more often in a proximal site. Patients then present at a more advanced stage with subsequent 
poorer outcomes(228,229). In one study, 7% of CRC patients had dementia and these patients were 
diagnosed at a more advanced stage and were often under-treated(230).  
Deprivation is known to impact adversely on CRC survival, both in countries with universal health care 
entitlement, such as England, and in countries without, such as the United States(231-233). The reason 
for this is not entirely clear. Some studies have found that deprived patients are more likely to have 
advanced local disease and metastasis at presentation(234), while others have shown the stage of disease 
is unaffected by deprivation. It seems likely that later stage disease at diagnosis is at least partly 
responsible for the poorer outcomes seen in more deprived patients(235). A number of studies have 
looked at whether deprived patients have a longer duration of symptoms before seeking medical 
attention. Findings are inconclusive, with some studies pointing to an association(154,236) and others 
not(237,238). Even after accounting for differences in stage at diagnosis, deprived patients are more 
likely to receive no treatment or late treatment following initial first contact with the NHS(235). This is 
confirmed by the finding that outcomes for individual cancer treatments are unaffected by 
deprivation(239). One explanation for this may be that physicians perceive deprived patients more 
negatively leading to inequality in access to treatment(240). Overall, the literature suggests that 
deprived patients do less well because they have more advanced stage disease at diagnosis and inferior 
access to treatments. 
With regard to cancer site, survival is slightly higher for rectal cancer than colon cancer. However, this 
predominately reflects the higher rate of rectal cancers diagnosed at a localized stage, with stage-specific 
survival similar between the two types(241). 
The literature suggests that CRC outcomes are negatively associated with increasing age, female gender, 
deprivation and colonic cancer site. I will use my cohort of patients to explore these findings in more 
detail.  
 
2.2. Hypothesis 
The methodological research described in this chapter is based on the idea that it should be possible to 
generate clinically meaningful algorithms and linkage techniques that compensate for the limitations of 
the HES dataset and for variations in how care is coded. Specifically, that by using clinical logic and 
knowledge of CRC care, it is feasible to develop ways of analysing inpatient coding data to: Accurately 
identify ‘incident’ (new) patients diagnosed with CRC in English NHS hospitals over a one-year period; 
and Link together consecutive inpatient episodes to map the patient journey and determine key 
milestones (e.g. the first relevant day case or inpatient episode, and whether this was elective or as an 
emergency). For these methods to be deemed successful, the cohort of incident cases of CRC extracted 
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from HES data must show face-validity in terms of total numbers, clinical characteristics, mode of 
presentation and key outcomes when compared with independent published sources of data for CRC (in 
general, or for England specifically). 
 
2.3. Aims 
In this study I aimed: 
• To apply clinical knowledge to the analysis of administrative data for English hospitals (Hospital 
Episode Statistics, HES).  
• To develop methods for identifying a cohort of incident cases of CRC over a one-year period.   
• Identify all relevant procedures, including lower gastrointestinal endoscopy and surgical 
resections, within the study cohort. 
• To develop a novel procedure for identifying emergency presentation during the CRC pathway 
for this cohort, allowing me to explore algorithms to screen the full sequence of episodes 
recorded in HES (including admissions prior to the first coding of cancer) to find all clinically-
relevant episodes.   
• Identify each patient’s index admission to hospital with CRC, recognizing that the first coding 
of cancer may not always coincide with the first clinically relevant admission to hospital. 
• Identify whether each patient’s first clinically relevant hospital admission was elective or an 
emergency. 
• To compare this new methodology to the traditional analytical approach that focuses solely on 
episodes coded with a cancer diagnosis. 
• To describe the socio-demographic characteristics of the study population (age, gender, co-
morbidity, deprivation status and cancer site).  
• To use external sources of information to verify the face-validity of case numbers, 
sociodemographic characteristics and selected outcomes. 
• To identify any associations between the patient characteristics, presentation type and 
outcomes in the study cohort and to compare with existing knowledge in the published 
literature. 
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2.4. Methods 
2.4.1. Defining my Study Cohort  
I extracted a valid one-year cohort of incident CRC cases from England and then mapped their patient 
pathways. This allowed me to explore associations between patient characteristics, mode of presentation 
and outcome. My population included all patients aged 16 or over and who were discharged with a 
diagnosis of CRC from all English National Health Service (NHS) hospitals between October 2006 and 
September 2007.  
In this chapter, I describe the method for correctly identifying a patient’s presenting admission and 
whether it was as an emergency or elective. I also explain the steps taken to validate my cohort against 
external data sources. In chapter 3, I explore the patient and population associations with an emergency 
presentation. In chapter 4, I use the new methodologies to study whether the benefits of launching the 
BCSP extended beyond the minority of individuals actually screened. In particular was there an indirect 
benefit for the population as a whole, resulting from enhanced public, patient or professional awareness 
about CRC. This could be suggested if living in an area with a recently activated local BCSP was 
associated with a reduce risk of emergency presentation for CRC. Chapter 5 challenges whether 
confounding factors could explain the association between BCSP exposure and a reduced risk of 
emergency presentation. 
2.4.1.1. Study design, data sources and timescales 
I used a retrospective observational cohort design, based on data extracted from the HES for England. 
The source data comprised an extract of HES data for the years 2006-07 and 2007-08. This work 
formed part of a collaborative project with the NHS Information Centre examining the potential to use 
routine administrative data to derive clinically meaningful metrics of care for specific conditions 
(‘Engaging Clinicians in their Routine Data’) (242,243). The project dataset included data from all acute 
NHS Trusts, except those exclusively managing paediatric, maternity or psychiatric patients. The data 
were analysed within the secure University of Liverpool network using the statistical software package 
SPSS© (Version 18 and 20) as previously described(242,243). Data manipulation and analysis was 
undertaken mainly in SPSS, although some steps required importing/exporting between SPSS and the 
spreadsheet application Microsoft Excel©.  
I developed methods to extract those patients that presented for the first time with CRC over a one-year 
period (1st October 2006 – 30th September 2007) from this database, Figure 2.2. I excluded patients 
whose first CRC code was in the 6 months before or after the middle 12 month period. By selecting 
only cases coded for the first time in the ‘middle year’ of the data, this ensured there was exactly 12 
months of data for each study patient; six months of data before and after the first appearance of the 
cancer code. This approach ensured that I had the key diagnostic admission data from before the 
diagnosis was made and also details of treatments in the following six months. 
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Figure 2.2 The cohort included all patients diagnosed with CRC for the first time within the study 
period (black circle), thereby excluding cases whose first hospital episode was before or after this period 
(white circle).  
 
2.4.1.2. Methods to extract incident cases of CRC 
Initially, the two separate data years (2006/7 and 2007/8) were merged and all patients with one or 
more episodes containing a diagnostic code for CRC were identified. Using a unique anonymous 
identifier assigned to each patient, I extracted all of their ‘care episodes’ from the main HES dataset and 
ordered them chronologically. Patients coded with CRC for the first time during the one-year study 
period (CRC1) were identified as incident cases. Important symptom codes (such as ICD-10 codes for 
rectal bleeding), procedures (e.g. colonoscopy), operations and outcomes (e.g. death or readmission) 
were also identified if they occurred within six months either side of CRC1. This allowed me to map a 
patient’s pathway from their initial investigation and presentation (often in the absence of a CRC code) 
through to their outcome up to a year later, Figure 2.3. I then transformed the database from the 
‘episode’ level to the more clinically meaningful ‘admission’ level. I did this only after extracting the 
important diagnoses and procedures, to ensure no data was lost. Data can be lost when care is 
transferred from one consultant to another during an admission, because earlier events can be missed 
from the final episode record. 
Figure 2.4, shows the methodological steps taken to ensure the clinical richness of the database was 
maintained and that an equal period of data capture was recorded for all patients. 
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Selection of a one-year cohort of incident cases of colorectal cancer in England
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Figure 2.3 The steps taken to identify patients whose first CRC admission (CRC1) fell within the study 
year and include all admissions within six months. In the first bar, a blue circle represents the CRC1 
admission for various patients. In the second and third bars, the ‘blue circle’ represents a patient 
retained in the final study cohort and the ‘red circle’ represents a patient removed because they 
presented outside the study period. 
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Figure 2.4 A methodological flowchart describing the steps taken to derive the ‘incident cohort’ 
patients. 
 
2.4.1.2.1. Clean and merge the data  
The two HES database years (2006/07 and 2007/08) were cleaned of irrelevant, invalid and nonsensical 
data. Examples of excluded data included inputs from maternity and paediatric hospitals and any data 
with missing or corrupted dates. This ensured that retained episodes referred to patients with a valid age 
(16 years or over), that care was provided by a medical or surgical team and the admission was to one of 
the 152 Acute Hospital Trusts in England, Table 2.1. The two data years were then merged into a single 
master file called ‘All admissions merged file for 2006/2007 and 2007/2008’.  
1.Access and store the data 
2.Clean and merge the data 
3.Identify the CRC cohort via 
ICD-10 codes 
4.Extract patients with CRC coded at 
any diagnostic position 
5.Extract all EPISODES of care 
related to patients who have a cancer 
code 
6.Identify and group the key ICD-10 
and  OPCS-4 codes 
7. Flag key diagnostic and procedural 
events on the patient’s journey 
8.Move from the episode level to 
admission level 
9. Identify the middle year cohort of 
'incident' patients 
10.Cut the retained admissions to 
6/12 either side of CRC first record 
11.Flag the start of the CRC care 
pathway (index admission) 
12. Analyse the incident cohort 
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Table 2.1 The individual HES year datasets were cleaned to include only patients aged 16 years or over, 
with a valid admission code, under a relevant specialty (medicine or surgery) and managed in a trust 
treating CRC patients. 
 Episodes in 2006/07 Episodes in 2007/08 
Dataset containing medical and surgical 
episodes 11,580,198 12,181,932 
Less;   
  excluded admission methods 3,393 3,155 
  age not shown 5,699 10,296 
  under 16 404,875 422,100 
  invalid ages 28,267 30,141 
  excluded trusts 380,273 560,307 
Selected Episodes 10,757,691 11,155,933 
 
2.4.1.2.2. Identify all CRC patients using coding 
Most studies using HES data only include admissions where the disease of interest is coded in position 1 
of the database (DIAG01, the ‘primary’ diagnosis). This approach ignores the diagnostic codes in the 
other thirteen or more secondary diagnostic fields. This simplistic coding convention assumes that 
diagnoses coded in lower positions are co-morbidities, although our group has shown that non-specific 
symptom codes or complications of the disease of interest can appear in position 1 with the key diagnosis 
coded in a lower order position (242,243). To maximise the chances of capturing all cases of CRC, the 
methodology required screening of the first seven diagnostic positions (DIAG01-DIAG07) of all 
episodes in the master file for CRC specific ICD-10 codes, Table 2.2. Position seven (DIAG07) 
accounted for 0.2% (561/252,885) of CRC codes and beyond this position very few CRC codes was 
recorded at all. I considered it improbable that such an important diagnosis would not be mentioned at a 
higher position and so judged any CRC code beyond position seven almost certainly reflected a historical 
diagnosis.  
The CRC ICD-10 codes are generally site specific, covering each section of the large bowel from the 
rectum to the caecum. However, in 14.4% (36,526/252,885) of cases, the code C189 (Malignant 
neoplasm of colon unspecified) was used, highlighting how HES data can sometimes lack clinical detail. 
Using the SPSS, I created syntaxes (the standard programming function in SPSS) to screen for codes 
representing CRC in the large bowel. The syntax identified a total of 252,885 such episodes from 
diagnosis position one to seven, Table 2.3. Screening at diagnosis position one found 203,770 episodes, 
thus searching at the other positions identified a further 49,115 episodes or 19.4% of the total. This 
validates the importance of including episodes beyond position one, which substantially increased the 
total number of episodes identified and hence identified further CRC cases.  
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Patients with CRC often have multiple admissions to hospital and so these 252,885 episodes only 
represent some of the hospital visits. There are also occasions when patients with CRC have a hospital 
admission that does not lead to a CRC code being recorded in HES due to admissions prior to a formal 
diagnosis being made (see 2.5.2 for more details) or clinical note keeping not being clear about the CRC 
diagnosis. I deemed it important to record every hospital admission for patients occurring in the study 
period. Thus the final step in this process was to record all episodes occurring for patients with at least 
one CRC code. Using syntaxes based on the unique patient identifier in HES, I identified a total of 
360,993 episodes belonging to patients with at least one CRC code in the study period, Table 2.3. These 
steps allowed me to glean as much information as possible from HES on the pathways followed by 
patients newly diagnosed with CRC.  
 
Table 2.2 A table showing the frequencies of the different site specific CRC ICD-10 codes are shown at 
each of the first 7 diagnostic positions in the HES master file. 
ICD-
10 
CRC site DIAG01 DIAG02 DIAG03 DIAG04 DIAG05 DIAG06 DIAG07 Total 
C20X Rectum 58,706 7,290 4,061 2,113 803 438 170 73,581 
C19X Rectosigmoid 20,849 2,458 1,179 519 220 77 40 25,342 
C187 Sigmoid colon 39,637 4,238 2,247 836 358 179 78 47,573 
C186 Descending 
colon 
4,893 550 264 86 49 17 6 5,865 
C185 Splenic flexure 3,485 367 225 112 46 23 18 4,276 
C184 Transverse 
colon 
8,609 887 424 198 71 45 16 10,250 
C183 Hepatic 
flexure 
4,510 460 177 96 49 30 11 5,333 
C182 Ascending 
colon 
12,451 1,034 571 226 94 58 19 14,453 
C180 Caecum 24,410 2,728 1,516 595 245 134 58 29,686 
C189 Colon 
unspecified 
26,220 4,958 2,981 1,295 649 278 145 36,526 
Total  203,770 24,970 13,645 6,076 2,584 1,279 561 252,885 
 
 
Table 2.3 A table showing how the inclusion of all episodes belonging to patients with a CRC code 
substantially increased the size of the two year HES database. 
Episodes 2006/2007 
episodes 
2007/2008 
episodes 
2006-2008 
episodes (all) 
Total medical and surgical  10,757,691 11,155,933 21,913,624 
CRC coded 125,792 127,093 252,885 
Extended CRC database 177,147 183,846 360,993 
2.4.1.3. Study cohort population  
It was important to identify only incident CRC cases. To achieve this, I created algorithms to exclude 
cases where the CRC code referred to an established diagnosis from a previous data year. I excluded 
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these patients, as they would have been diagnosed and treated prior to the beginning of the study period 
and this may have affected outcomes.  
2.4.1.3.1. Identify incident CRC patients exclusively 
To identify when the first CRC code was recorded, patients had all their admissions placed in 
chronological order. Patients had already been excluded if their first CRC admission occurred outside of 
the middle year (1st October 2006 – 30th September 2007). This step identified 34,270 patients with a 
first CRC code within the study period.  
Three further adjustments were then made to ensure only patients with a new diagnosis of CRC were 
included. Each of these steps therefore led to the exclusion of patients that had a pathway incompatible 
with a new diagnosis of CRC;  
1. Historical cases; Patients with no CRC codes in either position 1 or 2 at any admission 
within the study period. These patients were judged unlikely to represent a new diagnosis and 
were removed as the CRC code in all likelihood represented a past diagnosis and thus a co-
morbidity.  
2. Miscoding (different cancer); When a patient had multiple codes for another gastrointestinal 
malignancy, such as Oesophageal and Gastric (OG) cancer and only a single CRC code within 
the study period, it was judged that the CRC code more likely represented a miscoding rather 
than a second de novo cancer.  
3. Pre-diagnostic colorectal operations; Patients with a colorectal resection in the six months 
prior to the study period. In this instance it appeared likely that the diagnosis of CRC had 
occurred before the study year.  
This left a final middle year incident cohort of 32,299 patients, with 137,498 admissions, Table 2.4.  
 
Table 2.4 Patients were excluded from the cohort when the patient pathway appeared to show the CRC 
code was either historical (a co-morbidity) or entered by error. 
Adjustments to the incident cohort No. 
Patients with a CRC code within the 2 years 74,142 
-1st year 40,876 
-2nd year 33,266 
-Middle year 34,270 (137,498 admissions) 
Historical 1,673 (4.9%) leaving 32,597 
Miscoding (different cancer) 100 (0.3%) leaving 32,497 
Pre-diagnostic Colorectal operations 198 (0.6%) leaving 32,299 
Incident patient group 32,299 
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2.4.1.4. Exclusion criteria  
In this section, I demonstrate that historical cases have been excluded. To do this, I studied the 
frequency of codes at the first diagnostic (primary diagnosis) and first procedural position (primary 
procedure) for the admission when the 1st coding for CRC (CRC1) appeared. If the primary codes at 
CRC1 (the patients first admission with a cancer code at any position) were either CRC codes per se or 
symptoms, diagnoses or procedures closely related to CRC then historical cases were unlikely to have 
been retained. However if the dataset contained a significant number of non-CRC related codes 
appearing at the first diagnostic and procedural position, then there was a risk that prevalent cases were 
retained and unrelated admissions were included where the cancer code appeared as co-morbidity or 
previously treated condition. While all admissions contained at least one diagnostic code for CRC, not 
all admissions contained a procedure.  
Table 2.5 summarizes the 20 commonest primary diagnosis codes recorded at CRC1 for the cases 
retained in the study population. In many cases, the primary code was the specific CRC code itself. In 
some cases, the primary diagnosis recorded was a complication of cancer (e.g. intestinal obstruction) 
and the CRC code appeared as a secondary diagnosis.  
I found that 90.9% of the CRC1 primary diagnoses were for CRC codes, Table 2.5. All the other 
remaining top 20 codes (accounting for 92.7% of patients), coded symptoms or diagnoses strongly 
linked to a new CRC diagnosis. These included symptom codes such as anaemia and rectal bleeding.  
Manual review of all primary diagnostic codes were undertaken to generate a grouping system based on 
the primary diagnosis recorded. Although there is no systematic coding of symptoms for all patients, I 
looked at whether the recording of certain R-codes (symptom or sign codes that can be ill-defined, such 
as rectal bleeding) or specific diagnostic codes compatible with CRC complications were more 
prevalent. The groups were: a) CRC diagnosis, b) unverified cancer e.g. a malignant polyp, c) a red flag 
symptom, e.g. rectal bleeding, d) metastases e.g. liver metastasis, e) other gastrointestinal diagnoses 
e.g. diverticular disease, f) other gastrointestinal symptoms e.g. nausea or g) other non-gastrointestinal 
related symptoms or diagnoses. Table 2.6 demonstrates the strong predominance of CRC codes and 
lack of non-CRC related diagnoses among the 20 commonest primary diagnoses. This makes it unlikely 
that historical CRC cases remained in my cohort.  
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Table 2.5 The 20 commonest ICD-10 codes in the primary diagnosis position at the CRC1 admission. 
Diagnosis No. (%) 
Malignant neoplasm of rectum 8,655 (26.8) 
Malignant neoplasm of sigmoid colon 5,725 (17.7) 
Malignant neoplasm of caecum 3,675 (11.4) 
Malignant neoplasm of colon unspecified 3,331 (10.3) 
Malignant neoplasm of rectosigmoid junction 2,194 (6.8) 
Malignant neoplasm of ascending colon 2,000 (6.2) 
Malignant neoplasm of transverse colon 1,318 (4.1) 
Malignant neoplasm of descending colon 783 (2.4) 
Malignant neoplasm of hepatic flexure 730 (2.3) 
Malignant neoplasm of splenic flexure 555 (1.7) 
Malignant neoplasm of appendix 185 (0.6) 
Other and unspecified intestinal obstruction 116 (0.4) 
Malignant neo overlapping lesion of rectum, anus and anal 
canal 112 (0.3) 
Anaemia unspecified 112 (0.3) 
Secondary malignant neoplasm of liver 108 (0.3) 
Malignant neoplasm overlapping lesion of colon 95 (0.3) 
Haemorrhage of anus and rectum 77 (0.2) 
Non-infective gastroenteritis and colitis unspecified 65 (0.2) 
Polyp of colon 54 (0.2) 
Iron deficiency anaemia unspecified 52 (0.2) 
Total 
29,942 
(92.7) 
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Table 2.6 The 20 commonest primary diagnostic codes at CRC1 merged into clinically coherent groups 
following manual review. These groups demonstrate the overwhelming majority of primary diagnoses 
were associated with a new diagnosis of CRC. 
Diagnostic & Symptom groups No. (%) 
Colorectal cancer 29,358 (90.9) 
Pending confirmation e.g. polyp 54 (0.2) 
Metastasis 108 (0.3) 
Symptom codes (R codes)*  
 Red flag symptoms** 422 (1.3) 
 Anaemia* 164 (0.5) 
Non CRC related* 0  
Total, top 20 codes 29,942 (92.7) 
Cohort total  32,299 
*Symptom codes (which can be ill-defined) are given an R prefix within Chapter XVIII of the 
International Classification of Diseases-10.  
** Red flag alarm symptoms included rectal bleeding, change in bowel habit, abdominal mass, 
abdominal pain and anaemia. 
  
Table 2.7 summarizes the 20 commonest primary procedural codes recorded at the first CRC coded 
admission (CRC1). All of these codes were relevant to the investigation and management of CRC and 
the commonest were lower gastrointestinal endoscopies and surgical resections. In 15.7% of patients 
there was no procedure recorded. I manually reviewed the 20 commonest codes and placed them into 
clinically related groups, Table 2.8. The commonest group was lower gastrointestinal endoscopy 
(36.8%), followed by major surgical resections (16.6%), radiological investigations (2.8%) and other 
gastrointestinal procedures e.g. OGD (1.2%). Other colorectal operations (E.g. defunctioning 
colostomies and ileostomies) were infrequent (2.3%). 
I have demonstrated that, at the CRC1 admission, the majority of my cohort had a procedure related to 
managing CRC. However this did not necessarily mean the CRC1 admission was the first admission in a 
patient’s CRC pathway. The relatively low rate of lower endoscopies and high operative rate made me 
conclude that there were likely to be earlier relevant admissions – consistent with the hypothesis that 
the first recording of a cancer code does not always signify the first relevant inpatient episode. In the 
following section, I will describe which patients’ had an earlier relevant admission and whether it was 
more accurate at marking the start of their CRC pathway. This introduces the new concept of a ‘first 
relevant admission’ (REL1) and the development and testing of methods to identify the true ‘index 
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admission’ – the first hospital care episode in the patient’s cancer care pathway, when the cancer code 
may, or may not, be recorded. 
 
Table 2.7 The 20 commonest primary procedures at CRC1. All of these procedures were relevant to 
the investigation and management of CRC. 
OPCS-
4 Procedure No. (%) 
H221 Diagnostic fibreoptic endoscopic examination of colon and biopsy of lesion of colon 6,019 (18.6) 
- Not recorded 5,087 (15.7) 
H251 Diagnostic endoscopic examination of lower bowel and biopsy of lesion of lower bowel using fibreoptic sigmoidoscope 3,721 (11.5) 
H201 Fibreoptic endoscopic snare resection of lesion of colon 969 (3.0) 
H072 Right hemicolectomy and side to side anastomosis of ileum to transverse colon 897 (2.8) 
H073 Right hemicolectomy and anastomosis  780 (2.4) 
H229 Unspecified diagnostic endoscopic examination of colon 711 (2.2) 
H071 Right hemicolectomy and end to end anastomosis of ileum to colon 660 (2.0) 
H333 Anterior resection of rectum and anastomosis of colon to rectum using staples 642 (2.0) 
H334 Anterior resection of rectum and anastomosis  615 (1.9) 
H335 Rectosigmoidectomy and closure of rectal stump and exteriorisation of bowel 598 (1.9) 
H336 Anterior resection of rectum and exteriorisation of bowel 503 (1.6) 
U081 Computed tomography of abdomen  491 (1.5) 
H259 Unspecified diagnostic endoscopic examination of lower bowel using fibreoptic sigmoidoscope 457 (1.4) 
U071 Computed tomography of chest 413 (1.3) 
H151 Loop colostomy 402 (1.2) 
H331 Abdominoperineal excision of rectum and end colostomy 391 (1.2) 
G451 Fibreoptic endoscopic examination of upper gastrointestinal tract and biopsy of lesion of upper gastrointestinal tract 374 (1.2) 
H412 Peranal excision of lesion of rectum 354 (1.1) 
H062 Extended right hemicolectomy and anastomosis of ileum to colon 286 (0.9) 
Total  24,370 (75.5) 
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Table 2.8 The 20 commonest primary procedural codes at CRC1 merged into clinically coherent groups 
following manual review. The commonest groups were for lower gastrointestinal endoscopy (36.8%) 
and for major surgical resections (16.6%). 
Procedural group No. (%) 
GI endoscopy (lower) 11,877 (36.8) 
Major resection 5,372 (16.6) 
Other colorectal operations 756 (2.3) 
Other GI procedures, inc. OGD 374 (1.2) 
Radiological investigation 904 (2.8) 
Non recorded 5,087 (15.7) 
Total 24,370 (75.5) 
Cohort total 32,299 
 
2.4.2. Index admission  
I initially considered that a patient’s pathway began with the first admission recording a CRC code 
(CRC1). However, some studies have shown that the first CRC coding admission was not always the 
patients’ first relevant contact with the hospital(2,244). Furthermore, the findings from the section 
above, made me consider whether on occasions an earlier relevant admission (REL1) marked the cancer 
presentation. This suspicion was heightened by a line-by-line manual review of the HES records, 
revealing that some patients had relevant hospital admissions in the weeks prior to their first coding of 
cancer. Therefore, if an earlier admission (REL1) had a diagnosis or procedure, in keeping with their 
CRC presentation, then the REL1 and not the CRC1 should be the index admission marking the 
beginning of a patient’s pathway.  
REL1 admissions prior to the CRC1 admission may occur when an outpatient colonoscopy is performed 
to investigate red flag symptoms such as rectal bleeding. In these patients, a CRC code will not be 
recorded until the histology is known, at the subsequent hospital admission. 
To identify relevant admissions prior to CRC coding; I created a steering group that comprised of three 
clinical specialists (gastroenterologists), two NHS data specialists and as a general physician with 
experience of NHS data analysis. This was consistent with the original wider project whereby clinical 
engagement in the analysis of the data was seen as a means to extract greater value from HES (242,243). 
They used their combined skills and knowledge to identify all diagnoses and procedures considered 
relevant in the presentation of CRC. Codes were agreed by consensus. Examples included symptoms 
such as constipation, signs compatible with underlying cancer such as iron deficiency anaemia and lower 
gastrointestinal endoscopic procedures. A full list of the included codes is found in Appendices 1 
and 2. 
2.4.2.1. Definition and Identification 
To identify a patient’s index admission I searched for the presence of a ‘relevant’ hospital admission 
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(REL1) prior to the CRC1. I screened all the admissions in the six months prior to CRC1 for primary 
diagnoses and procedures relevant to the CRC pathway. A patient’s presentation date (index admission) 
was therefore defined as the CRC1 admission date unless there was a REL1 admission within in the 
preceding 6 months, in which case this was the index admission date.  
2.4.2.1.1. Identification of ICD-10 codes relevant to clinical presentation of CRC 
The stages involved identifying all diagnostic codes that might represent CRC presentation were as 
follows; 
1. I used pivot tables in Microsoft ‘Excel®’ to interrogate diagnostic positions 1-7 for all 
episodes during the study period. I then calculated the number of times each diagnosis 
appeared.  
2. The steering group then interrogated each diagnostic code that appeared in 10 or more 
episodes, selecting codes for inclusion, which were deemed clinically relevant. Initially, the 
steering group selected diagnostic codes from two groups; ‘red flag’ codes (e.g. rectal 
bleeding), shown in Appendix 1.1 and ‘anaemia codes’ (e.g. iron deficiency), shown in 
Appendix 1.2. The list was expanded to include a group of gastrointestinal type diagnoses 
and symptoms including, for example, diverticulosis or nausea respectively, shown in 
Appendix 1.3. This was because HES coding tends initially to be vague and rely heavily on 
symptom codes. The merged group was called ‘Gastrointestinal type diagnoses and 
symptoms’. 
2.4.2.1.2. Identification of OPCS-4 procedure codes relevant to clinical presentation of CRC 
I identified all procedures that strongly indicated a diagnosis of CRC. These procedures comprised of 
three groups that occur at different stages of the CRC pathway;  
• Those that make the diagnosis (endoscopic procedures) 
• Those that stage the CRC (radiological investigations)  
• Those that treat the CRC (surgical resection, stoma formation) 
Only admissions in the first two groups were selected to screen for earlier relevant admissions (REL1). 
The third group (treatment options) identified the treatment options that patients had received. 
The stages involved in identifying all procedural codes that might represent CRC presentation were as 
follows; 
1. Pivot tables in Microsoft ‘Excel’® were used to interrogate procedural positions 1-14 for all 
episodes in my study cohort.  
2. The steering group interrogated all procedural codes that appeared in 10 or more episodes 
and selected codes that were deemed ‘clinically relevant’. They selected gastrointestinal 
endoscopies, shown in Appendix 2.1, as well as radiological imaging such as Computer 
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Tomography, Ultrasound and Magnetic Resonance Imaging of the gastrointestinal tract, 
shown in Appendix 2.2. The merged group was named ‘Gastrointestinal type procedures’. 
The main treatment modalities that were identified separately include surgical resections (e.g. anterior 
resection) and palliative defunctioning procedures (e.g. colostomy), shown in Appendix 3.1.  
The codes for ‘Gastrointestinal type diagnoses and symptoms’ were merged with the investigative 
procedures ‘Gastrointestinal type procedures’ to form a group called ‘Gastrointestinal relevant 
episodes’. Using this group of codes I was able to determine if an earlier relevant admission existed for 
an individual patient. I did this by creating a syntax to search for the first admission containing any 
‘Gastrointestinal relevant episodes’ in the six months prior to the CRC1. This admission was called the 
first relevant admission (REL1) and created a milestone, when present, denoting the beginning of the 
patient’s cancer pathway (index admission). When there was no earlier relevant admission in the six 
months prior to first coding of cancer then the index admission was CRC1. Further detail of how this 
approach was applied to describe the patient pathways is explained later in the chapter.  
2.4.2.2. Validating the “first relevant admission” (REL1) 
23.2% (7,503/322,99) of patients were identified as having a REL1 admission prior to the first CRC 
coding admission (CRC1). The mean time interval between the two admissions was 52 days (SD 41.3) 
with 74.2% of REL1 admissions occurring less than three months before CRC1.  
The reasoning for identifying earlier relevant admissions was based on the assumption that these would 
more accurately reflect the starting point for a patient’s journey. For this methodological approach to be 
valid, the diagnostic and procedural codes for REL1 admissions needed to be consistent with the 
beginning of a CRC pathway. In this section, I have identified the types of diagnoses and procedures at 
the REL1 and compared them to CRC1 admissions. 
At the REL1 admission there were by definition no CRC codes. Instead, the 20 commonest primary 
diagnostic codes (representing 60.7% of patients) were all relevant to the presentation of CRC. The 
commonest codes were either for signs or symptoms related to CRC (e.g. anaemia) or other lower 
gastrointestinal symptoms, as shown in Table 2.9. In Table 2.10, the codes were grouped according to 
clinical themes: the commonest groups were red flag symptoms (20.5%), anaemia (16.1%) and codes 
where CRC confirmation was pending (e.g. uncertain neoplasm) (15.4%), all of which potentially identify 
the start of a CRC pathway.  
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Table 2.9 The 20 commonest primary diagnostic codes at the REL1 admission were predominately for 
red flag symptoms, such as rectal bleeding and for anaemia. 
Diagnoses No. (%) 
Anaemia unspecified 613 (8.2) 
Haemorrhage of anus and rectum 518 (6.9) 
Iron deficiency anaemia unspecified 369 (4.9) 
Polyp of colon 357 (4.8) 
Other and unspecified abdominal pain 276 (3.7) 
Other iron deficiency anaemias 225 (3.0) 
Diverticular dis of large intestine without perforation or 
abscess 222 (3.0) 
Benign neoplasm of rectum 184 (2.5) 
Neoplasm uncertain or unknown behaviour colon 184 (2.5) 
Rectal polyp 183 (2.4) 
Non-infective gastroenteritis and colitis unspecified 178 (2.4) 
Other and unspecified intestinal obstruction 169 (2.3) 
Constipation 165 (2.2) 
Benign neoplasm of sigmoid colon 156 (2.1) 
Change in bowel habit 117 (1.6) 
Pain localized to other parts of lower abdomen 117 (1.6) 
Gastritis unspecified 113 (1.5) 
Diaphragmatic hernia without obstruction or gangrene 105 (1.4) 
Diverticular disease without perforation or abscess 94 (1.3) 
Neoplasm uncertain or unknown behaviour rectum 93 (1.2) 
Total 4,551 
 
Table 2.10 The 20 commonest primary diagnostic codes at the REL1 admission were placed into 
clinically related groups. This showed codes related to red flag symptoms, anaemia as well as those 
stating confirmation of CRC was pending were most frequently found.   
Diagnostic & Symptom groups No. (%) 
Pending confirmation e.g. polyp 1,157 (15.4) 
Metastasis 0 
Red flag symptoms 1,540 (20.5) 
Anaemia 1,207 (16.1) 
Other Gastrointestinal diagnosis e.g. Diverticular 
disease 534 (7.1) 
Other Gastrointestinal symptoms 113 (1.5) 
Other symptoms & diagnoses 0 
Total from Table 2.9 4,551 (60.7) 
Cohort total 32,299 
The 20 commonest primary procedural codes were all consistent with the start of a CRC pathway, Table 
2.11. Putting the codes in clinically related groups, showed that over half of patients had a lower 
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gastrointestinal endoscopy, Table 2.12. The rate of lower gastrointestinal endoscopy was significantly 
higher at the REL1 admission than at the CRC1 admission (52.5% vs. 36.8%, P<0.001). Lower GI 
endoscopy was the investigation that most commonly diagnosed CRC, validating the methodology for 
identifying the index admission.  
If I had used only the CRC1 admission (as is standard practice for HES studies) rather than the more 
sophisticated method of identifying the REL1, then 7,503 patients or 23.2% of the cohort would have 
been assigned a later presentation date (an error rate of almost 1 in 4). This is important as the 
presentation type (elective or emergency) was used as an important outcome measure in later chapters 
and inaccuracy at this stage would introduce errors. 
In conclusion, evidence has been presented to support my assertion that the REL1 admission was a more 
accurate starting point than CRC1. In particular, the higher rate of lower gastrointestinal endoscopy 
codes implies this milestone is a more accurate. Henceforth in this thesis, when a REL1 admission is 
present, it is used instead of the CRC1 admission to denote presentation (index admission).  
 
Table 2.11 The 20 commonest primary procedural codes at the REL1 admission. 
Procedure No. (%) 
Non-recorded 2,214 (29.5) 
Fiberoptic endoscopic examination of upper gastrointestinal tract and biopsy of 
lesion of upper gastrointestinal tract 1,066 (14.2) 
Diagnostic fiberoptic endoscopic examination of colon and biopsy of lesion of colon 717 (9.6) 
Diagnostic endoscopic examination of lower bowel and biopsy of lesion of lower 
bowel using fiberoptic sigmoidoscope 563 (7.5) 
Unspecified diagnostic endoscopic examination of lower bowel using fiberoptic 
sigmoidoscope 425 (5.7) 
Unspecified diagnostic fiberoptic endoscopic examination of upper gastrointestinal 
tract 369 (4.9) 
Unspecified diagnostic endoscopic examination of colon 278 (3.7) 
Fibreoptic endoscopic snare resection of lesion of colon 215 (2.9) 
Unspecified other blood transfusion 206 (2.8) 
Computed tomography of abdomen  172 (2.3) 
Unspecified diagnostic endoscopic examination of sigmoid colon using rigid 
sigmoidoscope 112 (1.5) 
Endoscopic snare resection of lesion of lower bowel using fiberoptic sigmoidoscope 74 (1.0) 
Computed tomography of chest 67 (0.9) 
Intravenous blood transfusion of packed cells 55 (0.7) 
Computed tomography of head 54 (0.7) 
Fibreoptic endoscopic cauterisation of lesion of colon 44 (0.6) 
Unspecified endoscopic extirpation of lesion of colon 30 (0.4) 
Computerised tomography NEC 25 (0.3) 
Endoscopic cauterisation of lesion of lower bowel using fiberoptic sigmoidoscope 24 (0.3) 
Peranal excision of lesion of rectum 24 (0.3) 
Total 6,734 (89.8) 
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Table 2.12 At the REL1 admission, the 20 commonest procedures were placed into clinically related 
groups. The most prevalent group was GI endoscopy (lower) (52.5%). 
Procedural group No. (%) 
GI endoscopy (lower) 3,941 (52.5) 
Other procedures, inc OGD 261 (3.5) 
Radiological test 318 (4.2) 
Non-recorded 2,214 (29.5) 
Total from Table 2.11 6,734 (89.8) 
Cohort total 7,503 
 
2.4.3. Patient characteristics  
The baseline patient characteristics described in my patient population included patient age, gender, co-
morbidity, deprivation and the cancer site. Establishing how frequently these characteristics occurred 
was important for a number of reasons. Firstly, it allowed me to gauge how well I had identified the full 
national cohort of patients. I did this by comparing the crude totals with other externally validated 
national data sources. Secondly, it allows others to assess the applicability of my study results compared 
with the populations they are studying. Finally, as individual characteristics, such as age and co-
morbidity were important prognostic factors, knowing how frequently they occurred, helped 
understand the outcomes data.  
These same characteristics were used throughout my thesis to describe the presentation and outcome 
findings. In my study cohort, a patient’s age and gender were recorded from the CRC1 admission 
record. 
2.4.3.1. Co-morbidity  
Co-morbidity describes the presence of one or more additional disorders (or diseases) co-occurring with 
the CRC. It is important to identify all relevant co-morbidities as they may have a large impact on a 
patient’s presentation and their outcome. 
The Charlson co-morbidity index predicts the ten-year mortality for a patient by taking into account a 
range of comorbid conditions, such as heart disease and cancer. Each condition is assigned a weighted 
score of 1, 2, 3, or 6, depending on the risk of dying associated with each one. Scores are then summed 
to provide a total score to predict mortality(245-247). I used the Charlson co-morbidity index in this 
thesis and calculated a patient’s co-morbidity from their CRC1 admission. The first seven diagnostic 
positions were scored appropriately and added together to create the total Charlson score. There are 14 
fields available for diagnostic codes in each episode. However co-morbidities in position 8 or above 
were only recorded in <1% of patients and so not recorded in this thesis. I assigned co-morbidity based 
on the weighted Charlson score after excluding the score for the CRC diagnosis. This categorized 
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patients into one of three groups (None, score of 1 or ≥2) (2,30,244,247). I restricted the number of 
co-morbidity groups to three to partially control for variations in the case-mix adjustment caused by a 
number of trusts taking different policies regarding the depth of coding. See the description of the 
‘constant risk fallacy’ in section 2.2.1.2 for more information. 
2.4.3.2. Deprivation  
I have already described how relative deprivation is associated with poorer outcomes in CRC(248). It is 
therefore important that any CRC outcome study measures individual patient deprivation. 
Unfortunately there was no direct record of a patient’s level of deprivation in HES. Instead, a 
deprivation score is derived from where the patient lives, their Lower Super Output Area (LSOA). The 
LSOA is a geographical area specifically designed for the analysis of small area statistics and contains 
approximately 400 houses. The LSOA score is based on 10 sets of data that include income, 
employment, education, health and disability indices within that area. These 10 sets of data were then 
individually weighted and summed to provide an Index of Multiple Deprivation (IMD) score. This 
allows deprivation levels to be compared between small geographical areas and, by inference, between 
their populations. A patient’s recorded level of deprivation was therefore based on their IMD score at 
the CRC1 admission. A rank of 1 is the most deprived and 32,482 the least deprived. In my study 
cohort, as with previous studies, patients were divided into five quintiles to allow comparison between 
the different ‘relative’ deprivations(30,244). 
2.4.3.3. Cancer site 
The incidence of cancer at the different sites varies depending on age and gender. Cancer presentation 
and outcomes also depend on the site involved. Rectal cancers tend to present earlier and, when 
matched for stage, stage C and above rectal cancers do better(241). The cancer site used in this thesis 
was based on the coding used at the CRC1 admission. HES codes exist for each anatomical section of the 
large bowel (for example cancer of the caecum). To follow the approach used by the majority of cancer 
registries and so allow comparison with external data sources I merged the individual codes for large 
bowel cancer into three groups; colonic, rectosigmoid and rectum. This also allowed me to include 
colonic cancers that had been given a non-site specific code.  
2.4.4. Patient Presentation   
Knowing the admission type when the patient first presented with CRC enabled me to understand 
whether the overall patient pathway began as an emergency or electively. As emergency presentation 
was associated with adverse outcomes and it was very important that all such cases were accurately 
recorded. In subsequent chapters the causes and implications following emergency presentations will be 
described in more detail. 
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In the analysis described in this section, I made further checks on the validity of my methodological 
approach as well as describing the consequences of different presentations identified at the index 
admission. 
2.4.4.1. Emergency Vs. Elective Admission 
This defines whether the individual patient’s pathway was elective or an emergency, to do this I 
identified the admission method (ADMIMETH field) at their index admission (16).  
Patients with ADMIMETH field terms “emergency admission via A and E, via the GP, the bed bureau, 
out-patient clinic or from another hospital” were identified as an emergency admission. All other 
admission codes recorded in the ADMIMETH field were recorded as an elective admission. 
2.4.4.2. The six presentation pathways  
A patient’s index admission was found by screening all admissions in the six months prior to the CRC1 
for the earliest ‘Gastrointestinal relevant admission’. For many patients there were no earlier relevant 
admissions (REL1), so CRC1 was used. However, when an earlier relevant admission (REL1) existed, it 
was recorded as the index admission. This approach created six distinct pathways based on the type of 
presentation at the REL1 and CRC1 that describe the beginning of a patient’s journey, Table 2.13.  
 
Table 2.13 The six potential presentation pathways based on the mode of admission (elective or 
emergency) at the first relevant admission (REL1) and first coding with CRC admission (CRC1). 
Pathway No. of 
patients 
Percentage 
of patients 
Description 
1. El 16,430 50.9% Patients for whom the CRC1 code was given after an elective 
admission, and had no earlier gastrointestinal related 
admissions. 
2. ElEl 3,584 11.1% Represents patients with an elective gastrointestinal related 
admission before the first CRC coded elective admission 
3. EmEl 1,954 6.0% Represents patients with an emergency gastrointestinal 
related admission before elective CRC1 admission. 
4. Em 8,366 25.9% Represents patients for whom the CRC1 code was given 
during an emergency admission and who had no earlier 
gastrointestinal related admissions. 
5. EmEm 1,331 4.1% Represents patients with an emergency gastrointestinal 
related admission before the CRC1 emergency admission. 
6. ElEm 634 2.0% Represents patients with an earlier elective gastrointestinal 
related admission before the emergency CRC1 admission.  
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This approach allowed a patient’s pathway to be identified as fully elective, fully emergency or switching 
between emergency and elective care, Figure 2.5. The key question was: ”are patients whose 
presentation type has switched based on the REL1 admission truly more like the presentation group they 
have joined than the group they have left?” That is, are the rates of diagnostic and procedural codes for 
patients in the EmEL pathway really closer to other patients with emergency presentations, i.e. Em and 
EmEm? 
 
 
Figure 2.5 This flowchart demonstrates the six pathways that patients with CRC can take 
El= elective admission type, Em= emergency admission type 
2.4.4.3. Validating the pathways  
In this section I presented evidence suggesting my methodological approach had correctly identified 
patients presenting as an emergency or electively. I have already shown that, compared to CRC1, a 
REL1 admission more accurately reflected the patient’s presentation (index admission) to hospital care 
(methods; section 2.5.2.2).  
If my methodological approach was correct then the three pathways that began electively (El, ElEm, 
ElEl) would have rates of diagnostic and procedural codes distinct from the three pathways that begin as 
an emergency (Em, EmEl, EmEm).  
For most patients (n=24,796, [76.8%]), the index admission was also their CRC1 admission (i.e. the 
patient belonged to the group El or Em). The remaining patients (n=7,503 [23.2%]), all had an earlier 
REL1 admission. This encompassed two pathways (EmEm and EmEL) with an earlier emergency 
admission (n=3,285 [10.2%]) and two pathways (ElEl and ElEm) with an earlier elective admission 
(n=4,218 [13.1%]).  
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I found the three elective groups (El, ElEl and ElEm) had similar rates of primary procedure codes at the 
index admission. These code profiles were distinct from the three emergency groups (Em, EmEm and 
EmEl), which also shared similar profiles to each other, Figure 2.5.    
Looking at the frequency of procedure rates, the elective groups (El, ElEl and ElEm) all had high rates of 
lower gastrointestinal endoscopy codes (61.0%, 85.5% and 75.9%). This was not the case for the EmEl 
group (18.5%), whose lower gastrointestinal endoscopy rate was closer to the other emergency groups 
(Em 12.8% and EmEm 12.2%), Figure 2.6. This was an important finding because it suggested that 
changing the presentation type based on identifying an earlier relevant admission has allowed patients 
with similar diagnoses and procedures at presentation to be grouped together. In other words it 
identified when patients had actually presented. Finally, I found that the procedural rates for the ElEm 
and EmEl groups were markedly different. This demonstrated that it was not the presence of an 
emergency admission at any point in the pathway that makes the difference, but its presence at the start.  
Accepting that the index admission was actually the start of the patient’s pathway, led to an increase in 
the number of cases defined as an emergency from 32.0% to 36.1%. This was because the EmEl group 
(n=1,954) was larger than the ElEm group (n=634). This was an important observation, as it shows my 
methodology identified more patients as having an emergency presentation than would be identified 
using traditional methods. Furthermore, this approach lengthens these patients’ diagnostic journeys and 
thus slightly increases overall projected survival. 
In summary, the groups El, ElEl and ElEm are similar to each other, as are the groups Em, EmEm and 
EmEl, Figure 2.5, 2.6. This supports the hypothesis that, when present the index admission should be the 
REL1 admission.  
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Figure 2.6 The rates of clinically related types of procedures in the six presentation pathways. 
 
2.4.5. Patient outcomes 
To validate my study population against external data sources, my primary outcome measures were 
major surgical resection and one-year mortality taken from the index admission. These outcomes are 
commonly described in the literature and thus allowed me to compare my results to external data 
sources later in the chapter. Secondary outcome variables included: any colorectal operation; the timing 
of surgery; length of stay and readmission after surgery, all of which are validated measures of care 
quality(150).  
2.4.5.1. Primary outcome measures  
2.4.5.1.1. Major surgical resections  
Major surgical resections were classified as operations that removed a segment of the colorectum either 
with direct anastomosis or with a temporary or permanent stoma. This was the most important 
intervention for most patients with CRC and offers the greatest chance of cure. A syntax was run, to 
search for surgical resection codes at every admission including and following the index admission. I also 
defined the operation type and whether it involved a laparoscopic approach or required stoma 
formation. 
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2.4.5.1.2. One-year mortality 
To identify patients dying within one-year of presentation HES data was combined with data from the 
Office of National Statistics (ONS). HES records deaths during an in-patient episode and not those 
occurring out of hospital, therefore, HES did not capture some deaths amongst my patient population. 
To capture all deaths occurring during follow-up, out of hospital deaths were added by external linkage 
to the statutory register of deaths held by the ONS, using the unique patient identifier. The one-year 
mortality was calculated from the date of the index admission.  
2.4.5.2. Secondary outcome measures 
I identified secondary outcome measures that were all widely accepted quality markers(150). Secondary 
outcomes were classified as:  
1. All colorectal operations; this was a broader definition of colorectal surgery than the outcome 
‘major surgical resection’ and included all the above mentioned resections, along with 
defunctioning ileostomies and colostomies. These operations are often reserved for palliative 
patients or those with co-morbidities that precluded more aggressive surgical management. 
2. The length of stay, where I described the number of nights in hospital after the index admission 
and at the admission when major surgical resection occurred. 
3. Hospital re-admission in the 30-days following discharge from hospital, after a major surgical 
resection.  
 
2.5. Results 
2.5.1. Overview of my study cohort  
There were 32,299 incident cases of CRC in my one-year cohort and patient characteristics are 
summarized in Table 2.14. Patients were allocated to the following age groups: <55 yrs, 55-64 yrs, 65-
74 yrs, 75-84 yrs and ≥85 yrs. Co-morbidity was defined with Charlson scores (None, score of 1 or 
≥2). Finally, cancer site was split into three distinct areas; rectal, rectosigmoid or colon. In most 
patients with colon cancer, the anatomical site was accurately defined (i.e. ascending or transverse colon 
cancer) however unlike in the rectal cancers, it can be difficult to describe the exact site of a colon 
cancer endoscopically. For this reason, some patients were given the code ‘malignant neoplasm of colon 
unspecified’. Patients were given a deprivation score, from 1-32,482 and then split into equally matched 
quintiles. These groups of categorical variables have been described in the literature 
extensively(212,244,249). 
The mean age at diagnosis was 71 years (sd 12.1) and 55.7% of patients were male. At the CRC1 
admission, 67.6% of patients had no co-morbidities, 7.4% had one and 25.0% had two or more. A 
lower proportion of my CRC cohort of patients lived in deprived areas; there were 17.1% of cases in 
the most deprived quintile, compared to 20.4% in the least deprived quintile. Colon cancer accounted 
 100	
for 62.6% of cases, rectosigmoid 7.6% and rectal 29.8%, Table 2.14.  
 
Table 2.14 Characteristics of CRC patients diagnosed in English NHS hospitals over a one-year period 
(October 2006 to September 2007). 
Patient characteristics 
Total cases, N 
(%) 
No. 32,299 
Age group  
<55 yrs 3,044 (9.4) 
55-64 yrs 5,872 (18.2) 
65-74 yrs 9,474 (29.3) 
75-84 yrs 10,080 (31.2) 
≥85 yrs 3,829 (11.9) 
Gender  
Male 17,981 (55.7) 
Female 14,318 (44.3) 
Co-morbidity  
0 21,847 (67.6) 
1 2,383 (7.4) 
≥2 8,069 (25.0) 
Deprivation  
IMD not recorded 322 (1.0) 
1 (most deprived) 5,516 (17.1) 
2 6,044 (18.7) 
3 6,844 (21.2) 
4 6,980 (21.6) 
5 (least deprived) 6,593 (20.4) 
Site  
Rectal 9,631 (29.8) 
Rectosigmoid 2,440 (7.6) 
Colon 20,228 (62.6) 
 
2.5.1.1. Patient presentation 
In my cohort the emergency presentation rate was 36.1% at the index admission. This was higher than 
the 32.0% found at the CRC1 (p<0.001). Therefore, the index admission methodological approach 
increased the number of patients regarded as having presented as an emergency, Table 2.15. Clearly a 
proportion of patients were experiencing an emergency admission early in their cancer journey, before 
the cancer code was first recorded. This is a key finding of this methodological work and crucial to the 
accurate study of factors associated with emergency presentation for cancer care.  
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Table 2.15 Presentation mode and outcomes for the 32,299 CRC patients diagnosed in English NHS 
hospitals over the one-year period October 2006 to September 2007. 
Patient outcomes Total cases, N (%) 
Index admission  
Elective 20,648 (63.9) 
Emergency 11,651 (36.1) 
First colorectal cancer coding  
Elective 21,968 (68.0) 
Emergency 10,331 (32.0) 
Outcomes  
Any colorectal operation  20,674 (64.0) 
Major surgical resection 16,332 (50.6) 
1-year mortality (index admission) 9,469 (29.3) 
1-year mortality (CRC1 admission) 9,637 (29.8) 
 
2.5.1.1.1. Short stay emergency admission  
I challenged the assumption that all patients with an emergency presentation should be treated equally. 
In particular, that patients whose initial emergency admission length of stay was <1 day, should be 
treated as “true emergency presentations”. I have termed such cases “short stay emergency admissions”. 
In the emergency presentation group, 777 of the 11,651 (6.7%) patients had a short stay emergency 
admission at their index admission. If these patients had much better outcomes than other emergency 
admission patients, it would raise the question of whether these were truly emergencies. The short stay 
emergency group had a slightly lower one-year mortality rate than longer stay emergencies (43.9% 
versus 49.8%; p=0.001) but both were substantially higher than that of the elective group (18.0%).  
Resection rates for the short stay emergency group was actually inferior to those presenting with a 
longer stay emergency (31.0% vs. 35.7%; p=0.009) but rates for elective presentations were much 
high (59.1%). Taken together this showed it was reasonable to include patients whose initial length of 
stay was <1 day within the overall emergency group. 
2.5.1.2. Patient outcomes 
Overall, 50.6% of patients had a major surgical resection and the one-year mortality from the index 
admission was 29.3%, Table 2.15.  
2.5.2. Comparison between my study cohort and external CRC data sources 
In this section I explore the validity of my study cohort by comparing the patient characteristics, 
presentation type and outcomes with matched external sources of data. My aim was to show that my 
cohort contained all incident CRC patients with characteristics similar to other published population-
based cohorts. The external data sources used include the National Bowel Cancer Audit Programme 
(NBOCAP), Office for National Statistics (ONS) cancer registration data and key studies from England 
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and elsewhere(2,150). Stringent efforts were made to match the time period and populations as closely 
as possible. Where there are differences in the populations or time period between my data and external 
sources, they are stated in the text. The patient characteristics and outcomes of my study cohort are 
shown in Tables 2.14 and 2.15 and were compared with external sources in Table 2.24. 
I identified 32,299 incident CRC cases in England during my study year, which was comparable to an 
independent estimate of 33,604 new cases for England in 2007(2). The external source for this estimate 
was the Office for National Statistics (ONS), which publishes annual data on CRC registrations in 
England, compiled from regional cancer registries, Table 2.24 (External data 1). 
2.5.2.1. Patient characteristics 
   
2.5.2.1.1. Age 
In my study cohort the mean age was 71 years and the median age 77 years. CRC was rare among 
younger patients and steadily increased with age, especially above 55 years, with the highest numbers of 
cases occurring among 60-85 year olds and falling thereafter, Figure 2.7. In my study cohort 83.4% 
(n=26,952) of patients were aged 60 years and over. The closest external age specific data came from 
the ONS for 2007 where a closely comparable 84.0% (n=33,970) of cases were 60 and over, Table 16, 
24 (External data 2)(2). This age distribution was consistent with other similar studies(2,30). 
Next I compared the number of patients in my study cohort at the extremes of age, with matched 
external data. In my cohort: 1.5% (n=493) of cases were aged <40 years compared to 1.4% 
(583/40,440) in the ONS data for 2007. At the other end of the age spectrum, 11.9% (n=3,829) of my 
cases were aged ≥85 years compared to 12.8% (5,187/40,440) in the 2007 ONS data for the UK(2). 
The similarity of the age profile data, between my cohort and a closely matched external data source 
reassured me that my methodology was not excluding any group of patients based on age. 
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Figure 2.7 My study cohort showed similar trends in crude cancer cases according to age, as a matched 
external source (ONS 2007, colorectal and anal cancers in the UK)(2).  
2.5.2.1.2. Gender  
In my study cohort 55.7% of cases were male and 44.3% female. Similar findings were reported in the 
2007 ONS data, with 55.2% of cases males and 44.8% female, Table 2.16, Table 2.24 (External data 
1)(2). This gender ratio was also found in comparable international studies(218). 
In the study cohort, there were more male patients at all age ranges, except for those aged over 85 
years, Figure 2.10. This finding was exactly matched by external sources from Cancer Research UK data, 
Figure 2.8. 
 
Table 2.16 The Office for National Statistics annual incidence data for 2007 in England was comparable 
to my cohort, in terms of total incident cases reported and gender distribution(2). 
Cases Study cohort, N 
(%) 
ONS, N, (%) 
Total 32,299 33,604 
Male 17,981 (55.7) 18,538 (55.2) 
Female 14,318 (44.3) 15,066 (44.8) 
*Adapted from ONS for 2007. 
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Figure 2.8 Chart taken directly from Cancer Research UK 2007, showing the number of new cases by 
age group and age-specific incidence rates per 100,000 population in the UK (for colorectal and anal 
cancer).  
 
2.5.2.1.3. Co-morbidity 
In my study cohort, the weighted Charlson co-morbidity score was 0 for 67.6% (n=21,847) of patients, 
one for 7.4% (n=2,383) and ≥2 for 25.0% (n=8,069). In one study of 246,469 patients, in England, 
undergoing a colorectal resection between 2000 and 2008, 144,518 (58.6%) had CRC, 64.2% had a 
Charlson score of 0, a further 9.4% had a score of 1-4 and 26.4% had a score ≥5 (150 had the score 
missing)(212). A similar Danish study found 53% of patients had a score of 0, 37% a score of 1-2 and 
the remaining 10% a score of 3 or more(250). A study of 11,524 patients in New Zealand was perhaps 
the most closely matched, finding a Charlson score of 0 in 67.1%, 1 in 17.5% and ≥2 in 15.1%, Table 
2.17, 24 (External data 3)(36). Overall, these data showed that in most studies, including my own, 
around two-thirds of patients have no co-morbidities. There was less agreement between the studies, on 
the frequency of either single or multiple co-morbidities. This was likely to be due to differences in 
coding strategies between the groups.  
 
Table 2.17 A comparison of the frequency of co-morbidities in my study cohort and a matched 
population from New Zealand (36). 
Co-morbidity 
score) Study cohort, N (%) Sarfati et al, N (%)  
0 21,847 (67.6) 7,732 (67.1%) 
1 2,383 (7.4) 2,013 (17.5%) 
≥2 8,069 (25.0) 1,740 (15.1%) 
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2.5.2.1.4. Deprivation   
My study cohort found slightly more patients belonging to the least deprived quintiles (20.4%), 
compared with the most deprived quintile (17.1%), the other quintiles were equally populated. These 
data showed the crude numbers of cancer cases across the deprivation quintiles – and not the ‘rate’ (i.e. 
cases per unit population per year). However as each LSOA contains a similar number of patients 
dividing the country into ‘fifths’ according to LSOA based deprivation scores was also crudely dividing 
the population into five equal groups. Because of this it was reasonable to compare the crude annual 
number of cases in England to external published estimates. There were no directly comparable data of 
CRC cases in deprivation quintiles across England between 2006 and 2007. However, a cross sectional 
study from England (1999-2006) showed no relationship between the level of deprivation and the crude 
number of CRC cases, Table 2.18, 24 (External data 4)(30). The closest ONS data for England covered 
the period 2000-2004 also reported no significant association between CRC rates and deprivation. 
However, in common with our findings, the crude rate for the least deprived quintile was slightly higher 
than for the most deprived, Table 2.19(35). Another study from England during a similar time period 
(1996-2004), found no clear relationship between the CRC frequency and deprivation levels, Table 
2.20(251). A Scottish study for the period covering our cohort (2006-2010) showed similar crude rates, 
but with age-standardised rates higher among more deprived patients, Table 2.21(252).  
Overall, the external data agrees with our findings that, in England, there was no substantial variation in 
crude rate of CRC across categories of socioeconomic deprivation. 
 
Table 2.18 The proportion of CRC patients in each deprivation quintile; comparing my study cohort 
against a cross sectional study from England (1999-2006). 
Deprivation Study cohort, N 
(%) 
Raine et al (30), N 
(%) 
Missing 322 (1.0) 0 (0) 
1 (Least deprived) 6,593 (20.4) 37,041 (19.8) 
2 6,980 (21.6) 39,753 (21.3) 
3 6,844 (21.2) 39,309 (21.0) 
4 6,044 (18.7) 36,470 (19.5) 
5 (Most deprived) 5,516 (17.1) 34,404 (18.4) 
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Table 2.19 A study comparing the crude and age-adjusted rates of CRC in each deprivation quintile in 
England between 2000-2004(35). 
Deprivation N Crude rate ASR* 95% CI 
1 (Least deprived)  27,402 55.3 41.2 40.7-41.6 
2 30,545 61.6 42.3 41.8-42.8 
3 30,821 62 42.9 42.4-43.4 
4 28,953 58 43.4 42.9-43.9 
5 (Most deprived)  24,976 49.8 43.8 43.3-44.3 
*Age standardised rate 
 
Table 2.20 A study from England during the period 1996-2004, found no clear association between 
CRC frequency and the level of deprivation (251).  
Deprivation Male Colon Female 
Colon 
Male 
Rectum 
Female 
Rectum 
Total, N 
(%) 
1 (Least 
deprived) 
16,346 15,492 10,782 6,927 49,547 
(19.3) 
2 
17,563 17,687 11,866 7,964 55,080 
(21.5) 
3 
16,971 17,774 11,611 8,203 54,559 
(21.3) 
4 
15,916 16,469 11,315 7,918 51,618 
(20.1) 
5 (Most 
deprived) 
14,205 13,888 10,869 6,734 45,696 
(17.8) 
 
Table 2.21 The association between deprivation and the frequency and age-standardised incidence rates 
(ASR) of CRC in Scotland between 2006-2010(252). 
Deprivation N ASR Confidence Interval (CI) 
1 (Least deprived) 3,638 50.8 49.1-52.5 
2 3,655 48.6 47.0-50.2 
3 3,972 52.9 51.2-54.6 
4 4,147 56.7 54.9-58.6 
5 (Most deprived) 3,654 56.5 54.6-58.4 
 
 
2.5.2.1.5. Cancer site  
My study cohort was comprised of 9,631 (29.8%) rectal cancers, 2,440 (7.6%) recto-sigmoid cancers 
and 20,228 (62.6%) colonic cancers. The ONS data for 2007-2008, with 38,091 cases, was comparable 
to my study cohort, Table 2.22. There were 10,740 (28.2%) rectal, 2,807 (7.4%) recto-sigmoid and 
24,544 (64.4%) colonic cancers, Table 2.22, 2.24 (External data 2)(2). In both my cohort and the ONS 
data, overlapping or unspecified colonic site codes were included in the colonic cancer group. The fact 
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that these figures are closely matched suggests that it is unlikely that my cohort had systematically failed 
to record cancer from a particular site.   
 
Table 2.22 A comparison of the frequency of CRC cases at different anatomical sites between my cohort 
and the ONS cohort for the United Kingdom in 2007(2). 
Cancer site  Study cohort, N 
(%) 
ONS data N 
(%) 
Rectal 9,631 (29.8) 10,621 (27.9) 
Rectosigmoid 2,440 (7.6) 2,807 (7.4) 
Colon 20,228 (62.6)* 24,663 (64.7)** 
Total 32,299 38,091  
*contains 3,538 overlapping and unspecified colonic case, **contains 3,323 overlapping and unspecified 
colonic cases 
2.5.2.2. Patient presentation  
In my cohort, 63.9% of patients presented electively and 36.1% as an emergency. In Scotland between 
1991 and 1994 comparable proportions of patients presented as elective (69.2%) and emergency 
(30.8%) admissions(198). More recently between 1999 and 2006, an English study of 186,977 CRC 
patients showed 32.5% (n=60,684) of presentations were an emergency, Table 2.24 (External data 
5)(30).   
Many studies only reported on whether surgery was during an elective or emergency admission. In a 
large study of CRC surgery in England 76.8% (n=111,025) of operations were elective and 23.2% 
(n=33,493) emergencies(212). By comparison, I found 74.7% (n=12,284) of operations were during 
elective admissions and 25.3% (n=4,152) during emergency. 
2.5.2.3. Primary outcomes 
2.5.2.3.1. Surgical resection rates  
In my study cohort, 64.0% of patients had operative management, with 50.6% having a major 
resection. This contrasts with the NBOCAP report for 2006/07, which covered most trusts in England 
(135 out of 152) and a smaller number of trusts from elsewhere in the British Isles (n=16, including one 
from the Republic of Ireland), Table 2.23 (150). This report found 73.7% of patients received some 
form of operative management and 59.6% had a major resection. Although the NBOCAP study 
reported a higher operative rate, it had identified far fewer patients (21,170 vs. 32,299). The age, 
gender and cancer site rates were all very similar between the two groups, Table 2.24 (External data 5).  
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Table 2.23 A comparison of data between my study cohort and the NBOCAP report (2006/07), which 
contained 21,170 CRC patients from the UK and Republic of Ireland. The NBOCAP response rate was 
61.5%.  
Variable Study cohort, N (%)  NBOCAP, N (%)  
Cases       Total 32,299 21,170 
            Surgically treated 20,674 (64.0) 15,670 (73.7) 
            Major resections 16,332 (50.6) 12,612 (59.6) 
Gender     Male 17,981 (55.7) 11,785 (55.7) 
            Female 14,318 (44.3) 9,351 (44.2) 
            Not reported 0 34 (0.2) 
Age         ≤ 60 6,053 (18.7) 4,020 (19.0) 
            61-70 8,171 (25.3) 5,535 (26.1) 
            71-80 10,686 (33.1) 7,121 (33.6) 
            >80 7,389 (22.9) 4,492 (21.2)  
            Unknown 0 2 (0.0) 
Site         Colon 20,228 (62.6) 12,478 (58.9) 
            Rectosigmoid 2,440 (7.6) 1,786 (8.4) 
            Rectum 9,631 (29.8) 6,698 (31.6) 
            Unknown 0 208 (1.0) 
   
2.5.2.3.2. One-year mortality 
The one-year mortality rate in my study cohort was 29.3% (28.7% in men and 30.1% in women). This 
was marginally higher than the ONS figures that, between 2004 and 2008, reported rates of 23.7% for 
men and 26.9% for women(253). The ONS one-year mortality rate for 2007 alone was 24.0% for men 
and for 25.0% women, Table 2.24 (External data 1). In another study in England between 2005 and 2007 
the one-year mortality was 25.3%(27).  
 
2.5.2.3.3. Conclusions 
In conclusion, the external data sources results closely match those of my own cohort. This was 
particularly the case for patient characteristics and presentation. In terms of outcomes, I found the 
operative rate was lower in my study cohort and the one-year mortality was higher than the external 
data. 
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Table 2.24 A comparison of the patient characteristics, procedure types and outcomes between my 
study cohort and matched external data sources. 
Variables Total cases External data 1 (2) 
External 
data 2 
(253) 
External 
data 3 (36) 
External 
data 4 (35) 
External 
data 5 
(150) 
Total 32,299 33,604 40,440 11,524 186,977 21,170 
Time period 1 year 1 year 1 year 7 years 7 years 1 year 
Gender, N 
(%)       
Male 17,981 (55.7) 
18,538 
(55.2)     
Female 14,318 (44.3) 
15,066 
(44.8)     
Age group, 
N (%)       
<55 yrs 3,044 (9.4)  3,784 (9.4)    
55-64 yrs 5,872 (18.2)  7,452 (18.4)    
65-74 yrs 9,474 (29.3)  11,701 (28.9)    
75-84 yrs 10,080 (31.2)  
12,316 
(30.4)    
≥85 yrs 3,829 (11.9)  5,187 (12.8)    
Site, N (%)       
Rectal 9,631 (29.8)  10,740 (28.2%)    
Rectosigmoid 2,440 (7.6)  2,807 (7.4%)    
Colon 20,228 (62.6)  
24,544 
(64.4%)    
Co-
morbidity, 
N (%)  
     
0 21,847 (67.6)   
7,732 
(67.1)   
1 2,383 (7.4)   2,013 (17.5)   
≥2 8,069 (25.0)   1,740 (15.1)   
Deprivation, 
N (%)       
IMD missing 322 (1.0)    0 (0)  
1 (most 
deprived) 5,516 (17.1)    
37,041 
(19.8)  
2 6,044 (18.7)    39,753 (21.3)  
3 6,844 (21.2)    39,309 (21.0)  
4 6,980 (21.6)    36,470 (19.5)  
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5 (least 
deprived) 6,593 (20.4)    
34,404 
(18.4)  
Start 
diagnostic 
journey, N 
(%) 
      
Elective 20,648 (63.9)    
126,293 
(67.5)  
Emergency 11,651 (36.1)    
60,684 
(32.5)  
Outcomes, 
N (%)       
Operation 
ever 
20,674 
(64.0)     
15,670 
(73.7) 
Major 
resection 
16,332 
(50.6)     
12,612 
(59.6) 
One year 
mortality 
 9,469 
(29.3) 
males 25.0%, 
females 26.0 
% 
    
 
2.5.3. Associations between patient characteristics and outcomes 
In this section associations between patient characteristics (age, gender, co-morbidity, deprivation and 
cancer site) are described, as well as those between patient characteristics and outcomes. By confirming 
known associations, I again tested the cohort validity.  
2.5.3.1. Age  
 
2.5.3.1.1. Age and other patient characteristics  
In my study cohort older patient groups contained a higher proportion of colon (proximal) cancers. 
56.5% of patients aged <55 years had colon cancer; this increased to 67.7% in those aged over 85 years 
(p<0.001), Table 2.25, Figure 2.9. Overall, the mean age of rectal cancer patients was 69.7 years (sd 
12.2), which was lower than for rectosigmoid cancer patients at 70.2 years (sd 11.7) and colon cancer 
patient at 71.6 years (sd 12.1)(P>0.05). This association has been found in other studies(254).  
I found that patients over 55 years old, had a significant increase in co-morbidity scores of one or higher, 
compared to younger patients, (p<0.001), Table 2.26. This has also been shown in a systematic review 
of 28 studies(255).  
In older age groups, there were progressively fewer patients from deprived quintiles. Compared to the 
other quintiles in patients over 74 years there were significantly fewer patients in the most deprived 
quintile (p<0.001), Table 2.27. Once again this finding has been reported previously (252). 
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Table 2.25 A table showing the association between age and cancer site my study cohort. 
Site  
Total, N 
(%) 
<55, N (%) 
55-64 yrs, 
N (%) 
65-74 yrs, 
N (%) 
75- 84 yrs, 
N (%) 
≥85 yrs, N 
(%) 
Rectal 9,631 (29.8) 
1,077 
(35.4) 
2,030 
(34.6) 
2,841 
(30.0) 
2,680 
(26.6) 
1,003 
(26.2) 
Rectosigmoid 2,440 (7.6) 246 (8.1) 473 (8.1) 778 (8.2) 709 (7.0) 234 (6.1) 
Colon 
20,228 
(62.6) 
1,721 
(56.5) 
3,369 
(57.4) 
5,855 
(61.8) 
6,691 
(66.4) 
2,592 
(67.7) 
 
 
 
Figure 2.9 Increasing age was associated with a proportionally more proximal cancers in the study 
cohort.  
 
Table 2.26 A table showing the association between age and co-morbidity my study cohort. 
Co-
morbidity 
score 
Total, N 
(%) 
<55, N (%) 55-64 yrs, 
N (%) 
65-74 yrs, 
N (%) 
75-84 yrs, 
N (%) 
≥85 yrs, N 
(%) 
0 
21,847 
(67.6) 
2,221 (73.0) 
4,160 (70.8) 6,500 (68.6) 6,550 (65.0) 
2,416 (63.1) 
1 2,383 (7.4) 100 (3.3) 324 (5.5) 699 (7.4) 906 (9.0) 354 (9.2) 
≥2 8,069 (25.0) 723 (23.8) 1,388 (23.6) 2,275 (24.0) 2,624 (26.0) 1,059 (27.7) 
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Table 2.27 A table showing the association between age and deprivation in my study cohort. 
Deprivation Total, N  <55, N (%) 55-64 yrs, N 
(%) 
65-74 yrs, N 
(%) 
75-84 yrs, N 
(%) 
≥85 yrs, N  
(%) 
IMD missing 322 (1.0) 67 (2.2) 74 (1.3) 92 (1.0) 69 (0.7) 20 (0.5) 
1 (most 
deprived) 
5,516 (17.1) 608 (20.0) 1,004 (17.1) 1,665 (17.6) 1,599 (15.9) 640 (16.7) 
2 6,044 (18.7) 580 (19.1) 1,068 (17.1) 1,729 (18.2) 1,948 (19.3) 719 (18.8) 
3 6,844 (21.2) 580 (19.1) 1,219 (20.8) 2,010 (21.2) 2,178 (21.6) 857 (22.4) 
4 6,980 (21.6) 574 (18.9) 1,302 (22.2) 2,035 (21.5) 2,220 (22.0) 849 (22.2) 
5 (least 
deprived) 
6,593 (20.4) 635 (20.9) 1,205 (20.5) 1,943 (20.5) 2,066 (20.5) 744 (19.4) 
 
2.5.3.1.2. Age and outcomes   
In my study cohort, older patients (≥85 years) were significantly less likely to have a major surgical 
resection (p<0.001), Table 2.28. In patients under 65 years old the rate was over 50%, this fell to 
31.4% in patients over 65 years (p<0.001). Furthermore, older patients had a higher chance of death 
within one year. Amongst the oldest age group (≥85 years) one-year mortality was 50.5%, compared 
with 18.0% in the youngest age group (<55 years). Other studies have also found that age was a 
negative predictor for survival(256).  
 
Table 2.28 A comparison between age and outcomes (surgical resection and one-year mortality). In my 
cohort, the oldest age group had significantly fewer operations and lower one-year survival. 
Age groups (years) Surgical Resection, N 
(%) 
One-year Mortality, N (%) P value 
<55  1,662 (54.6) 548 (18.0)  
55-64  3,367 (57.3) 1,164 (19.8)  
65-74  5,243 (48.2) 2,301 (24.3)  
75-84  4,856 (48.2) 3,522 (34.9)  
≥85 1,204 (31.4) 1,934 (50.5) <0.001 
 
2.5.3.2. Gender 
 
2.5.3.2.1. Gender and other patient characteristics   
In my study cohort, female patients were on average older at presentation than male patients (71.9 years 
vs. 70.2 years, [p<0.05]). Males made up a larger proportion of cases up until 80 years, after that 
improved female life expectancy reversed the trend, Figure 2.10. Patients aged 80 and over accounted 
for 31.2% of female patients, but only 22.0% of male patients, Table 2.29. One consequence of the 
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different age distributions was the proportion of male and female CRC patients that could be “exposed” 
to the Bowel Cancer Screening Programme (BCSP). At the time of my study, the BCSP recruited 
patients aged 60-69 years. This age range covered 27.0% of male and 21.0% of female CRC patients 
(p<0.001), Table 2.29. According to the census in 2011, there are 6,824,000 individuals aged 60-69 
years in the UK. This equates to 10.8% of the population. The Cancer Reform Strategy announced that 
from April 2010, the NHS BCSP would increase its screening age up to the 75th birthday for both men 
and women. According to the 2011 census this equated to 14.7% of the total population. In my cohort, 
this covers 44.3% of male and 35.4% of female CRC patients, Table 2.30. Numerous other studies have 
shown that women present at an older age than men(257,258).  
 
 
Figure 2.10 A chart describing the number of male (blue) and female (red) CRC patients at different 
ages. Male patients were more numerous and on average were diagnosed at a younger age.  
 
Table 2.29 The number of male and female patients in different age groups in my study cohort. In 
particular this highlights that a significantly higher proportion of male patients (27% vs. 21%) were in 
the BCSP age range (60-69 years). 
Age groups (years) Male, N (%) Female, N (%) P value 
<60 2,962 (16.5) 2,385 (16.7)  
60-69* 4,861 (27.0) 3,007 (21.0) <0.001 
70-79 6,196 (34.5) 4,455 (31.1)  
>79 3,962 (22.0) 4,471 (31.2)  
*The screening age group. 
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Table 2.30 The number of male and female patients in different age groups in my study cohort, after the 
age extension of the BCSP to include 70-74 year old patients (from April 2010). A significantly higher 
proportion of male CRC patients were within the screening age group. 
Age groups (years) Male, N (%) Female, N (%) P value 
<60 2,962 (16.5) 2,385 (16.7)  
60-74* 7,969 (44.3)  5,074 (35.4) <0.001 
75-84 5,446 (30.3) 4,634 (32.4)  
>84 1,604 (8.9) 2,225 (15.5)  
*The screening age group. 
 
Male patients were more likely to have rectal cancer (32.9%, [5,915/17,981]) than female patients 
(26.0% [3,716/14,318]), Table 2.31. This may be another reason for the superiority of screening men, 
as rectal cancer is more often picked up by FOBt than colon cancer(73). At all three cancer sites (rectal, 
recto-sigmoid and colon) male patients are diagnosed at an earlier age, Table 2.32.   
Gender did not appear to have any significant impact on the level of co-morbidity reported at the first 
CRC coded admission, Table 2.33. There were almost identical rates of male and female patients having 
a Charlson co-morbidity score of 0 (67.3% vs. 68.1%, P=0.149). Finally, male and female patients had 
almost identical levels of deprivation, Table 2.34. 
 
Table 2.31 A comparison of cancer site and gender identified that male patients were significantly more 
likely to present with rectal cancer.  
Site  Total, N (%) Male, N (%) Female, N (%) P value 
Rectal 9,631 (29.8) 5,915 (32.9) 3,716 (26.0) <0.001 
Rectosigmoid 2,440 (7.6) 1,429 (7.9) 1,011 (7.1)  
Colon 20,228 (62.6) 10,637 (59.2) 9,591 (67.0)  
  
Table 2.32 A comparison of cancer site and the age of presentation for male and female patients. At all 
sites male patients were diagnosed at a younger age 
Site Total, N (sd) Male, N (sd) Female, N (sd) P value 
All 71.0 (12.1) 70.2 (11.5) 71.9 (12.8) <0.001 
Rectal 69.7 (12.2) 69.1 (11.5) 70.7 (13.3) <0.001 
Rectosigmoid 70.2 (11.7) 69.8 (11.0) 70.7 (12.6) 0.056 
Colon 71.6 (12.1) 70.9 (11.6) 72.4 (12.6) <0.001 
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Table 2.33 A comparison of co-morbidity and gender. 
Co-morbidity Total, N (%) Male, N (%) Female, N (%) P value 
0 21,847 (67.6) 12,102 (67.3) 9,745 (68.1) 0.151 
1 2,383 (7.4) 1,370 (7.6) 1,013 (7.1)  
≥2 8,069 (25.0) 4,509 (25.1) 3,560 (24.9)  
 
Table 2.34 A comparison of deprivation and gender. 
Deprivation Male, N (%) Female, N (%) 
IMD missing 181 (1.0) 141 (1.0) 
1 (most deprived) 3,139 (17.5) 2,377 (16.6)  
2 3,285 (18.3) 2,759 (19.3) 
3 3,772 (21.0) 3,072 (21.5) 
4 3,898 (21.7) 3,082 (21.5) 
5 (least deprived) 3,706 (20.6) 2,887 (20.2) 
 
2.5.3.2.2. Gender and outcomes   
In my cohort, gender did not have a significant impact on the crude surgical resection rate. The crude 
one-year mortality rate was higher among females but this was not adjusted for females presenting on 
average later, Table 2.35. 
   
Table 2.35 A comparison of the surgical resection and one-year mortality rates between male and 
female patients in my cohort. 
Gender Surgical Resection, N 
(%) 
One-year Mortality, N 
(%) 
Male 9,142 (50.8) 5,156 (28.7) 
Female 7,190 (50.2)* 4,313 (30.1)** 
*P=0.264, **P=0.005 
2.5.3.3. Co-morbidity 
2.5.3.3.1. Co-morbidity and other patient characteristics  
I have already confirmed the expected increase in co-morbidity with advancing age (section 2.6.3.1). In 
this section, I demonstrate an association between co-morbidity and colon cancer. Amongst patients 
with colon cancer 27.5% had ≥2 co-morbidities, compared with 18.3% of rectal cancer patients 
(p<0.001). This can be partially explained by the increased proportion of colon cancers with advancing 
age. As already shown, the mean age of presentation with colon cancer was higher than for rectal cancer 
(71.6 yrs vs. 69.7 yrs vs. p<0.05), Table 2.36. 
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There was a moderate association between increasing levels of co-morbidity and increasing deprivation. 
The most deprived quintile had more patients with one or more co-morbidities than the other quintiles 
combined (p=0.003), Table 2.37. 
 
Table 2.36 A comparison of co-morbidity and cancer site. Patients with colon cancer had higher co-
morbidities than those with rectal cancer (p<0.001). 
Co-
morbidity 
Total, N 
(%) 
Rectal, N 
(%) 
Rectosigmoid, N 
(%) 
Colon, N (%) P value 
0 21,847 (67.6) 7,149 (74.2) 1,550 (63.5) 13,148 (65.0)  
1 2,383 (7.4) 720 (7.5) 150 (6.1) 1,513 (7.5)  
≥2 8,069 (25.0) 1,762 (18.3) 740 (30.3) 5,567 (27.5) <0.001 
 
Table 2.37 A comparison of deprivation and co-morbidity. More patients in the most deprived quintile 
had a co-morbidity than in the other quintiles (p=0.003). 
Deprivation Total,  
N (%) 
Co-morbidity 0, 
N (%) 
Co-morbidity 1, 
N (%) 
Co-morbidity ≥2, 
N (%) 
P value 
IMD missing 322 (1.0) 183 (56.8) 20 (6.2) 119 (37.0)  
1 (most 
deprived) 
5,516 (17.1) 3,644 (66.1)  
461 (8.4) 1,411 (25.6) 0.003* 
2 6,044 (18.7) 4,015 (66.4) 478 (7.9) 1,551 (25.7)  
3 6,844 (21.2) 4,626 (67.6) 537 (7.8) 1,681 (24.6)  
4 6,980 (21.6) 4,736 (67.9) 477 (6.8) 1,767 (25.3)  
5 (least 
deprived) 
6,593 (20.4) 4,643 (70.4) 
410 (6.2) 1,540 (23.4)  
*excluding IMD missing.  
 
2.5.3.3.2. Co-morbidity and outcomes   
I found the presence of even a single co-morbidity led to significantly lower surgical resection rates 
(49.9% vs. 57.3%, p<0.001). Equally, a single co-morbidity was associated with a higher one-year 
mortality rate (20.4% to 30.0%, p<0.001), Table 2.38. This finding is supported by a study from 
Denmark that used a similar definition of co-morbidity and found that increasing co-morbidity and 
proximal site interacted to reduce major surgical resection rates(250).  
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Table 2.38 A comparison of the surgical resection and one-year mortality rates between patients with 
different levels of co-morbidity. 
Co-
morbidity 
Surgical Resection, N (%) One-year Mortality, N (%) P value 
0 12,511 (57.3) 4,452 (20.4)  
1 1,189 (49.9) 715 (30.0)  
≥2 2,632 (32.6) 4,302 (53.3) >0.001 
 
2.5.3.4. Deprivation 
2.5.3.4.1. Deprivation and other patient characteristics  
In my cohort, I have already shown that increasing deprivation is associated with an earlier age of CRC 
diagnosis and increased likelihood of co-morbidity (section 2.6.3.1 and 2.6.3.3). The mean age of 
patients in the most deprived quintile was 70.2 years (sd 12.7), compared to 71.1 years (sd 12.0) among 
patients from other quintiles (p<0.001]), Table 2.39.  
 
Table 2.39 Showing the age of CRC presentation for patients in the different deprivation quintiles.  
Deprivation Age, yrs. (sd) 
IMD missing 65.2 (14.3) 
1 (most deprived) 70.2 (12.7) 
2 71.0 (12.2) 
3 71.4 (11.9) 
4 71.3 (11.8) 
5 (least deprived) 70.9 (12.0) 
 
 
2.5.3.4.2. Deprivation and outcomes  
I found surgical resection rates were lower, and one-year mortality rates higher, in patients in the most 
deprived quintile, Table 2.40. The crude surgical resection rate fell from 54.1% in the least deprived 
quintile to 41.0% in the most deprived quintile (p<0.001), while the one-year mortality rate increased 
from 26.9% to 32.2% (p<0.001).  
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Table 2.40 A comparison of the surgical resection and one-year mortality rates between patients with 
different levels of deprivation. 
Deprivation Surgical Resection, N (%) One-year Mortality, N (%) P value 
Missing 132 (41.0) 58 (18.0)  
1 (most deprived) 2,566 (46.5) 1,775 (32.2)  
2 2,959 (49.0) 1,905 (31.5) >0.001 
3 3,495 (51.1) 1,991 (29.1) >0.001 
4 3,614 (51.8) 1,965 (28.2) >0.001 
5 (least deprived) 3,566 (54.1) 1,775 (26.9) >0.001 
 
2.5.3.5. Cancer site 
2.5.3.5.1. Cancer site and other patient characteristics  
I have already shown the association between cancer site and age (colon type cancer appears more 
commonly in older patients), gender (rectal cancer was commoner among males) and co-morbidity 
(colon cancer patients had greater co-morbidity). In the final comparison between CRC site and other 
patient variables I found no association between site and the level of deprivation. This included a 
comparison of the most deprived quintile to the other quintiles that showed no significant difference in 
the proportion of colon site cancers to rectal and rectosigmoid cancers (p=0.215), Table 2.41. There 
was limited data in the literature regarding CRC site and deprivation, although one study from the USA 
reported a higher incidence rate of proximal cancer among patients from deprived areas(259). 
 
Table 2.41 A comparison of deprivation and the site of CRC. 
Deprivation Total, N (%) Rectal, N (%) Rectosigmoid, 
N (%) 
Colon, N (%) P value 
IMD missing 322 (1.0) 94 (29.2) 22 (6.8) 206 (64.0)  
1 (most 
deprived) 
5,516 (17.1) 1,684 (30.5) 
419 (7.6) 3,413 (61.9)  0.215 
2 6,044 (18.7) 1,856 (30.7) 459 (7.6) 3,729 (61.7)  
3 6,844 (21.2) 1,993 (29.1) 539 (7.9) 4,312 (63.0)  
4 6,980 (21.6) 2,060 (29.5) 542 (7.8) 4,378 (62.7)  
5 (least 
deprived) 
6,593 (20.4) 1,944 (29.5) 
459 (7.0) 4,190 (63.6)  
*excluding IMD missing.  
 
2.5.3.5.2. Cancer site and outcomes 
In my cohort, I found that rectal cancers had a lower resection rate than colon cancer. I also found that 
one-year mortality was lower for rectal cancers, Table 2.42, as shown in other studies(241). 
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Table 2.42 A comparison of the surgical resection and one-year mortality rates between patients with 
CRC at different sites. Compared to colon cancer, distal cancer site was associated with significantly 
lower surgical resection rates and lower rates of one-year mortality. 
 
Cancer site Surgical Resection, N (%) One-year Mortality, N 
(%) 
P value 
Rectal 4,647 (48.1) 2,488 (25.8)  
Rectosigmoid 1,164 (47.7) 756 (31.0)  
Colon 10,531 (52.1) 6,225 (30.8) >0.001 
 
2.5.3.6. Summary  
2.5.3.6.1. Summary of the associations between patient characteristics 
This section summarizes the relationships found in my cohort between fixed patient characteristics and 
the findings from other studies. 
1. Increasing patient age and a shift to more colon cancers 
I found a proximal shift in CRC site with increasing age, as has been described in other 
comparative studies(254,260).  
2. Increasing age and increasing co-morbidity 
I found increasing co-morbidity was associated with increasing age, as has been described 
previously(254,255). In fact age has often been used as a surrogate marker for co-morbidity. 
3. Male patients were diagnosed at a younger age and a higher proportion were in the BCSP age range 
I found men develop CRC at an earlier age than women and this can affect access to the BCSP. 
Other comparative studies support this finding (257,258,261). 
4. Male patients have a higher incidence of rectal cancer 
I found male patients are more likely to have distal cancers, with the gender disparity 
increasing steadily from the caecum to the rectum. Other comparative studies support this 
finding(254,262,263). 
5. Increasing co-morbidity and prevalence of colon cancer site 
I found patients with increasing levels of co-morbidity are more likely to have a proximal CRC. 
This is supported by a comparative study(264).  
6. Increasing co-morbidity and increasing deprivation 
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Among my cohort, I found an association between patients with higher levels of co-morbidity 
and increasing levels of deprivation. As expected, levels of co-morbidity were higher among 
people living in more deprived areas, consistent with known population trends (265). 
7. Increasing deprivation and diagnosis at a younger age  
I found that that deprived patients are diagnosed at an earlier age. I also showed they had higher 
emergency presentation rates and lower resection rates, which is supported by another UK 
CRC cohort 
(235).  
2.5.3.6.2. Summary of the associations between patient characteristics and outcomes  
This section summarises the relationships I found in the study cohort between the fixed patient 
characteristics and the primary outcomes (surgical resection and one-year mortality). I found statistically 
significant associations between: 
• Increasing age and reduced surgical resection and higher one-year mortality. 
• Women and increased one-year mortality (likely confounded by age at presentation). 
• Increasing co-morbidity and reduced access to surgical resection and higher one-year mortality. 
• Proximal cancer and reduced surgical resection and higher one-year mortality. 
• Increasing deprivation and reduced surgical resection and higher one-year mortality. 
2.6. Discussion 
2.6.1. Overview 
This chapter demonstrated my novel methodological approach to creating a dataset from HES could 
accurately identify patients diagnosed with CRC in England in the one-year period from October 2006 
to September 2007. I applied clinically sound algorithms to the HES data to identify when patients first 
presented with CRC (index admission), how they presented and what their outcome was.   
My approach allowed me to capture all incident CRC patients and exclude the prevalent ones. My 
database contained all patient admissions and gave me access to: the important patient characteristics; 
the date and mode of initial presentation (elective or emergency) and outcomes (major surgical 
resection and one-year mortality). I recorded other important milestones such as the date of lower 
gastrointestinal endoscopy.  
I demonstrated a novel methodology to identify the date patients first presented to hospital along with 
data to suggest that this approach was an improvement upon the standard approach to analysing HES 
data. I called this first relevant admission the ‘index admission’. Importantly, this allowed me to identify 
a patient’s mode of presentation; elective or an emergency. This mode of presentation is strongly 
associated with CRC outcome and is discussed in more detail in chapter 3. My method of identifying the 
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index admission did not rely only on the first coding of CRC, but on establishing the first relevant 
admission. I believe this better identifies the earliest point of secondary care contact for patients. This 
approach established that there was a substantial group of patients (23.1%) with a relevant admission 
before CRC had first been coded, which I believe represents the beginning of the patient journey. I 
substantiated this by showing that the coded procedures at the earlier ‘index admission’ were more 
predictive of a CRC presentation than those at the first CRC coding. In fact, the first coding of cancer 
admission was often the second cancer related admission. It was particularly striking that at the ‘index 
admission’; the proportion of patients having a lower gastrointestinal endoscopy (the key diagnostic 
tool) was substantially higher than at the first CRC coding (the admission used in most of the published 
literature in the field).  
This novel methodological approach identified more patients with an emergency presentation than 
traditional methods. This was because CRC codes were often lacking at the index admission, especially 
when the presentation was as an emergency(214). This was important because, as I describe in chapter 
3, the presentation method is highly correlated with outcomes such as access to major resection and 
one-year mortality. Once we can accurately identify how a patient presents, we can study how changes 
in healthcare delivery affect the rate of emergency presentations. For example, a reduction in 
emergency presentation with the introduction of the BCSP might suggest more positive outcomes 
would be likely to occur downstream, such as overall survival at five years. I hope my approach may 
provide a model for future studies. 
I compared the results in my study cohort with comparable and matched external studies. The relative 
equivalence of these results provided further evidence supporting my methodology. Having established 
the validity of the methodological approach, I further investigated the associations between the key 
patient characteristics and looked at the rates of the different presentation types (elective or emergency) 
and outcomes (surgical resection and one-year mortality rates). 
2.6.2. Discussion of the methodological approach 
I took a number of steps to identify all incident cases of CRC in the study period. Firstly, I identified all 
patients with a code for CRC at any position in the HES record. Next, I identified all admissions to 
hospital for these patients, even if a given admission did not code for CRC. Finally, I removed patients 
that appeared to have the CRC code as co-morbidity and not as an incident case.  
I showed that identifying cases that had a CRC code at any position, rather than just the primary 
diagnosis (or first position code) was a good way of capturing the maximum number of patients through 
the HES system. The advantage of this was especially apparent for emergency cases and patients that 
presented in extremis with a short survival from presentation. Identifying such patients was obviously 
important in attempting to understand the full spectrum of disease in England. Yet these cases could be 
missed if a presentation initially coded a symptom code such as rectal bleeding or obstruction at position 
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one, with CRC at a later coding position. In particular, patients presenting as an emergency are coded 
poorly, as are those who died during the presenting episode or shortly afterwards and did not have 
further elective admissions where the coding may have been more accurate. Therefore my 
methodological approach was likely to have made two significant adjustments not seen in traditional 
approaches; a) to identify a proportion of patients whose earliest contact with secondary care is with an 
emergency presentation that was not previously recognised because the CRC code was lacking and b) to 
include a group of patients not previously identified, those lacking a CRC code at position one. These 
patients will tend to have worse outcomes with a lower rate of surgery and higher one-year mortality 
rate than patients identified from primary diagnosis code alone. I believe this was one reason why the 
cohort study outcomes were slightly worse than similarly matched external reports (e.g. the NBOCAP 
report for 2006/7) - I was identifying some patients not picked up by other analyses of HES data and 
cancer registries. When considering the reverse possibility, that I had included patients with a CRC code 
as co-morbidity or coded incorrectly one needs to understand the steps taken to mitigate this risk. 
Identifying patients with the worst outcomes is important because they are the group with most to 
benefit from interventions. By reducing this variation in outcomes, the overall care of English patients 
with CRC will be improved. 
By identifying all admissions for patients with one or more CRC codes, I maximised the information 
obtainable for each patient. Recording only episodes where CRC was coded would create a database of 
around 250,000 episodes, while my approach identified 360,000 episodes. This was especially 
important for identifying when the index admission was from an earlier relevant admission (see section 
2.5.2.2). Without this analysis a day case admission for a diagnostic colonoscopy before the CRC1 
admission would not have been identifiable as the ‘index admission’ despite its obvious relevance to the 
CRC pathway.  
I also demonstrated methodological rigour by firstly searching for important codes at the episode level. 
This eliminated the possibility of missing a code only recorded in a finished consultant episode that was 
not recorded in the final episode for that admission.  
Prevalent cases and cases incorrectly coded with CRC would initially have been captured by my 
approach. I needed refinement to remove these cases and to do so I made three adjustments to the 
cohort. Firstly, for any patient without a CRC code in the first two diagnostic positions at any admission 
I judged it unlikely that the case was active or new and these were excluded. Secondly, patients with a 
miscoding were removed; these were taken to be patients with more than one non-CRC gastrointestinal 
malignancy code and only a single CRC code. If there were two or more CRC codes then the patients 
was retained with the presumption this referred to synchronous cancers. Lastly, patients with a 
colorectal operation before the CRC1 were removed. Again the justifiable assumption was made that 
this was more likely to represent an operation for a cancer diagnosed before the start of the study period 
(i.e. a prevalent CRC case).    
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I incorporated other strategies to try and improve the study cohort’s accuracy. For example, I was 
aware that some hospitals have a policy of coding many more co-morbidities than others. This creates 
the ‘constant risk fallacy’ whereby patients of comparable health appear to have more co-morbidity in 
highly coding units. The effect of this is to imply these highly coding units have better outcomes for 
matched co-morbidity, compared to units that code less thoroughly. To mitigate against this, I restricted 
co-morbidity to three groups (0, 1 and more than 1) thus reducing the effect of case mixed adjustment 
caused by some units recording a much greater number of co-morbidities(244).  
2.6.3. How to accurately identify the admission when the patient first presents  
As mentioned in the introduction (section 1.4.3), HES data does not contain a date of diagnosis. Yet 
knowing the date when a patient first presents is vital for understanding a patient’s journey as well as 
mortality outcomes (such as death within one-year of presentation). Previous studies have tended to 
mark the diagnosis date as the same admission when the cancer code first appeared. This is despite 
evidence showing the first coding of a disease is often not the patient’s first presentation with the 
condition (2,244). This was why I went to lengths to identify if there was an earlier relevant admission 
(REL1). I identified the REL1 as the first admission within six months of the CRC1, with a diagnosis or 
procedure code consistent with CRC presentation. If no such admission was found, I retained the CRC1 
as the ‘index admission’. Codes were only defined as relevant after appraisal by a steering group with 
experience in CRC and large database analysis. I used a broad inclusion criterion for relevant diagnoses 
and procedures, as my entire cohort would eventually be diagnosed with CRC. These admissions with a 
relevant diagnosis code, but not a CRC code, were more likely to mark the beginning of the patient’s 
journey. Put another way, if a patient presents with a symptom or sign of cancer but the cancer is not 
recorded, the admission was still caused by the underlying cancer.  
I next set out to show that these REL1 admissions more accurately identified a patient’s presentation 
than the CRC1. To do this I compared the procedures recorded at the REL1 and CRC1 admissions. The 
most important observation was the rate of lower gastrointestinal endoscopy codes (the primary method 
of diagnosing CRC) were significantly higher in the REL1, rather than CRC1 admission (52.5% vs. 
36.8%, P<0.001).  
Having demonstrated the improved accuracy of using REL1 as the index admission I next described how 
the rates of elective and emergency admissions were affected by a change in presentation date. By 
accepting the REL1 admission as the start of the patient’s pathway, the number of cases defined as an 
emergency increased from 32.0% to 36.1%. This was because the EmEl group (n=1,954) was larger 
than the ElEm group (n=634). This was an important observation, as it showed my methodology had 
identified more patients as having an emergency presentation, than using traditional methods. This 
approach also lengthens these patients’ diagnostic journeys and slightly increases overall survival.  
 124	
The final evidence supporting the use of the first relevant admission comes from comparing the rates of 
procedural codes for all six possible cancer pathways. I showed that the three pathways starting with an 
elective presentation (El, ElEl and ElEm) all had very similar rates of lower gastrointestinal endoscopies. 
Likewise those from the three emergency pathways (Em, EmEm and EmEl) all had similar rates of 
lower gastrointestinal endoscopies to each other. In conclusion, patients that started their care pathway 
electively were distinct from those starting with an emergency.  
2.6.4. Proving the accuracy of the study cohort 
Before accepting the findings from my study cohort, I needed to further test its validity, by comparing 
the findings to accurate and comparable external data sources. After this I would be justified in using the 
cohort data to explore standard and novel associations in this chapter and in the rest of the thesis.  
In terms of the number of case identified and patient characteristics the study cohort was very close to 
other external data sources. The total number of patients in my cohort (n=32,299) closely matched 
other data sources for the annual incidence of CRC in England. Furthermore, the basic demographic 
profile for age, gender, cancer site and deprivation closely matched other published findings(150). The 
exception was for co-morbidity, it was difficult to find closely matched studies for comparison(36). The 
fact that the overall number of cases identified was so similar, and that the majority of characteristics 
were matched, made it unlikely there was any systematic failure to identify any specific group of 
patients.  
With regards to presentation type, my cohort had a slightly higher emergency presentation rate than 
comparable studies. I believe this was actually the result of better patient identification, for one reason, 
emergency admissions are more poorly coded than elective admissions. This meant it was more likely 
that a CRC code will not appear at an emergency index admission than an elective one(214). Secondly, 
emergency patients are often sicker patients, more likely to die without a full investigation and certainly 
before definitive surgery. Therefore cancer registries fail to identify more of these types of patients. 
Both of these reasons suggest that traditional methodological approaches will have tended to 
underreport the emergency presentation rate. Patients with an elective CRC1 admission and an earlier 
emergency REL1 admission provided supporting evidence for this observation. This group of patients 
had rates of diagnoses and procedures (in particular red flag symptoms and lower endoscopies) at the 
REL1 admission that more closely matched those of other patients presenting as an emergency. 
My study cohort had lower rates of major surgical resection than recorded in the NBOCAP during the 
same time period. This report may have under-reported non-surgically managed cases due to selection 
bias(202). This may be because data entry relies on input from colorectal surgeons who may not be 
closely involved in the care of patients unsuitable for any operative intervention (e.g. palliative cases). 
The NBOCAP report estimated a data capture rate of 61.5%, based on analysis from the cancer 
registries that inform ONS data(150). It is therefore possible that the operative rate in the unrecorded 
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patients was considerably lower. Under-reporting of operations in HES was unlikely because it is such 
an important intervention and results in a large PbR tariff. Similarly, recordings of procedures in HES is 
known to be very high(203).  
In my cohort the one-year mortality rate was 29.3% compared to 25.3%, in the most closely matched 
external data (27). As with the surgical resection data the slightly worse outcome in my cohort made me 
consider whether I had included in my cohort a population of patients normally missed from other 
registries. In these groups there would be more emergency presentations, less accurate coding, at least 
at the start of the pathways, and worse overall outcomes. Therefore reasons for the disparity may be the 
exclusion of some advanced CRC cases from the cancer registries databases or potentiality the retention 
of some prevalent cases in our cohort.  
Overall the distributions of patient characteristics were similar to those from comparative data sources. 
There were differences in the rates of emergency presentation, surgical resection and to a lesser degree 
one-year mortality. However, the reasons for this may relate to better data capture of advanced cancer 
cases in my cohort. 
As explained above (in sections 2.5.1, 2.5.2), I took a number of additional steps to ensure accuracy and 
completeness of my cohort. This level of scrutiny has not normally been described by groups using HES 
data in general(266) and specifically in using HES to investigate CRC(267). Some HES based studies 
have used a similar approach to my own but not in the context of CRC or screening(244). 
Most of the published work on CRC outcomes arise from single centres or are based on evaluating 
specific treatments(72). There is less work on unexplained variation in the quality of care delivered at 
the national level, despite this having been identified as a significant issue(268). The annual report from 
the NBOCAP is the most comprehensive and highly regarded report and should be used to benchmark 
any new analysis of CRC care in England(150). It is a clinical database and as such it was relevant to 
consider the differences between information obtained from a clinical registry and that from routinely 
collected data, such as HES. 
Firstly, although HES-based studies have been criticized in the past for having poor data quality, this 
tended to come from studies from a decade or more ago(269). The latest evidence shows that routinely 
collected hospital data are improving and of sufficient quality to be used for both research and clinical 
decision making purposes (203,204).  
Only one study has looked at the accuracy of HES data against a CRC specific clinical registry 
(NBOCAP)(211). Garout et al, a decade ago compared CRC patients undergoing surgery and found 
HES recorded 53% more patients than the ACPGBI audit(211). This discrepancy was partly due to 
some units not returning any outcomes to the NBOCAP, however even in units returning data, the rate 
was 12% lower than HES. On average the NBOCAP reported 13 fewer cases per unit. Interestingly the 
difference in surgical rates between the two databases was lowest for the more for complex operations 
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(e.g. anterior resection) usually performed by dedicated colorectal surgeons and highest for simpler 
emergency operations (e.g. Hartmann’s procedure, often performed as an emergency by the on-call 
non-specialist surgeon on the sickest patients). This supports my view that my methodology for data 
capture was robust for capturing more CRC patients and especially those patients that were sickest and 
potentially received substandard or limited hospital care. These patients are often the oldest patients and 
it is interesting to note that patients in the NBOCAP audit (2007/8) were younger (21.2%; of patients 
aged >80 years) compared with my cohort (22.9%). In the same study, the mortality rates following 
surgery were comparable (with a <1% difference), but this study did not identify out of hospital deaths 
in the HES database. I could safely assume that including “out of hospital deaths” would increase the 30-
day mortality rate in the NBOCAP cohort and bring the result closer to the rate identified in my cohort. 
One final thought is that combining both data sources could be a useful way of monitoring outcomes in 
units. If both analyses identified concerns with performance, then a more enhanced assessment of quality 
could be instigated.  
Finally, compared with the cost of maintaining a clinical registry the cost of a single HES patient record 
is far cheaper, estimated at £1 compared to £60(270). 
2.6.5. Associations between patient characteristics  
I found that older patients were more likely to be diagnosed with colon cancers. This proximal shift in 
CRC site with increasing age has been described in other studies(254,260). This was important as 
compared with distal CRC proximal CRC tends to present with more advanced disease and has worse 
outcomes (264). This may be another reason why there are more emergency presentations and worse 
outcomes in older patients and another reason why flexible sigmoidoscopy alone is not an acceptable 
way to investigate symptoms in older patients. 
Unsurprisingly I found that older patients (over 74 years) were significantly more likely to have one or 
more co-morbidities than younger patients. Increasing co-morbidity has previously been associated with 
older patients diagnosed with CRC(254,255). This was unsurprising, as age is commonly perceived to 
be a surrogate marker for co-morbidity. It needs to be remembered that older patients with CRC are a 
heterogeneous group that include patients with an otherwise excellent health status. If age is solely used 
instead of co-morbidity then there is a risk of undertreating older patients, because of biased clinician 
preferences. I have shown that increasing age is associated with worse outcomes. This is reported in 
other studies, especially when the patient is unmarried and living alone(256).  
I found male patients were diagnosed on average earlier than females. This finding has been replicated in 
other studies (257,258,261). This has a number of potential implications; firstly it means any data 
looking to see if outcomes differed by gender would need to be matched for age and secondly that a 
higher proportion of males are in the BCSP age range. This will be discussed in chapter 4 but could 
create bias in the potential effect of screening irrespective of different uptake rates of screening based on 
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gender. Along with gender variation in screening test sensitivity, the age distributions for males and 
females may be one reason for the apparent superiority of screening for male patients(271). Some 
authors have even suggested this is should mean CRC screening should be offered at different age ranges 
depending on gender (261). 
In my cohort male patients have a higher rate of rectal cancer than females, with proximal CRC being 
found more commonly in women. It has been described previously how the proportion of CRC cases 
that are men increases steadily on moving from the caecum to the rectum (254,257,262,263,272,273). 
This maybe another reason for the apparent better outcomes for men. Finally, it has been shown that 
proximal CRC becomes more common as women get older but not for men(272). This again has 
implications for CRC screening (as screening for proximal cancer is less accurate) and especially for the 
roll out of one-off flexible sigmoidoscopy screening, which is less effective for older women. 
Cardiovascular diseases, hypertension and previous cancers are the main co-morbidities found in 
patients with CRC. Patients with co-morbidity were more likely to have a proximal CRC in the study 
cohort(264). It may be that some common co-morbidities such as diabetes and cardiovascular disease are 
associated with common risk factors or pathophysiological pathways that increase the risk of proximal 
cancer. These might include factors such as dietary or the presence of micro-vascular disease, which 
themselves increase the risk of cancer at a proximal site (274).  
My cohort also demonstrated a relationship between increasing co-morbidity and deprivation, which has 
been previously described(265). I also found deprivation was associated with a CRC diagnosis at a 
younger age. A search of the literature failed to identify any other study from the UK has shown that 
deprived patients are diagnosed at an earlier age(235). If patients from deprived areas were more likely 
to be diagnosed at a younger age it is especially important that these patients are targeted for 
preventative strategies such as the screening programme because this is a difficult group to reach with 
health promotion strategies and they have a lower uptake of screening (171).  
Looking at the associations between patient characteristics and outcomes the main route to long-term 
survival is through a successful surgical resection of the cancer. If I could identify unexplained low rates 
of resection for a particular patient characteristic then this opens up the possibility of preventing under-
treatment. If the rationale for the under-treatment could not be backed up by clinical evidence of 
inferior outcomes then the argument could be made that there was some bias with in the healthcare 
system preventing access to surgery for these patients. 
In my cohort I found that increasing age was associated with a reduced crude surgical resection rate and 
higher one-year mortality, which is backed up by other studies(256). This main reason for this was that 
the stage of cancer is higher in older patients(8,275). However over the last few decades survival 
differences based on age has reduced substantially. The predominant reason for this is thought to be the 
increased resection rates among the elderly(276). Unfortunately, my patient cohort does not have a 
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record of the patient’s cancer stage so I cannot directly challenge whether there is under treatment 
based on age bias or simply that older patients had more advanced disease that would not benefit from 
surgical resection. 
In my study cohort there was no significant difference in the resection rate based on gender. This was 
interesting because while most other studies have reported rates approximately equal between the 
genders (258,272), a small number of studies have reported more women undergoing an attempt at 
curative surgery(257). The crude one-year mortality rate was higher among females, but this was likely 
to be a confounding effect caused by age. 
Increasing co-morbidity was associated with reduced surgical resection and higher one-year mortality in 
my study cohort. In other studies, increased co-morbidity was negatively associated with short-term 
survival(277). This association was especially strong for older male patients(274). I showed co-
morbidity was strongly associated with poor outcomes. This was in agreement with the “competing 
demands” model, which argues that co-morbidity is associated with delayed diagnosis and also other 
work showing poorer survival in patients with co-morbidity(250).  
Increasing deprivation was associated with reduced surgical resection and higher one-year mortality. 
This was supported by other studies which found that the most socioeconomically deprived patients had 
higher mortality rates, largely explained by excess early mortality especially in the first month after 
diagnosis(251). 
I found that a proximal cancer site was associated with reduced surgical resection and higher one-year 
mortality. Other studies support this finding in particular that outcomes tend to be better in patients 
with rectal cancer(223). 
There are some weaknesses in my methodological approach. Several of these are common to all HES 
related studies and the most significant of these are associated with missing clinical information. 
Important omissions from the database include, as already mentioned, a date of diagnosis. Also missing 
are the stage of cancer, which is of course of great prognostic impact, and patient ethnicity. There will 
always be some problems associated with the accuracy of clinical recordkeeping and transposition into 
codes by clinical coders. Other problems include under-reporting of co-morbidity in some hospitals and 
maybe missing codes for some day case procedures such as colonoscopy.  
I acknowledge that the codes included to define the REL1 admission were somewhat subjective, 
however I mitigated this by using an expert panel to select those included. Only a separate analysis of 
the patients’ medical records at the time of the REL1 admission could determine for certain if all the 
included codes were truly relevant. 
Finally, while I was able to identify some risk factors, such as increasing age, to explain variation in 
outcomes. I was not able to exclude all potential cofounding factors. Therefore I could not directly 
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apply causality to the outcomes. I will however look into the causes for variations in outcome in 
subsequent chapters and especially the impact of the introduction of the BCSP. 
In conclusion, I believe my methodological approach is superior to traditional analytical approaches that 
focus solely on episodes coded with a cancer diagnosis. This was because it contained more patients with 
incident CRC, including patients with advanced CRC and those not suitable for surgical resection. 
These cases are possibly excluded from other cancer registry databases. Furthermore for each patient, I 
identified more of the relevant episodes of care and therefore increased the completeness of the patients 
journeys compared to other studies. In particular, I believe I have captured a more accurate start date 
for the patient’s journey, by identifying the first relevant admission (REL1). Almost a quarter of patients 
had an earlier relevant admission and this process identified a higher rate of emergency presentation than 
was previously believed to be the case. This is very important as it creates a target to focus resources on, 
which will hopefully lead to improvements in CRC outcomes.  
I then validated my cohort against external data sources to show already established associations and also 
describe some new findings. My study cohort is therefore an accurate representation of CRC across 
England, and forms my main data source in the subsequent chapters of this thesis.
Chapter 3 - Emergency presentation: establishing my 
primary outcome measure  
3.1. Introduction 
In the United Kingdom the mean five-year survival for CRC is 50%. This is significantly lower than 
other countries of comparable wealth(140,171). The rate of emergency presentations in the UK is 
approximately 30%,(69,72,99) which is high compared with international rates of between 3-34%(67-
71,184). The five-year survival after an elective presentation is 58%, but following an emergency 
presentation it is only 39%(198). Therefore any strategy to prevent emergency presentations is also 
likely to improve overall survival.  
3.1.1. What is an emergency presentation?    
I have defined an emergency presentation as one where the presenting admission was an unplanned 
hospitalisation. These should be avoidable in the majority of cases. This is because symptoms will usually 
have been present for some time and the NHS is now geared towards providing rapid access to 
diagnostic services (endoscopic and radiological) for patients with potential CRC. Therefore any patient 
with slowly progressive symptoms that presents as an emergency could be described as an ‘avoidable 
emergency presentation’, while those presenting as an acute deterioration with an event such as 
obstruction or perforation could be described as ‘unavoidable emergency presentation’. Either way a 
high rate might imply inappropriate delays either in seeking medical attention or in the diagnostic 
process.   
I identified the patient’s admission type, according to the ADMIMETH field in the HES database (Table 
1.8, chapter 1). HES defines an emergency admission as one that is unpredictable and at short notice 
because of clinical need. In practice, this means presenting;   
• directly via the Emergency Department 
• as an emergency GP referral 
• as an emergency admission from the out-patient department 
• or as an emergency transfer from another hospital 
All other admission types were defined as elective admissions. Several studies have used this approach 
(89,244,278) while others have used more clinically defined metrics, such as presentation with large 
bowel obstruction, perforation or significant rectal bleeding(97,279). 
3.1.2. Possible causes of emergency presentation 
Symptoms caused by CRC include rectal bleeding, a change in bowel habit or weight loss and are usually 
slowly progressive. These symptoms eventually reach a threshold that compels patients to attend 
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primary care. Therefore most patients present electively via their GP(6,95,97). There are also some 
patients diagnosed asymptomatically following a primary care consultation, for example following 
investigation of anaemia. Once CRC is suspected, the NHS aims to ensure that patients are speedily 
referred through to hospital care for rapid assessment and diagnosis, using a two week wait referral 
pathway(280). As already described in chapter 1, patients can also be diagnosed electively, as part of 
surveillance programmes and more recently through the BCSP. 
The remaining patients present as an emergency and are more likely to be acutely unwell(72). At the 
most serious end of the spectrum patients may have severe and immediately life-threatening symptoms, 
resulting from large bowel obstruction, often requiring emergency surgical interventions. This may lead 
to perforation or severe haemodynamic derangements. Patients may also present directly to secondary 
care with significant bleeding(97). However, not all emergency patients are acutely unwell and the 
reason these patients present as an emergency directly to secondary care is not fully understood. Table 
3.1 describes where in the care pathway, delays may occur, that lead to emergency presentations.  
Despite the attractive mechanistic idea that delay causes emergency presentation, so far the supporting 
data are mixed. Some studies have described longer delays in the patient’s pathway for those presenting 
as an emergency, especially when the delays are caused by primary care and secondary care(281). Scott et 
al found that, on average, symptoms in elective patients were present for three weeks before diagnosis 
compared to eleven weeks for emergency patients(72). This doesn’t however explain why the delay 
occurred and symptom delay on its own (regardless of the presentation type) has not been shown to 
effect CRC stage or prognosis(167). However a small study looking at patient delay found no significant 
difference in the time between the onset of the first CRC symptom and first medical visit, in emergency 
or elective patients (27 vs. 30 days)(214).  
Primary care delay may contribute to emergency presentation for some patients as studies have found 
around two-thirds of emergency patients had visited their general practitioner with symptoms of CRC 
before being admitted(282). There may also be poor integration of services between primary and 
secondary care and within secondary care. Together this creates the so called ‘waiting iceberg’ of delays 
between outpatient appointments and investigations(160,283).  
Aggressive tumours, which have poorer outcomes, will tend to present soon after symptoms appear. By 
contrast, slow growing tumours may be diagnosed after a longer duration of symptoms and still have 
better outcomes(85). This may complicate the association between delay and outcomes as some patients 
with significant delays from first symptom to diagnosis may have a nonaggressive and ultimately 
treatable cancer, while an aggressive cancer may be rapidly diagnosed but still resistant to effective 
treatment.  
Overall, there is no convincing data yet that shows delay in a given part of the patient pathway is 
responsible for emergency presentations. 
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Table 3.1 The type and cause of different delays that can lead to the breakdown in the elective care 
pathway. 
Type of 
delay 
Description Cause 
Patient The time between noticing a 
symptom and consulting a GP 
The non-specific nature of early CRC symptoms 
The patient ignoring symptoms until a crisis is 
reached  
A failure to understand how to access elective 
care (e.g. not being registered with a GP). 
Primary care The time between a patient’s 
first GP consultation and 
referral 
Delay in accessing a primary care appointment  
Receiving false assurances regarding their 
symptoms. 
Secondary care The time between referral and 
cancer diagnosis 
Delay in accessing a secondary care appointment 
Delay in the investigation of their symptoms  
Receiving false assurances regarding their 
symptoms. 
 
3.1.3. Differences between emergency and elective presentations 
There is some evidence to suggest symptom patterns differ between elective and emergency 
presentations, notwithstanding there being a significant overlap. Patients admitted as an emergency 
more often present with the 'constitutional syndrome' (weakness, anorexia and weight loss) along with 
intestinal-specific symptoms such as diarrhoea, vomiting and abdominal pain(214). This may be because 
these symptoms are more associated with bowel obstruction. Additionally, patients with acute 
complications from their CRC such as a major bleed, colonic perforation or obstruction are much more 
likely to present as an emergency(97). Elective patients more commonly present with specific lower 
gastrointestinal symptoms, such as rectal bleeding or a change in bowel habit(72,214,282). There is 
some evidence that presenting to hospital over the weekend is associated with worse outcomes(284). 
What is less well understood is whether patients presenting electively or as an emergency are affected 
differently depending on the day of the week(284). 
3.1.4. Factors known to be associated with emergency presentation  
In addition to particular symptoms previous studies have suggested that certain patient characteristics 
are associated with emergency presentation. These include patients that are: older, have co-morbidities, 
are female and from lower socioeconomic groups. Emergency presentation is also more likely in 
patients with colonic rather than rectal cancer and in patients with advanced stage disease 
(69,97,219,285). However, these studies are either from single centres or from different countries, 
with a different healthcare model to the UK. There are currently no robust national studies from the 
UK, which identify the patient characteristics most associated with emergency presentation.  
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3.1.5. Outcomes following an emergency presentation  
Importantly for my thesis there is already some evidence showing that emergency presentation is 
associated with adverse outcomes. Emergency presentation has been linked to reduced access to major 
resection and reduced survival at one-year. Furthermore these patients have on average a longer length 
of stay in hospital and more postoperative complications (285,286). These findings are partly explained 
by the characteristics of the patients themselves, who are more likely to be older, female, poor and have 
co-morbidities(72,85,287). However these studies are again either from single centres, from countries 
with different healthcare models or were conducted over 25 years ago. This means that while there is 
evidence to suggest an association between emergency presentation and poorer outcomes, there is still a 
need to study the results in an up-to-date English population of CRC patients.  
3.2. Hypothesis 
My hypothesis is that even after adjusting for patient characteristics, emergency presentation is a strong 
independent predictor of poor CRC outcomes. Patients presenting as an emergency, have reduced 
access to surgical resection and reduced one-year survival. Therefore emergency presentation can be 
used as a used as a metric in studies to examine factors associated with variation in CRC outcomes. 
3.3. Aims 
My aims in this chapter are to: 
• Describe differences in the types of presenting symptoms and initial management between 
emergency and elective patients.  
• Identify the characteristics associated with emergency presentation of CRC. 
• Describe how outcomes following emergency presentation differ from those of elective 
patients; primarily in terms of mortality and access to surgical resection. Secondary quality 
indicators including the length of stay during the operative admission and readmission rate 
following surgery are also described. 
• Demonstrate that emergency presentation is an independent predictor of adverse outcomes. 
3.4. Methods 
Chapter 2 described how I identified my patient cohort and the methodology for identifying a patient’s 
index admission. I have produced evidence to support the use of the presentation mode (emergency or 
elective) at the index admission to define how a patient’s journey begins. Therefore I can use my cohort 
to look at differences between the two groups. 
This chapter will compare the characteristics and outcomes of patients with an emergency or elective 
presentation. The characteristics compared include: age, gender, co-morbidity, cancer site and 
deprivation. The primary outcomes measured were surgical resection and one-year mortality. Groups 
were compared using the chi-square test and binary logistic regression (univariate and multivariate). I 
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used Kaplan-Meier survival curves to demonstrate the impact of an emergency admission at presentation 
on survival. The secondary outcomes include: the length of stay at the presenting admission and during 
the admission for surgery and the readmission rate following surgery.  
3.5. Results 
3.5.1. Characteristics of patients presenting as an emergency  
In this section I describe the correlation between patient characteristics and emergency presentation. 
Overall in my cohort 11,651 (36.1%) patients presented as an emergency, with 20,648 (63.9%) 
presenting electively, Table 3.2.   
Patients presenting in an emergency were significantly older with an average age of 73.1 years (sd 12.8), 
compared with 69.8 years (sd 11.6, p<0.001) for elective patients. The proportion of patients with 
emergency presentation in the oldest group (>85 years) was 56.3%, compared with 28.8% in the 55-64 
year group (p<0.001). Women were more likely to present as an emergency (38.6% vs. 34.1%, 
p<0.001). 
Increasing co-morbidity was associated with emergency presentation. In patients with a Charlson co-
morbidity score of ≥2 the emergency rate was 58.3%, compared to only 27.0% in patients without co-
morbidities (p<0.001).  
Proximal CRC was also associated with emergency presentation. In patients with colon cancer, the 
emergency rate was 42.4%, compared with only 23.4% in rectal cancer (p<0.001). Finally, patients in 
the most deprived quintile had an emergency presentation rate of 42.0% (2,319/5,516), compared with 
31.9% (2,104/6,593) in the least deprived quintile, Table 3.2. Each of these patient characteristics will 
be examined in greater depth below. 
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Table 3.2 Characteristics of patients presenting electively and as an emergency.  
Patient 
characteristic Total cases, N (%) Elective, N (%) Emergency, N (%) P value 
No. 32,299 20,648 (63.9) 11,651 (36.1)  
Age groups     
Mean age yrs (sd) 71.0 (12.1) 69.8 (11.6)  73.1 (12.8)   
<55 yrs 3,044 (9.4) 2,043 (67.1) 1,001 (32.9)  
55-64 yrs 5,872 (18.2) 4,183 (71.2) 1,689 (28.8)  
65-74 yrs 9,474 (29.3) 6,564 (69.3) 2,910 (30.7)  
75-84 yrs 10,080 (31.2) 6,186 (61.4) 3,894 (38.6)  
≥85 yrs 3,829 (11.9) 1,672 (43.7) 2,157 (56.3) <0.001 
Gender     
Male 17,981 (55.7) 11,853 (65.9) 6,128 (34.1) <0.001 
Female 14,318 (44.3) 8,795 (61.4) 5,523 (38.6)  
Co-morbidity     
0 21,847 (67.6) 15,941 (73.0) 5,906 (27.0) <0.001 
1 2,383 (7.4) 1,340 (56.2) 1,043 (43.8)  
≥2 8,069 (25.0) 3,367 (41.7) 4,702 (58.3)  
Site     
Rectal  9,631 (29.8) 7,375 (76.6) 2,256 (23.4)  
Rectosigmoid 2,440 (7.6) 1,613 (66.1) 827 (33.9)  
Colon 20,228 (62.6) 11,660 (57.6) 8,568 (42.4) <0.001 
Deprivation     
IMD missing 322 (1.0) 193 (59.9) 129 (40.1)  
1 (most deprived) 5,516 (17.1) 3,197 (58.0) 2,319 (42.0)  
2 6,044 (18.7) 3,770 (62.4) 2,274 (37.6)  
3 6,844 (21.2) 4,363 (63.7) 2,481 (36.3)  
4 6,980 (21.6) 4,636 (66.4) 2,344 (33.6)  
5 (least deprived) 6,593 (20.4) 4,489 (68.1) 2,104 (31.9) <0.001 
3.5.2. Associations between emergency presentation and patient characteristics 
3.5.2.1. Age 
Table 3.3 shows that emergency presentation rates generally increase with age. However amongst the 
relatively small group of patients aged 54 years and younger, the rate is actually higher than in patients 
aged 55-74 years. Emergency rates then rise sharply and significantly in the elderly group (over 85 
years), Figure 3.1.  
Looking at the data in more detail; emergency rates are highest at both extremes of age, with the lowest 
rates between 50-70 years. Patients under 30 years and over 80 years, had rates up to 70%, while those 
in the middle of the age distribution were around 30%. 
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Binary logistic regression confirmed that patients under 55 years have a greater chance of an emergency 
presentation than patients aged 56-75 years. Above 75 years the odds of emergency presentation 
increased and were highest in the oldest patient group (over 85 years) with an Odds Ratio (OR) of 2.63 
(2.39-2.91) compared to patients <55 years, Table 3.3.  
 
Table 3.3 A binary logistic regression analysis showing the association between a patients age group and 
the risk of emergency presentation. 
Age 
groups 
Emergency 
presentations/ total (%) 
Univariate 
OR CI P value 
<55 yrs 1,001/3,044 (32.9) 1 - - 
55-64 yrs 1,689/5,872 (28.8) 0.82 0.75-0.91 <0.001 
65-74 yrs 2,910/9,474 (30.7) 0.91 0.83-0.99 0.025 
75-84 yrs 3,894/10,080 (38.6) 1.29 1.18-1.40 <0.001 
≥85 yrs 2,157/3,829 (56.3)*  2.63 2.39-2.91 <0.001 
*p<0.001 
 
 
 
Figure 3.1 The relationship between age and emergency presentation. Over the age of 55, emergency 
presentation became more common with increasing age. 
3.5.2.2. Gender 
A higher proportion of female patients presented as an emergency (38.6% vs. 34.1%, p<0.001). This 
association was supported by univariate regression analysis, which showed female patients have an OR of 
1.22 (1.16-1.27), Table 3.4.  
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Table 3.4 The risk of emergency presentation in male and female patients.  
Gender Emergency 
presentations/ total (%) 
Univariate 
OR CI P value 
Male 6,128/17,981 (34.1) 1 - - 
Female 5,523/14,318 (38.6)* 1.22 1.16-1.27 <0.001 
*p<0.001 
 
3.5.2.3. Co-morbidity 
Compared to no co-morbidity, the presence of even a single co-morbidity was associated with a near 
doubling of the emergency presentation rate (43.8% vs. 27.0%, p<0.001). This is supported by binary 
logistic regression analysis with an OR of emergency presentation of 2.10 (1.93-2.29) with a single co-
morbidity, Table 3.5. 
 
Table 3.5 The risk of emergency presentation in patients with different levels of co-morbidity. 
Co-
morbidity 
Emergency presentations 
/ Total (%) 
Univariate 
OR CI P value 
0 5,906/21,847 (27.0) 1 - - 
1 1,043/2,383 (43.8)* 2.10 1.93-2.29 <0.001 
≥2 4,702/8,069 (58.3)* 3.77 3.57-3.98 <0.001 
* p<0.001 
 
 
3.5.2.4. Site 
Colon cancers are significantly more likely than rectal cancers to result in an emergency presentation 
(42.4% vs. 23.4%, p<0.001). Taking rectosigmoid cancers as the baseline for binary logistic regression 
analysis, rectal cancers have a smaller chance of presenting as an emergency (OR 0.60 [0.52-0.66]) and 
colon cancer a greater chance (OR 1.43 [1.31-1.57]), Table 3.6. 
 
Table 3.6 The risk of emergency presentation in patients with cancer at different sites. 
Site Emergency 
presentations / Total 
(%) 
Univariate 
OR CI P value 
Rectosigmoi
d 827/2,440 (33.9) 
1 - - 
Rectal  2,256/9,631 (23.4) 0.60 0.52-0.66 <0.001 
Colon 8,568/20,228 (42.4)* 1.43 1.31-1.57 <0.001 
 
3.5.2.5. Deprivation 
The risk of an emergency presentation is associated with increasing deprivation. There was a 10.1% 
difference in emergency presentation rates between the most and least deprived quintiles. This was 
supported by binary logistic regression analysis, which showed that compared to the most deprived 
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quintile, the risk of emergency presentation in the least deprived was 0.65 (0.60-0.70, p<0.001), Table 
3.7. 
 
Table 3.7 The risk of emergency presentation in patients with different levels of deprivation. 
Deprivation Emergency 
presentations/ 
Total (%) 
Univariate 
OR CI  P value 
IMD missing 129/322 (40.1)    
1 (most 
deprived) 
2,319/5,516 (42.0)* 1 - - 
2 2,274/6,044 (37.6) 0.83 0.77-0.90 
<0.001 
3 2,481/6,844 (36.3) 0.78 0.73-0.84 
<0.001 
4 2,344/6,980 (33.6) 0.70 0.65-0.75 
<0.001 
5 (least 
deprived) 
2,104/6,593 (31.9) 0.65 0.60-
0.70 
<0.001 
     
3.5.3. Multivariate analysis of patient characteristics 
The multivariate model in Table 3.8 shows that all included patient characteristics showed significant 
and independent associations with emergency presentation.  
The strongest associations with emergency presentation were increasing co-morbidity, followed by 
increasing age and deprivation. An analysis of links between deprivation and emergency presentation, 
showed a near perfect social gradient from least to most deprived, with significance shown across the 
entire gradient (p <0.001). Female gender and proximal cancer had a weaker association. 
Interestingly, increasing age, co-morbidity and female gender were less strongly associated with 
emergency presentation in the multivariate model than in the univariate model.  
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Table 3.8 A univariate and multivariate analysis of factors associated with emergency presentation. 
Variable Emergency 
presentations/ 
Total (%) 
Unadjusted (univariate) Adjusted (multivariate) 
OR CI P value OR CI P value 
Age group (years)        
<55 1,001/3,044 (32.9) 1 - - 1 - - 
55-64 1,689/5,872 (28.8) 0.82 0.75-0.90 <0.001 0.79 0.72-0.88 <0.001 
65-74 2,910/9,474 (30.7) 0.89 0.82-0.98 0.016 0.83 0.75-0.91 <0.001 
75-84 3,894/10,080 (38.6) 1.28 1.17-1.39 <0.001 1.15 1.04-1.26 0.004 
≥85  2,157/3,829 (56.3) 2.61 2.37-2.89 <0.001 2.44 2.19-2.71 <0.001 
Gender        
Male 6,128/17,981 (34.1) 1 - - 1 - - 
Female 5,523/14,318 
(38.6) 
1.22  1.16-1.27 <0.001 1.10 1.04-1.15 <0.001 
Co-morbidity 
groups 
       
No co-morbidity  5,906/21,847 (27.0) 1 - - 1 - - 
1 co-morbidity  1,043/2,383 (43.8) 2.10 1.93-2.29 <0.001 1.99 1.82-2.18 <0.001 
≥ 2 co-morbidity 4,702/8,069 (58.3) 3.81 3.61-4.02 <0.001 3.71 3.51-3.92 <0.001 
Site        
Rectosigmoid 827/2,440 (33.9) 1 - - 1 - - 
Rectal  2,256/9,631 (23.4) 0.60 0.54-0.66 <0.001 0.67 0.61-0.74 <0.001 
Colon 8,568/20,228 (42.4) 
1.45 1.32-1.58 <0.001 1.48 1.35-1.63 <0.001 
Deprivation        
IMD missing 129/322 (40.1) - - - - - - 
1 (most deprived) 2,319/5,516 (42.0) 1 - - 1 - - 
2 2,274/6,044 (37.6) 0.83 0.77-0.90 <0.001 0.80 0.74-0.87 <0.001 
3 2,481/6,844 (36.3) 0.78 0.73-0.84 <0.001 0.75 0.69-0.81 <0.001 
4 2,344/6,980 (33.6) 0.70 0.65-0.75 <0.001 0.66 0.61-0.71 <0.001 
5 (least deprived) 2,104/6,593 (31.9) 0.65 0.60-0.70 <0.001 0.63 0.58-0.68 <0.001 
3.5.4. Risk tables for predicting emergency presentation 
Risk tables were created to better demonstrate how patient characteristics influenced the risk of an 
emergency presentation. Rates of emergency presentation ranged from 11.9%, in females aged 55-64 
years with rectal/rectosigmoid cancer and no co-morbidities, up to 77.2% among female patients aged 
≥85 years with co-morbidities and colon cancer, Table 3.9, 3.10.  
 
Table 3.9 Risk tables for emergency presentation (%) based on age, co-morbidity and site (male 
patients). 
Age 
Group 
Co-Morbidity 0 Co-Morbidity ≥ 1 
Rectal/ 
Rectosigmoid 
Colon Rectal/ 
Rectosigmoid 
Colon 
<55 15.7 38.4 37.9 62.0 
55-64 13.5 27.1 36.8 52.1 
65-74 13.3 27.2 38.2 55.3 
75-84 20.1 30.8 46.0 59.1 
≥85  34.7 47.7 64.4 72.5 
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Table 3.10 Risk tables for emergency presentation (%) based on age, co-morbidity and site (female 
patients). 
 
Age 
Group 
Co-Morbidity 0 Co-Morbidity ≥ 1 
Rectal/ 
Rectosigmoid 
Colon Rectal/ 
Rectosigmoid 
Colon 
<55 14.4 32.5 38.2 55.9 
55-64 11.9 28.8 37.8 54.7 
65-74 14.2 28.2 43.9 53.9 
75-84 23.6 34.8 47.2 64.0 
≥85  42.8 53.0 66.0 77.2 
 
3.5.5. Diagnoses and procedures recorded at presentation 
3.5.5.1. The frequency of diagnostic codes at position one at the index admission  
At the presenting (index) admission, the commonest primary diagnostic codes were, unsurprisingly, for 
CRC itself. Of interest, only 58.2% of emergency presentations had a primary CRC code at 
presentation, compared to 75.7% of elective presentation. This implies a greater degree of diagnostic 
uncertainty at presentation in the emergency group. This is depicted in Figure 3.2, which also shows 
that in place of CRC codes, there were significantly higher rates of red flag symptoms (11.8% vs. 2.6%, 
p<0.001) and anaemia (5.0% vs. 3.6%, p<0.001) codes, among the emergency group.  
 
 
Figure 3.2 A chart showing the frequency of diagnostic codes at position one at the index admission for 
elective and emergency patients.  
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3.5.5.2. The frequency of procedural codes at position one at presentation 
For elective patients, a lower gastrointestinal endoscopy was the commonest primary procedure 
recorded at presentation (65.7%). However in the emergency group only 13.6% of patients had a lower 
gastrointestinal endoscopy recorded at presentation. Instead patients presenting as an emergency more 
often had ‘no procedure’ (43.5%) or ‘other procedure’ (21.2%) recorded. The rates of major surgical 
resections during the index admission were similar for both emergency (16.9%) and elective (16.1%) 
groups, Figure 3.3.      
These results unsurprisingly show that elective patients are more likely to follow an optimal 
management pathway with early access to the key diagnostic procedure, a lower gastrointestinal 
endoscopy. 
 
 
 
Figure 3.3 A chart showing the frequency of procedural codes at position one at the index admission for 
elective and emergency patients.  
 
3.5.5.3. Selected symptoms, signs and complications at presentation; ‘unavoidable’ versus ‘avoidable’ 
emergencies  
I next looked at whether selected symptoms, signs and acute CRC complications were more prevalent 
in either group at presentations, Table 3.11, Figure 3.4. Together, anaemia was recorded in 12.3% of 
patients, rectal bleeding in 5.2%, while the complications I stated would lead to an ‘unavoidable 
emergency presentation’; obstruction and perforation were present in 2.1% and 0.9% of patients 
respectively. The emergency group had a much higher rate of CRC complications. In particular 
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an obstruction or perforation) was 6.5%. This suggests the majority of emergency presentations remain 
‘avoidable’, Table 3.11.  
 
Table 3.11 A table showing the rates of selected symptoms, signs and complications at CRC 
presentation for elective and emergency patients.  
Symptoms/Signs Total 
Elective, N 
(%) 
Emergency, N 
(%) 
P value 
Total 32,299 20,648 (63.9) 11,651 (36.1)  
Rectal bleeding 1,656  910 (4.4) 746 (6.4) <0.001 
Large bowel 
obstruction 
691  208 (1.0) 483 (4.1) <0.001 
Perforation 296 (0.9) 15 (0.1) 281 (2.4) <0.001 
Anaemia 
3,966 
(12.3) 
2,124 (10.3) 
1,842 (15.8) 
<0.001 
 
 
 
Figure 3.4 A chart showing the frequency of selected symptoms and CRC complications at presentation 
for the elective and emergency groups. 
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3.5.6.1. Primary outcomes 
3.5.6.1.1. Access to surgical resection 
There was a considerable difference in rates of surgery between the two groups. Emergency patients 
were significantly less likely to have surgical resection within six months of presentation (35.4% vs. 
59.1%, p<0.001). The same association was seen for ‘any colorectal operation’, a definition that 
included de-functioning procedures (e.g. colostomies and ileostomies), with 71.0% of elective patients 
and 51.6% of emergency patients receiving an operation, Table 3.12.  
Out of a total of 20,674 (64.0%) colorectal operations, 8,702 (42.1%) occurred in the presenting 
admission. In elective patients the rate was 26.5% (5,469/20,648) and among emergency patients the 
rate was 27.7% (3,233/11,651, p=0.015). 
Patients in the emergency group were significantly less likely to have a laparoscopic assisted resection 
(6.2% vs. 17.4%, p<0.001), to receive an anterior resection (9.8% vs. 41.7%, p<0.001) or 
Abdomino-Perineal Excision of the Rectum (APER) (2.4% vs. 9.6%, p<0.001). Patients in the 
emergency group were more likely to receive a Hartmann’s procedure (11.7% vs. 5.2%, p<0.001), 
Table 3.13. 
In patients undergoing a major resection within six months of presentation, the majority of the elective 
group also had their surgery performed electively (96.8%). Conversely, in patients with an emergency 
presentation and resection, just over half (56.7%) of these patients going on to resection, had the 
surgery during an emergency admission, Figure 3.5. 
 
Table 3.12 A comparison of the rates of surgery for patients presenting electively and as an emergency.  
Outcomes Total cases, N 
(%) 
Elective, N (%) Emergency, N 
(%) 
P value 
Any colorectal 
operation 20,674 (64.0) 14,658 (71.0) 6,016 (51.6) <0.001 
Major resection 16,332 (50.6) 12,204 (59.1) 4,128 (35.4) <0.001 
Laparoscopic 2,377 (14.6)* 2,121 (17.4)* 256 (6.2)* <0.001 
*proportion of major resections 
 
 
Table 3.13 A comparison of the types of surgical operations for patients presenting electively and as an 
emergency. 
 
 
Operations Elective, N (%)  Emergency, N (%) P value 
Major resections 12,204 4,128 <0.001 
    Anterior resection 5,083 (41.7) 403 (9.8) <0.001 
    APER 1,167 (9.6) 101 (2.4) <0.001 
    Hartmann’s 630 (5.2) 485 (11.7) <0.001 
    Other resection 
operations 5,324 (36.3) 3,139 (52.2) <0.001    
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Figure 3.5 A chart illustrating the risk that operated patients will require an emergency (or elective) 
operation depending on whether the initial presentation was elective or an emergency. Following an 
elective presentation, the likelihood of elective surgery is very high, with only 3.2% requiring an 
emergency operation (p<0.001). However patients with an emergency presentation are more likely to 
have an emergency rather than elective operation (p<0.001). 
 
3.5.6.1.2. One-year mortality 
Emergency patients had a significantly higher mortality rate at one-year (49.4% vs. 18.0%, p<0.001), 
Table 3.14. This discrepancy in survival was even greater within the first 30 days of presentation, where 
the mortality rate was almost four times higher in emergency patients (6.5% vs.1.7%, P<0.001).  
This early and continued survival advantage associated with an elective presentation is clearly 
demonstrated by Kaplan-Meier survival curves, Figures 3.6, 3.7. The curves begin to diverge soon after 
the index presentation and are widely separated after 100 days. Beyond 100 days the curves separate to a 
much lesser degree, implying that most of the difference in mortality is due to excess early deaths in the 
emergency group. As a total of all deaths in the first year after presentation 30.4% of emergency group 
deaths appeared within the first 30 days compared to 9.6% in the elective group. 
The mortality rate 30 days after a surgical resection was significantly associated with the mode of 
presentation. Emergency presentations had a significantly higher mortality rate (10.8% vs. 2.8%, 
p<0.001). This difference persisted in the year following surgery (25.6% vs. 9.4%, p<0.001), Table 
3.14.  
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Table 3.14 A comparison of 30-day and one-year mortality following presentation and major resection 
for patients presenting electively and as an emergency. 
Outcomes Total cases, N 
(%) 
Elective, N 
(%) 
Emergency, N 
(%) 
P value 
30 day mortality following index 
admission 
2,106 (6.5) 357 (1.7) 1,749 (15.0) <0.001 
One-year mortality following 
index admission 
9,469 (29.3) 3,712 (18.0) 5,757 (49.4) <0.001 
30 day mortality following major 
resection 
791 (4.8) 345 (2.8) 446 (10.8) <0.001 
One-year mortality following 
major resection 
2,208 (13.5) 1,152 (9.4) 1,056 (25.6) <0.001 
 
 
Figure 3.6 Kaplan-Meier survival curves demonstrating cumulative survival out to one year following 
presentation for elective (blue line) and emergency (green line) patients. The discordance in survival 
began early in the post-presentation period with most of the separation in survival curves established in 
the first 100 days (log rank test p<0.001). 
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Figure 3.7 Kaplan-Meier survival curves demonstrating cumulative survival for the 30 days after 
presentation for elective (blue line) and emergency (green line) patients. There was early diverge in 
survival between the curves (log rank test p<0.001). 
 
3.5.6.2. Secondary outcomes 
3.5.6.2.1. Length of stay at the index admission and at the major resection admission 
In this section I looked at whether emergency patients had a different length of stay at their initial 
presenting admission. The mean length of stay was considerably longer for emergency patients (14.6 
days [sd 18.5] vs. 3.5 days [sd 10.5], p<0.001). This was largely explained by the higher number of day 
case index admissions in the elective group. There were 14,203 (68.8%) elective day case presentations, 
compared with just 777 (6.7%) short stay emergency admissions. Even if all these admissions were 
excluded, then the mean length of stay for emergency patients was still significantly longer (15.6 days 
vs. 11.2 days, p<0.001).  
I also addressed the question of whether patients who present as an emergency experience a longer 
(more complicated) period of hospitalisation for their subsequent surgery. I found when the index 
admission was elective, the surgical length of stay was 12.4 (sd 10.2) days, compared to 20.3 (sd 16.5) 
days in emergency presentations (p<0.001), Figure 3.8. 
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Figure 3.8 A box and whisker plot showing the length of stay following a major resection for elective 
and emergency presentation type (the numbers denote individual patient data points). 
 
3.5.7. Emergency presentation as an independent risk factor for one year mortality 
After adjusting for available patient case-mix factors (age, gender, co-morbidity and socioeconomic 
deprivation) emergency presentation was a strong independent predictor of one-year mortality. Patients 
with an emergency mode of index admission had a four-fold increased risk of death compared to 
adjusted elective cases (OR=4.11, CI: 3.88-4.35, p<0.001). The next strongest association with one-
year mortality was an age of over 85 years (OR 4.05) and having a Charlson co-morbidity score of ≥ 2 
(OR 3.14) Table 3.15. 
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Table 3.15 A univariate and multivariate analysis showing the associations between patient 
characteristics and presentation type and survival at one-year. 
Variable One-year 
mortality/ 
Total (%) 
Unadjusted (univariate) Adjusted (multivariate) 
OR CI P value OR CI P value 
Age group 
(years) 
       
<55 548/3,044 (18.0) 1 - - 1 - - 
55-64 
1,164/5,872 
(19.8) 
1.12 1.00-
1.25 
0.059 1.17 1.03-
1.32 
0.014 
65-74 
2,301/9,474 
(24.3) 
1.44 1.30-
1.60 
<0.001 1.53 1.37-
1.72 
<0.001 
75-84 
3,522/10,080 
(34.9) 
2.41 2.17-
2.66 
<0.001 2.49 2.23-
2.78 
<0.001 
≥85  1,934/3,829 (50.5) 
4.57 4.08-
5.11 
<0.001 4.05 3.58-
4.58 
<0.001 
Gender        
Male 5,156/17,981 
(28.7) 
1 - - 1 - - 
Female 4,313/14,318 
(30.1) 
1.07 1.02-
1.13 
0.004 0.94 0.89-
0.99 
0.025 
Co-morbidity 
groups 
       
No co-morbidity  4,452/21,847 
(20.4) 
1 - - 1 - - 
1 co-morbidity  715/2,383 (30.0) 1.67 1.52-
1.83 
<0.001 1.21 1.09-
1.34 
<0.001 
≥ 2 co-
morbidity 
4,302/8,069 
(53.3) 
4.52 4.28-
4.77 
<0.001 3.14 2.95-
3.33 
<0.001 
Site        
Rectosigmoid 756/2,440 (31.0) 1 - - 1 - - 
Rectal  2,488/9,631 (26.3) 
0.78 0.71-
0.86 
<0.001 1.03 0.92-
1.15 
<0.001 
Colon 6,225/20,228 (30.8) 
1.00 0.91-
1.10 
0.999 0.88 0.79-
0.97 
<0.001 
Deprivation        
IMD missing 58/322 (18.0)       
1 (most 
deprived) 
1,775/5,516 
(32.2) 
1 - - 1 - - 
2 1,905/6,044 
(31.5) 
0.97 0.90-
1.05 
0.447 1.00 0.91-
1.09 
0.921 
3 1,991/6,844 
(29.1) 
0.87 0.80-
0.93 
<0.001 0.89 0.82-
0.97 
0.009 
4 1,965/6,980 
(28.2) 
0.83 0.77-
0.89 
<0.001 0.87 0.79-
0.95 
0.001 
5 (least 
deprived) 
1,775/6,593 
(26.9) 
0.78 0.72-
0.84 
<0.001 0.86 0.79-
0.94 
0.001 
Presentation        
Elective 3,712/20,648 
(18.0) 
1 - - 1 - - 
Emergency  5,757/11,651 
(49.4) 
5.76 5.47-
6.07 
<0.001 4.11 3.88-
4.35 
<0.001 
 
 
 149	
3.6. Discussion   
For the first time in a national cohort of English CRC patients I have shown that emergency presentation 
has very significant prognostic implications. Having adjusted for other prognostic factors, the Odds 
Ratio for mortality at one year following emergency presentation was 4.11. This is the single strongest 
predictor of adverse outcomes, even more than age, co-morbidity, site or deprivation. This is especially 
important given my finding that many emergency presentations are likely to be avoidable. Because of 
these findings; emergency presentation can be used as the primary outcome measure in my thesis, and to 
assess the impact of interventions on national CRC care.  
The emergency presentation group had a one-year mortality rate of 49% (5,757/11,651) compared to 
18% (3,712/20,648) in the elective group. It was also associated with much lower rates of major 
surgical resection, a higher percentage of emergency operations, a longer length of stay, more 
readmissions and suboptimal types of operations (e.g. Hartmann’s procedure).  
Increased mortality was apparent just 30 days following presentation. This implies not only that 
emergency presentation is an adverse quality indicator, but that it is associated with late presentation 
and late stage disease. Therefore interventions to reduce emergency presentations should reduce late 
presentation CRCs and so, reduce early mortality. That fact that mortality after emergency presentation 
rises so soon after the presentation, makes it a useful early outcomes metric for assessing the impact of 
interventions, such as a CRC awareness campaign. This is especially helpful as other markers used to 
measure quality and variations in CRC care take a long time to be measurable e.g. five-year CRC 
specific mortality. Overall the risks associated with an emergency presentation are substantial and 
strategies to reduce its occurrence warrant serious attention. 
In my cohort emergency presentation was common, occurring in 36.1% of cases. This is in line with 
other studies from the UK and Ireland(70,72). Patient characteristics associated with emergency 
presentation included; female gender, older patients, those with co-morbidity and greater deprivation. 
Patients with colon cancer (as opposed to rectal cancer) also had a higher risk. Therefore all of these 
factors need to be adjusted for when using emergency presentation rates as a quality indicator, for 
example when comparing care between different units or studying tends over time. 
There has been little attempt so far to firstly understand why emergency presentations occur and 
secondly why they are associated with such negative outcomes. To do this requires an understanding of 
why some patients and primary and secondary care physicians delay accessing the appropriate services, 
which would lead to an elective diagnosis. Some of this requires information not available for my thesis. 
I have, however, explored patient and cancer characteristics, that appear more commonly in 
emergencies. This chapter also shines light on two other interesting factors applicable to emergency 
presentation patients. Firstly, that emergency presentation is associated with early deaths suggesting 
many of these patients are presenting late, with advanced malignancy. Secondly the finding that rates of 
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presentations with severe complication such as a perforation or obstruction were low (6.5%) and that 
only a minority of emergency patients (27.7%) needed surgery in the presenting admission. This 
suggests that only a small percentage of emergency presentations were truly ‘unavoidable’. In turn this 
allows me to speculate that reducing ‘avoidable’ emergency presentations can make substantial outcome 
gains. Increasing patient awareness of the symptoms of CRC and ensuring their flow through to 
diagnosis and definitive treatment is rapid might do this. This hypothesis is developed further in later 
chapters. 
I have shown that increasing age was generally associated with more emergency presentations. Many 
studies have confirmed this (97). Waldron et al, found that patients over 70 years had a higher rate 
compared to younger patients (58% vs. 43%, p<0.001), while Scott et al, found that the median age was 
74 years for emergency patients, compared to 72 years in the elective group and Bass et al, found the 
median age was 72 and 69 years respectively(70,72,288,289). However, one study of 273 patients 
found emergency presentation was not commoner among those patients aged 70 and above(223). I 
found emergency presentations were more common among the small number of patients under 40 years 
of age as well as among the elderly. This was a new finding and requires further study. Taken with the 
increased emergency rate among the elderly, I have shown higher emergency rates at both extremes of 
age. The reasons are unclear but may be because at extremes of age, both patients and medical 
professionals fail to consider CRC until symptoms and the disease are more advanced. It also bears 
consideration that patients within the BCSP age range have some of the lowest rates, which will be 
discussed further in chapter 4.  
There are a number of reasons why older patients are more likely to present as an emergency(97). 
Elderly patients tend to have more advanced stage cancer at diagnosis (275) and some but not all studies 
have shown a longer delay in making the diagnosis(223,290). Age is also associated with social isolation 
and being widowed is certainly a factor behind emergency presentation(72). One study showed that 
elderly patients more commonly present with symptomatic anaemia and nonspecific symptoms, such as 
falls, and it is likely that this uncertainty creates delays for both patients and in primary care(223). There 
is also a trend for elderly patients to report lower rates of specific symptoms such as a rectal bleeding or 
change in bowel habit. Finally, it has been shown that there are more missed opportunities for 
diagnosing CRC among older patients, such as uninvestigated iron deficiency anaemia and rectal 
bleeding(291).  
I found many young patients (<40 years) presented as an emergency. Some studies do show an 
increasing incidence of CRC among younger patients. The same studies also describe an association with 
later-stage and higher-grade tumours, but equivalent or better 5-year cancer specific survival(5,292). 
Younger patients are also more likely to be male and to have colon (as opposed to rectal) 
cancer(293,294). It is not known whether there are differences in the duration of symptoms at diagnosis 
based on the age of the patient. Some studies have found comparable times between younger and older 
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patients(294) and others that patients under 65 are more likely to delay seeking medical attention(221). 
The type of symptoms reported (e.g. rectal bleeding or change in bowel habit) appear to be similar 
between younger and older patients(294). Young age was not a poor prognostic factor in itself, but 
familial CRC risk factors were and this demonstrates the need for screening and surveillance of those at 
risk(295). 
The association between younger age and emergency presentation may due to a reduced public and 
health professional awareness of the possibility of cancer in younger patients, a more aggressive cancer 
phenotype (especially in patients with cancer syndromes) or even the impact of bowel cancer screening 
between the ages of 60-69 years (covered in detail in chapter 4). 
I found female patients had a greater risk of emergency presentation and this is supported by other 
studies and applies especially to widows and those living on their own (72,97,198). A study with a 
similar population to my own found comparable results, with 35.3% (n=29,751) of females and 30.1% 
(n=30,933) of males presenting as an emergency(30). The reason for this is unknown, but it has been 
suggested that women are more reluctant to present with symptoms, as they are more reluctant to 
undergo lower endoscopy. Women experience more embarrassment and fear related to having an 
endoscopic procedure, especially if performed by a male endoscopist and that this can be strong enough 
to cause delay(296,297). It is also established that women experience more pain than men during lower 
endoscopy(298). However women are more likely to respond to an invitation to join a bowel cancer 
screening programme(171). I found that women are more likely to present with proximal cancer and 
this is itself associated with emergency presentation. Therefore increased emergency presentations 
among women may relate more to proximal CRC predominance and to more negative attitudes towards 
invasive investigations. These associations may partially explain why the female OR for emergency 
presentation is 1.22 on univariate analysis but only 1.09 when multivariate analysis is performed. 
There was a strong association between co-morbidity and emergency presentation. Even a single co-
morbidity increased the OR to 2.10, while two or more increased the OR to 3.81. It has previously 
been shown that patients with poorer overall health and specific co-morbidities are more likely to 
present as an emergency(72,97,291). The reasons for this are not completely understood. Interestingly, 
increased co-morbidity does not appear to be associated with delays to diagnosis, which might otherwise 
explain a greater propensity to emergency presentation(219). One explanation may be that patients 
with co-morbidities are more likely to develop proximal cancer, which is itself a risk factor for 
emergency presentation(274). Finally, it has been shown that there are more missed opportunities for 
diagnosing CRC among patients with co-morbidities, such as uninvestigated iron deficiency anaemia or 
rectal bleeding(291).  
In my cohort and others, colonic or right-sided cancers are more likely to present as an emergency. In 
my study the odds ratio was 1.48 (1.35-1.63, p<0.001) in a multivariate analysis, while in another 
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study it was 1.70 (1.57-1.84)(69,97,198,214). Right-sided lesions tend to present with less specific 
symptoms, such as abdominal pain, malaise and vomiting. Patients and clinicians can easily misinterpret 
these symptoms. By comparison, patients with rectal cancer report more localised symptoms, such as 
rectal bleeding(223). While more colon cancers present as emergency, their survival at one year is 
actually higher than for rectal cancer(69). 
There was a trend between increasing deprivation and emergency presentation. In the most deprived 
quintile, 10.1% more patients presented as an emergency than in the least deprived quintile, which had 
a multivariate OR of 0.63 (0.58-0.68). Deprivation has previously been associated with emergency 
CRC presentation(97). In the UK, between 1992 and 1995, the emergency presentation rate was 56% 
for the tenth most deprived decile compared to 35% in the most affluent decile, equating to an OR of 
2.29 (2.09-2.52)(299). Deprivation is also associated with mortality following colorectal surgery and 
early readmission post operatively(267). Deprivation appears to have a greater effect on emergency 
presentation than on one-year mortality, where the OR is 0.86 (0.79-0.94). The greater use of Accident 
and Emergency by deprived patients might be because these patients tend to be more unwell at 
presentation (248). Equally, on the whole patients with greater levels of deprivation tend to make less 
use of primary care and present more often directly to secondary care(300). Another reason may be that 
deprived patients are perceived more negatively by health professionals and offered fewer 
comprehensive investigations and treatments (235,240).     
I next analysed the types of symptoms and diagnoses that appeared more commonly for patients with an 
emergency presentation. Emergency patients were less likely to be coded with CRC at presentation, 
which suggests greater diagnostic uncertainty. Emergency patients were also less likely to have the 
optimal diagnostic test (lower gastrointestinal endoscopy) at presentation, again signifying uncertainty at 
the outset of hospital care.  
Anaemia caused by CRC might be considered an insidious problem, more likely to be investigated in an 
elective pathway. However, it was more likely to be coded in the emergency group than the elective 
group (15.8% vs. 10.3%). Predictably, bowel obstruction was four times more common and bowel 
perforation twenty times more common with emergency presentation. Although large bowel 
obstruction and perforation were recorded significantly more often among emergency patients, coding 
for these specific acute emergency events accounted for only a small proportion of total emergencies. 
Of this selected group of codes, anaemia was by far the most frequent. This observation would support 
the possibility that a significant proportion of emergency hospitalisations are ‘avoidable’ and not 
predominantly for acute emergency complications of CRC. As many emergency presentations are 
potentially avoidable this again raises the possibility that interventions could be introduced that will 
reduce this risk and potentially improve overall CRC outcomes. 
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On the whole, when a CRC patient presents initially as an emergency it appears that patients and 
medical teams are less certain about what is happening. This may be because the symptoms that 
emergency patients more commonly present with are not those classically considered to be caused by 
CRC. One study that looked at the different presentations for emergency and elective patients, found 
that abdominal pain was more common [interaction odds ratio 2.3 (1.6-3.3); P=0.047] and rectal 
bleeding less common [0.30 (0.08, 1.0); P=0.040] in the emergency group(282). Therefore perhaps 
both patient and medical teams are unclear how to manage symptoms that they don’t consider likely to 
be caused by CRC. This could be improved by raising awareness of CRC symptoms for both patients 
and health professionals. 
In summary, the codes and procedures recorded at emergency presentations hint at more uncertainty 
for the patient and primary and secondary care teams. If medical professionals place more focus on 
particular symptoms (e.g. abdominal pain) and particular types of patients (e.g. the elderly) then 
emergency presentations could be reduced and patients diagnosed earlier. However at present HES is 
not yet detailed enough for detailed symptom-level analysis. 
In order to use emergency presentation as my primary outcome measure in subsequent studies, I had to 
establish its association with adverse outcomes. Specifically this meant reduced surgical intervention and 
one-year mortality. 
It is well established that CRC patients have the greatest chance of long-term survival if they undergo 
elective surgical intervention. I found emergency patients were less likely to have surgical resection 
(35.4% vs. 59.1%, p<0.001). This was supported by findings from a large UK series, which found 
resection rates of 64% for emergency patients and 72% for elective patients(198).  
When surgical resection follows an emergency presentation both morbidity (45–50%) and mortality 
(15–45%) are high(69,73,89,99,214). In my cohort, emergency and elective patients having major 
surgical resections had significantly different mortality rates. Only 2.8% of elective group patients died 
in hospital following the operation. This compared with 11% of emergency patients (data not shown in 
the results section). These differences were also seen with both 30-day (10.8% vs. 2.8%) and one-year 
(25.6% vs. 9.4%) mortality rates. At 30-days following surgery, the mortality rate is 3.9 times higher in 
the emergency presentation group. At one-year, it is 2.7 times higher. This shows there is an early 
excess of deaths following surgery in emergency patients. However, it also shows that after the initial 
period, differences in survival rates do not get progressively worse. The danger for patients could be 
mostly related to their acute clinical health and not to more advanced cancer. This is supported by 
studies that have shown that the inferior survival following emergency surgery is limited to the early 
postoperative period, representing the danger in operating following acute presentation and 
uncorrected medical complications (71,301). However further work would be required with a longer 
follow-up period to definitively show this. 
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The reasons for the poorer outcomes relate to the patient factors described above and also the fact the 
surgery is more likely to be performed by a non-specialist(302). I found that when patients presented as 
an emergency then any subsequent surgery was also much more likely to be as an emergency operation. 
In contrast, only 3% of elective presentations had emergency surgery. The type of surgery is also 
affected by admission type, with much higher rates of Hartmann’s procedure in emergency 
presentations and a much lower rate of laparoscopy use.   
I found significantly higher mortality following an emergency presentation. This is partially related to 
adverse patient and disease factors but even adjusting for these factors, including disease stage, my study 
and others have shown mortality was higher following an emergency presentation(214). It seems that 
emergency presentation was especially associated with early mortality. I found striking differences in the 
30-day mortality between the presentation types (7% vs. 1%). Similarly, a UK study found the in-
hospital mortality rate following CRC diagnosis was 19% for emergency patients and 8% for elective 
patients(72).  
One study found the median survival was 8 months after an emergency presentation and 30 months 
following a elective admission. Even after adjusting for age, gender, site and stage, the excess risk of 
death was 61%(214). In my cohort, one-year mortality was 49.4% in the emergency group compared to 
18.0% in elective patients. While another study found, survival at 5 years was 46% in the elective group 
and 28% in the emergency group(214). This effect is seen even after case adjustment and in emergency 
patients having attempted curative resection. It has been hypothesised that the later excess of deaths is 
due to presence of residual occult disease(198). Certainly, the type of disease explains some of the 
difference, with metastatic disease rates higher rates at the time of presentation in emergency cases 
(40% vs. 28%)(69).   
It seems that the majority of excess mortality is confined to the early period following presentation and 
the early postoperative period. Therefore, although emergency patients had worse outcomes at one-
year, most of the difference was accounted in the few first months following presentation. This suggests 
emergency presentation is an adverse prognostic marker because patients have presented following an 
unspecified delay, with more advanced disease.  
In my cohort, length of stay (LOS) of the presenting hospital admission was longer for emergency 
patients. This group stayed a mean of 16 days compared to 11 days for elective patients (after excluding 
day case admissions). Another study found the average emergency stay was 24 days compared with 11 
days for elective patients(285). This substantially increases costs and also exposures patients to 
additional complications associated with prolonged hospital admissions(71). These include clostridium 
difficile infection and venous thromboembolism. One study found that after the presenting admission, 
discharge to a long term care facility was needed for 25% of emergency patients compared with 2% of 
elective patients(285).  
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The negative impact of emergency route to diagnosis has already been established in upper 
gastrointestinal cancers(278), other cancers (89) and in other major surgical disciplines(303). I have 
now shown that emergency presentation is an independent predictor of adverse CRC outcomes. The 
next challenge is to study why this is the case. The answer is likely to be multifactorial. Clearly, some 
patients presenting as an emergency will be sicker, often with significant metabolic abnormalities 
increasing the likelihood of early morbidity and mortality. In addition, patients are often older and with 
more co-morbidity, which will reduce the chance of surgery being offered and increase the risk 
associated with it. The cancer itself is likely to be more advanced with a reduced chance of successful 
treatment. This will affect the decision to operate and offer other treatment modalities and therefore 
influence medium to long-term survival. However beyond this there appears to be a large group of 
patients that present as an emergency because either: they do not understand how to access the health 
service electively or the elective services are not available. These patients are somehow excluded from 
the standard primary care referral model and subsequently fail to be optimally managed. They then 
present later with vague, slow to be diagnosed symptoms, with delays to important investigations and 
reduced access to surgery. The challenge is to implement changes in healthcare that allow these patients 
to access diagnostic services quicker. Some strategies have been discussed already in chapter 1 and 
include: rapid referral policies, such as two-week wait referrals, and speedy access to diagnostic services 
for all cases. Other solutions include raising public awareness of CRC symptoms and the introduction of 
the BCSP, which is discussed in chapter 4. In countries with an established screening programme, there 
are lower rates of emergency presentations (6-19%) compared to countries without a national 
programme (22-34%)(67,68,70,71,286,304). Additional resources could be given to tackle specific 
subgroups with the worst outcomes. Examples include changing the current cancer referral guidelines 
for patients at the extremes of age or direct advertising campaigns to target hard to reach groups, such as 
the most deprived and socially isolated. Changes could be made to further extend the screening age 
range and also to ensure young patients with a family history are screened. Other technological solutions 
include the wider use of computed tomographic colonography or the colon capsule endoscopy to help 
screen more elderly and frail patients with co-morbidities. A significant proportion of emergency 
presentations could be avoided if patients had a greater awareness of symptoms and medical teams 
referred more quickly when alerted to the possibility of CRC. 
The main weaknesses in using emergency presentation as the primary outcome measure is that it has not 
yet been confirmed to predict long-term survival (past one-year). It could also be argued that for many 
patients we don’t understand why the patient presented as an emergency, was it the severity of the 
symptoms or an inability to access primary care. 
In conclusion, in this chapter I have shown that an emergency presentation is independently an adverse 
prognostic marker, associated with one-year mortality and lack of surgical resection. More specifically, 
it is associated with an excess of early deaths after presentation, suggesting it is associated with the late 
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presentation of cancer. I also offered evidence to suggest that most emergency presentations are 
avoidable. Most importantly I have shown that emergency presentation can be used in my thesis as a 
quality indicator and as my primary outcome measure.  
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Chapter 4 - Introduction of the Bowel Cancer Screening 
Program (BCSP) in England and its association with 
emergency presentations for colorectal cancer  
4.1. Introduction 
The NHS BCSP began in 2006 with the aim of reducing CRC mortality in screened individuals. In this 
chapter, the cohort of CRC patients derived using my novel methodological approach was used to test 
whether the early benefits of launching a BCSP might have extended beyond the minority of individuals 
who are targeted by the screening program.  
4.1.1. How CRC presents 
Most patients present electively with symptoms or signs to their primary care doctor. Patients may also 
present as an emergency directly to secondary care or be detected asymptomatically through routine 
surveillance or since 2006 by the BCSP. 
4.1.2. The NHS Bowel Cancer Screening Programme (BCSP)  
As discussed in chapter 3 it is thought that the poor outcomes for UK CRC patients is largely the result 
of late presentation and consequent advanced stage of the disease, which reduces the chance of curative 
surgical resection(143,305). The national BCSP aims to detect cancers at a pre-symptomatic stage, 
leading to the earlier elective diagnosis of less invasive cancers(184). The secondary aim of screening is 
to remove adenomas that can develop into cancer, with the expectation that this will reduce the national 
incidence of CRC. This is supported by a number of large studies from the United States showing 
colonoscopy screening can reduce CRC incidence (306,307). 
Prior to the introduction of the UK programme, pilot studies between 2000 and 2005 in Scotland 
(Tayside, Grampian and Fife) and England (Coventry and North Warwickshire) established that the 
performance of the FOBt in randomised controlled trials could be replicated in a UK setting(308,309). 
In the English pilot, uptake was between 50% and 60% in line with the randomised trials. Cancer was 
detected in 2.3/10,000 screened subjects(310). In randomised trials this screening strategy reduced 
CRC mortality by 16% in those invited for screening and by 25% in those accepting 
screening(11,96,98). This provided positive evidence driving the British government to implement a 
national screening programme. However, there have been criticisms of the effectiveness of these 
screening trials, most importantly that they failed to show any difference in all-cause 
mortality(182,311). 
National screening began in July 2006 with a phased roll out, achieving national coverage by January 
2010. There were three waves of rollout for the BCSP. Screening centres in the first and second waves 
became operational prior to April 2008 while the third wave, covering the rest of the country, became 
operational from April 2008, with complete coverage achieved by January 2010, Figure 4.1.  
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Screening involves biennial Faecal Occult Blood tests (FOBt), initially inviting all men and women aged 
from 60–69 years. From 2010, this was extended up to 75 years. Approximately 10% of the UK 
population is aged 60–69 years, with half the invitations sent out in year one of the screening round and 
the remainder in year two. The latest UK figures show that 26% of CRCs occur in this age group(312).  
In England, the BCSP is coordinated through five programme hubs, each with a population of roughly 
10 million in total, Figure 4.2. These hubs provide a call and recall service to patients, supply the FOBt 
kits and despatch test results. Beneath the screening hubs are the local screening centres, in England 
there are 56, each serving a population of 500,000 to 2 million people. These centres see people who 
have presented with positive test results through the screening programme. Most people (approximately 
98%) will have a negative test result, with no positive FOBt results. These subjects will be invited to 
participate again in two years’ time(171). Those participants with a positive FOBt result are invited to 
the local screening centre and offered a colonoscopy as the investigation of choice. Depending on the 
findings they are then offered screening again in two years’ time, entered into the polyp surveillance 
programme or referred for CRC treatment at a local hospital following a multi-disciplinary team (MDT) 
assessment, Figure 4.3.   
Screening would be most effective if all individuals took a test which was 100%, sensitive to CRC. This 
is not the case with the current programme for a number of reasons. Firstly, many cancer patients don’t 
have access to screening, as only 25% of cancers are currently diagnosed in the screened age group of 
60-69 years and uptake in this group is only 50%(30). Even with the age extension of the screening 
programme to 75 years, a large proportion of patients with CRC still won’t be screened and 
furthermore the FOBt sensitivity for CRC is poor. A systematic review found its sensitivity ranged from 
6.2% to 83.3%. This variability is due to the different test thresholds, study populations and study 
design used in the trials(313).  
Therefore the current screening programme will fail to identify many cases of CRC. However it could 
be speculated that a fortunate byproduct of the screening programme is a greater awareness of CRC 
among all individuals and healthcare providers. This may alter health seeking behaviour and result in a 
reduction in late presenting cancers. I speculate that this ‘indirect effect’ will operate by increasing 
awareness and reducing barriers for patients to come forward. Secondly general practitioners will have a 
lower threshold for referral for investigation, both leading to improved outcomes. 
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Figure 4.1 Uptake of the BCSP in late 2008, according to primary care trusts(314). 
 
 
Figure 4.2 Areas of England covered by the five regional Bowel Cancer Screening Programme hubs. 
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Figure 4.3 Configuration of programme hubs, screening centres and multidisciplinary teams (MDTs). 
*MDT at the treating hospital, ** a screening centre more have one or more colonoscopy sites 
 
4.1.3. Evidence for the effectiveness of the BCSP in screened individuals 
Screening success relies on individual participation and this varies according to age, gender, co-
morbidity, ethnic background, and deprivation status(305). An early analysis of the first 2.1 million 
subjects invited to screening showed the overall uptake was 55-60%, but in London was only 40%. This 
resulted in 1,772 cancers being diagnosed, 70% of which were early stage (Dukes A or B)(171). The 
proportion of Dukes A cancers among the screened group was significantly higher than among non-
screened patients (35% vs. 13%)(73).  
It is estimated that if uptake remains at 60% then over the next 20 years, there would be 20,000 fewer 
CRC deaths in the UK (315). With CRC screening there is the extra potential benefit from removing 
adenomatous polyps, and so prevent cancer from ever developing(58). However, the case for the UK 
BCSP has not yet been conclusively proven. In particular it will take many years before we can establish 
long-term mortality benefits. This is partially because patients responding to a screening invitation are 
on average healthier than those that don’t participate(305). It is also unclear whether screen-detected 
cancers behave in the same way as symptomatic cancers and whether they are as dangerous for patients. 
This demonstrates the problem at the heart of understanding the effectiveness of any screening 
programme. It is tempting to assume that the ‘progressive disease model’ can be used. This is where a 
disease fits neatly into three stages; a) a disease free state, where no existing technology could identify 
the cancer, b) the pre-clinical disease stage, where the patient does have cancer but is symptom free and 
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where a screening test can identify the cancer and c) the clinical stage, where the cancer causes 
symptoms that instigate investigation and diagnosis of the cancer.  
Screening effectiveness is predicated on cancer being detectable in the pre-clinical stage and that this 
time is long enough to allow treatments to occur earlier and improve patient outcome (i.e. to reduce 
cancer-associated mortality). The critical time period is therefore between a cancer being screen 
detected (in the pre-clinical phase) and death. The problem with this approach is that early end points 
(such as disease stage and early survival) rely on false assumption that the natural history of screen 
detected (asymptomatic) and symptomatic cancers are the same. In reality, screen detected cancers are 
often more benign and readily treatable(316).  
To understand the effectiveness of screening, the cancer mortality rate in the screening population is 
required. This is the number of cancers deaths in a given time for a given population(317). Reducing 
cancer mortality in a population is the best indication of the programmes effectiveness as it is derived 
not only from the ability to detect cancer but the effectiveness of the treatment given. However this 
requires costly long-term follow-up on large populations.  
Using short-term surrogate markers, such as one-year mortality and surgical resection rates, poses four 
main problems: 
1) The “healthy volunteer effect” relates to the fundamental differences between people 
who participate in screening programs and those that do not. On average participants are 
more affluent, more educated, healthier and have a longer life expectancy(316). CRC 
screening participants have markedly lower mortality rates compared to the general 
population(11).  
2) Lead-time bias: Lead-time is the time period that exists between when the cancer was 
diagnosed by screening, to the time when it would have presented without screening. As 
survival is measured from the date of diagnosis, this creates “lead-time bias”. This means 
that the apparent duration of the disease and by that, the survival is lengthened. This does 
not mean the patient lives any longer and it is why case survival rates in screening 
programmes should be assessed with care.  
3) Length-bias relates to differences in the cancers found in screen detected and clinically 
detected groups. Cancers that are screen detected have a longer pre-clinical duration than 
clinical cases. These cancers are slow growing and not only have a longer pre-clinical stage, 
but also a longer clinical phase than clinical detected cancers. Furthermore, these indolent 
cancers are more likely to have a favourable outcomes even without screening, because they 
are less likely to have spread to lymph nodes and metastasised(318).   
4) The final bias, “over-diagnosis bias”, is linked to the lead-time and length biases 
mentioned above and relates to a subset of cancers that are either non-progressive or even 
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regress in the pre-clinical stage. Therefore this group of cancers can be detected by a 
screening test but would not progress to clinical disease and would not negatively affect a 
patient’s quality or quantity of life. These non-progressive cancers remain pre-clinical for a 
long time and are therefore more likely to be detected by a screening programme.  
Due to all of these biases simply identifying lower stage cancers or an increase in survival is not evidence 
of screening efficacy. Conclusive proof will not be seen until trends in CRC and overall mortality data 
can be shown and this will take many years and is beyond the scope of this thesis. Although the concept 
of screening is straightforward, screening for some cancers has proved controversial (e.g. breast and 
prostate cancer), with doubts whether the overall gains from specific programmes warrant the cost or 
harms(190,319,320). In practice, quantifying the real-world benefits of population-based cancer 
screening is difficult. Survival benefit takes many years to realise (190,191) and a range of other 
healthcare advances may occur during this period to confound the interpretation of national trends in 
cancer incidence or survival. In the case of CRC screening, a recent meta-analysis of trial data estimated 
that it took 10.3 years before one death from CRC was prevented for 1,000 patients screened(191). By 
studying the association between start-up of local screening and risk of presentation as an emergency for 
CRC, it may be possible to generate evidence of the early and population wide benefits of launching the 
programme. 
4.1.4. Evidence for the effectiveness of the BCSP in non-screened individuals 
In the United Kingdom awareness of CRC symptoms is poor, with 24% of adults unable to correctly 
name any warning signs and over half (58%) unable to correctly recall any risk factors(163). By 
contrast, the BCSP has been very proactive in advertising the benefits of screening and improved 
outcomes with early detection. Information is supplied to participants through their kits and also spread 
by word of mouth to friends and family. There is prominent advertising both in GP surgeries and by 
local and national media campaigns. Therefore, additional benefits from the BCSP may include increased 
awareness of CRC among all individuals and healthcare providers. This will heighten the general public’s 
understanding of the disease and thus may contribute a general benefit to the whole population reflected 
in fewer emergency presentations and a reduction in late presenting cancers. 
The most direct way that screening raises awareness is through the postal invitation that is sent to the 
participants. This initial letter explains that they will shortly be invited to take part in the programme 
and encloses a booklet called ‘Bowel Cancer Screening – The Facts’ (Appendix 4). There is then an 
opportunity to opt out by contacting the screening hub on a free telephone number. Otherwise, one 
week later a screening kit, which includes leaflets, sample sticks and a foil-lined envelope are dispatched 
to the participant’s address. Following a positive test, participants are invited to a nurse-led clinic. At 
the clinic appointment the patient will receive; counselling, a health questionnaire, information, consent 
for colonoscopy and a leaflet about the test. Other forms of awareness promotion include posters 
designed for GP surgeries and local community centres (Appendices 5,6), media campaigns including 
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posters on billboards and buses and local and national media campaigns. More direct approaches were 
used in some areas, such as creating community clinics in each Primary Care Trust. These were held so 
that participants could easily access screening assessment clinics locally, with the aim of increasing 
uptake.  
Once members of the public have an increased awareness of screening programmes they are more likely 
to be screened themselves and encourage their peers to be screened(69,72,172). Standard advertising 
methods are less likely to be reach individuals that are: older, male, from ethnic minorities, suffering 
from mental health problems or learning disabilities and living in deprived areas(321). To try and 
improve awareness in these groups, targetted advertising was used. This included leaflets especially 
designed for men, that were specifically designed around a sports theme (Appendix 7) and also used 
spouse encouragement to increase the likelihood of participation (Appendix 8). To reach ethnic 
minorities the booklets were made available in 20 languages and outreach clinics were provided in 
community centres. Pictorial booklets, including all the steps required to complete the stool test, were 
used to support patients with learning difficulties (Appendix 9). Finally, specific DVDs were designed for 
black and racial minorities, patients who are deaf and hard of hearing and those with low literacy skills 
and learning difficulties.  
To raise awareness within primary healthcare before each Primary Care Trust (PCT) went live with the 
programme the key members of the PCTs were invited to education sessions. The education sessions 
highlighted the public health issues of CRC including health inequalities, the background to the 
screening programme and its impact on Primary Health Care Teams, the process of screening, and the 
signs and symptoms of CRC. 
In conclusion, the BCSP in raising awareness of CRC, will not only improve screening uptake among 
invited subjects but also encourage patients with symptomatic CRC, to present earlier (73,322). Such a 
benefit would reduce the risk of emergency presentation for both “screened” and “non-screened” CRC 
patients living in an area with an active BCSP. 
4.1.5. Evidence screening programmes reduce emergency presentations  
Chapter 3 demonstrated that emergency presentation with CRC was a marker of poor outcomes. 
Interventions that reduce emergency presentations and emergency surgery lead to increased survival for 
patients and reduced costs to healthcare providers(323). Therefore, one early sign that screening is 
beneficial to an area could be a reduction in the risk of emergency presentations, following the 
introduction of screening. 
The Nottingham screening study ran from 1981 to 1991 and involved 75,253 patients in the screened 
group (60% response rate) and 74,998 well-matched, unscreened controls. The emergency presentation 
rate was 23.9% in the screened group, compared to 27.9% in the control group, which was not a 
statically significant difference(88). Interestingly, a study from Coventry and North Warwickshire as 
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part of the English pilot study reported 29.4% of patients presented as an emergency in 1999 (the year 
before bowel screening began) and by 2004, the end of the pilot, the rate had fallen to 15.8%, which 
was statistically significant (p=0.001). Surprisingly, the proportion of Dukes stage cancers was 
unchanged over the study period and the number of cases did not rise as would be expected with the 
finding of “additional” screened cases(324). It is therefore unclear whether screening itself, or other 
changes in CRC care over the 5 years, caused the reduction in emergency presentations. Interestingly, 
one study showed how introducing a fast-track, flexible sigmoidoscopy service for patients with any of 
six high-risk criteria for CRC could potentially reduce emergency presentations. Before the service 
began in the area, the emergency rate was 36%, while in the three years after this had reduced to 26% 
(p= 0.059)(210).  
 
4.2. Hypothesis 
I believe my cohort of CRC patients derived from HES data and refined using clinical logic and 
algorithms can be used in a retrospective, observational study to investigate the roll-out of the BCSP 
across England. Using emergency presentation as my metric of outcome, I will investigate whether 
there was an early, population wide and indirect benefit, particularly for those of non-screening age. 
I consider the risk of emergency presentation with CRC may be reduced among people living in an area 
with an active BCSP. My exposure of interest was “living in an area with an active BSCP”. This was not 
the same as a patient actually taking part in the screening programme, simply that they lived in an area 
where the BCSP was active. This reduction in risk may be due to both direct and indirect effects. The 
“direct” effect applies only to a small number of screened individuals, where their asymptomatic cancer 
will be detected. The “indirect” effect is due to a heightened awareness of the symptoms of CRC among 
patients and health professionals in areas with an active BCSP.  
I am unable to tell how an individual case was affected by the programme; whether it was increased 
personal awareness of CRC symptoms due to the BCSP that lead to the patient seeking help sooner 
(reduced patient delay) or whether it was because the patient was seeing a GP who had heightened 
awareness of CRC, because of the programme, and therefore a lower referral threshold (reduced 
practitioner delay). It may of course also be a combination of factors that lead to a quicker referral for 
definitive diagnostic tests. 
I also aim to quantify the “dose of exposure”, in terms of the duration of time that the programme has 
been active in an area and whether this was associated with a reduced risk of emergency presentation. 
Therefore, I propose that the longer the exposure to screening a patient has, the lesser the risk of an 
emergency presentation.  
I consider that no part of the non-screening population will be adversely affected by the introduction of 
the BCSP.  
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4.3. Aims 
My aim is to study whether “living in an area with an active BSCP” was associated with a reduced risk of 
emergency presentation for CRC. Specifically in this chapter, I will; 
1) Identify whether screening exposure was associated with a reduced risk of emergency 
presentation in patients within the screening age group.  
2) Identify whether screening exposure was associated with a reduced risk of emergency 
presentation in patients within the non-screening age group.  
3) Investigate the effects of screening exposure on patient characteristics. 
4) Identify whether the dose of exposure (the duration of time that BCSP had been active 
locally) was associated with a reduced risk of emergency presentation. 
I cannot, at this stage, know whether any association was causal or related to a confounding factor. For 
example, was living in an area with an active BCSP just a surrogate for parts of the country where risk of 
emergency was “already lower”, perhaps because of better diagnostic services. Therefore, I will compare 
the effects of screening exposure on outcomes for CRC against a control group. I selected oesophageal 
and gastric cancer (OG cancer) as the most appropriate disease control, since these are gastrointestinal 
tumours that have similarities to CRC in terms of clinical presentation (patients can present with non-
specific gastrointestinal symptoms, plus or minus alarm features, with considerable overlap with 
common benign conditions) and pathway of diagnosis (a major emphasis on referral from primary care 
for diagnostics, in this case gastroscopy). As with CRC, there are similar concerns in the UK regarding 
diagnostic delay and potentially ‘avoidable’ emergency presentations for OG cancer(244).  
My goal was to demonstrate that there was no association between a locally active BCSP and the risk of 
emergency presentation for OG cancer. This would make it less likely that there was a general 
confounding effect caused by local factors unrelated to the programme. Hence, the study aimed to 
determine whether living in an area with an active BCSP was associated with a reduced risk of 
emergency presentation for CRC but without any such association apparent for OG cancer. 
 
4.4. Methods 
To address the aims in this chapter I needed to identify two separate populations. My primary 
population was the one-year (October 2006 to September 2007) CRC cohort derived in chapter one. 
The secondary population contained patients presenting with OG cancer during the same time period.  
As my original database in chapter 1 covered the period April 2006 to March 2008, I restricted inclusion 
in this chapter to patients that presented with a minimum of 6 months admission data before and after 
their index admission. Therefore, my cohort in this chapter is termed the “middle year cohort” as it 
encompassed those patients whose initial index admission occurred between October 2006 to 
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September 2007, (Figure 2.2, chapter 2).  
In order for me to be able to determine a patient had been “exposed” to screening at presentation I 
needed to know when a) the patient first presented with CRC and b) when their local screening centre 
started screening. Therefore, any patient without these dates was excluded from the study. I used this 
information to study the association between screening exposure and emergency presentation in patients 
in the screening age and also those outside the screening age, the non-screening population. My primary 
outcome was emergency presentation of CRC and secondary outcomes were surgical resection and one-
year mortality.  
The second population contained all patients presenting with OG cancer from October 2006 to 
September 2007 that also had a date for when their local screening centre started screening.  
 
4.4.1. Identifying the Primary Care Trusts (PCTs) in England  
During the study period general practices in England were grouped administratively and geographically 
into primary care trusts (PCTs). These PCTs were responsible for commissioning services for the local 
population of registered patients. PCTs decided which screening centre to refer to and, once the centre 
became operational, individuals within the PCT become liable for enrollment in the programme. 
At the beginning of the middle year cohort in October 2006, the BCSP was active in only a few parts of 
England. During the year, it became active in other areas but not all, Figure 4.1. Hence, there was 
variation in exposure to start-up of BCSP between PCTs during the period of study, Figure 2.2, chapter 
2. Appendix 10 shows the date that each screening centre became operational and which PCTs it covered. 
This provided an opportunity to develop logistic regression models to estimate the association between 
start-up of BCSP in a patient’s area and the risk of emergency presentation during the diagnostic 
pathway. This information was obtained from the BCSP(325). I thus generated a list identifying each 
PCT in England and the date when screening began. On 1st October 2006 there were 152 PCTs in 
England, with an average population of just under 330,000 each. There was one trust (North East 
Lincolnshire), which used two identification codes and this required reconciliation of the data.  
The decision to refer which population to which screening centre, was made by the Strategic Health 
Authorities (SHAs). To eliminate uncertainty of screening exposure, I excluded 10 PCTs that referred 
patients to more than one screening centre, when the start-up dates of the screening centres were 
different. This was because it was not possible to allocate the entire PCT population to a single 
screening start-up date. Following removal of all patients belonging to those 10 PCTs my study cohort 
comprised of 142 PCTs. The number of CRC patients was reduced from 32,299 to 27,640(2).  
Of the 142 PCTs included in my study 17 had commenced screening prior to the start of the study 
period, therefore all these patients were placed in the “exposed” group. 48 PCTs began active screening 
during my study year so some of these patients were in the “exposed” group and others were in the 
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“non-exposed ” group. Finally, 77 PCTs had not yet started screening by the end of my study cohort and 
all of these patients were in the “non-exposed” group. There were 7,142 patients in the “exposed” group 
and 20,498 patients in the “non-exposed” group.   
4.4.2. Identifying the time period that patients were exposed to the BCSP 
Each patient was first assigned a variable to indicate whether or not they were living in a PCT that had 
active BCSP at the date of presentation, Figure 4.4. For those cases in which the BCSP was active, I 
calculated the duration that screening had been active in the area, relative to the patient’s presentation. I 
categorised patients according to exposure status into three groups: (1) No active local screening at the 
time of presentation (the control or “non-exposed” group); (2) “Exposed” to screening for less than six 
months (<6 months); and (3) “Exposed” to screening for more than 6 months (≥6 months). I split the 
exposed patients into two groups, in order to look for an early effect from screening introduction. This 
was because such a finding would have been very unlikely to come from the direct effect alone. 
I categorized patients according to age, gender, co-morbidity and deprivation to correct for case-mix in 
the overall analysis and also to explore whether any risk reduction for emergency presentation was 
different among particular sub-groups of patients. To further evaluate any ‘dose-response’ effect from 
screening exposure, I undertook sensitivity analysis using an alternative continuous exposure variable 
(duration of locally active BCSP, expressed in months).  
 
Figure 4.4 Screening exposure status for each patient in the cohort was determined relative to the 
startup date of the BCSP in his or her PCT. The black dot represents a patients index admission. 
 
4.4.3. Identifying a comparative group of patients (OG cancer)  
I examined whether there was any relationship between screening programme exposure and emergency 
presentation rates for OG cancer, using data from our group’s recent study.  The development and 
validation of this dataset was undertaken by Shawihdi et al and has been reported (16). The OG cancer 
data was extracted from the same national HES database as I used for the CRC cases. The methods for 
extracting the OG cancer data were comparable to those described for CRC (see section 2.5.1) and the 
study covered the same time period (October 2006 to September 2007). In total there were 9,319 
patients with OG cancer compared with 27,640 patients with CRC. 
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I determined exposure status of each OG cancer patient based on the start date of screening in their 
PCT of residence and the date of their presentation. I selected the same patient characteristics for the 
OG cancer cases as for the CRC cohort. These were; age group, gender, co-morbidity, deprivation and 
each patient had their presentation defined as elective or emergency.  
 
4.5. Results 
4.5.1. Association between locally active bowel cancer screening program and emergency 
presentation of CRC   
My study cohort contained 27,640 CRC patients belonging to the 142 included PCTs. Out of this group 
7,142 (25.8%) were living in an area with an active BCSP at the time of presenting with CRC 
(“exposed” group) and for each patient I was aware exactly how long the programme had been active 
for. The remaining 20,498 patients (74.1%) were classed as “non-exposed” and were living in an area 
where the BCSP had not yet started. 
The characteristics of these patients were comparable to the original cohort of 32,299 patients in 152 
PCTs, described in chapter 1, Table 4.1. In my study cohort the mean age at diagnosis was 70.9 years, 
55.9% of cases were male and 67.9% had no co-morbidities. The level of deprivation was relatively 
evenly spread across the cohort, with 18.8% in the most deprived quintile and 19.6% in the least 
deprived quintile. Overall, in my study cohort, 36.5% of patients presented as an emergency.    
In patients “exposed” to screening for any length of time the crude emergency presentation rate was 
significantly lower at 34.9% (2,492/7,142) than the 37.0% (7,599/20,520) in the “non-exposed” group 
(p=0.002). In the screening age only group (60-69 years), the crude emergency presentation rate was 
significantly lower in the “exposed” group 27.2% (515/1,893), compared to the “non-exposed” group 
at 30.3% (1,460/4,825)(p=0.013). In the non-screening age only group (all others), the crude 
emergency presentation rate was not significantly lower in the “exposed” group 37.7% (1,977/5,248), 
compared to the “non-exposed” group at 39.1% (6,135/15,673)(p=0.060), Figure 4.5.  
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Table 4.1 Characteristics of CRC patients presenting in English NHS hospitals over a one-year period 
(October 2006 to September 2007). 
Patient 
characteristics 
 
Total, N 
(%) 
Study 
cohort, N 
(%) 
Non-
exposed, N 
(%) 
Exposed <6 
months, N 
(%) 
Exposed ≥6 
months, N 
(%) 
Number of cases 32,299 27,640 20,498 4,151 2,991 
Age, mean (sd)                    71.0 (12.1) 70.9 (12.1) 71.0 (12.3) 70.8 (11.6) 70.7 (11.8) 
Age groups                          
 < 60                  5,347 (16.6) 4,583 (16.6) 3,435 (16.8) 684 (16.5) 464 (15.5) 
 60 to 69                 7,868 (24.4) 6,719 (24.3) 4,825 (23.5) 1,078 (26.0) 816 (27.3) 
 70 to 79                   10,651 
(33.0) 
9,134 (33.0) 6,748 (32.9) 1,374 (33.1) 1,012 (33.8) 
 >79                   8,433 (26.1) 7,204 (26.1) 5,490 (26.8) 1,015 (24.5) 699 (23.4) 
Gender      
 Male 17,981 
(55.7) 
15,437 (55.9) 11,337 (55.3) 2,387 (57.5) 1,713 (57.3) 
 Female 14,318 
(44.3) 
12,203 (44.1) 9,161 (44.7) 1,764 (42.5) 1,278 (42.7) 
Co-morbidity groups                     
 1 (No co-morbidity)                 21,847 
(67.6) 
18,760 (67.9) 13,933 (68.0) 2,781 (67.0) 2,046 (68.4) 
 2 (1 co-morbidity)                 2,383 (7.4) 2,067 (7.5) 1,513 (7.4) 323 (7.8) 231 (7.7) 
 3 (2 or more co-
morbidity)             
8,069 (25.0) 6,813 (24.6) 5,052 (24.6) 1,047 (25.2) 714 (23.9) 
Patient deprivation              
IMD missing* 322 (1.0)      
 1 (Most deprived)                 5,516 (17.1) 5,197 (18.8) 3,567 (17.4) 1,012 (24.4) 618 (20.7) 
 2 6,044 (18.7) 5,324 (19.3) 3,851 (18.8) 873 (21.0) 600 (20.1) 
 3 6,844 (21.2) 5,794 (21.0) 4,279 (20.8) 846 (20.4) 669 (22.4) 
 4 6,980 (21.6) 5,897 (21.3) 4,472 (21.8) 823 (19.8) 602 (20.1) 
5 (Least deprived)                 6,593 (20.4) 5,428 (19.6) 4,329 (21.1) 597 (14.4) 502 (16.8) 
Emergency admission 11,651 
(36.1) 
10,087 (36.5) 7,595 (37.1) 1,513 (36.4) 979 (32.7) 
*Patients from the original cohort with a missing IMD were excluded from the other columns 
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Figure 4.5 A chart comparing the rates of emergency presentations, in patients exposed and non-
exposed to the BCSP in all ages and then split into those in screening (60-69 years) and non-screening 
(other ages) ages. 
 
Of the “exposed” group, 4,151 patients presented within the first six months of the local start-up date 
(<6 months) and 2,991 patients presented six months or more after screening had started in their area 
(≥6 months). The mean exposure time was 5.7 months (ranging from 0.1 to 15.2 months). It should be 
noted that only approximately half the target population of 60-69 year olds would have been offered 
screening within the first year of activation of the programme.  Hence, few cancers within this 
population-based study of all ages are likely to have been screen-detected. 
There was a small but significant difference in mean age of patients across the three groups (“non-
exposed”: 71.0 yrs; <6 months exposure: 70.8 yrs; ≥6 months exposure: 70.7 yrs; p<0.01 ANOVA), 
Table 4.1. This may be explained by the predictable finding that the proportion of CRC patients in the 
screening age group (60-69 years) was higher for “exposed” than “non-exposed” groups, thereby 
bringing down the mean age by a small amount. Comparing areas where the screening had been active 
for 6 months or more to the “non-exposed” group; significantly more patients are aged within the 
screening age (60-69 years) (27.3% vs. 23.5%, p<0.001). This suggests that there was enhanced 
detection of CRC among people of screening age either within the programme (asymptomatic, screen 
detected cases) or via normal diagnostic routes. 
There was no difference in gender mix or levels of co-morbidity across the exposure groups.  
The crude rate of emergency presentations was lowest in the “exposed” group when the BCSP had been 
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active in their local population for over 6 months (32.7%) and highest in the “non-exposed” group of 
patients diagnosed before screening began in their area (37.1%, p<0.001), Table 4.1, Figure 4.6. Those 
cases of CRC diagnosed within six months (<6 months) of local start-up of BCSP had an intermediate 
rate of emergency admission.  
In binary logistic regression, the adjusted odds ratio for emergency presentation in patients presenting 
≥6 months in the “exposed” group was 0.83 (CI: 0.76-0.90, p<0.001) compared to “non-exposed” 
(control) cases. Those patients with less than 6 months exposure, had an odds ratio between the two 
other groups, at 0.95 (CI: 0.88-1.02, p=0.170), Table 4.2. Hence, after adjusting for patient 
characteristics I was able to confirm that exposure to locally active screening was an independent 
patient-level factor associated with emergency admission for CRC in England.  
As expected from my earlier work, increasing age, especially 80 years and over (2.09, CI: 1.93-2.27), 
female gender (1.17, CI: 1.11-1.24) and two or more co-morbidities (4.06 CI: 3.83-4.31) were 
associated with increased odds of emergency admission for CRC patients.  Patients in the lowest quintile 
of deprivation had the lowest risk of emergency presentation (0.64, CI: 0.59-0.70). Therefore patients 
that were: over 80 years of age; female; afflicted with multiple co-morbidities or from the most 
deprived quintile were all more likely to present with an emergency presentation. The strongest 
independent predictor was two or more co-morbidities.  
 
 
Figure 4.6 A chart showing emergency presentation rates, in patients with different levels of exposure 
to the BCSP. The unadjusted emergency rate is significantly lower in the group with more than 6 
months exposure to the BCSP than the control group (p<0.001).  
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Table 4.2 A binary logistic regression analysis of 27,640 CRC cases diagnosed between October 2006 
and September 2007, showing factors associated with emergency presentation. 
Variable Emergency 
presentations / 
total cases (%) 
Unadjusted (univariate) Adjusted (multivariate) 
 OR CI p value OR CI p value 
Age group 
(years) 
       
<60 years  1,440/4,583 
(31.4) 
1 - - 1 - - 
60-69 years 1,975/6,719 
(29.4) 
0.91 0.84-0.99 0.021 0.90 0.83-0.98 0.019 
70-79 years  3,087/9,134 
(33.8) 
1.11 1.03-1.20 0.005 1.08 1.00-1.17 0.063 
>79 years 3,585/7,204 
(49.8) 
2.16 2.00-2.34 <0.001 2.09 1.93-2.27 <0.001 
Gender        
Male 5,320/15,437 
(34.5) 
1 - - 1 - - 
Female 4,767/12,203 
(39.1) 
1.22 1.16-1.28 <0.001 1.17 1.11-1.24 <0.001 
Co-morbidity 
groups 
       
No co-morbidity  5,085/18,760 
(27.1) 
1 - - 1 - - 
1 co-morbidity  914/2,067 (44.2) 2.13 1.94-2.34 <0.001 2.02 1.84-2.22 <0.001 
≥ 2 co-morbidity 4,088/6,813 
(60.0) 
4.03 3.81-4.28 <0.001 4.06 3.83-4.31 <0.001 
Deprivation        
1 (most deprived) 2,194/5,197 
(42.2) 
1 - - 1 - - 
2 2,013/5,324 
(37.8) 
0.83 0.77-0.90 <0.001 0.80 0.73-0.87 <0.001 
3 2,122/5,794 
(36.6) 
0.79 0.73-0.85 <0.001 0.76 0.70-0.83 <0.001 
4 2,012/5,897 
(34.1)  
0.71 0.66-0.77 <0.001 0.67 0.62-0.73 <0.001 
5 (least deprived) 1,746/5,428 
(32.2) 
0.65 0.60-0.70 <0.001 0.64 0.59-0.70 <0.001 
BCSP Exposure        
Control  7,595/20,498 
(37.1) 
1 - - 1 - - 
BCSP <6 months 1,513/4,151 
(36.4) 
0.97 0.91-1.04 0.463 0.95 0.88-1.02 0.170 
BCSP ≥6 months 979/2,991 
(32.7) 
0.83 0.76-0.90 <0.001 0.83 0.76-0.90 <0.001 
 
4.5.1.1. Association between risk reduction for emergency admission and duration of screening exposure   
My results showed that living in an area where the BCSP had been active for more than 6 months was 
associated with a significantly lower rate of emergency presentations. In addition, patients with more 
than 12 months exposure to local screening had substantially lower rates of emergency presentations 
than those with 6-12 months exposure (26.6% vs. 33.7%, p=0.005). Both groups had substantially 
lower rates than the “non-exposed” group (37.1%), Table 4.3, Figure 4.7. This suggests that the 
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magnitude of risk reduction is greater when the BCSP has been active for a longer time period, at least 
over the first 1-2 years. 
I next studied whether the impact of screening was incremental, such that each additional period of time 
was associated with progressively lower rates of emergency presentations. To do this, I substituted the 
categorical exposure variable (“non-exposed”; <6 months “exposed”; ≥6 months “exposed”) with a 
continuous exposure variable (the duration in months) that BCSP had been active at the time of the 
patient’s presentation. Exposure was thus expressed as the number of months that screening was active 
at the time of the patient’s diagnosis. Using this continuous exposure variable, the adjusted OR provided 
an estimate of risk reduction per month of exposure. For every month of exposure, the OR was 0.98 
(CI: 0.97-0.99, p<0.001), thus representing a 2% reduction in relative risk of emergency presentations 
for every month “exposed” to local screening. Among those “screened” patients (60-69 years) the effect 
was slightly higher, with an OR of 0.97 (CI: 0.96-0.99, p<0.001), while for patients “non-screened” 
(not of screening age), the OR was 0.98 (CI: 0.97-0.99, p<0.001). These analyses confirmed an 
independent association between incrementally increasing exposure time and risk of emergency 
presentation for patients overall. This association was seen for both those in the screening and non-
screening age-groups, Table 4.4.  
 
Table 4.3 The emergency presentation rate for patient groups depending on their length of exposure to 
the BCSP at time of presentation. Compared to other groups, those exposed for >12 months had the 
lowest rate of emergency presentation (p<0.001). 
Exposure Emergency presentations/total 
(%) 
P value 
Non Exposed 7,595/20,498 (37.1)  
<6 months exposure 1,513/4,151 (36.4)  0.170 
6-12 months 
exposure 
870/2581 (33.7)* <0.001 
>12 months 
exposure 
109/410 (26.6)** <0.001 
 
 
 174	
 
Figure 4.7 A chart of emergency presentation rates for patients with different lengths of exposure to the 
BCSP. 
Table 4.4 A continuous variable analysis of exposure to the BCSP. The table showed the impact that 
each month of exposure to screening had on all patients and those specifically in the screening and non-
screening age groups. Results were shown before and after adjusting for age, gender, co-morbidity and 
deprivation in multivariate logistic regression. 
Variable Emergency 
presentations / 
total cases (%) 
Unadjusted (univariate) Adjusted (multivariate) 
OR CI P value OR CI P value 
BCSP exposure 
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4.5.1.2. The direct and indirect effect of screening exposure 
The patients with the greatest reduction in risk of emergency presentation were those of screening age 
(60-69 years) who were potentially “exposed” to screening directly. However, there was also a 
significantly lower risk of emergency presentation for patients outside the age targeted by the screening 
programme, Tables 4.5, 4.6, Figures 4.6, 4.7. This is a key finding of the study, as it suggests that both 
the direct and indirect effects contribute to any reduction in emergency rates.  
4.5.1.2.1. Risk reduction for emergency presentation according to age group 
The section aims to examine whether the risk reduction for emergency presentation associated with an 
active BCSP was different for those of screening age (60-69 years) compared to those of non-screening 
age. This is at the heart of my hypothesis that sought to produce evidence that there is both a direct 
effect of screening and an indirect effect, caused by increased awareness of CRC in the local population 
and healthcare system. 
To determine whether the exposure variable (active BSCP) was associated with reduced risk of 
emergency presentation for screening age and non-screening age patients, I constructed two models 
(Tables 4.5 & 4.6), one that included only the 6,719 CRC patients of screening age (60-69 years) and 
another that included the remaining 20,921 non-screening age cases.  
For the 6,719 screening age cases, the crude emergency presentation rate was lower in those patients 
presenting with ≥6 months exposure than in the “non-exposed” controls (24.8% vs. 30.3%, p<0.001), 
Table 4.5, Figure 4.8. The adjusted odds ratio for emergency admission in patients diagnosed ≥6 months 
after screening started was also reduced at 0.75 (CI: 0.63-0.90).  
The same pattern was observed in the unadjusted emergency presentation rates for patients in the non-
screening age. Patients with ≥6 months screening exposure had lower rates than those that were “not 
exposed” (35.7% vs. 39.1%, p<0.001), The adjusted OR for emergency presentation in patients with 
≥6 months screening exposure was 0.85 (CI: 0.77-0.94), Table 4.6, Figure 4.9.  
These findings are consistent with my hypothesis that the start-up of BCSP resulted in indirect, general 
benefits across the whole local population during this period. It also showed, as expected, that the 
magnitude of risk reduction were greatest for those that were of screening age.  
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Table 4.5 A binary logistic regression analysis of 6,719 CRC cases of screening age (60-69 years) 
diagnosed between October 2006 and September 2007, showing factors associated with emergency 
presentation. 
Variable Emergency 
presentations / 
total cases (%) 
Unadjusted (univariate) Adjusted (multivariate) 
 OR CI P value OR CI P value 
Age group 
(years) 
       
60-69 years  1,975/6,719 
(29.4) 
1 - - 1 - - 
Gender        
Male 1,180/4,142 
(28.5) 
1 - - 1 - - 
Female 795/2,577 
(30.8) 
1.12 1.01-
1.25 
0.039 1.10 0.98-
1.23 
0.096 
Co-morbidity 
groups 
       
No co-morbidity  1,006/4,739 
(21.2) 
1 - - 1 - - 
1 co-morbidity  153/453 (33.8) 1.89 1.54-
2.33 
<0.001 1.87 1.52-
2.30 
<0.001 
≥ 2 co-morbidity 816/1,527 (53.4) 4.26 3.77-
4.81 
<0.001 4.24 3.75-
4.79 
<0.001 
Deprivation        
1 (most deprived) 444/1,310 (33.9) 1 - - 1 - - 
2 377/1,271 (29.7) 0.82 0.70-
0.97 
0.021 0.79 0.67-
0.95 
0.009 
3 409/1,381 (29.6) 0.82 0.70-
0.97 
0.017 0.80 0.68-
0.95 
0.011 
4 413/1,450 (28.5) 0.78 0.66-
0.91 
0.002 0.78 0.66-
0.93 
0.005 
5 (least deprived) 332/1,307 (25.4) 0.66 0.56-
0.79 
<0.001 0.67 0.56-
0.80 
<0.001 
BCSP Group        
Control  1,460/4,825 
(30.3) 
1 - - 1 - - 
BCSP <6 months  313/1,078 
(29.0) 
0.94 0.82-
1.09 
0.428 0.92 0.79-
1.07 
0.270 
BCSP ≥6 months 202/816 (24.8) 0.76 0.64-
0.90 
0.001 0.75 0.63-
0.90 
0.002 
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Figure 4.8 A chart showing emergency presentation rates, in screening age (60-69 years) patients, 
depending on the different length of exposure to the BCSP. The unadjusted emergency rate is 
significantly lower in the group with more than 6 months exposure to the BCSP than the control group 
(p<0.001).  
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Table 4.6 A binary logistic regression analysis of 20,921 non-screening age CRC patients diagnosed 
between October 2006 and September 2007, showing factors associated with emergency presentation. 
Variable Emergency 
presentations / 
total cases (%) 
Unadjusted (univariate) Adjusted (multivariate) 
 OR CI p value OR CI p value 
Age group 
(years) 
       
<60 years  1,440/4,583 
(31.4) 
1 - - 1 - - 
70-79 years  3,087/9,134 
(33.8) 
1.11 1.03-
1.20 
0.005 1.08 1.00-
1.17 
0.063 
>79 years 3,585/7,204 
(49.8) 
2.16 2.00-
2.34 
<0.001 2.09 1.92-
2.27 
<0.001 
Gender        
Male 4,140/11,295 
(36.7) 
1 - - 1 - - 
Female 3,972/9,626 
(41.3) 
1.21 1.15-
1.28 
<0.001 1.20 1.13-
1.27 
<0.001 
Co-morbidity 
groups 
       
No co-morbidity  4,079/14,021 
(29.1) 
1 - - 1 - - 
1 co-morbidity  761/1,614 (47.1) 2.17 1.96-
2.41 
<0.001 2.07 1.86-
2.30 
<0.001 
≥ 2 co-morbidity 3,272/5,286 
(61.9) 
3.96 3.71-
4.23 
<0.001 4.01 3.75-
4.29 
<0.001 
Deprivation        
1 most deprived 1,750/3,887 
(45.0) 
1 - - 1 - - 
2 1,636/4,053 
(40.4) 
0.83 0.76-
0.90 
<0.001 0.80 0.73-
0.88 
<0.001 
3 1,713/4,413 
(38.8) 
0.78 0.71-
0.85 
<0.001 0.75 0.69-
0.83 
<0.001 
4 1,599/4,447 
(36.0) 
0.69 0.63-
0.75 
<0.001 0.64 0.59-
0.71 
<0.001 
5 least deprived 1,414/4,121 
(34.3) 
0.64 0.58-
0.70 
<0.001 0.63 0.58-
0.70 
<0.001 
BCSP Group        
Control  6,135/15,673 
(39.1) 
1 - - 1 - - 
BCSP <6 months 1,200/3,073 
(39.0) 
1.00 0.92-
1.08 
0.922 0.96 0.88-
1.04 
0.337 
BCSP ≥6 months 777/2,175 
(35.7) 
0.86 0.79-
0.95 
0.002 0.85 0.77-
0.94 
0.001 
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Figure 4.9 A chart showing emergency presentation rates, in non-screening age CRC patients, 
depending on the different length of exposure to the BCSP. The unadjusted emergency rate is 
significantly lower in the group with more than 6 months exposure to the BCSP than the control group 
(p<0.001).  
 
4.5.1.3. Secondary outcomes: surgical resection rates and one-year mortality 
There was a numerically higher rate of major surgery among patients living in an area with an active 
BCSP (50.9% vs. 49.5%; p=0.049), Table 4.7. In the group with more than 12 months exposure at 
presentation, the resection rate was 57.2%, Table 4.8. This suggested that at least with longer screening 
exposure, more patients were receiving operations and therefore the best chance of long-term survival.  
Among patients diagnosed at a time when the local BCSP was active, the crude one-year mortality rate 
was non-significantly lower than for those diagnosed before the programme started in their area (29.9% 
vs. 28.8%; p=0.399) in the main cohort group, Table 4.9. However, when patients were split according 
to the length of screening exposure, the sub-group “exposed” to more than 12 months had a significantly 
lower one-year mortality rate, compared to the “non-exposed” group (22.1% vs. 29.9%, p=0.002), 
Table 4.10. 
 
Table 4.7 A table comparing the rates of major resection in patients that presented before and after local 
start up date (LSUD) of screening. 
 
P=0.049 
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Table 4.8 A table comparing the rates of major resection, depending on the length of screening 
exposure. The rate was significantly higher for people presenting when screening had been active for 
over twelve months compared to the non-exposed group. 
 
*P=0.002 
 
Table 4.9 A table comparing the one-year mortality rates in patients that presented before and after 
local start up date (LSUD) of screening. 
Exposure 
One-year mortality, N 
(%) 
Before LUSD 6,138/20,948 (29.9) 
After LUSD 2,055/7,142 (28.8) 
P=0.399 
 
 
Table 4.10 A table comparing the one-year mortality rates, depending on the length of screening 
exposure. The rate was significantly higher for people presenting when screening had been active for 
over twelve months compared to the non-exposed group. 
Exposure 
One-year mortality, N 
(%) 
Non exposed 6,138/20,948 (29.9)* 
<6 months 1,209/4,151 (29.1) 
6-12 months 755/2,580 (29.3) 
>12 months 91/411 (22.1)* 
*P<0.001 
 
4.5.2. Control Study To Explore Confounding:  Association between locally active bowel 
cancer screening program and emergency presentation of oesophageal and gastric cancer  
To verify that any associations of the BCSP are specific to CRC, rather than reflecting more general 
features of local services I studied changes in OG cancer presentations with screening exposure. The 
characteristics of 22,450 cases of OG cancer diagnosed in England over a two year period (2006-2008) 
have already been described(244). Of these patients 9,319 were diagnosed during the one-year study 
period (October 2006 and September 2007). Relative to their presentation, 6,787 OG cancer patients 
were diagnosed at a time when BCSP was not active in their PCT (“non-exposed”) and 2,532 (37.3%) 
were diagnosed after the BCSP had started (“exposed”). Crude rates of emergency presentation during 
the diagnostic pathway for OG cancer showed no difference between the exposure groups. The 
emergency presentation rate in the “non-exposed” group was 28.0%, compared to 29.7% in those 
“exposed” for less than 6 months and 28.0% in these “exposed” for longer. 
The results of the binary logistic regression analysis are shown in Table 4.11. I found no association 
between emergency presentation rates of OG cancer and my predictor variable defining exposure of the 
Exposure Major resection, N (%) 
Non exposed 10,150/20,498 (49.5)* 
0/12-6/12 2,074/4,151 (50.0) 
6/12-12/12 1,324/2,580 (51.3) 
>12/12 235/411 (57.2)* 
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local population to BCSP. This suggests that the impact of BCSP exposure was specific for CRC and that 
outcomes for other gastrointestinal malignancies were unaffected.  
 
Table 4.11 A binary logistic regression analysis of 9,319 OG cancer cases diagnosed between October 
2006 and September 2007. The table shows there was no association between BCSP exposure and 
emergency presentations in either the univariate or multivariate analysis. 
Variable Emergency 
presentations/ 
total (%) 
Unadjusted (univariate) Adjusted (multivariate) 
OR CI p value OR CI p value 
Age group 
(yrs) 
       
 <60  293/1,454 (20.2) 1 - - 1 - - 
 60-69  460/2,171 (21.2) 1.07 0.90-
1.26 
0.451 1.06 0.89-
1.26 
0.498 
 70-79  769/3,023 (25.4) 1.35 1.16-
1.57 
<0.001 1.32 1.12-
1.55 
0.001 
 >79  1,110/2,671 
(41.6) 
2.82 2.43-
3.27 
<0.001 3.02 2.57-
3.54 
<0.001 
Gender        
 Male 1,634/6,090 
(26.8) 
1 - - 1 - - 
 Female 998/3,229 
(30.9) 
1.22 1.11-
1.34 
<0.001 1.10 0.99-
1.22 
0.070 
Co-morbidity        
 0 1,345/6,757 
(19.9) 
1 - - 1 - - 
 1  770/1,744 (44.2) 3.18 2.85-
3.56 
<0.001 3.14 2.80-
3.52 
<0.001 
 ≥2 517/818 (63.2) 6.91 5.92-
8.06 
<0.001 7.72 6.58-
9.05 
<0.001 
Deprivation        
 1 (most 
deprived) 
676/2,130 (31.7) 1 - - 1 - - 
 2 551/1,936 (28.5) 0.86 0.75-
0.98 
0.023 0.87 0.75-
1.00 
0.052 
 3 522/1,830 (28.5) 0.86 0.75-
0.98 
0.028 0.84 0.72-
0.92 
0.019 
 4 494/1,840 (26.8) 0.79 0.69-
0.91 
0.001 0.76 0.65-
0.88 
<0.001 
 5 (least 
deprived) 
389/1,583 (24.6) 0.70 0.61-
0.82 
<0.001 0.65 0.55-
0.76 
<0.001 
BCSP 
Exposure 
       
 Control 1,900/6,787 
(28.0) 
1 - - 1 - - 
 BCSP <6 
months 
417/1,406 
(29.7) 
1.08 0.96-
1.23 
0.207 1.07 0.93-
1.22 
0.350 
 BCSP ≥6 
months 
315/1,126 
(28.0) 
1.00 0.87-
1.15 
0.989 0.95 0.82-
1.11 
0.510 
4.6. Discussion 
This chapter was first and foremost about testing the application of my new methodological approach, 
which extracts greater value from HES data. I have shown that combining clinical logic and the newly 
 182	
developed metric of emergency presentation can test associations between exposure and outcomes in 
large populations. In this case whether living in an area with a (recently) activated BCSP was associated 
with a reduced risk of emergency admission for CRC. This form of retrospective, observational study, 
focussed on the roll-out of the BCSP across England, is a useful example of how enhanced HES data can 
help us to understand complex and important questions of national health policy.	
My results suggest that following the introduction of the BCSP across England there was a significant 
reduction in the risk of CRC patients presenting as an emergency. This effect was greatest among 
screening age patients. In this group, the risk of emergency presentation in patients presenting more 
than six months after the local start-up of screening was 0.75 times that of someone “not exposed” to 
screening. However, the risk reduction was not only confined to the screening age group but also to the 
non-screening group. In this group, the risk of emergency presentation after 6 months of screening 
exposure was 0.85 times that of someone “not exposed”. This suggests that indirect, population-wide 
benefits accrued as screening was introduced. 
As already mentioned, two smaller studies exploring the impact of bowel cancer screening on 
emergency presentations for CRC have been carried out in England, which have helped to inform my 
results.  
One was a randomized controlled trial assessing FOBt screening (the Nottingham screening study), 
which compared 75,253 patients in the screened group (60% response rate) and 74,998 well matched, 
unscreened controls (age range; 45-74 years)(88). The emergency presentation rate was 23.9% in the 
screened group, compared to 27.9% in the control group, but the difference was not statistically 
significant (p-value reported as non-significant, the actual number was not stated in the manuscript). 
This may have been due to a lack of study power. On initial inspection the baseline rate of emergency 
presentations appeared to be considerably lower than the overall rate of 36.5% in my cohort. The 
reason for this was likely to be the age cutoff of 74 years in the Nottingham study. When compared to 
my screening age patients the results were more comparable. In patients “not exposed” to screening my 
cohort had a 30.3% emergency rate and in those “exposed” for more than 6 months, the rate was 
24.8%. Therefore, there was a 4% reduction in the Nottingham study and 5.5% reduction in my cohort 
of screening age patients. Of interest was how large the reduction was for both studies compared to the 
detection of cancer in screened subjects of just 2.3/10,000 (310). This suggests the direct effect of 
identifying CRC at screening was unlikely to have accounted for the full 4-5% reduction in emergency 
presentations. 
In an uncontrolled observational study from Coventry and North Warwickshire, where the bowel 
cancer screening pilot targeted patients aged 50 to 69 years, the authors reported that 29.4% of CRC 
patients presented as an emergency in the year before the pilot (1999) but that the local rate had fallen 
to just 15.8% by 2004. Surprisingly, the proportion of Dukes stage cancers was unchanged over the 
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study period and the annual number of cases did not increase as might be expected if extra screen-
detected cases were contributing to the reported totals(208). Expert commentators questioned whether 
screening itself, or other changes in local or national CRC care over the 5 year period, was responsible 
for the time-trends reported(209). It is difficult to compare these results to my own, especially as my 
study lacks data on the cancer stage at presentation. However they suggest that factors outside the direct 
effect of the screening programme were responsible for the changes in emergency presentation.   
My study had the advantage of nationwide coverage and a design that sought to control for sources of 
bias. For example, by studying the results over only a one-year period I eliminated confounding caused 
by changes in NHS practice over time. I also studied patients presenting with OG cancer over the same 
time period in order to have a control group. This demonstrated that the impact of screening exposure 
only affected CRC patients and thus the results for CRC patients were unlikely to have been caused by 
underlying differences in the quality of care provided by areas that began screening sooner.  
The staged roll out of screening across the country meant that simple observation of temporal trends in 
annual emergency presentation rates would not provide an accurate means of assessing the impact of the 
programme on unplanned care. Hence I conceived a study design that took advantage of the variation in 
exposure of local populations to start-up of BCSP during the roll out period. In my analysis there were 
significantly fewer patients “exposed” to screening than not (7,142 vs. 20,498). Ideally, the groups 
would have been more evenly matched.  
Most patients in my cohort were  “not exposed” to the BCSP at the time of their CRC presentation. 
Furthermore most patients that were “exposed”, could only be affected indirectly by screening as only 
24.3% of CRC patients were in the screening age. Furthermore, only half of patients are called for 
screening in the first year of the programme and the average length of exposure to screening was only 
5.7 months at presentation. These explanations go some way towards supporting what the baselines 
figures of my study and the Nottingham and Coventry trials have shown, namely that despite the clear 
evidence of a role for the screening programme in reducing emergency presentations, there is little 
evidence that this occurs directly through the early diagnosis of asymptomatic patients. This was very 
important because it goes to the heart of how a screening programme may reduce the burden of late-
presenting CRC. While there may be a role for improving the technical sophistication of the screening 
test or performance of the colonoscopy, it seems likely that greater benefit will come from increasing 
the overall population’s awareness of CRC symptoms and the need to seek urgent medical attention. 
The first key finding in my results was the significant association between any exposure to screening in 
patients of all ages and a reduced risk of emergency presentation. In patients “exposed” to screening for 
any length of time, the rate was 34.9% compared to 37.0% in the “non exposed” group. My next 
finding was that longer exposure, in particular over 6 months, was more strongly associated with 
improved outcomes. On multivariate analysis, the OR for patients with >6 months exposure was 0.83 
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compared to the “non-exposed” group. This was a highly significant finding. However, the group of 
patients “exposed” for less than 6 months had an OR of 0.95 and this was not significantly lower. This 
supports my hypothesis, which stated that living in an area with an active BCSP was associated with a 
reduced risk of an emergency presentation, through both direct and indirect effects.  
I further studied the effect of screening duration on outcomes by splitting those patients with more than 
6 months exposure into “6-12 months exposure” and “more than 12 months exposure”. This showed 
that the longer the duration of exposure, the lower the emergency rates became; the exposure effect 
was not a one off effect but a continuing positive effect. In fact, every month of exposure was associated 
with a 2% reduction in the risk of emergency presentation. Showing the same association when 
exposure was used as a continuous rather than categorical variable supported the incremental (or dose-
response) nature of screening exposure.  
I next consider what factors may be behind the association between exposure and reduced emergency 
presentations. Patients of screening age may benefit from the programme both directly through the 
diagnosis of the asymptomatic cancer and indirectly through enhanced awareness of the need to present 
their symptoms to medical professional. Meanwhile non-screening patients can only be helped 
indirectly.  
Evidence for the direct effect comes from the higher proportion of screening age group patients in the 
>6 months exposure group, compared with the “non-exposed” group (27.3% vs. 23.5%). Not knowing 
which patients were diagnosed directly through the BCSP, meant it was not possible to quantify the 
direct and indirect effects of screening. However, unsurprisingly this does point to there being a greater 
increase in CRC detection in screening age patients once screening was established. I also described a 
greater reduction in the odds of emergency presentation in screening age compared to non-screening 
age after 6 months exposure (0.75 compared with 0.85). Ultimately, it must also be remembered that 
some of the patients in the screening age may have benefitted from the enhanced awareness brought 
about being enrolled in a campaign (and having letters and FOBt kits sent through the post).  
While screen-detected cancers will have contributed to the reduced risk of emergency presentation 
observed in the screening age group, this cannot explain the major risk reduction also seen in the non-
screening age group. In this case, increased awareness among patients and health professionals will have 
been a factor (i.e. the indirect effect). Moreover, I have shown a risk reduction within 6-12 months of 
start-up, when screening will have been offered to fewer than half of eligible 60-69 year olds and so 
before the full benefits of the screening programme have been realised.   
I was not able to fully quantify the indirect benefits of the programme because HES cannot identify 
screen-detected cancers. Hence, I cannot know how much of the observed reduction in risk of 
emergency presentation was attributable to the elective diagnosis of symptomless cancers within the 
programme itself. I do, however, know the date when a PCT joined the screening programme and 
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therefore whether screening was available at the time of a given patient’s presentation. I also know that 
any reduction in the non-screening age group must be due to the indirect effect and could only be 
influenced by the screening programme increasing public and professional awareness. In fact, relative to 
the total number of new CRC cases diagnosed nationally, the absolute numbers of screen-detected 
tumours is low. In a report of cumulative findings from the BCSP until October 2008 (a full year after 
the end of my study period) only 1,772 screen-detected CRC cases had been recorded(171). It follows 
that our study cohort of 27,640 cases will have contained only a few hundred screen-detected cancer 
patients. Evidence of this effect can be seen in the 4% increased rate of CRCs diagnosed in screening age 
patients (60-69 years) in areas where screening had been active for ≥6 months compared to “non-
exposed” areas. 
Overall my data for major surgical resections and one-year survival was not strong enough to support 
the claim that these outcomes are improved in the early period after screening was introduced. 
However the 12-month exposure group data suggests there may be a trend for better outcomes with a 
longer follow-up period. Despite this, these positive results have to be interpreted with caution, as early 
outcome metrics such as access to surgery and early survival are liable to be affected by lead time, length 
time and over-diagnosis bias that has been discussed already. For that reason, I have not studied these 
outcomes in detail. 
In my national cohort I also showed that increasing age, female gender, increased levels of co-morbidity 
and socioeconomic deprivation are all associated with an increased risk of emergency admission for 
CRC. This was consistent with previous research(30,36,69,70,72,97,251).  
There is a well-established correlation between deprivation and CRC-related mortality, which needs to 
be addressed(326). A UK study from 1992-95 that also used HES found the emergency rates varied 
significantly from the least deprived (35%) to the most deprived decile (56%)(299). In trying to 
understand why this is, one must first exclude data-related artifacts, with patients misattributing 
deprivation levels. This theory, called the “ecological fallacy”, seemed implausible given that studies 
have demonstrated that excess mortality associated with census designated deprived areas was fully 
explained by the concentration in those areas of people with adverse personal or household 
socioeconomic factors(327). A second complication was the exclusion from HES data of operations 
carried out in private hospitals. As private operations are more common among wealthier patients then 
the deprivation gradient I found is actually more likely to be an underestimate of the inverse outcomes 
associated with deprivation. Actual causes for the poor outcomes associated with deprivation are partly 
explained by the later stage of disease among deprived patients, however this simply begs the question of 
why they present with later stage disease(248). One reason is the increased prevalence of co-morbidities 
among deprived patients(328). In addition, deprived patients use health resources less in proportion to 
need than wealthier patients and are more likely to fail to access primary care at an early disease 
stage(329). This is, at least partially, due to a lower awareness of CRC symptoms among the most 
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deprived groups of patients. 20% of the most deprived group couldn’t name any cancer symptom 
compared to 9% of the least deprived. Blood in the stool was mentioned as a cancer symptom by 13% of 
the least deprived compared to 4% of the most deprived patients. Similarly, tiredness or fatigue by 12% 
and 5% respectively(330). This has further repercussions, with low CRC knowledge being associated 
with negative attitudes towards participation in CRC screening(322). 
Even when symptoms have been bought to medical attention deprived patients can have a more difficult 
patient journey, with a breakdown in elective care more likely, leading to delays and emergency 
presentation. One major problem is related to communication between healthcare workers and patients 
with low literacy skills. This is the case for CRC screening in the UK, where a lack of literacy skills was 
associated with increasing levels of deprivation and participants with adequate literacy had a 58% uptake 
rate, compared to only 48% among those with limited health literacy skills(331). This finding has also 
been found in cervical screening(332). Deficient health literacy skills affect patients ability to understand 
health promotion literature, website advice and especially reading and understanding official letters 
which can lead to missed appointments(333). There are 5.2 million adults the UK with low literacy 
skills(334). This problem is compounded by the discrepancy between the reading age required to 
understand important medical information and the average reading age. For example, the average 
reading age in the UK is nine years old yet the NHS Direct website requires an average reading age of 17 
years(335). 
I also considered whether the ‘inverse equity hypothesis’ might explain how the introduction of 
screening might affect patients of different levels of deprivation. This hypothesis states that after new 
public health programmes are enacted, they are initially taken up more by the least deprived groups, 
which causes a short term increase in health inequalities. However, following this first phase the benefits 
to the least deprived plateau and the more deprived sections of the population take up the health 
programme leading to a reduction in overall health inequalities. A similar patterns has already been 
commented on for the more established cervical cancer screening programme where rates of inequality 
between the least and most deprived areas narrowed over time(336). The follow-up period in this 
chapter was too short to investigate whether this occurred with the BCSP.  
Most of the survival disadvantage associated with deprivation occurs shortly after diagnosis and then 
reduces or disappears completely over a longer period of time(142). If socioeconomic-based inequality 
was reduced following the introduction of screening then I might have expected a greater fall in the one-
year mortality among deprived patients presenting after screening had begun. Therefore I looked at 
changes in survival following the introduction of screening using the main cohort based on deprivation 
level. All deprivation quintiles showed a reduction in mortality in the exposed group of around 2% and 
this was not dependent on the deprivation level, Table 4.1. I am therefore unable to venture whether 
screening is reducing deprivation-related inequality or even if there is evidence for the ‘inverse equity 
hypothesis’.  
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My analysis of 9,319 cases of oesophageal and gastric cancer diagnosed during the study period found no 
association between the risk of emergency presentation for this unrelated tumour type and local roll-out 
of the BCSP. This made it more likely that any associations are specific to CRC, rather than reflecting 
more general features of local services. 
The full impact of the BCSP will take some years to quantify but this chapter suggests that the 
introduction of screening has produced benefits that extended beyond those people targeted by and 
participating in the programme. These indirect benefits are likely to have translated into savings in acute 
hospital bed days and improvement in cancer outcomes. This strengthens the case supporting the cost-
effectiveness of introducing bowel cancer screening in the UK(337). The roll out of national screening 
based on FOBt has now been completed and services in England are preparing for implementation of 
screening with flexible sigmoidoscopy. It will be interesting to see whether this next phase is associated 
with similar population-wide benefits. 
In January 2012 the UK launched the first ever cancer awareness campaign ‘Be Clear on Cancer’ with 
TV, radio and newspaper advertisements encouraging people to look out for early signs of bowel and 
other cancers and to seek early help from their GP. Pilot data already shows an increase in the number 
of patients attending their GP with symptoms and a subsequent increase in the number of urgent 
hospital referrals(338). It will be interesting to see whether this has further positive population-wide 
effects on CRC outcomes. This is a poorly understood area and warrants further research. 
There were several weaknesses in this chapter. In the study cohort, 20,498 (71.0%) cases occurred 
before screening was active in their PCT; therefore most patients were “not exposed”. This meant that 
there were comparatively few patients to judge the effect of different lengths of screening exposure. 
Furthermore, as already mentioned, I was unable to state whether an individual patients was diagnosed 
through the screening programme or thorough the normal symptomatic service. Part of my thesis 
hypothesis was to show that the significant improvements in emergency presentation rates following the 
introduction of screening were beyond what could be achieved through directly diagnosing 
asymptomatic cases. However among patients in the screening age, I was unable to show which patients 
were and were not “exposed”, simply that it would be approximately one quarter of the screening age 
population or 7% of the overall population.  
I could also not completely determine whether the quality of local services at the time of presentation 
affected outcomes. However the lack of association between exposure and OG cancer outcomes does at 
least partially address this question. There is also the general problem with observational studies on 
screening programmes, which is that the true benefit or not of a programme is only really revealed 
when long-term cancer mortality or even all-cause mortality is known. The lack of any association 
between screening exposure and OG cancer outcomes helps to partially refute this possibility. Although 
my logistic regression models included key potential confounders, I cannot entirely eliminate the 
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possibility of residual confounding given the observational nature of the work. Nevertheless, I 
undertook sensitivity and sub-group analyses and found consistent results. I found patients with the 
greatest potential exposure to screening had the greatest benefit in terms of reduced emergency 
presentation. Indeed, there was a gradient of improved outcomes, running from those with no exposure 
through to those with over 12 months exposure. This evidence also makes it less likely that the finding 
were due to an overall improvement in care driven by ‘The NHS Cancer plan for England’ (2000). This 
drive to reducing waiting times and standardise referral practices, co-incidentally achieved full role out 
in 2006, around the same time as screening began. If this were the driving factor behind the reduction in 
emergency presentation rates then the results would be seen for all CRC patients, irrespective of 
screening exposure (27).  
Finally, it could also be argued that my assumption about increased awareness only beginning with the 
introduction of local screening was simplistic. In fact awareness could have increased from the start of 
screening in the first pilot area and then slowly filtered out nationally. Patients may have become aware 
of the importance of having CRC symptoms fully investigated through national news reports or from 
friends and family living in areas of the country that adopted screening sooner.    
In conclusion, I have used enhanced HES data and a novel metric of CRC care to show substantial 
improvements in outcomes for patients presenting after the introduction of screening in their area. This 
risk reduction extended to cases outside the screening age group and was apparent within just 6-12 
months of start-up of the programme. These findings of an early and population-wide reduction in risk 
of emergency presentation suggest that the launch of the programme was associated with indirect 
benefits for symptomatic cases diagnosed during the roll out period. I believe that this study provides 
observational evidence that the benefits of launching a public screening programme for CRC are not 
limited to people of screening age with asymptomatic cancer but extend to the wider population. This is 
likely to reflect enhanced public and/or professional awareness of colon cancer leading to more timely 
clinical presentation and investigation in the symptomatic population. 
There are however several important concerns about the applicability of the results presented so far. 
The most important being whether screening exposure explained the perceived improvement in 
outcomes. This concern stems from whether areas starting screening sooner had better services already 
and this caused the apparent association with positive outcomes and adopting screening. This better 
service hypothesis (BSH) stated that PCTs that starting screening earlier were better and hence this 
explained the better results. I have shown that the screening effect was only seen in CRC outcomes and 
that no similar improvements were seen in a matched population of OG cancers. Further work 
defending the findings presented in this chapter, is presented in chapter 5. 
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Chapter 5 - Supplementary studies to explore confounding 
and expand the evidence 
5.1. Introduction 
In the preceding chapter (Chapter 4), I reported the findings of a cross-sectional study designed to 
examine factors associated with risk of emergency presentation during the diagnostic pathway for a 
cohort of patients presenting with CRC over a defined one-year period (Oct 2006 – Sept 2007). This 
was an opportunity to deploy my metric of CRC care (emergency presentation), developed using novel 
approaches to interrogating hospital discharge coding data (HES). The availability of a dataset spanning 
2006-2008 allowed me to test an idea relating to the roll out of the BCSP across England. 
My original study suggested that ‘living in an area with an active BCSP’ was associated with a reduced 
risk of emergency presentation and that this risk reduction was apparent within six-to-twelve months of 
local start-up (implying early and indirect, as opposed to direct, benefits to the population). As might be 
predicted, the magnitude of risk reduction was greater for those patients living in an area where 
screening had been active for a longer period.  Importantly, this ‘effect’ was observed for both screening 
age and non-screening age patients – consistent with my idea that the launch of the programme would 
be associated with population wide benefits that go beyond the minority of people that are actually 
screened. 
To explore confounding in my original study, in Chapter 4 I compared associations between the exposure 
variable (‘living in an area with an active BCSP’) and the risk of patients with OG cancer presenting as 
an emergency.  The logic of choosing this control group was that emergency presentations for another 
form of GI cancer would be a marker of the overall status of local diagnostic pathways across primary 
and secondary care within each PCT.  If the PCTs in the first wave of roll-out of the program (‘early 
adopters’) tended to be those with the ‘best’ local services, then all the patients from these areas in my 
original study would have been regarded as ‘exposed’ to living in an area with an active programme. If 
these areas already had superior cancer outcomes in general, then this would confound the study.  
Similarly, ‘later adopter’ PCTs may have had inferior services.  My control group sought to test this 
idea, examining whether living in an area with an active BCSP during the study time frame was 
associated with a reduced risk of emergency presentations for OG cancer. By showing no such 
association I have gone some way to excluding this possible source of confounding (henceforth referred 
to as the ‘better care hypothesis’). 
In the present chapter, I will report a series of supplementary analyses of the original two-year HES 
dataset. In this work, I aimed to re-test my main hypothesis on the national data but with the application 
of more restrictive selection criteria for the PCTs to include in the study. Within the available national 
dataset (2006-2008), I designed a ‘longitudinal’ study, extracting data on all CRC patients diagnosed six 
months before and after local screening start-up within each individual PCT.  These supplementary 
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studies aimed to eliminate or refute potential bias related to the ‘better care hypothesis’– the idea that 
‘early adopter’ PCTs were simply places having superior local services at the outset, or ‘late adopters’ 
were areas with inferior services. 
In addition, I explore variation in rates of emergency presentations across the individual PCTs.  I wanted 
to determine whether any individual PCTs included in the analysis had implausible rates of emergency 
presentations (i.e. extreme data ‘outliers’) – as might occur as a result of some systematic local coding 
problem.    
A key finding in Chapter 4 was evidence to suggest the possibility that the launch of a local BCSP was 
associated with population-wide benefit – reducing the risk of emergency presentation of CRC for people 
presenting with CRC.  This implies a better chance of elective diagnosis for symptomatic patients in the 
population who presented with CRC during the initial period after the launch of screening. 
Colonoscopy is the gold standard investigation for CRC and it has also been shown that a higher 
discretionary use of colonoscopy is associated with improved outcomes (180).  Hence, I was interested 
to examine whether changes in elective colonoscopy volume or rates were implicated as a mechanism 
for improved outcomes in the early period following start-up of local BCSP.  If there was an expansion 
of total elective diagnostic capacity in services at the time of the launch of screening, then this may have 
resulted in easier access to elective diagnostics for the general population. Colonoscopies performed 
within the BCSP program account for only a small percentage of total colonoscopies and, more 
importantly, there is a time lag of several months between being called for FOBt screening and 
attending the colonoscopy.  Hence, any significant, early rise in local colonoscopy activity would be 
among the symptomatic (i.e. not screened) population and not as a result of screening colonoscopies. 
 
5.2. Methods 
5.2.1 Grouping of PCTs into ‘Early’, ‘Middle’ and ‘Later’ adopters according to local start-up 
date of BCSP 
The original dataset reported in Chapter 4 contained CRC patients from 152 PCTs.  For the present 
analysis, I categorized the PCTs into three sub-groups: ‘Early adopters’ were those PCTs that had 
launched their screening program before October 2006; ‘Middle year adopters’ were those that 
commenced screening between October 2006 and September 2007; and ‘Later adopters’ where 
those PCTs that had not yet started screening. Data for CRC patients from the original cohort were then 
aggregated according to these groupings.  This allowed comparison of the basic demographic features 
and emergency presentation rates of CRC patients according to the three PCT sub-groups. The purpose 
was to see if there was any systematic difference between crude rates of emergency presentation for 
patients living in PCTs that were at different stages of adoption of the screening program.  The ‘better 
care hypothesis’ would predict lower rates of emergency presentation for people living in ‘Early 
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adopter’ PCTs and/or higher rates for those living in ‘Later adopter’ PCTs.  Furthermore, by allocating 
each patient with a new variable to reflect group membership of their PCT of residence, a new binary 
logistic regression model could be developed to test whether this candidate predictor variable was 
associated with risk of emergency presentation.  In other words, to see whether the patient’s PCT sub-
group (Early adopter, Middle Year Adopter of Later Adopter) was associated with risk of emergency 
admission for CRC. 
5.2.2 Exclusion of ‘Early’ and ‘Late’ adopter PCTs and alternative longitudinal study designs 
Next, I focused exclusively on the PCTs that began their screening programme between the October 
2006 and September 2007, of which there were forty-eight.  Hence, I excluded the so-called ‘Early’ and 
‘Later’ adopter PCTs entirely. By selecting only those PCTs that began screening within the ‘Middle 
Year’, my original 2-year master dataset would allow for analysis of at least six months of HES data 
before and after the screening start date for each of the 48 ‘Middle Year’ PCTs included in the new 
analysis.  I identified all the patients presenting with CRC from six months before the start date of local 
screening to up to six months after, Figure 5.1.  Hence, for each PCT there would be a ‘pre-screening’ 
cohort diagnosed in the six months immediately before the launch date of the local programme, and a 
‘post-screening’ cohort of patients diagnosed during the six months after that date. The original cross-
sectional study reported in Chapter 4 included 142 PCTs, with early adopting PCTs contributing mainly 
patients ‘exposed’ to screening and later adopting PCTs contributing ‘unexposed’ patients. This new 
approach allowed me to remove the potential of bias related to my ‘better care hypothesis’.  By 
eliminating this confounding factor, I would be able to re-test my overall hypothesis about the early 
impact of launching a screening programme and refute the idea that my original results were biased by 
the cross-sectional study design.  The identification of these patient cohorts required identification of 
each patient’s index admission, as per the methodology described in Chapter 2, in order to accurately 
capture only those patients presenting for the first time in the relevant time windows for each PCT. This 
process identified 7,920 patients.  With only six months of observational data available for the ‘post-
start-up’ period for each selected PCT, this alternative study design focused specifically on risk of 
emergency admission during the earliest phase of local start-up – seeking evidence for early, population-
wide, indirect benefits as opposed to direct effects of screening.  
As a further variation on PCT selection criteria and study design, I tightened the parameters further by 
including only 39 PCTs that started screening in the first six months of the middle year (October 2006-
March 2007). This involved selecting PCTs with an even closer match in terms of their local launch 
dates. The available national dataset would then allow for capture of all cases presenting in the 12 
months after launch for each of these PCTs, Figure 5.2.  This identified 8,772 patients.  I further divided 
this group of patients according to those presenting 0-6 months and 6-12 months after the local start-up 
date (LSUD) of screening.  This extended the observation period to cover the first year after local start 
up for this group of PCTs. 
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Figure 5.1 Diagram to show how local cohorts of CRC cases were selected for each of the PCTs that 
launched screening in the ‘Middle Year’ (n=48). For each PCT two cohorts of incident cases of CRC 
were identified. The first cohort (‘before’) contained all CRC cases diagnosed during the six month 
period before the local start-up date for the BCSP. The second cohort (‘after’) contained those 
diagnosed in the six months after this date. 
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Figure 5.2 Diagram to show how local cohorts of CRC cases were selected for each of the PCTs that 
launched screening in the first six months of the ‘Middle Year’ (n=39). For each PCT three cohorts of 
incident cases of CRC were identified. The first cohort contained all CRC cases diagnosed during the six 
month period before the local start-up date for the BCSP (‘Pre-LSUD’). The second cohort were those 
diagnosed at 0-6 months (Post 0-6) after start-up, and the third cohort were those diagnosed 6-12 
months after this date (Post 6-12).  Pooled data for all cases diagnosed in year after LSUD was also 
analysed (Post 0-12). 
 
5.2.3 Extraction of data for elective daycase colonoscopy 
This section describes how I extracted data for elective day case colonoscopies for the 48 PCTs that began 
screening in the middle year. I wanted to investigate what happened to colonoscopy volume in both 
screening and non-screening age groups following local introduction of screening, using the six month 
period prior to local start-up (‘pre’) and the six month period after (‘post’) for each PCT. I was 
interested in exploring whether there was evidence for any expansion in overall colonoscopy volume (or 
rate) in the immediate period after start-up of the program.  In the early period after launch of a BCSP, 
only small numbers of people in the general population would be undergoing colonoscopy as a direct 
result of screening, and this would be confined to people in the screening age group who tested positive 
for FOBT. Hence, a significant increase in overall population levels of colonoscopy would suggest that 
the launch of screening had been coincident with increased activity within the elective diagnostic service 
for symptomatic patients – especially if the increase was observed among the population outside of the 
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target age for screening.  The impact of launching screening programmes on local service provision and 
demand has not been reported. 
Returning to the original ‘All admissions merged file for 2006/2007 and 2007/2008’ described in 
chapter 2, I identified all recorded patients who had received colonoscopies using a syntax that 
contained all possible OPCS-4 procedural codes for colonoscopy.  I excluded any patients not in the 48 
middle year PCTs and those performed outside of the middle year. I also excluded those who had 
colonoscopies during an in-patient hospital stay, as this was not a reflection of elective services. I 
retained only the first colonoscopy performed for any individual patient in the cohort. This produced a 
total of 454,560 day case procedures occurring across England in the 48 PCTs over the middle year.  
The procedure involved four key steps:  
1. The first day case colonoscopy for all patients occurring in the 2 years of data (n=454,560) was 
identified. 
2. Colonoscopies for patients not in the 48 middle-year start up PCTs were removed 
(n=122,248). 
3. Procedures not within 6 months either side of the PCTs LSUD were removed. This left 62,152 
day case colonoscopies in a new file was called ‘FINALColonoscopy’. 
4. I split cases into those colonoscopies occurring before the LSUD (n=30,347) and those after 
the LSUD (n=31,805). I called these files ‘FINALPreLSUD’ and ‘FINALPostLSUD’ 
respectively. 
5.2.4 Estimation of crude colonoscopy rates per capita of local population  
For each of the 48 PCTs (‘Middle Year’ group), I calculated the number of patients undergoing their 
first daycase colonoscopy during the six months before and after the LSUD and divided this by the total 
adult population in the PCT. The adult PCT population (16 years and over) was taken from ONS data 
for 2007/07 (2). This yielded a crude rate of daycase colonoscopy per 1,000 population per year.   
The procedure involved four key steps:  
1. I matched the number of colonoscopies in each PCT to a file containing each PCT’s population 
and age and gender distribution. 
2. Then for each PCT, I calculated; 
a. the crude adult rate of colonoscopies/1,000 adult population 
b. the age-specific rate for pre-screening age (<60 years)/1,000 adult population 
c. the age-specific rate for screening age/1,000 adult population 
3. I then appended data on the number of emergency CRCs and total CRCs in the 6 months 
either side of the LSUD for the 48 middle year PCTs.     
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5.3. Results 
5.3.1. Grouping of PCTs into ‘Early’, ‘Middle’ and ‘Late’ adopters according to start-up date 
of local BCSP 
Of the 152 PCTs in the original study reported in Chapter 4, just over half were late adopters (n=77), 
with screening beginning in their area after September 2007, Table 5.1. These PCTs accounted for 
52.9% of patients, none of whom would have been living in an area with an active screening programme 
at the time of their clinical presentation. 10.8% of patients were from the 17 early adopting PCTs, in 
which screening began before October 2006. All of these patients would have been living in an area with 
an active local screening program at the time of presentation. The remaining 22.3% of the original 
cohort of CRC patients were living in the 48 PCTs that started screening within the middle year 
(October 2006 – September 2007). Within this group some of the patients would have been diagnosed 
before the local program went live, others afterwards. Finally, 10 PCTs accounting for 14.0% of cases 
were excluded because of uncertainty over when local screening began. This was because these PCTs 
referred patients to two or more screening centres with different start times.  
Table 5.2 illustrates the “exposure status” of patients according to their PCT of residence at the time of 
their clinical presentation – showing the proportion of cases living in the area when there was no active 
programme, the proportion diagnosed at a time when the local programme had been active for 0-6 
months, and the proportion diagnosed at a time when the local programme had been active for 6-12 
months. The crude emergency presentation rates were almost identical between the early adopters 
(36.7%), middle year adopters (36.6%) and late adopters (36.5%), Tables 5.1 to 5.3. Likewise, the 
CRC patient characteristics (age, gender and co-morbidity) were comparable across the three types of 
PCT, Table 5.3. The only significant difference was that the early adopter group contained a higher 
proportion of deprived patients than the late adopter group (23.2% vs. 15.6% in the most deprived 
quintile, p<0.001), Table 5.3. 
Both univariate and multivariate analysis failed to show any significant difference in the odds of an 
emergency presentation based on sub-group of PCT that each case was drawn from. Compared with the 
early adopter group, the OR for an emergency presentation was 1.04 (0.95-1.14, p=0.405) for the 
middle year adopter group and 1.05 (0.97-1.14, p=0.256) for the late adopter group, Table 5.4.  These 
data provide evidence against the ‘better services hypothesis’ and add weight to the associations 
reported in Chapter 4.  Membership of these PCT sub-groups was not a predictor of risk of emergency 
admission.  
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Table 5.1 Registered adult population, CRC cases and crude rates of emergency presentation for PCTs 
in England:  PCTs are divided into three groups (Early adopters, Middle year or Later adopters) 
according to whether the local start-up date for BCSP fell within the middle year of the data period (Oct 
2006 – Sept 2007). 
Primary Care Trust 
Group 
PCTs, N Registered 
adult 
population, N 
CRC cases, N 
(%) 
Emergency 
presentation, N 
(%) 
Early adopters (screening 
began before Oct 2006) 
17 4,205,043 3,486 (10.8) 1,208 (36.7) 
Middle year adopters 
(Oct 2006 – Sept 2007) 
48 10,850,134 7,197 (22.3) 2,637 (36.6) 
Later adopters (screening 
began after Sept 2007) 
77 23,501,536 17,080 (52.9) 6,228 (36.5) 
Excluded PCTs 10 5,474,162 4,536 (14.0) 1,506 (33.2) 
Total 152 44,030,875 32,299 (100.0) 11,579 (35.8) 
 
Table 5.2 Exposure status of CRC cases according to three PCT groupings (Early adopter, Middle year 
and Later adopter). By definition, all patients in the early adopter group had some screening programme 
exposure, while in the middle group around half of patients were “exposed”. None of the late adopter 
group were “exposed” at presentation.  
 Patients in Early 
adopter PCTs 
(screening 
began before 
Oct 2006) 
Patients in PCTs 
starting 
screening in 
Middle year 
(Oct '2006 – 
Sept 2007) 
Patients in Later 
adopter PCTs 
(screening 
began after Sept 
2007) 
Patients 
excluded 
Number of 
cases 
3,486 7,197 17,080 4,536 
BCSP Exposure     
 None  0  3,249 (45.1) 17,080 (100) 0 
 BCSP <6 
months 
1,240 (35.6) 2,990 (41.5) 0 0 
 BCSP ≥6 months 2,246 (64.4) 958 (13.3) 0 0 
Excluded      
 No PCT 
recorded 
0 0 0 204 (4.5) 
 >1 screening 
start time in PCT 
0 0 0 4,332 (95.5) 
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Table 5.3 Patient characteristics and emergency presentation rates for the three PCT groupings (Early 
adopter, Middle year and Later adopter) 
 Early adopters 
(screening 
began before 
Oct 2006), N (%) 
Started 
screening in 
Middle year 
(Oct 2006 – 
Sept 2007), N 
(%) 
Later adopters 
(screening 
began after 
Sept 2007), N 
(%) 
Excluded 
PCTs, N (%) 
Number of cases 3,486 7,197 17,080 4,536 
Age, mean (sd)                    70.9 (11.5) 70.6 (12.2) 71.1 (12.3) 71.1 (12.0) 
Age group (years)     
<60 years  544 (15.6) 1,242 (17.3) 2,831 (16.6) 730 (16.1) 
60-69 years 916 (26.3) 1,820 (25.3) 4,013 (23.5) 1,119 (24.7) 
70-79 years  1,184 (34.0) 2,360 (32.8) 5,622 (32.9) 1,485 (32.7) 
>79 years 842 (24.2) 1,775 (24.7) 4,614 (27.0) 1,202 (26.5) 
Gender     
Male 2,025 (58.1) 4,084 (56.7) 9,398 (55.0) 2,474 (54.5) 
Female 1,461 (41.9) 3,113 (43.3) 7,682 (45.0) 2,062 (45.5) 
Co-morbidity 
groups 
    
No co-morbidity  2,254 (64.7) 4,914 (68.3) 11,660 (68.3) 3,019 (66.6) 
1 co-morbidity  279 (8.0) 560 (7.8) 1,237 (7.2) 307 (6.8) 
≥ 2 co-morbidity 953 (27.3) 1,723 (23.9) 4,183 (24.5) 1,210 (26.7) 
Deprivation     
Missing 9 (0.3) 25 (0.3) 89 (0.5) 199 (4.4) 
1 most deprived 810 (23.2) 1,722 (23.9) 2,665 (15.6) 319 (7.0) 
2 669 (19.2) 1,653 (23.0) 3,002 (17.6) 720 (15.9) 
3 756 (21.7) 1,439 (20.0) 3,599 (21.1) 1,050 (23.1) 
4 697 (20.0) 1,357 (18.9) 3,843 (22.5) 1,083 (23.9) 
5 least deprived 545 (15.6) 1,001 (13.9) 3,882 (22.7) 1,165 (25.7) 
Emergency 
presentation 
1,208 (36.7) 2,637 (36.6) 6,228 (36.5) 1,506 (33.2) 
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Table 5.4 Factors associated with emergency presentation for CRC patients diagnosed in England during 
the study period (Oct 2006 – Sept 2007).  Each patient was allocated a variable to indicate whether they 
were living in an early adopter, middle year or late adopter PCT. Binary logistic regression established 
there was no significant difference in the OR for an emergency presentation based on the time PCTs 
adopted the screening programme. 
Variable* Emergency 
presentations / 
total cases (%) 
Unadjusted (univariate) Adjusted (multivariate) 
  OR CI p value OR CI p value 
Age group 
(years) 
       
<60 years  1,440/4,583 
(31.4) 
1 - - 1 - - 
60-69 years 1,975/6,719 
(29.4) 
0.91 0.84-0.99 0.021 0.90 0.83-0.98 0.016 
70-79 years  3,087/9,134 
(33.8) 
1.11 1.03-1.20 0.005 1.08 1.00-1.17 0.068 
>79 years 3,585/7,204 
(49.8) 
2.16 2.00-2.34 <0.001 2.09 1.93-2.27 <0.001 
Gender        
Male 5,320/15,437 
(34.5) 
1 - - 1 - - 
Female 4,767/12,203 
(39.1) 
1.22 1.16-1.28 <0.001 1.18 1.12-1.24 <0.001 
Co-morbidity 
groups 
       
No co-morbidity  5,085/18,760 
(27.1) 
1 - - 1 - - 
1 co-morbidity  914/2,067 (44.2) 2.13 1.94-2.34 <0.001 2.02 1.84-2.22 <0.001 
≥ 2 co-morbidity 4,088/6,813 
(60.0) 
4.03 3.81-4.28 <0.001 4.06 3.83-4.31 <0.001 
Deprivation        
1 (most deprived) 2,194/5,197 
(42.2) 
1 - - 1 - - 
2 2,013/5,324 
(37.8) 
0.83 0.77-0.90 <0.001 0.80 0.74-0.87 <0.001 
3 2,122/5,794 
(36.6) 
0.79 0.73-0.85 <0.001 0.76 0.70-0.84 <0.001 
4 2,012/5,897 
(34.1) 
0.71 0.66-0.77 <0.001 0.68 0.62-0.73 <0.001 
5 (least deprived) 1,746/5,428 
(32.2) 
0.65 0.60-0.70 <0.001 0.65 0.59-0.70 <0.001 
Time screening 
adopted by 
PCT 
       
Early adopter 1,275/3,477 
(36.7) 
1 - - 1 - - 
Middle adopter 2,625/7,172 
(36.6) 
1.00 0.92-1.08 0.945 1.04 0.95-1.14 0.405 
Late adopter 6,187/16,991 
(36.4) 
0.99 0.92-1.07 0.775 1.05 0.97-1.14 0.256 
*after removing patients with excluded PCTs and deprivation codes, there were 27,640 patients 
5.3.2. Longitudinal studies focusing on the ‘middle year’ PCTs only 
Although in the last section I found no association between ‘adopter’ status (early, middle or later) and 
risk of emergency presentation for patients from all the original PCTs, I wanted to explore alternative 
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ways to reduce the risks of confounding when testing my overall hypothesis. Hence, I undertook a 
selective analysis for the 7,920 patients living in the 48 PCTs that started screening during the ‘middle 
year’ study period (October 2006 – September 2007).  This removed patients from the ‘early’ and 
‘later’ adopter PCTs entirely, thereby focusing on a group of PCTs that began their local programs 
within a similar time period (i.e. over the course of one year). However, the exact start date for each 
PCT was spread widely throughout the study year, hence the proportion of the original middle year 
cohort of patients ‘exposed’ to screening would vary substantially from one PCT to the next if I applied 
the same cross-sectional approach to the data as employed in Chapter 4. Hence, I conceived a 
longitudinal study design, whereby I extracted all CRC patients that presented six months before and six 
months after the LSUD for each PCT (See METHODS, Figure 5.1). This allowed comparison of the 
impact of screening exposure between a “non-exposed” group (six months before LSUD) and an 
“exposed” group (six months after LSUD) with closely matched populations for each PCT.  By limiting 
the exposure period to only six months after start up, this design would further explore the early, 
‘indirect’ effects of screening on the wider population.  
There was no significant difference in patient characteristics between the six month before- versus the 
six month after-LSUD groups with respect to age, gender, co-morbidity or deprivation (Table 5.5). The 
proportion of CRC patients falling within the screening age group (60-69 yrs) was slightly higher in the 
‘after’ group but this did not reach significance (26.0% [1,056/4,067] vs. 24.1% [928/3,853], 
p=0.055). Overall, the crude rates of emergency presentation were 37.3% and 35.6%, respectively, 
representing a 1.7% absolute reduction in rate. Hence, the unadjusted OR for emergency presentation 
was 0.92 for those diagnosed in the six months after local start-up (0.82 – 1.00, p=0.054). This result is 
on the borderline of statistical significance (Figure 5.3).  In Chapter 4, the crude rates of emergency 
admission for cases ‘exposed’ for ≤6 months versus ‘non-exposed’ cohorts of cases across all PCTs were 
36.4% and 37.1%, respectively (0.7% reduction, p=0.170).  Hence, the absolute ‘effect’ size appears 
greater in the present study (in which I focus on a more restricted group of PCTs) compared to the 
original analysis – again, making it less likely that the original association is confounded by differences in 
baseline quality of services (i.e. ‘better care’ hypothesis for early adopter PCTs).  
Multivariable binary logistic regression analysis yields similar findings to the results in Chapter 4 in terms 
of the association between emergency presentation and the basic patient characteristics. Hence, 
increased OR for emergency presentation was associated with older patients (apart from in the 60-69 
year group), females, those with co-morbidity and patients with increasing deprivation. Membership of 
the 60-69 year group was associated with the lowest OR of 0.82 (0.71-0.96, p<0.05) relative to the 
comparator group of under 60 year olds, in line with my chapter 4 findings, Table 5.6.  The adjusted OR 
for emergency presentation for patients diagnosed in the six months after local start up was 0.92, again 
just on the borderline of statistical significance (p=0.054). This is similar to the unadjusted odds ratio, 
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reflecting the fact that the populations of CRC cases in the ‘before’ versus ‘after’ cohorts were closely 
matched in terms of their other characteristics. 
5.3.3. Variability in emergency presentation rates across the ‘48 middle year’ PCTs 
The funnel plots in Figures 5.4 and 5.5 show that the number of PCTs at or beyond the curve 
representing two standard deviations from the mean were very few in number and there were no 
extreme outliers to skew the overall data.  This analysis was undertaken using crude (unadjusted) data, 
so there is no adjustment for case-mix and hence this funnel plot is not intended for benchmarking 
purposes but simply to screen for extreme data points. Interestingly, there were fewer PCT outliers 
with ‘high’ rates of emergency admission (beyond 2 sd) in the six month period after launch of the local 
BCSP, compared to the period prior to launch (three versus six PCTs). 
 
Table 5.5 The patient characteristics in the “Before” and “After” LUSD groups (no significant 
differences).  
Patient characteristics 
 
Total, N 
(%) 
“Before” 
LUSD, N (%) 
“After” 
LUSD, N 
(%) 
Number of cases 7,920 3,853 4,067 
Age, mean (sd)                    70.5 (12.3) 70.2 (12.4) 70.8 (12.2) 
Age groups                        
 < 60                  1,386 (17.5) 727 (18.9) 659 (16.2) 
60-69 years 1,984 (25.1) 928 (24.1) 1,056 (26.0) 
 70 to 79                   2,630 (33.2) 1,295 (33.6) 1,335 (32.8) 
 >79                   1,920 (24.2) 903 (23.4) 1,017 (25.9) 
Gender    
 Male 4,487 (56.7) 2,173 (56.4) 2,314 (56.9) 
 Female 3,433 (43.3) 1,680 (43.6) 1,753 (43.1) 
Co-morbidity groups                    
 1 (No co-morbidity)                 5,361 (67.7) 2,608 (67.7) 2,753 (67.7) 
 2 (1 co-morbidity)                 652 (8.2) 311 (8.1) 341 (8.4) 
 3 (2 or more co-morbidity)             1,907 (24.1) 934 (24.2) 973 (23.9) 
Patient deprivation            
IMD missing 26 (0.3) 14 (0.4) 12 (0.3) 
 1 (Most deprived)*                 1,853 (23.4) 906 (23.5) 947 (23.3) 
 2 1,849 (23.3) 911 (23.6) 938 (23.1) 
 3 1,585 (20.0) 766 (19.9) 819 (20.1) 
 4 1,519 (19.2) 743 (19.3) 776 (19.1) 
5 (Least deprived)                 1,088 (13.7) 513 (13.3) 575 (14.1) 
Emergency presentation 2,884 (36.4) 1,438 (37.3) 1,446 
(35.6)* 
*P=0.054 
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Figure 5.3 Comparison of percentage emergency presentation rates before and after LSUD. There was a 
1.7% reduction in the emergency presentation rate between patients presenting before and after the 
LSUD of screening (this was on the borderline of statistical significance, at p=0.054). 
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Table 5.6 Binary logistic regression analysis of the patient characteristics associated with emergency 
presentation in the 48 PCTs starting screening in the middle year. Increasing age, female gender, co-
morbidity and deprivation continued to be associated with emergency presentation as was presenting 
before the LUSD of screening (the latter has p value 0.054). 
Variable Emergency 
presentations
/ Total (%) 
Unadjusted (univariate) Adjusted (multivariate) 
OR CI P value OR CI P value 
Age group 
(years) 
       
<60 years  445/1,377 
(32.3) 
1 - - 1 - - 
60-69 years 565/1,975 
(28.6) 
0.84 0.72-0.97 0.021 0.82 0.71-0.96 0.015 
70-79 years  902/2,626 
(34.3) 
1.10 0.95-1.26 0.196 1.05 0.91-1.22 0.496 
>79 years 957/1,915 
(50.0) 
2.09 1.81-2.42 <0.001 1.95 1.68-2.27 <0.001 
Gender        
Male 1,545/4,473 
(34.5) 
1 - - 1 - - 
Female 1,324/3,421 
(38.7) 
1.20 1.09-1.31 <0.001 1.19 1.08-1.32 0.001 
Co-morbidity 
groups 
       
No co-morbidity  1,426/5,344 
(26.7) 
1 - - 1 - - 
1 co-morbidity  319/652 (48.9) 2.63 2.23-3.10 <0.001 2.51 2.12-2.97 <0.001 
≥ 2 co-morbidity 1,124/1,898 
(59.2) 
3.99 3.58-4.45 <0.001 3.97 3.55-4.44 <0.001 
Deprivation*        
1 most deprived 751/1,853 
(40.5) 
1 - - 1 - - 
2 721/1,849 
(39.0) 
0.94 0.82-1.07 0.340 0.94 0.81-1.08 0.349 
3 588/1,585 
(37.1) 
0.87 0.75-0.99 0.040 0.88 0.76-1.02 0.096 
4 484/1,519 
(31.9) 
0.69 0.60-0.79 <0.001 0.69 0.60-0.81 <0.001   
5 least deprived 325/1,088 
(29.9) 
0.63 0.53-0.73 <0.001 0.63 0.54-0.75 <0.001   
BCSP Exposure        
Before LSUD 1,433/3,839 
(37.3) 
1 - - 1 - - 
After LSUD 1,436/4,055 
(35.4) 
0.92 0.84-1.01 0.077 0.92 0.82-1.00 0.054 
*26 patients with missing deprivations scores were excluded 
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Figure 5.5 Funnel plot of the crude rate of emergency presentations for each of the 48 PCTs that started 
screening in the middle year: Data for the six month period after the LSUD of screening.  
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Figure 5.4 Funnel plot of the crude rate of emergency presentations for each of the 48 PCTs that started 
screening in the middle year: Data for the six-month period before the LSUD of screening. 
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5.3.4. Stratification of data from the 48 ‘Middle Year’ PCTs according to screening age and 
non-screening age groups 
Restricting the analysis to the screening age group (60-69 year olds) showed a significantly lower rate of 
emergency presentations among patients that presented in the six months after the LSUD (26.4% vs. 
31.0%, p=0.025), Figure 5.6. Given the two years it takes to roll-out of screening to this age group, this 
early reduction may reflect an indirect benefit rather than any direct effect of screening. In the non-
screening age group, the emergency rate was numerically lower in the group of patients presenting after 
the LSUD but this difference was not significant (39.3% vs. 38.8%, p=0.670), Figure 5.7. These results 
were comparable to those in chapter 4. 
 
Figure 5.6 Among the 48 PCTs that began screening in the middle year; emergency presentation rate 
before and after the LSUD among screening age patients (60-69 year olds). Patients presenting within 
six months of screening starting had a significantly lower emergency presentation rate (p=0.025). 
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Figure 5.7 Among the 48 PCTs that began screening in the middle year; emergency presentation rate 
before and after the LSUD among non-screening age patients. Patients presenting within six months of 
screening starting, had a numerically lower emergency presentation rate but this did not reach 
significance. 
 
5.3.5. Longitudinal study focusing on the 39 PCTs that started screening in the first six months 
of the middle year  
As a further variation on the study design and inclusion criteria, I examined data for the 39 PCTs that 
began screening in the first six months of the middle year period. This was to ensure I could include 
patients diagnosed up to one year after the LSUD.  My study of 48 PCTs (above) found a signal to 
suggest a reduction in rates was apparent within just six months of start-up but at borderline significance 
(p=0.054) and the main effect seen in the screening age population of 60-69 year olds (where p value 
was significant). The short time scale of observation makes it likely that any ‘effects’ are early and 
indirect benefits, rather than resulting from direct impact of screen-detected cancers.  However, by 
extending the observation to 12 months after local launch, I hoped to improve the chance of 
demonstrating a benefit across the whole population. It was vital to seek evidence to show that people 
outside the target age group for the BCSP were experiencing a reduction in rate of emergency admission 
– this would support the notion of a wider population benefit arising from enhanced patient and 
professional awareness of colon cancer in the immediate wake of a local launch of a screening 
programme for this condition. 
Table 5.7 summarizes the basic patient characteristics of the ‘before’ and ‘after’ groups (0-6 months, 6-
12 months and combined 0-12 months).  The crude rate of emergency presentations was significantly 
lower in the 6-12 month group, compared with the ‘before’ (34.1 vs. 38.9%, p<0.001), Table 5.8, 
Figure 5.8. Binary logistic regression showed that the adjusted OR for an emergency presentation was 
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0.86 (CI: 0.76-0.96, p=0.007) for CRC cases diagnosed 6-12 months after their local programme was 
launched. 
In conclusion, this analysis of people living in PCTs that began their screening programs at a very similar 
time-point shows that risk of emergency presentation among people with CRC is reduced within 6-12 
months of local launch. These findings are consistent with the results shown for the full cohort in Chapter 
4. 
 
Table 5.7 Patient characteristics and rate of emergency presentation for patients living in the 39 PCTs 
that began screening in the first six months of the middle-year period. 
Patient 
characteristics 
 
Study 
cohort, N 
(%) 
Before-
LSUD, N 
(%) 
After (0-6 
months), N 
(%) 
After (6-12 
months), N 
(%) 
After (0-
12months), 
N (%) 
Number of cases 8,740 3,117 2,751 2,872 5,623 
Age, mean (sd)                    70.5 (12.1) 70.1 (12.3) 70.8 (12.1) 70.5 (11.9) 70.7 (12.0) 
Age groups                          
 < 60                  1,533 (17.5) 588 (18.9) 460 (16.7) 485 (16.9) 945 (16.8) 
 60 to 69                 2,232 (25.5) 752 (24.1) 716 (26.0) 764 (26.6) 1,480 (26.3) 
 70 to 79                   2,856 (32.7) 1,041 (33.4) 887 (32.2) 928 (32.3) 1,815 (32.3) 
 >79                   2,119 (24.2) 736 (23.6) 688 (25.0) 695 (24.2) 1,383 (24.6) 
Gender      
 Male 4,919 (56.3) 1,746 (56.0) 1,574 (57.2) 1,599 (55.7) 3,173 (56.4) 
 Female 3,821 (43.7) 1,371 (44.0) 1,177 (42.8) 1,273 (44.3) 2,450 (43.6) 
Co-morbidity groups                     
 1 (No co-morbidity)                 5,967 (68.3) 2,065 (66.2) 1,864 (67.8) 2,038 (71.0) 3,902 (69.4) 
 2 (1 co-morbidity)                 694 (7.9) 251 (8.1) 223 (8.1) 220 (7.7) 443 (7.9) 
 3 (2 or more co-
morbidity)             
2,079 (23.8) 801 (25.7) 664 (24.1) 614 (21.4) 1,278 (22.7) 
Patient deprivation              
 1 (Most deprived)*                 2,054 (23.5) 755 (24.2) 645 (23.4) 654 (22.8) 1,299 (23.0) 
 2 2,035 (23.3) 730 (23.4) 641 (23.3) 664 (23.1) 1,305 (23.1) 
 3 1,779 (20.4) 627 (20.1) 566 (20.6) 586 (20.4) 1,152 (20.4) 
 4 1,684 (19.3) 589 (18.9) 523 (19.0) 572 (19.9) 1,095 (19.4) 
5 (Least deprived)                 1,188 (13.6) 416 (13.3) 376 (13.7) 396 (13.8) 772 (13.7) 
Emergency 
presentation 
3,220 (36.8) 1,213 (38.9)  1,029 (37.4) 978 (34.1) 2,007 (35.7) 
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Table 5.8 A binary logistic regression analysis of the 39 PCTs that began screening in the first six months 
of the middle-year period. Living in an area where the BCSP had been active for 6-12 months was 
associated with a significantly reduced odds ratio for emergency presentation. 
Variable Emergency 
presentations/ 
total cases (%) 
Unadjusted (univariate) Adjusted (multivariate) 
  OR CI P value OR CI P value 
Age group 
(years) 
       
<60 years  512/1,533 (33.4) 1 - - 1 - - 
60-69 years 614/2,232 (27.5) 0.76 0.66-0.87 <0.001 0.75 0.64-0.87 <0.001 
70-79 years  1,004/2,856 (35.2) 1.08 0.95-1.23 0.244 1.02 0.89-1.18 0.746 
>79 years 1,090/2,119 (51.4) 2.11 1.84-2.42 <0.001 1.98 1.71-2.29 <0.001 
Gender        
Male 1,724/4,919 (35.0) 1 - - 1 - - 
Female 1,496/3,821 (39.1) 1.19 1.09-1.30 <0.001 1.16 1.06-1.28 0.002 
Co-morbidity 
groups 
       
No co-morbidity  1,562/5,967 (26.2) 1 - - 1 - - 
1 co-morbidity  337/694 (48.6) 2.66 2.27-3.12 <0.001 2.49 2.11-2.93 <0.001 
≥ 2 co-morbidity 1,321/2,079 (63.5) 4.92 4.42-5.47 <0.001 4.85 4.35-5.41 <0.001 
Deprivation        
1 (most deprived) 703/1,700 (41.4) 1 - - 1 - - 
2 746/1,896 (39.3) 0.87 0.77-0.98 0.027 0.88 0.76-1.00 0.053 
3 652/1,740 (37.5) 0.84 0.74-0.96 0.008 0.91 0.79-1.04 0.167 
4 614/1,797 (34.2) 0.67 0.58-0.77 <0.001 0.69 0.60-0.80 <0.001 
5 (least deprived) 505/1,605 (31.5) 0.66 0.57-0.77 <0.001 0.69 0.59-0.81 <0.001 
BCSP Exposure        
Before-LSUD 1,213/3,117 (38.9) 1 - - 1 - - 
After (0-6 
months) 
1,029/2,751 (37.4) 0.94 0.84-1.04 0.235 0.95 0.85-1.07 0.393 
After (6-12 
months) 
978/2,872 (34.1) 0.81 0.73-0.90 <0.001 0.86 0.76-0.96 0.007 
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Figure 5.8 In the 39 PCTs that began screening in the first six months of the middle-year period, longer 
exposure to the BCSP, was associated with an incremental reduction in the emergency rate.  
 
Compared to the six month period before the local start-up of screening, the proportion of total CRC 
cases that were of screening age (60-69 years) during the year after was greater (24.1% [752/2,365] vs. 
26.3% [1,480/4,143], p=0.024). These findings were comparable to the results in Chapter 4.  Given the 
PCT populations are matched within the longitudinal study design, this finding suggests a small rise in 
the age-specific incidence rate of CRC for people of screening age. Some of this increase could reflect 
additional cases due to screen-detected symptomless cancers in the population.  However, it might also 
reflect the fact that this age group would be more likely to seek early medical attention for symptomatic 
cancers since they were targeted for information about screening. 
5.3.6. Stratification of data from the 39 PCTs according to screening age and non-screening age 
groups 
Among screening age patients (60-69 years), the emergency rate was 31.3% in the ‘before’ LSUD 
group, 28.5% in the 0-6 month ‘after’ group and 23.0% in the 6-12 month ‘after’ group, Figure 5.9. 
The cumulative risk reduction was 8.3%. In the non-screening age group the emergency rate was 41.4% 
in the ‘before’ LSUD group, 40.8% in the 0-6 month ‘after’ group and 38.2% in the 6-12 month ‘after’ 
group. The cumulative risk reduction was 3.2%. Amongst screening age patients, there was a significant 
difference in the emergency rates between the before LSUD group and the 6-12 month group 
(p<0.001), in the non-screening age group there was also a significant difference (p=0.030).  In order 
to support my hypothesis of an ‘early, indirect’ benefit to the general population, I required evidence to 
suggest that the launch of the screening programme resulted in a risk reduction following only a short 
period of exposure (i.e. “early effect") and from patients not exposed directly to screening by virtue of 
age group (i.e. “indirect effect”). 
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There was no overall risk reduction for people living in an area where a programme had been active for 
0-6 months (OR 0.95, p=0.393). Given that it takes 2 years to roll-out the BCSP, this time period is 
certainly too short to see any direct effect from screening and it may be too soon to have detected 
indirect benefits across the whole population. There may have been an effect within this very short time 
period but my study may have been underpowered to detect it. It seems reasonable for the 6-12 month 
period following start-up of BCSP to be regarded as ‘early’ in the course of a local program, since only 
half of eligible 60-69 year olds in the area would have been targeted directly by the programme at the 
end of year one. Overall, patients diagnosed during this period did exhibit a reduction in risk of 
emergency presentation, with an OR of 0.86 (p=0.007), Table 5.8. This provides evidence of an “early 
effect". 
 
 
Figure 5.9 Patients belonging to the 39 PCTs that began screening in the first six months of the middle 
year screening. More than six months exposure was associated with a significant reduction in the risk of 
emergency presentation for screening age (p<0.001) and non-screening age patients (p=0.030).  
 
5.3.7. Study of trends in colonoscopy volume and rate 
This section presents data on the overall volume of colonoscopy in the period when the screening 
programme was introduced, examining the 48 PCTs that began screening in the middle year.  By 
focusing on colonoscopy activity in the six month periods either side of local start-up for each individual 
PCT, the populations from which the patients are drawn are assumed to be identical. Hence the pooled 
results can be expressed as total numbers or crude rates without the need to standardize for potential 
differences in sociodemographics. 
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5.3.7.1. Changes in colonoscopy volume in the six months either side of the introduction of screening 
I was interested to determine whether there was any change in colonoscopy activity between the six 
month period before and the six months immediately after the start up of local screening. Within the 48 
PCTs that began screening in the middle year, there were 11,128,234 residents aged over 16 years. Of 
these 49.8% (n=5,542,805) were male and 50.2% (n=5,585,429) were female. The age distribution of 
the population is shown in Figure 5.10. In the period spanning six months either side of each of the 48 
PCTs local start up date, a total of 62,152 colonoscopies were performed. The mean age of patients 
having a colonoscopy was 58.4 years, with almost half (47.5%) performed on patients under 60 years. A 
total of 53.8% of colonoscopies were performed on females. The most deprived quintile of the 
population had the lowest share of colonoscopies at 12.8% and this did not change between the before 
and after LSUD groups, Table 5.9.   
The total number of day case colonoscopies performed in this population during the six month period 
before local start-up of the screening programme was 30,347, rising to 31,805 for the six months after 
(an overall increase of 1,458 procedures, or 4.8%, from baseline). This represents an increase in the 
overall crude rate of colonoscopy from 5.4 to 5.8 per 1,000 population over the year.  The 
sociodemographic structure of the population is assumed to be stable over a one year period, hence 
crude rates suffice for studying overall trends.  As shown in Table 5.9, there was an increase in total day 
case colonoscopy numbers for all age groups except 70-79 year olds.  Although the greatest percentage 
rise was seen among the 60-69 year old population (8.8%), there was an increase for those under 60 
years of 5%.  The latter suggests that there was an early rise in elective investigations for lower GI 
problems among the wider population following start-up of screening – perhaps as a result of increased 
referrals and consistent with some indirect benefits for the non-screened, symptomatic population. 
 
 
Figure 5.10 The age distribution of the resident population of the 48 middle year PCTs.  
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Table 5.9 The characteristics of the 62,152 patients having a colonoscopy in the 6 months before and 
after the LSUD of screening in the 48 PCTs in the middle year group. 
Patient characteristics Total, N (%) Before LSUD 
N (%) 
After LSUD N 
(%) 
Number of cases 62,152 30,037 31,805 
Age, mean (sd)                    58.4 (15.9) 58.5 (15.9) 58.3 (15.8) 
Age groups                        
 < 60                  29,532 (47.5) 14,397 (47.4) 15,135 (47.6) 
 60-69 15,946 (25.7) 7,636 (25.2) 8,310 (26.1) 
 70 to 79                   12,061 (19.4) 6,038 (19.9) 6,023 (18.9) 
 >79                   4,613 (7.4) 2,276 (7.5) 2,337 (7.3) 
Gender    
 Male 28,735 (46.2) 13,946 (46.0) 14,789 (46.5) 
 Female 33,417 (53.8) 16,401 (54.0) 17,016 (53.5) 
Patient deprivation            
Missing IMD 110 (0.2) 48 (0.2) 62 (0.2) 
 1 (Most deprived)*                 15,379 (24.7) 7,614 (25.1) 7,765 (24.4) 
 2 14,583 (23.5) 7,147 (23.6) 7,436 (23.4) 
 3 12,508 (20.1) 6,058 (20.0) 6,450 (20.3) 
 4 11,600 (18.7) 5,592 (18.4) 6,008 (18.9) 
5 (Least deprived)                 7,972 (12.8) 3,888 (12.8) 4,084 (12.8) 
 
5.4. Discussion 
5.4.1. Overview  
Chapter 5 has presented evidence to support the key findings of Chapter 4, namely that the introduction 
of the BCSP programme was associated with early, population-wide benefit. These supplementary 
studies were designed to exclude potential sources of bias or confounding in the original work reported 
in Chapter 4.  I have shown that the proportion of CRC cases presenting as an emergency was reduced 
within 6-12 months of local launch, both for people of screening age and (crucially for my hypothesis) 
for people outside the target age group for the BCSP.  These findings were unlikely to have resulted 
from confounding due to major differences in the availability or quality of services between PCTs that 
rolled out screening at different times (I found no evidence to support the ‘better care hypothesis’), nor 
from data quality issues (I found no extreme outliers among PCTs included in the study).  
The mechanism for this reduction cannot be determined in my studies, although I have shown a short 
term increase in elective day case colonoscopy activity across most age groups – suggesting a rise in the 
number of people being referred for elective investigation. This 4.8% increase (in particular in the non-
screening age) could be caused by: 
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(a) An increase in the number people presenting to their doctor for investigation [indirect benefit 
of screening – enhanced public awareness] 
(b) A lower threshold for referring people for colonoscopy [indirect benefit of screening – 
enhanced professional awareness] 
(c) A period of increased capacity and reduced waiting times, so that people already waiting for 
colonoscopies are getting them done more quickly [indirect benefit of screening programme –
expanded colonoscopy services] 
Whichever factor is dominant there is a real increase in numbers of colonoscopies per unit time, which 
could imply extra capacity or extra referrals.  Either of these is a positive way that the launch of the 
programme led to benefits.   
Heightened public and professional awareness of CRC should increase the likelihood of symptomatic 
patients consulting their GP for medical advice and being referred promptly for investigation. The 
observation that patients in the screening age group had the greatest reduction in risk of emergency 
presentation is predictable, since some of the elective diagnoses will have been screen-detected cancers. 
It is not possible within HES data to identify CRC cases diagnosed in symptomless individuals as a direct 
consequence of the screening programme.  However, within the first year of the BCSP, only half of all 
60-69 years old would be invited for screening, 57% will have responded and only 2% of these will test 
positive on FOBT. Of those invited for a colonoscopy, 88% attend, and of these 9% will be diagnosed 
with CRC. In total, for the 1,215,911 screening age subjects in the 48 PCTs, an estimated 608 CRCs 
would be identified. Instead people in the 60-69 year old age group are likely to have benefitted both 
from the direct effect of screening and from indirect effects of raised awareness.  It has been reported 
that many supposedly asymptomatic patients undergoing screening in fact report that they had 
experienced large bowel symptoms before enrollment (339) – we do not know whether some people of 
screening age opted to consult their GP rather than participate in screening. 
My work has suggested that the introduction of the NHS BSCP resulted in indirect benefits to the whole 
population at risk of CRC – a phenomenon not previously described. The evidence for this relates to 
demonstrating early reductions in risk of emergency admission (before a major direct impact of 
screening might be expected) and by showing benefits extending to people outside of screening age. 
Ideally, future work would identify which cases were, and were not, diagnosed through the screening 
programme(73) and to thereby identify the relative contributions of the direct and indirect effect of 
screening. This could then lead to further work to identify ways of improving both of these effects by: a) 
finding ways of improving the direct effect of screening, such as ways of increasing screening uptake (i.e. 
reaching populations which have a low uptake rate such as the deprived and those living in London) and 
b) to look at ways to improve the existing FOBt screening test (for a further explanation of this see 
chapter 6) and other changes to the screening programme such as Flexi-scope trial (a one-off flexible 
sigmoidoscopy offered to patients at or around their 55th birthday) and also extending access to 
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screening up to the age of 75 years. There is also a need to introduce new and improved stool based 
tests such as the Faecal Immunochemical Test (FIT) and, in the future, DNA tests, c) conducting 
research to build up our understanding of how the indirect effect of screening can be best utilised to 
increase awareness and reduce barriers to patient presentation to health care professionals. This needs to 
include looking at how to improve health-related behaviour in hard to reach populations. Further, it will 
be important to ensure that professionals rapidly refer patients for the best diagnostic test (in the 
majority of cases, a colonoscopy). This is more difficult research and to date what work that has been 
done has been largely qualitative with short term follow-up(340). However, the results from my thesis 
strongly point to the importance of the BCSP as a way of reducing later-presenting CRC that is also, 
potentially, very cost-effective. Work such as the ‘Be clear on cancer’ campaigns have already been 
shown that CRC awareness can be increased within a population, the problem being that the impact 
appeared to be short lived (341,342), Therefore, while individual advertising campaigns may affect 
public awareness only in the short-term, one potential advantage of the BCSP is that, because patients 
are continually invited to screening, then awareness is continually reinforced in communities containing 
patients of the screening age. My results showing that the crude rate of colonoscopy increased very 
quickly after screening began. This suggests more work is required to identify whether populations with 
higher rates of colonoscopy (more opportunistic screening) have better outcomes. 
As with any screening programme the proof of success lies in a reduction in ‘all cause mortality’ (as well 
as CRC-specific mortality) and a positive effect on screened and non-screened patients. It is also 
essential to identify interventions to reduce inequalities based on deprivation and ways to increase CRC 
awareness in these areas. 
5.4.2. Conclusion   
In summary, in this thesis I have described methodological work to enhance the value and improve the 
clinical validity of metrics of cancer care based on HES data. I applied clinical logic to overcome 
limitations of this administrative data source – for example, the lack of a date of diagnosis and the failure 
to record a cancer code at the time of initial clinical presentation.  This has allowed a real world 
ecological level study to be conducted. In exploring the application of my metric of care (emergency 
admission during the diagnostic pathway), I have been able to suggest for the first time in a national 
study that there is an early and population-wide benefit arising from the introduction of the BCSP. That 
the BCSP affects not only individuals targeted for screening, but also the whole population by virtue of 
heightened public and professional awareness, suggests that the overall benefits of the programme may 
exceed those predicted from data relating to expected numbers of screen-detected cancers (i.e. benefits 
from earlier cancer diagnosis in symptomless people) and polyps (i.e. benefits from reducing future 
cancer risk in screened individuals without cancer).  Further longer term work would be needed to 
establish the time course for any indirect benefits, although I expect most of the impact on the general 
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population would be during the first 1-2 years of the programme. Finding ways to sustain or improve 
upon the wider benefits of screening programmes could be a focus of future research.   
In the next chapter, I report a parallel research project in which I explored potential ways to maximize 
the direct benefits of the screening programme through optimizing the interpretation of the faecal occult 
blood screening test employed in the UK BCSP. 
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Chapter 6 - Optimising faecal occult blood screening – 
retrospective analysis of NHS Bowel Cancer Screening data 
to improve the screening algorithm 
 
6.1. Abstract  
Background: Colorectal neoplasia causes bleeding, enabling detection using Faecal Occult Blood tests 
(FOBt). The NHS Bowel Cancer Screening Programme (BCSP) guaiac-based FOBt (gFOBt) kits contain 
6 sample windows (or ‘spots’) and each kit returns either a positive, unclear or negative result. Test kits 
with 5 or 6 positive windows are termed “abnormal” and the subject is referred for further investigation, 
usually colonoscopy. If 1-4 windows are positive, the result is initially “unclear” and up to two further 
kits are submitted; further positivity leads to colonoscopy (“weak positive”). If no further blood is 
detected, the test is deemed “normal” and subjects are tested again in two years’ time. I studied the 
association between Spot Positivity % (SP%) and neoplasia. 
 
Methods: Subjects in the Southern Hub completing the first of two consecutive episodes between 
April 2009 and March 2011 were studied. Each episode included up to three kits and a maximum of 18 
windows (spots). For each positivity combination, the percentage of positive spots out of the total 
number of spots completed by an individual in a single screening episode was derived and named ‘Spot 
Positivity %’ (SP%). Fifty-five combinations of Spot Positivity can occur if the position of 
positive/negative spots on the same test card is ignored. 
The proportion of individuals for whom neoplasia was identified in Episode 2 was derived for each of the 
55 spot combinations. In addition, the Episode 1 spot pattern was analysed for subjects with cancer 
detected in Episode 2.   
  
Results: During Episode 2, 284,261 subjects completed gFOBT screening and colonoscopies were 
performed on 3,891 (1.4%) subjects. At colonoscopy, cancer was detected in 7.4% (n=286) and a 
further 39.8% (n=1,550) had adenomas. Cancer was detected in 21.3% of subjects with an abnormal 
first kit (5 or 6 positive spots) and in 5.9% of those with a weak positive test result.     
The proportion of cancers detected was positively correlated with SP%, with an R2 correlation (linear) 
of 0.89. As the SP% increased from 11-100%, so the CRC detection rate increased from 4-25%. At the 
lower SP%s, from 11-25%, the CRC risk was relatively static at approximately 4%. Above an SP% of 
25%, every 10-percentage points increase in the SP%, was associated with an increase in cancer 
detection of 2.5%.  
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Conclusion: This study demonstrated a strong correlation between SP% and cancer detection within 
the NHS BCSP. At the population level, subjects’ cancer risk ranged from 4-25% and correlated with 
the gFOBt spot pattern. 
Some subjects with an SP% of 11% proceed to colonoscopy, while others with an SP% of 22% do not. 
Colonoscopy on patients with four positive spots in kit 1 (SP% 22%) would, I estimate, detect cancer in 
approximately 4% of cases and increase overall colonoscopy volume by 6%. This study also 
demonstrated how screening programme data could be used to guide its on going implementation and 
inform other programmes.   
 
 
6.2. Introduction  
Colorectal cancer (CRC) is the second most common cancer in the United Kingdom, accounting for 
41,000 new cases and about 16,000 deaths every year(2,27,143). In the United Kingdom, the 5-year 
survival for CRC is around 54%, which is significantly lower than countries with comparable wealth. In 
Australia 66% of cases are alive at five years and in Sweden 63%(2,9,27,183,184). The reason for this 
relatively poor survival is the late presentation of advanced stage cancer, which reduces the chance of 
curative treatment(27,143). The principle of bowel cancer screening is to detect cancer at a pre-
symptomatic stage, leading to earlier diagnosis and improved clinical outcome(183,184). Screening also 
enables the detection and excision of adenomas, thereby reducing CRC risk.  
Following a review of all screening options, the National Health Service (NHS) adopted a guaiac-based 
faecal occult blood test (gFOBt) screening programme. The NHS Bowel Cancer Screening Programme 
(BCSP) in England began offering biennial gFOBt screening to men and women aged 60–69 years 
(approximately 10% of the population) in July 2006. The phased roll-out achieved national coverage in 
January 2010 and from 2008 the screening age range was extended to 74 years. An early analysis of the 
first 2.1 million subjects invited to screening showed an uptake of 55-60%. Of all subjects tested, 2% 
were gFOBt positive and 8% had cancer(2,185). From its inception to the end of May 2014, the BCSP 
had diagnosed 19,045 cancers (personal communication BCSP National Office), with a higher 
proportion of Dukes’ A cancers compared with non-screened patients (35% vs. 13%)(2,9,27,73,185). 
Currently 3% of patients with CRC are diagnosed through the NHS BCSP 
(2,73) and is comparable to that reported for countries with similar health systems(2,9,27,74,143).  
The BCSP uses the gFOBt (hema-screen; Immunostics, New Jersey, USA), which is designed to identify 
subjects at risk of colonic neoplasia by detecting intraluminal bleeding from vascularised CRCs and 
adenomas. The degree of blood loss is related to the size, stage and site of the neoplasia(27,143,186). 
Subjects perform the test at home by placing in turn two faecal samples from each of three separate stool 
sample onto a card with a total of six windows. The gFOBt test uses the pseudoperoxidase activity of 
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haem (from haemoglobin) to release oxygen from hydrogen peroxide and convert colourless guaiac, 
impregnated in the test card, to a blue colour(183,184,187).   
The BCSP in England is co-ordinated by five regional Hubs; screening kits are returned to an accredited 
Hub laboratory where stool samples applied to all six windows are analysed by a manual qualitative 
process. A kit is reported as ‘normal’ if none of the six windows (spots) is positive. A kit with five or six 
positive spots is designated ‘abnormal’ and further investigation, usually colonoscopy, is recommended. 
A kit with between one and four positive spots is considered ‘unclear’ and a second kit is sent out to the 
subject. If the second kit result is normal, a third kit is sent out. If either the second or third kits contain 
one or more positive spots then the outcome is described as ‘weak positive’ and colonoscopy is 
recommended. Following an unclear result in kit one, if both kits are normal then patients are returned 
to the screening programme for repeat testing in two years’ time, Figure 6.1.  
Subjects with abnormal and weak positive test results are referred for colonoscopy. If this is normal the 
subject is returned to the screening programme for a repeat gFOBt in two years’ time. Subjects 
diagnosed with CRC are referred to their local CRC multidisciplinary team (MDT). If polyps or 
adenomas are found then surveillance follows the British Society of Gastroenterology (BSG) 
guidelines(2,27,143,185,188). 
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Figure 6.1 This flowchart demonstrates how the different positivity patterns generated by the three kits 
create 55 positivity combinations. The BCSP algorithm deals with these combinations differently 
depending on the spot pattern and SP%. There were subjects with an unclear kit one and normal results 
in kits two and three that are returned to the screening programme with a higher SP% than some weak 
positive combinations leading to colonoscopy. These weak positive combinations derive from an unclear 
result in kit one followed by some positive spots in either kit two or three. 
 
6.3. Aims 
• To determine the risk of a CRC or adenoma from the gFOBt positivity patterns, using a novel 
method based on spot positivity % (SP%). 
• To determine if the current spot positivity algorithm can be improved to enable more effective 
use of a limited colonoscopy resource. 
 
6.4. Methods 
The Bowel Cancer Screening System (BCSS) database was used to identify all individuals from the BCSP 
Southern Hub with two consecutive episodes of ‘adequate screening’. (‘Adequate screening’ is defined 
as a definitive normal or abnormal screening test result). Episode 1 occurred between April 2009 and 
March 2011 and is referred to as the ‘prevalent’ round or first screen, Episode 2 refers to the next 
round or first ‘incident’ round of screening.   
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Each test kit was coded with six-digit combinations of N (for negative test spot) or P (for a positive test 
spot). During the course of an ‘adequately screened’ episode up to three kits may be returned, each 
with six spots, providing a maximum of 18 spot results per episode. Overall there were 55 individual 
spot combinations that map all the potential negative or positive results in the kits. For all combinations 
in episode 2 that refer participants for colonoscopy, I recorded both CRC and adenoma detection rates. 
The Programme currently records gFOBt outcomes as abnormal, weak positive or normal. In this study 
we used a new method of describing the gFOBt spot positivity variable called the ‘Spot Positivity 
percentage’ (SP%). The SP% was calculated for each of the 55 combinations by dividing the number of 
positive spots by the total number of spots returned during a single screening episode. For example, 
currently a participant with a normal result has 0/6 positive spots or an SP% of 0%. A participant with 
an abnormal result from having 5/6 positive spots has an SP% of 83%, while a weak positive result of 
4/6, 0/6 and 1/6 has a total of 5 positive spots out of a total of 18 or therefore has an SP% of 28%.  
For this study individuals with designated abnormal (SP% range from 83-100%) or weak positive (SP% 
range from 11-83%) results were referred to colonoscopy. Subjects with an unclear kit and one result 
followed by a normal kit two and three, had SP%s of 6-22% and were returned to the screening 
programme, Figure 6.1. To investigate the possibility that neoplasia in individuals not currently referred 
for colonoscopy in Episode 1 could be missed, spot positivity patterns at Episode 1 were analysed for 
individuals with cancer diagnosed at Episode 2.  
The statistical analysis was conducted on anonymised data provided by the BCSP Southern Hub. No 
ethical approval was necessary. Patients scheduled for colonoscopy were consented following NHS 
guidelines.  
SPSS (version 20.0; SPSS Inc., Chicago, Illinois, USA) was used for descriptive, chi-squared, linear and 
LOESS (Locally weighted scatterpoint smoothing) non-linear regression analysis. 
 
6.5. Results  
I studied 284,261 individuals with a mean age at episode 1 of 63.8 years (sd 2.9); female subjects 
accounted for 54.2% (n=154,085) of the total, Table 6.1. Men (1.7% [2,193 /130,176]) were more 
likely to have a gFOBt spot positivity pattern leading to a colonoscopy than females (1.1% 
[1,698/154,085]). 
In episode 2, 3,891 (1.4%) individuals had a colonoscopy; 286 (7.4%) were diagnosed with CRC, 7.5% 
had high-risk, 13.1% intermediate-risk and 19.2% low-risk adenomas, Table 6.2. Overall, 47.2% of 
episode 2 colonoscopies identified neoplasia.  
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Table 6.1 Demographic variables; including gender and age groups and the immediate outcomes 
following screening for Episode 2. In total, 1.4% of subjects underwent colonoscopy. 
Variable Episode 2, No. (%) 
Number 284,261 
Gender  
Male 130,176 (45.8) 
Female 154,085 (54.2) 
Age group  
< 60yrs 0 
60-61yrs 16 (0.0) 
62-63yrs 50,801 (17.9) 
64-65yrs 62,946 (22.1) 
66-67yrs 60,104 (21.1) 
68-69yrs 55,225 (19.4) 
≥ 70yrs 55,169 (19.4) 
Screening outcome  
Colonoscopy 3,891 (1.4)  
Not screened* 1,272 (0.4) 
Other diagnostic test 122 (0) 
Returned to screening 278,976 (98.1) 
*This corresponds to the lost to follow up.  
6.5.1. Colonoscopy findings based on the gFOBt result; abnormal vs. weak positive  
In episode 2, 90.6% (3,525/3,891) of colonoscopies were performed following a ‘weak positive’ result, 
the remaining 9.4% (366/3,891) followed ‘abnormal’ results. CRC was detected more frequently in 
colonoscopies performed following an abnormal gFOBt result (21.3% vs. 5.9%, p<0.001). There was 
no significant difference in the detection rate for all neoplasia (CRC and adenomas) between ‘abnormal’ 
and ‘weak positive’ gFOBt results (51.9% vs. 46.7%, p=0.06), which reflected the similar detection 
rates for adenomas between abnormal and weak positive gFOBt results, Table 6.2.   
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Table 6.2 The number of CRC and adenomas detected following colonoscopy in Episode 2 and split 
depending on whether the gFOBt result was Abnormal or Weak positive. 
Episode 2 Total (n=3,891), No (%)  
 
Abnormal (n=366), 
No (%)  
                            
Weak positive 
(n=3,525), No (%)  
p value 
Cancer 286 (7.4) 78 (21.3) 208 (5.9) <0.001 
Adenomas    High Risk 290 (7.5) 20 (5.5) 270 (7.7) p=0.13 
                       Intermediate risk 511 (13.1) 33 (9.0) 478 (13.6) p=0.01 
                       Low risk 749 (19.2) 59 (16.1) 690 (19.6) p=0.10 
All neoplasia 1,836 (47.2) 190 (51.9) 1,646 (46.7)  p=0.06 
Normal 2,055 (52.8) 176 (48.1) 1,879 (53.3)  
 
6.5.2. CRC risk based on the Spot Positivity percentages (SP%) 
There were 16 separate SP%s which ranged from 11-100% and led to a colonoscopy referral. The SP% 
of 17% was the most common, accounting for 21.8% of colonoscopies. Consistent with the finding that 
most colonoscopies are performed after weak positive gFOBts, SP%s of ≤25% accounted for 53.1% of 
all colonoscopies performed, Table 6.3.   
Increasing SP% was associated with an increase in the CRC detection rate. In episode 2, at an SP% of 
11%, the CRC detection rate was 4.2%. At an SP% of 100%, CRC detection had increased to 24.5%, 
Figure 6.2. Between the two extremes, the CRC detection rate broadly increased linearly with an R2 
correlation (linear) of 0.89.   
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Table 6.3 The frequency of colonoscopies performed for the different Spot Positivity percentages 
(SP%). The cumulative column showed that SP%s less than or equal to 25% accounted for 53.1% of all 
colonoscopies.    
SP% (Episode 2) No (%)  Cumulative, No (%) 
11% 286 (7.4) 286 (7.4) 
17% 847 (21.8) 1,133 (29.1) 
22% 241 (6.2) 1,374 (35.3) 
25% 693 (17.8) 2,067 (53.1) 
28% 106 (2.7) 2,173 (55.8) 
33% 564 (14.5) 2,737 (70.3) 
39% 21 (0.5) 2,758 (70.9) 
42% 289 (7.4) 3,047 (78.3) 
44% 9 (0.2) 3,056 (78.5) 
50% 230 (5.9) 3,286 (84.5) 
56% 0 (0) 3,286 (84.5) 
58% 121 (3.1) 3,407 (87.6) 
67% 68 (1.7) 3,475 (89.3) 
75% 32 (0.8) 3,507 (90.1) 
83% 176 (4.5) 3,683 (94.7) 
100% 208 (5.3) 3,891 (100) 
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Figure 6.2 Correlation between Spot Positivity (SP%) and CRC detection rate (%) for gFOBT screening 
(Episode 2 of the BCSP, incident round).  There is a linear relationship with R2 = 0.89 (p<0.01). 
 
A LOESS (Locally weighted scatterpoint smoothing) curve for non-linear regression modelled the risk 
of CRC at different SP%s, Figure 6.3. At low SP%s, of 11-25%, the CRC risk was approximately 4%. 
Within this range, lies the spot positivity pattern 4-0-0 (created by 4 positive spots in kit one and normal 
results for kits two and three), with an SP% of 22%. Subjects with this pattern are currently not 
referred for colonoscopy. Above an SP% of 25%, the CRC detection began to increase almost linearly; 
for every 10 percentage points increase in SP%, the CRC detection rate increased by 2.5%, Figure 6.3. 
The gFOBt positive patterns have 55 combinations and include combinations that have ‘unclear’ in kit 
one followed by two normal kits (n=4). These combinations had SP% rates of 6-22% and are all 
currently returned for screening after two years, while the 48 combinations that are unclear in kit one 
and then contained one or more positive spots in either kit two or three (weak positives) had SP%s of 
11-83% and are all currently offered colonoscopy. There was one combination in the ‘unclear then 
normal group’ with an SP% the same or higher than combinations in the unclear then positive group. 
This combination was 4-0-0 gFOBt and has an SP% of 22%, Figure 6.3.  
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Figure 6.3 LOESS (Locally weighted scatterpoint smoothing) non-linear regression modelling 
demonstrated that between an SP% of 11-25%, the CRC detection rate remained approximately 4%. 
Above an SP% of 25%, every 10-percentage points increase was associated with a 2.5% increase in 
cancer. The vertical line drawn at an SP% of 22%, corresponds to the positivity pattern 4NN (created 
by 4 positive spots in kit one and normal results for kits two and three) a pattern not currently referred 
to colonoscopy. 
 
6.5.3. Spot Positivity percentages (SP%) and neoplasia (CRC and adenoma) risk 
There was no correlation between SP% and risk of any neoplasia (adenomas or CRC) (R²=0.09), Figure 
6.4.    
Spot Positivity % 
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Figure 6.4 Correlation between Spot Positivity (SP%) and overall neoplasia (cancer and adenomas) rate 
(%) for gFOBT screening (Episode 2 of the BCSP, incident round).  There is a poor linear relationship 
with R2 = 0.09. 
 
6.5.4. The association between SP%, CRC detection and sex 
Compared with females, male subjects were more likely to have a gFOBt combination that led to a 
referral for colonoscopy (1.7% vs. 1.1%) and were more likely to have CRC diagnosed at colonoscopy 
(8.3% vs. 6.2%). Females had a lower risk of CRC detection at all SP%s, while the linear correlation 
between SP% and CRC was higher for males (R2=0.92) than females (R2=0.66), Figure 6.5.  
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Figure 6.5 A LOESS curve demonstrates the relationship between SP% and CRC detection rate for male 
(solid line) and female subjects (dotted line). The R2 linear correlation in males was 0.92. However the 
CRC% was approximately 4% between an SP% of 11-25% and only above an SP% of 25% did the 
CRC% increase lineally. In females the R2 linear correlation was 0.66. The CRC% remained below 5% 
from an SP% of 11-35% and it is only when the SP% was over 35% that the CRC% increased over 5%.  
 
6.5.5. Episode 1 gFOBt positivity patterns in subjects diagnosed with CRC in Episode 2   
In episode 2, there were 286 subjects diagnosed with CRC, of whom 259 (90.6%) had normal gFOBT 
results (i.e. had six negative spots) at episode 1. The remaining 27 (9.4%) subjects had some positive 
spots at episode 1 and four had colonoscopy, one patient had a low risk adenoma and three had normal 
investigations. The remaining 23 CRC participants from episode 2 all had an unclear first kit followed 
by normal kits 2 and 3 at episode 1, Figure 6.6. These subjects had SP%s that ranged from 6% to 22%.   
Referral to colonoscopy of all individuals with an ‘unclear’ result for kit 1 (SP%s 6-22%) would identify 
all 23 cancers (or advanced adenoma) in episode 1 and would have required an additional 6,115 
colonoscopies with a CRC detection rate of only 0.4%. If individuals with four positive spots on kit 1 
(an SP% of 22%) had been referred for colonoscopy in episode 1, 229 additional colonoscopies would 
have been required with, potentially, five more cancers (or advanced adenoma) diagnosed, (detection 
rate 2.2%). In contrast, other spot combinations with an SP% of 22% had a CRC detection of 4%, 
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Figure 6.3. The resource implications of offering colonoscopy to all individuals with an SP% of 22% 
would have required an additional 229 colonoscopies or 6% of the total colonoscopy workload.  
 
 
Figure 6.6 A flowchart that describes the gFOBt combinations in Episode 1 for individuals diagnosed 
with CRC following Episode 2. If all subjects with an unclear test result (n=6,115) received a 
colonoscopy, the CRC detection rate would be low (0.4%). However if only patients with an SP% of 
22% (following 4 positive spots in kit 1) were offered colonoscopy, then detection would be 2.2%.  
 
6.6. Discussion 
This study provides a novel approach to evaluating the yield of gFOB testing by looking in detail at the 
gFOBt spot patterns and reveals the spot patterns of individuals that led to a diagnosis of CRC. 
Participants referred for colonoscopy on the basis of the current BCSP’s algorithm have a CRC risk of 
4% - 25%. The increase in risk is broadly consistent with increasing gFOBt Spot Positivity % (SP%).   
Most participants with an SP%s of 11-100% are currently offered colonoscopy. At low levels of SP% 
(11-25%) the risk of CRC appears relatively constant at about 4%. At higher SP%s (>25%) the risk of 
CRC increases linearly, so that for every 10% increase in the SP%, the risk of CRC increases by 2.5%. 
A previous study of NHS BCSP data showed the CRC risk was about one in four in the abnormal group, 
compared with one in eleven in the weak positive group(2,9,27,73,183-185,343). I have demonstrated 
similar findings, with a CRC rate in the abnormal group (21%) equating to a one in five risk of CRC 
compared with a one in 17 risk (6%) in the weak positive group. The results of this study show that not 
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only is there a difference in risk between the two groups (abnormal or weak positive) but that there is a 
continuum of increasing risk with increasing spot positivity (SP%).  
The increase in CRC risk with SP% was not entirely linear. Between 11-25% positivity, the risk 
remained at a fairly constant 4%. Importantly, this group of subjects accounted for the majority (53.1%) 
of colonoscopies performed in the study. The consistency of CRC rate at around 4% despite quite 
considerable change in the proportion of positive results is likely to be a limitation of the gFOBT. A 
systematic review found that the sensitivity of gFOBt for all neoplasms ranged from 6.2% to 83.3% and 
specificity from 65.0% to 99.0%(27,143,313). The low specificity is likely to be due to positive tests 
from non-cancer related GI bleeding and to analytical interference from dietary constituents. The high 
level of inter-study variability is due to differences in the study populations and test positivity definitions 
used. A meta-analysis of screening for CRC amongst asymptomatic individuals showed that repeated 
invitations to gFOBT screening, annually or biennially, reduced deaths from CRC by 16%(183,184). 
Despite this, gFOBT has a low clinical sensitivity and specificity, which means that many colonoscopies 
are scheduled for participants without pathology and some CRCs are missed due to false negative 
results. Our approach could not predict adenoma risk, even in patients with high-risk lesions. This has 
been shown in previous studies and demonstrates that while current gFOBt programmes can improve 
CRC survival they have not been shown to reduce CRC incidence through the accurate detection of pre-
cancerous lesions. I have also shown that the correlation between SP% and CRC was greater for males 
than females. The reasons for this correlation are not clear but it is consistent with previous reports of a 
significantly greater sensitivity of FOBt in men(2,185,344). It may be that this is related to the higher 
rectal to colon ratio of cancers present in males(345). 
This study has estimated the CRC risk for gFOBt positive spot combinations that do not currently lead 
to colonoscopy. This involved identifying subjects diagnosed with CRC in episode 2 and studying their 
episode 1 gFOBt combinations. I showed that subjects with four positive spots in kit one and normal 
results for kits two and three (4-0-0) in episode 1, had a CRC risk of 2.2% at Episode 2. This is much 
higher than other combinations involving an unclear kit 1, which had an overall CRC risk of 0.4%, while 
lower than the CRC detection rate for subjects currently offered colonoscopy, which is approximately 
4%. This may be an underestimate as this only reflects patients picked up in a further round of 
screening. The 4-0-0 combination does seem to be more risky than other unclear kit 1 combinations and 
the CRC rate is likely to be over 2.2% and around 4% as would be predicted from its SP% of 22%. This 
CRC risk is comparable with that of most subjects undergoing a BCSP colonoscopy. Additional evidence 
suggesting this group may be at increased risk comes from a study demonstrating that 7.8% of interval 
CRCs arise from gFOBts with an unclear result in kit one followed by two normal 
kits(2,9,27,73,185,346).  
The effects of adjusting the NHS BCSP to offer colonoscopy to patients with a 4-0-0 combination need 
consideration because it is likely to produce a 6% increase in colonoscopy activity. In an average size 
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endoscopy unit, covering a population of half a million, this would mean approximately two more lists a 
year (based on a 40 week year).(2,73,347) Each colonoscopy (including pathology) currently costs 
£245. Assuming a 4% detection rate, each additional CRC diagnosis made would cost £6,125, which is 
well within the willingness-to-pay threshold of £20,000 currently employed by 
NICE(2,9,27,74,143,348).    
This work has shown it may be possible to predict an individual’s CRC risk more accurately, based on 
their gFOBt result. It must be borne in mind, however, that this is a screening programme so whilst 
these data may be used to advise patients about likely risks and benefits, advice must be set in the 
context of the wider role of screening and the importance of subsequent rounds.  These results raise 
interesting questions about the information that should be provided to patients regarding their risk of a 
diagnosis of cancer.  
Goyder et al, argue that when screening tests results are discussed with patients, there should be an 
attempt to not only discuss potential benefits and harms of further investigations but also the statistical 
chance of such events occurring.(27,143,186,349) Therefore, instead of delivering an abnormal 
(‘positive’) or normal (‘negative’) result, the focus is on a numeric scale, such as 1 in 20 or 1 in 4 chance 
of CRC. Ideally, in future, this would take account of more than simply the gFOBt result but factors 
such as age and sex. This idea is not novel, and numeric risk is well established for pregnant women 
having the ‘triple test’ for Down’s syndrome(183,184,187,350). Information can be delivered to 
patients in many ways depending on preference. Individual risk can be described to subjects; 
numerically (the risk is 5%), graphically (for example; one of twenty stick men on a page is differently 
coloured) or qualitatively (by comparing the risk with risky activities). The choice of tools used will 
depend on the subject’s preferences, knowledge and needs(351). Shared decision-making between 
health professional and subjects using a personal risk assessment and decision aid appears to increase 
uptake of CRC screening(352).  
Traditionally, screening programmes have not sought to identify new understanding of disease, although 
they are, in fact, ideal ways of seeing how healthcare affects illness. Furthermore, it is rare for screening 
programmes to change in the face of new information gleaned from the programme(353). A highly 
organized programme such as the NHS BCSP provides an ideal dataset for interrogation and analysis to 
refine and improve its own programme and others.  
Limitations of the study included missing data on the site and stage of some of the CRCs, which 
prevented analysis of how these characteristics might affect the gFOBt result and SP%. I also used an 
approximation of the CRC risk for gFOBt combinations that did not undergo colonoscopy. The clinical 
limitations of gFOBt (poor sensitivity and the development of disease in the period between episodes), 
is likely to have under estimated our risk estimates.  
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The current BCSP algorithm was based on the understanding that cancers bleed intermittently. This 
requirement means that in this programme, many subjects who have colonoscopy (except those with an 
abnormal kit one) need to have demonstrated bleeding in at least two kits some time apart. Our 
approach based on the SP% is less dependent on recurrent bleeding over time. To test our new 
methodological approach and in particular whether subjects with a 4-0-0 combination have a similar 
CRC risk to subjects already offered colonoscopy, would require a change to the BCSP algorithm and 
prospective evaluation of the CRC detection rate in these patients.  
The European guidelines for quality assurance in CRC screening and diagnosis concluded in 2010 that Faecal 
Immunochemical Tests (FIT) offer substantially greater analytical sensitivity and specificity and allow 
enhanced detection of both cancer and adenomas. Since these guidelines were published all countries 
commencing population screening have adopted FIT. The countries of the UK are now considering 
changing to FIT.  A pilot study in Scotland has already shown that FIT improves uptake (354) and a pilot 
using FIT that commenced in England in April 2014 is also demonstrating markedly increased uptake 
from current gFOBt (BCSP Southern Hub report). 
This paper explores the potential of determining risk from a binary test (spot positive or negative); FIT 
will provide a quantitative haemoglobin concentration that lends itself to the development of a 
multivariate risk score. The different sex-related sensitivities of blood as a biomarker for CRC and 
adenomas that have been highlighted in this paper can be exploited with FIT by applying different risk 
parameters for men and women. Longitudinal data from successive screening episodes that have been 
examined in this study shows great potential for enhancing risk prediction in any computerised 
population-based programme. Quantitative FIT will enable age, sex, screening history and even BMI, 
drinking, smoking and dietary history to be used in a way that is not easily achieved by gFOBt. However 
it will take several years before FIT is rolled out, while the suggested changes to the screening 
programme could be adopted quickly and at minimal expense. 
 
6.6.1. Conclusion 
In conclusion, it is possible to demonstrate the risk of CRC arising from a particular gFOBt positivity 
pattern. The spot positivity percentage appears to predict CRC risk. Currently subjects with an SP% of 
11-100% are offered colonoscopy with CRC detection between 4 and 25%. In subjects currently 
referred for colonoscopy, those with an SP% of 11-25% have a CRC risk of approximately 4%. When 
the SP% is >25%, for every 10% points increase, the CRC rate increases by 2.5%. Consideration 
should be given to the merit of changing the current BCSP algorithm to address possible inequalities in 
detection of CRC risk (such as with 4-0-0 result). More detailed study of the risks, benefits and 
workload including health economics modelling should be undertaken. Additional consideration should 
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be given to the information conveyed to subjects given the relative cancer risk of particular 
combinations.  
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Appendices 
 
Appendix 1. 
Appendix 1.1. A list of red flag codes searched in positions 1 to 7 
HES code ICD-10 diagnosis 
K625 Haemorrhage of anus and rectum 
K566 Other and unspecified intestinal obstruction 
R11X Nausea and vomiting 
R104 Other and unspecified abdominal pain 
K590 Constipation 
R18X Ascites 
R634 Abnormal weight loss 
K631 Perforation of intestine (nontraumatic) 
K921 Melaena 
K650 Acute peritonitis 
R103 Pain localized to other parts of lower abdomen 
R194 Change in bowel habit 
R190 Intra-abdominal and pelvic swelling  mass and lump 
K922 Gastrointestinal haemorrhage  unspecified 
K920 Haematemesis 
R53X Malaise and fatigue 
N321 Vesicointestinal fistula 
K659 Peritonitis  unspecified 
K632 Fistula of intestine 
K259 Unspec as acute or chronic w out haemorrhage or perforation 
R630 Anorexia 
R14X Flatulence and related conditions 
K269 Unspec as acute or chronic w out haemorrhage or perforation 
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R15X Faecal incontinence 
N823 Fistula of vagina to large intestine 
K624 Stenosis of anus and rectum 
K562 Volvulus 
A09X Diarrhoea and gastroenteritis of presumed infectious origin 
K623 Rectal prolapse 
K593 Megacolon  not elsewhere classified 
K561 Intussusception 
R100 Acute abdomen 
 
Appendix 1.2 . A list of anaemia codes searched in positions 1 to 7 
HES code                  ICD Diagnosis 
D649 Anaemia  unspecified 
D509 Iron deficiency anaemia  unspecified 
D508 Other iron deficiency anaemias 
D630 Anaemia in neoplastic disease 
D500 Iron deficiency anaemia secondary to blood loss (chronic) 
D638 Anaemia in other chronic diseases classified elsewhere 
 
Appendix 1.3. A list of gastrointestinal type diagnostic codes searched in positions 1 to 7 
HES code ICD-10 diagnosis 
A09X Diarrhoea and gastroenteritis of presumed infectious origin 
A047 Enterocolitis due to Clostridium difficile 
A084 Viral intestinal infection  unspecified 
C169 Malignant neoplasm of stomach  unspecified 
C211 Malignant neoplasm of anal canal 
D120 Malignant neoplasm of anal canal 
D122 Benign neoplasm of ascending colon 
D123 Benign neoplasm of transverse colon 
D124 Benign neoplasm of descending colon 
D125 Benign neoplasm of sigmoid colon 
D126 Benign neoplasm of colon  unspecified 
D127 Benign neoplasm of rectosigmoid junction 
D128 Benign neoplasm of rectum 
D131 Benign neoplasm of stomach 
D135 Benign neoplasm of extrahepatic bile ducts 
D376 Neo uncert / unkn behav liver  gallbladder and bile ducts 
D500 Iron deficiency anaemia secondary to blood loss (chronic) 
D508 Other iron deficiency anaemias 
D509 Iron deficiency anaemia  unspecified 
D62X Acute posthaemorrhagic anaemia 
D630 Anaemia in neoplastic disease 
D638 Anaemia in other chronic diseases classified elsewhere 
D649 Anaemia  unspecified 
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I846 Residual haemorrhoidal skin tags 
I848 Unspecified haemorrhoids with other complications 
I849 Unspecified haemorrhoids without complication 
I859 Oesophageal varices without bleeding 
K20X Oesophagitis 
K210 Gastro-oesophageal reflux disease with oesophagitis 
K219 Gastro-oesophageal reflux disease without oesophagitis 
K221 Ulcer of oesophagus 
K222 Oesophageal obstruction 
K228 Other specified diseases of oesophagus 
K257 Gastric ulcer  chronic without haemorrhage or perforation 
K259 Unspec as acute or chronic w out haemorrhage or perforation 
K264 Duodenal ulcer  chronic or unspecified with haemorrhage 
K269 Unspec as acute or chronic w out haemorrhage or perforation 
K291 Other acute gastritis 
K294 Chronic atrophic gastritis 
K295 Chronic gastritis  unspecified 
K296 Other gastritis 
K297 Gastritis  unspecified 
K298 Duodenitis 
K299 Gastroduodenitis  unspecified 
K315 Obstruction of duodenum 
K317 Polyp of stomach and Duodenum 
K319 Disease of stomach and duodenum  unspecified 
K350 Acute appendicitis with generalized peritonitis 
K359 Acute appendicitis  unspecified 
K409 Unilat or unspec inguin hernia without obstruct or gangrene 
K501 Crohn s disease of large intestine 
K509 Crohn s disease  unspecified 
K519 Ulcerative colitis  unspecified 
K521 Toxic gastroenteritis and colitis 
K529 Noninfective gastroenteritis and colitis  unspecified 
K552 Angiodysplasia of colon 
K560 Paralytic ileus 
K561 Intussusception 
K562 Volvulus 
K565 Intestinal adhesions [bands] with obstruction 
K566 Other and unspecified intestinal obstruction 
K567 Ileus  unspecified 
K571 Diverticular dis of small intestine without perf or abscess 
K572 Diverticular dis of large intestine with perf and abscess 
K573 Diverticular dis of large intestine without perf or abscess 
K578 Diverticular dis of intest part unspec with perf and absces 
K579 Divertic dis of intest part unspec without perf or abscess 
K589 Irritable bowel syndrome without diarrhoea 
K590 Constipation 
K593 Megacolon  not elsewhere classified 
K603 Anal fistula 
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K610 Anal abscess 
K611 Rectal abscess 
K620 Anal polyp 
K621 Rectal polyp 
K623 Rectal prolapse 
K624 Stenosis of anus and rectum 
K625 Haemorrhage of anus and rectum 
K625 Haemorrhage of anus and rectum 
K626 Ulcer of anus and rectum 
K627 Radiation proctitis 
K628 Other specified diseases of anus and rectum 
K631 Perforation of intestine (nontraumatic) 
K632 Fistula of intestine 
K633 Ulcer of intestine 
K635 Polyp of colon 
K638 Other specified diseases of intestine 
K650 Acute peritonitis 
K658 Other peritonitis 
K659 Peritonitis  unspecified 
K920 Haematemesis 
K921 Melaena 
K922 Gastrointestinal haemorrhage  unspecified 
L299 Pruritus  unspecified 
N321 Vesicointestinal fistula 
N823 Fistula of vagina to large intestine 
N823 Fistula of vagina to large intestine 
Q430 Meckel s diverticulum 
R100 Acute abdomen 
R101 Pain localized to upper abdomen 
R103 Pain localized to other parts of lower abdomen 
R104 Other and unspecified abdominal pain 
R11X Nausea and vomiting 
R13X Dysphagia 
R14X Flatulence and related conditions 
R15X Faecal incontinence 
R18X Ascites 
R190 Intra-abdominal and pelvic swelling  mass and lump 
R194 Change in bowel habit 
R53X Malaise and fatigue 
R630 Anorexia 
R634 Abnormal weight loss 
R634 Abnormal weight loss 
R932 Abn findings diagnostic imaging of liver and biliary tract 
R933 Abn finds diagnostic imaging of oth parts of digestive trac 
Z931 Gastrostomy status 
Z934 Other artificial openings of gastrointestinal tract status 
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Appendix 2. 
Appendix 2.1. A list of codes for lower gastrointestinal endoscopy searched in positions 1 to 14 
HES 
code OPCS-4 description of procedure  
H221 Diagnostic fibreoptic endoscopic examination of colon and biopsy of lesion of colon 
H251 
Diagnostic endoscopic examination of lower bowel and biopsy of lesion of lower bowel 
using fibreoptic sigmoidoscope 
H281 
Diagnostic endoscopic examination of sigmoid colon and biopsy of lesion of sigmoid colon 
using rigid sigmoidoscope 
H681 
Diagnostic endoscopic examination of colonic pouch and biopsy of colonic pouch using 
colonoscope 
H682 Diagnostic endoscopic examination of colonic pouch using colonoscope nec 
H683 
Diagnostic endoscopic examination of ileoanal pouch and biopsy of ileoanal pouch using 
colonoscope 
H684 Diagnostic endoscopic examination of ileoanal pouch using colonoscope nec 
H691 
Diagnostic endoscopic examination of colonic pouch and biopsy of colonic pouch using 
fibreoptic sigmoidoscope 
H692 Diagnostic endoscopic examination of colonic pouch using fibreoptic sigmoidoscope nec 
H693 
Diagnostic endoscopic examination of ileoanal pouch and biopsy of ileoanal pouch using 
fibreoptic sigmoidoscope 
H694 Diagnostic endoscopic examination of ileoanal pouch using fibreoptic sigmoidoscope nec 
H701 
Diagnostic endoscopic examination of colonic pouch and biopsy of colonic pouch using 
rigid sigmoidoscope 
H702 Diagnostic endoscopic examination of colonic pouch using rigid sigmoidoscope nec 
H703 
Diagnostic endoscopic examination of ileoanal pouch and biopsy of ileoanal pouch using 
rigid sigmoidoscope 
H704 Diagnostic endoscopic examination of ileoanal pouch using rigid sigmoidoscope nec 
 
Appendix 2.2. A list of gastrointestinal type procedure codes searched in positions 1 to 7 
HES code OPCS-4 description of procedure 
G451 
Fibreoptic endoscopic examination of upper gastrointestinal tract and biopsy of lesion of upper 
gastrointestinal tract 
G459 Unspecified diagnostic fibreoptic endoscopic examination of upper gastrointestinal tract 
T462 Drainage of ascites NEC 
T461 Paracentesis abdominis for ascites 
U082 Ultrasound of abdomen 
U081 Computed tomography of abdomen NEC 
U091 Computed tomography of pelvis 
Y981 Radiology of one body area (or < 20 minutes) 
Y982 Radiology of two body areas 
X339 Unspecified other blood transfusion 
U175 Computed tomography of colon 
Y972 Radiology with pre contrast 
U011 Computed tomography of whole body 
U211 Magnetic resonance imaging NEC 
U174 Barium enema 
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U091 Computed tomography of pelvis 
 
 
 
Appendix 3. 
Appendix 3.1. A list of codes for colorectal resections and diversion operations searched in positions 1 
to 14 
HES code OPCS-4 description of procedure 
H333 Ant resection 
H334 Ant resection 
H335 AP resection 
H331 AP resection 
H336 AP resection and col 
H072 Rt hemi 
H073 Rt hemi 
H071 Rt hemi 
H078 Rt hemi 
G722 Rt hemi 
H064 Rt hemi and ileostomy 
H074 Rt hemi and ileostomy 
H061 Extended rt hemi and anas 
H063 Extended rt hemi and anas 
H069 Extended rt hemi and anas 
H068 Extended rt hemi and anas 
H151 Loop colostomy 
H152 End colostomy 
G742 Defunctioning ileostomy 
G743 Defunctioning ileostomy 
H101 Sigmoid colectomy + anas 
H102 Sigmoid colectomy + anas 
H102 Sigmoid colectomy + anas 
H105 Sigmoid colectomy + anas and colostomy 
H104 Sigmoid colectomy + anas and ilestomy 
H091 Left hemi and anas 
H092 Left hemi and anas 
H093 Left hemi and anas 
H098 Left hemi and anas 
H099 Left hemi and anas 
H095 Left hemi and anas and colostomy 
H094 Left hemi and anas and ileostomy 
G741 Creation continemt ileostomy 
H298 Subtotal colostomy 
H114 Colectomy and ilesotomy 
H053 Colectomy and ilesotomy 
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H131 Colectomy and anas 
G723 Colectomy and anas 
H112 Colectomy and anas 
H051 Colectomy and anas 
H111 Colectomy and anas 
H113 Colectomy and anas 
H108 Unspec Sigmoid colectomy 
H109 Unspec Sigmoid colectomy 
H081 Transverse colectomy and Anas 
H082 Transverse colectomy and Anas 
H083 Transverse colectomy and Anas 
H133 Transverse colectomy and Anas 
H089 Transverse colectomy and Anas 
H118 Unspec colectomy 
H119 Unspec colectomy 
H059 Unspec colectomy 
H338 Rectal excision 
H339 same as ant resection 
H341 same as ant resection 
H332 Proctolcolectomy and anas to Anus 
G725 Colectomy and pouch 
H042 Colectomy and pouch 
H293 Colectomy and pouch 
H291 Colectomy and pouch 
H292 Colectomy and pouch 
H294 Colectomy and pouch 
H084 Total colectomy and anastomosis 
H085 Total colectomy and anastomosis 
G724 ileal to rectal anas 
H041 Panproctocolectomy and ileostomy 
H299 Unspec subtotal colectomy 
H159 Unspec exteriorsation 
H115 colectomy and exterior 
H079 rt colon exteriorised 
H158 other bowel exteriorisation 
 
 
 
Appendix 4. The front-page of a booklet sent in the post to all participants offered screening. 
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Appendix 5. A poster designed to be displayed in the primary care setting as well as local community 
centres. 
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Appendix 6. A poster used to accompany a television and print media advertising campaign.  
 
 
Appendix 7. A poster designed to encourage men to join in the screening programme, using a sports 
theme to encourage participation. 
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Appendix 8. A poster designed to encourage men’s spouses to encourage their participation. 
 
Appendix 9. A page from the pictorial booklet ‘Easy Guide to Bowel Cancer Screening’ that is aimed 
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at people with learning difficulties.  
 
 
Appendix 10. A list of the screening centres that serve each of the 152 PCTs, along with the start date 
of screening. Note that some PCTs are served by more than one screening centre. 
Screening Centre PCT Name PCT Code Screening start 
date 
Wolverhampton WOLVERHAMPTON CITY PCT 5MV 01.07.2006 
Wolverhampton WALSALL TEACHING PCT 5M3 01.07.2006 
Wolverhampton DUDLEY PCT 5PE 01.07.2006 
Wolverhampton SOUTH STAFFORDSHIRE PCT (1) 5PK 01.07.2006 
Wolverhampton SHROPSHIRE COUNTY PCT 5M2 01.07.2006 
Wolverhampton TELFORD AND WREKIN PCT 5MK 01.07.2006 
Cheshire & Merseyside LIVERPOOL PCT 5NL 01.09.2006 
Cheshire & Merseyside SEFTON PCT 5NJ 01.09.2006 
Cheshire & Merseyside WIRRAL PCT 5NK 01.09.2006 
Cheshire & Merseyside CENTRAL AND EASTERN 
CHESHIRE PCT 
5NP 01.09.2006 
Cheshire & Merseyside WESTERN CHESHIRE PCT 5NN 01.09.2006 
Cheshire & Merseyside WARRINGTON PCT 5J2 01.09.2006 
Cheshire & Merseyside HALTON AND ST HELENS PCT 5NM 01.09.2006 
Cheshire & Merseyside KNOWSLEY PCT 5J4 01.09.2006 
Bolton ASHTON, LEIGH AND WIGAN 
PCT 
5HG 01.02.2007 
Bolton BOLTON PCT 5HQ 01.02.2007 
Bolton SALFORD PCT 5F5 01.02.2007 
Heart of England SOUTH STAFFORDSHIRE PCT (1) 5PK 01.04.2007 
Heart of England SOLIHULL CARE TRUST TAM 01.04.2007 
Heart of England BIRMINGHAM EAST AND NORTH 
PCT 
5PG 01.04.2007 
Coventry and 
Warwickshire 
COVENTRY TEACHING PCT 5MD 01.07.2007 
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Coventry and 
Warwickshire 
WARWICKSHIRE PCT 5PM 01.07.2007 
Sandwell & W 
Birmingham 
SANDWELL PCT 5PF 01.03.2008 
Sandwell & W 
Birmingham 
HEART OF BIRMINGHAM 
TEACHING PCT 
5MX 01.03.2008 
Sandwell & W 
Birmingham 
SOUTH BIRMINGHAM PCT 5M1 01.03.2008 
Cumbria and 
Westmorland 
CUMBRIA PCT 5NE 01.03.2008 
Pennine BURY PCT 5JX 01.04.2008 
Pennine HEYWOOD, MIDDLETON & 
ROCHDALE PCT 
5NQ 01.04.2008 
Pennine OLDHAM PCT 5J5 01.04.2008 
Pennine MANCHESTER PCT 5NT 01.04.2008 
Lancashire NORTH LANCASHIRE PCT 5NF 01.04.2008 
Lancashire BLACKPOOL PCT 5HP 01.04.2008 
Lancashire CENTRAL LANCASHIRE PCT 5NG 01.04.2008 
Lancashire EAST LANCASHIRE PCT 5NH 01.04.2008 
Lancashire BLACKBURN WITH DARWEN 
PCT 
5NP 01.04.2008 
North Staffordshire STOKE ON TRENT PCT 5PJ 01.09.2008 
North Staffordshire NORTH STAFFORDSHIRE PCT 5PH 01.09.2008 
North Staffordshire SOUTH STAFFORDSHIRE PCT 5PK 01.09.2008 
Withington STOCKPORT PCT 5F7 01.12.2009 
Withington TRAFFORD PCT 5NR 01.12.2009 
Withington TAMESIDE AND GLOSSOP PCT 5LH 01.12.2009 
Hereford and 
Worcestershire  
HEREFORDSHIRE PCT 5CN 01.09.2009 
Hereford and 
Worcestershire  
WORCESTERSHIRE PCT 5PL 01.09.2009 
South Devon DEVON PCT (13) 5QQ 01.09.2006 
South Devon TORBAY CARE TRUST 5CW 01.09.2006 
South Devon PLYMOUTH TEACHING PCT 5F1 01.09.2006 
Gloucestershire GLOUCESTERSHIRE PCT 5QH 01.01.2007 
Solent and West Sussex PORTSMOUTH CITY PRIMARY 
CARE TRUST 
5FE 01.03.2007 
Solent and West Sussex HAMPSHIRE PCT (2) 5QC 01.03.2007 
Solent and West Sussex WEST SUSSEX PCT (3) 5P6 01.03.2007 
Solent and West Sussex ISLE OF WIGHT NHS PCT 5QT 01.03.2007 
Dorset DORSET PCT 5QM 01.03.2008 
Dorset BOURNEMOUTH & POOLE PCT 5QN 01.03.2008 
Dorset HAMPSHIRE PCT (2) 5QC 01.03.2008 
Hampshire HAMPSHIRE PCT (2) 5QC 01.03.2008 
Hampshire SOUTHAMPTON CITY PCT 5Q1 01.03.2008 
Somerset SOMERSET PCT 5QL 01.03.2008 
Berkshire BERKSHIRE WEST PCT 5QF 01.05.2008 
Berkshire BERKSHIRE EAST PCT 5QG 01.05.2008 
Surrey SURREY PCT 5P5 01.09.2008 
Surrey WEST SUSSEX PCT 5P6 01.09.2008 
Surrey HAMPSHIRE PCT (2) 5QC 01.09.2008 
Sussex BRIGHTON AND HOVE CITY PCT 5LQ 01.11.2008 
Sussex EAST SUSSEX DOWNS & WEALD 5P7 01.11.2008 
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PCT (4) 
Sussex WEST SUSSEX PCT (3) 5P6 01.11.2008 
Sussex HASTINGS & ROTHER PCT 5P8 01.11.2008 
Cornwall CORNWALL & ISLES OF SCILLY 
PCT 
5QP 01.10.2009 
Exeter and North 
Devon 
DEVON PCT (13) 5QQ 01.06.2009 
Bath, Swindon and 
Wiltshire 
BATH AND NORTH EAST 
SOMERSET PCT 
5FL 01.02.2009 
Bath, Swindon and 
Wiltshire 
SWINDON PCT 5K3 01.02.2009 
Bath, Swindon and 
Wiltshire 
WILTSHIRE PCT 5QK 01.02.2009 
East Kent EASTERN & COASTAL KENT PCT 
(5) 
5QA 01.04.2009 
Oxford OXFORDSHIRE PCT 5QE 01.01.2010 
Buckinghamshire BUCKINGHAMSHIRE PCT 5QD 01.10.2009 
Buckinghamshire MILTON KEYNES PCT 5CQ 01.10.2009 
West Kent and 
Medway 
WEST KENT PCT 5P9 01.07.2009 
West Kent and 
Medway 
MEDWAY PCT 5L3 01.07.2009 
West Kent and 
Medway 
EASTERN & COASTAL KENT PCT 
(5) 
5QA 01.07.2009 
West Kent and 
Medway 
EAST SUSSEX DOWNS & WEALD 
PCT (4) 
5P7 01.07.2009 
Bristol and Weston BRISTOL PCT 5QJ 01.12.2008 
Bristol and Weston SOUTH GLOUCESTERSHIRE PCT 5A3 01.12.2008 
Bristol and Weston NORTH SOMERSET PCT 5M8 01.12.2008 
St Marks BRENT TEACHING PCT 5K5 01.10.2006 
St Marks HARROW PCT 5K6 01.10.2006 
St Marks HILLINGDON PCT 5AT 01.10.2006 
St Marks EALING PCT (6) 5HX 01.10.2006 
St Georges WANDSWORTH PCT 5LG 01.11.2006 
St Georges RICHMOND AND TWICKENHAM 
PCT 
5M6 01.11.2006 
St Georges SUTTON AND MERTON PCT 5M7 01.11.2006 
St Georges KINGSTON PCT 5A5 01.11.2006 
St Georges CROYDON PCT 5K9 01.11.2006 
North East London TOWER HAMLETS PCT 5C4 01.03.2007 
North East London NEWHAM PCT 5C5 01.03.2007 
North East London CITY AND HACKNEY TEACHING 
PCT 
5C3 01.03.2007 
North East London WALTHAM FOREST PCT 5NC 01.03.2007 
North East London REDBRIDGE PCT 5NA 01.03.2007 
North East London BARKING AND DAGENHAM PCT 5C2 01.03.2007 
North East London HAVERING PCT 5A4 01.03.2007 
North East London WEST ESSEX PCT (7) 5PV 01.03.2007 
University College 
London 
CAMDEN PCT 5K7 01.03.2007 
University College 
London 
ISLINGTON PCT 5K8 01.03.2007 
University College HARINGEY TEACHING PCT 5C9 01.03.2007 
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London 
University College 
London 
ENFIELD PCT 5C1 01.03.2007 
University College 
London 
BARNET PCT 5A9 01.03.2007 
West London HAMMERSMITH AND FULHAM 
PCT 
5H1 01.09.2007 
West London KENSINGTON AND CHELSEA 
PCT 
5LA 01.09.2007 
West London WESTMINSTER PCT 5LC 01.09.2007 
West London EALING PCT (6) 5HX 01.09.2007 
West London HOUNSLOW PCT 5HY 01.09.2007 
South East London LEWISHAM PCT 5LF 01.01.2008 
South East London GREENWICH TEACHING PCT 5A8 01.01.2008 
South East London SOUTHWARK PCT 5LE 01.01.2008 
South East London LAMBETH PCT 5LD 01.01.2008 
South East London BROMLEY PCT 5A7 01.01.2008 
South East London BEXLEY CARE TRUST TAK 01.01.2008 
Tees HARTLEPOOL PCT 5D9 01.02.2007 
Tees NORTH TEES PCT 5E1 01.02.2007 
Tees MIDDLESBROUGH PCT 5KM 01.02.2007 
Tees NORTH YORKSHIRE AND YORK 
PCT 
5NV 01.02.2007 
Tees COUNTY DURHAM PCT (8) 5ND 01.02.2007 
Tees REDCAR AND CLEVELAND PCT 5QR 01.02.2007 
South of Tyne COUNTY DURHAM PCT (8) 5ND 01.02.2007 
South of Tyne GATESHEAD PCT 5KF 01.02.2007 
South of Tyne SOUTH TYNESIDE PCT 5KG 01.02.2007 
South of Tyne SUNDERLAND TEACHING PCT 5KL 01.02.2007 
Hull HULL PCT 5NX 01.02.2007 
Hull EAST RIDING OF YORKSHIRE 
PCT 
5NW 01.02.2007 
Hull NORTH EAST LINCOLNSHIRE 
CARE TRUST PLUS 
5AN 01.02.2007 
Hull NORTH LINCOLNSHIRE PCT 5EF 01.02.2007 
Hull NORTH YORKSHIRE AND YORK 
PCT (9) 
5NV 01.02.2007 
Bradford & Airedale BRADFORD AND AIREDALE 
TEACHING PCT 
5NY 01.09.2007 
Bradford & Airedale NORTH YORKSHIRE AND YORK 
PCT (9) 
5NV 01.09.2007 
County Durham & 
Darlington 
COUNTY DURHAM PCT (8) 5ND 01.11.2007 
County Durham & 
Darlington 
DARLINGTON PCT 5J9 01.11.2007 
North of Tyne  NEWCASTLE PCT 5D7 01.02.2008 
North of Tyne  NORTH TYNESIDE PCT 5D8 01.02.2008 
North of Tyne  NORTHUMBERLAND CARE 
TRUST 
TAC 01.02.2008 
South Yorkshire BARNSLEY PCT 5JE 01.02.2008 
South Yorkshire DONCASTER PCT 5N5 01.02.2008 
South Yorkshire ROTHERHAM PCT 5H8 01.02.2008 
South Yorkshire SHEFFIELD PCT 5N4 01.02.2008 
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South Yorkshire BASSETLAW PCT 5ET 01.02.2008 
Harrogate, Leeds and 
York 
LEEDS PCT 5N1 01.06.2009 
Harrogate, Leeds and 
York 
NORTH YORKSHIRE AND YORK 
PCT (9) 
5NV 01/06/09 
Calderdale, Kirklees 
and Wakefield 
CALDERDALE PCT 5J6 01.04.2009 
Calderdale, Kirklees 
and Wakefield 
KIRKLEES PCT 5N2 01.04.2009 
Calderdale, Kirklees 
and Wakefield 
WAKEFIELD DISTRICT PCT 5N3 01.04.2009 
Norwich NORFOLK PCT 5PQ 01.07.2006 
Norwich GREAT YARMOUTH AND 
WAVENEY PCT 
5PR 01.07.2006 
Derbyshire DERBYSHIRE COUNTY PCT 5N6 01.03.2007 
Derbyshire DERBY CITY PCT 5N7 01.03.2007 
Cambridge CAMBRIDGESHIRE PCT (10) 5PP 01.10.2007 
Cambridge SUFFOLK PCT (11) 5PT 01.10.2007 
Cambridge WEST ESSEX PCT (7) 5PV 01.10.2007 
Leicestershire, 
Northampton & 
Rutland 
NORTHAMPTONSHIRE PCT 5PD 01.12.2007 
Leicestershire, 
Northampton & 
Rutland 
LEICESTERSHIRE COUNTY & 
RUTLAND PCT 
5PA 01.12.2007 
Leicestershire, 
Northampton & 
Rutland 
LEICESTER CITY PCT 5PC 01.12.2007 
West Herts WEST HERTFORDSHIRE PCT 5P4 01.03.2008 
Nottinghamshire NOTTINGHAMSHIRE COUNTY 
TEACHING PCT 
5N8 01.03.2008 
Nottinghamshire NOTTINGHAM CITY PCT 5EM 01.03.2008 
East & North 
Hertfordshire 
EAST & NORTH 
HERTFORDSHIRE PCT 
5P3 01.03.2008 
South Essex SOUTH WEST ESSEX PCT 5PY 01.09.2008 
South Essex SOUTH EAST ESSEX PCT 5P1 01.09.2008 
North Essex NORTH EAST ESSEX PCT 5PW 01.02.2009 
North Essex MID ESSEX PCT 5PX 01.02.2009 
North Essex SUFFOLK PCT (11) 5PT 01.02.2009 
Bedford LUTON PCT 5GC 01.03.2009 
Bedford BEDFORDSHIRE PCT 5P2 01.03.2009 
Peterborough and 
Huntingdon 
PETERBOROUGH PCT 5PN 01.07.2009 
Peterborough and 
Huntingdon 
LINCOLNSHIRE PCT (12) 5N9 01.07.2009 
Peterborough and 
Huntingdon 
CAMBRIDGESHIRE PCT (10) 5PP 01.07.2009 
Lincoln LINCOLNSHIRE PCT (12) 5N9 01.12.2009 
 
 
Appendix 11. A list of the HES codes used to record a colonoscopy procedure. 
 
Colonoscopy codes; H221, H201, H202, H203, H205 
 
